WO2002064558A2 - Oxazole derivatives, their preparation and their use as cytokine inhibitors - Google Patents

Oxazole derivatives, their preparation and their use as cytokine inhibitors Download PDF

Info

Publication number
WO2002064558A2
WO2002064558A2 PCT/US2002/004326 US0204326W WO02064558A2 WO 2002064558 A2 WO2002064558 A2 WO 2002064558A2 US 0204326 W US0204326 W US 0204326W WO 02064558 A2 WO02064558 A2 WO 02064558A2
Authority
WO
WIPO (PCT)
Prior art keywords
groups
group
defined below
carbon atoms
substituted
Prior art date
Application number
PCT/US2002/004326
Other languages
French (fr)
Other versions
WO2002064558A3 (en
Inventor
Shunji Naruto
Yuichi Sugano
Tohru Tatsuta
Douglas Burdi
Alexander Porte
Corinna Grisostomi
Original Assignee
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company, Limited filed Critical Sankyo Company, Limited
Priority to AU2002248432A priority Critical patent/AU2002248432A1/en
Publication of WO2002064558A2 publication Critical patent/WO2002064558A2/en
Publication of WO2002064558A3 publication Critical patent/WO2002064558A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel oxazole derivatives which have activity in inhibiting inflammatory cytokines, particularly IL-4, to pharmaceutical compositions comprising said oxazole derivatives and to methods of prophylaxis and treatment of diseases mediated by cytokines, particularly allergic diseases.
  • Subsets of helper T cells can be functionally defined by their patterns of cytokine production as T helper cell type 1 (Thl) and T helper cell type 2 (Th2) in mice and humans (J. Immunol., 136, 2348-2357, 1986; Annu. Rev. Immunol., 12, 227-257, 1994; and Immunol. Today, 17, 138-146, 1996).
  • Cell-mediated immune responses are mainly mediated by the Thl subset of T cells, which produce interferon- ⁇ (IFN- ⁇ ), interIeukin-2 (IL-2), and tumor necrosis factor- ⁇ (TNF- ⁇ ).
  • Th2 cells are defined by their activity to secrete interleukin-4 (IL-4), interleukin-5 (IL-5), inter leukin- 10 (IL-10), and interleukin-13 (IL-13), which are important in antibody-mediated immune responses.
  • Thl cells facilitates Thl function and suppresses differentiation and function of Th2 cells.
  • IL-4 and IL-10 produced by Th2 cells enhance differentiation and function of Th2 cells and suppress differentiation of Thl cells (J. Immunol., 136, 2348-2357, 1986; Immunol. Today, 13, 379-381, 1992; Journal of Immunology, 159, 4686-4692, 1997; and Interferon Cytokine Res., 19, 1265-70, 1999). This therefore suggests that balanced function of Thl and Th2 cells is important for maintenance of immunity, and that abnormal bias of Thl/Th2 subsets is associated with the onset and progression of allergic diseases or autoimmune diseases (Science, 260, 547-549, 1993; Immunol. Today, 16, 34-38, 1995; and Nature, 383, 787-797, 1996).
  • IL-4 is an IgE class switching factor for B cells and an autocrine mitogenic factor for Th2 cells
  • IL-5 plays an important role in the regulation of eosinophil differentiation, migration and function
  • Th2 cells are clearly important in the pathogenesis of allergic inflammatory responses as well as IgE synthesis.
  • the importance of IL-4 and IL-5 in allergic diseases is also supported by evidence (Nature, 362, 245-247, 1993; J. Exp.
  • Th2 cytokines such as IL-4 or IL-5 could suppress abnormal Th2 dominance, IgE production, and eosinophil infiltration and that they could, as a result, act as anti-allergic agents for the treatment or prophylaxis of allergic diseases.
  • steroids, cyclosporin A and FK-506 have been clinically used as antiallergic agents. These strongly suppress disease severity in some patients.
  • side effects associated with the use of steroids such as gastrointestinal problems, water retention and osteoporosis
  • Cyclosporin A and FK-506 have powerful anti-allergic properties but they show little selectivity in inhibition of Th2- cytokine production, also inhibiting Thl -cytokines. This leads to non-specific suppression of immune functions causing a number of problems, the most significant of which is increased susceptibility to infections.
  • Th2 cytokines such as IL-4 and IL-5 could be found as they would be likely to act as better anti-allergic agents with greater specificity and fewer side effects, making them useful in the treatment and prophylaxis of allergic diseases including asthma, atopic dermatitis, allergic rhinitis, food allergies, and systemic anaphylaxis.
  • WO-A-99/33827 discloses imidazole derivatives that are said to show some specificity in inhibiting IL-4 and IL-5 production. There is a need, however, for compounds having good activity in inhibiting the production of IL-4 alone with greater specificity and lower toxicity.
  • the present invention provides in a first aspect a compound of formula (I):
  • CO X represents a substituent selected from the group consisting of phenyl groups, heteroaryl groups defined below and heterocyclyl groups defined below, said substituent X being substituted with at least one of substituents R 1 defined below and optionally further being substituted with at least one of Substituents ⁇ defined below, said heteroaryl groups and heterocyclyl groups optionally further being fused with an aryl group defined below or
  • X represents a pyridine group or a pyrimidine group
  • Y represents a substituent selected from the group consisting of phenyl groups, heteroaryl groups defined below and heterocyclyl groups defined below, said substituent Y optionally being substituted with from 1 to 5 substituents R 3 defined below, said heteroaryl groups and heterocyclyl groups optionally further being fused with an aryl group defined below;
  • R 1 represents a nitro group or a group of formula -NR 4 R 5 wherein R 4 and R 5 are the same or different and each is selected from the group consisting of hydrogen atoms, lower alkyl groups defined below, alkoxy groups defined below, alkylcarbonyl groups defined below which are unsubstituted or are substituted with at least one substituent selected from Substituents ⁇ defined below, aryl groups defined below, arylcarbonyl groups defined below which are unsubstituted or are substituted with at least one substituent selected from Substituents ⁇ defined below, heteroarylcarbonyl groups defined below, cycloalkylcarbonyl groups defined below and alkenylcarbonyl groups defined below which are unsubstituted or are substituted with aryl group(s);
  • R 2 represents a substituent selected from the group consisting of hydroxy groups, alkoxy groups defined below and groups of formula -NR 6 R 7 wherein R 6 and R 7 are the same or different and each is selected
  • R 6 and R 7 together with the nitrogen atom to which they are attached represent a heterocyclyl group defined below or a heteroaryl group defined below, said groups being unsubstituted or substituted with at least one substituent selected from the group consisting of lower alkyl groups which are unsubstituted or are substituted with at least one substituent selected from the group consisting of groups of formula -NR 4 R 5 wherein R 4 and R 5 are as defined above and heterocyclyl groups defined below, aryl groups defined below which are unsubstituted or are substituted with at least one substituent selected from Substituents ⁇ defined below, aralkyl groups defined below, carboxy groups, and alkoxycarbonyl groups defined below, said heterocyclyl and heteroaryl groups further optionally being fused with an aryl group defined below;
  • R 3 represents a substituent selected from the group consisting of lower alkyl groups defined below, alkoxy groups defined below, alkylthio groups defined below, haloalkyl groups defined below, halogen atoms, alkylcarbonyl groups defined below, aryl groups defined below which are unsubstituted or are substituted with at least one alkoxy group defined below, aralkyl groups defined below, aralkyloxy groups defined below, heterocyclyl groups defined below and heteroaryl groups defined below; and
  • Substituents ⁇ are selected from the group consisting of alkoxy groups defined below, cycloalkyl groups defined below, arylamino groups defined below, heterocyclyl groups defined below which are unsubstituted or are substituted with at least one lower alkyl group defined below, and heteroaryl groups defined below which are unsubstituted or are substituted with at least one substituent selected from the group consisting of lower alkyl groups defined below and alkoxycarbonyl groups defined below;
  • Substituents ⁇ are selected from the group consisting of lower alkyl groups defined below, alkoxy groups defined below, alkylthio groups defined below, haloalkyl groups defined below, halogen atoms, alkylcarbonyl groups defined below, aryl groups defined below which are unsubstituted or are substituted with at least one alkoxy group defined below, aralkyl groups defined below, aralkyloxy groups defined below, heterocyclyl groups defined below and heteroaryl groups defined below;
  • Substituents ⁇ are selected from the group consisting of lower alkyl groups defined below, carboxy groups and alkoxycarbonyl groups defined below;
  • Substituents ⁇ are selected from the group consisting of lower alkyl groups defined below, haloalkyl groups defined below and alkoxy groups defined below;
  • Substituents ⁇ are selected from the group consisting of alkoxy groups defined below, halogen atoms, aryl groups defined below, aryloxy groups defined below, cycloalkyl groups defined below, alkylcarbonyloxy groups defined below j alkoxycarbonyl groups defined below, hetero aryl groups defined below; or a pharmacologically acceptable salt thereof;
  • said lower alkyl groups referred to above are straight or branched alkyl groups having from 1 to 6 carbon atoms; said aryl groups referred to above are aromatic hydrocarbon groups having from 6 to 14 carbon atoms in one or more rings, said aromatic hydrocarbon groups optionally being fused with a cycloalkyl group as defined below or a heterocyclyl group as defined below; said alkoxy groups referred to above are lower alkyl groups as defined above which are bonded to an oxygen atom; said cycloalkyl groups referred to above are cycloalkyl groups having from 3 to 7 carbon atoms; said arylamino groups referred to above are amino groups which are substituted with an aryl group as defined above; said heterocyclyl groups referred to above are non-aromatic heterocyclic groups having from 4 to 10 ring atoms in one or more rings, at least one of said ring atoms being a heteroatom selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms; said
  • the invention further provides a pharmaceutical composition
  • a pharmaceutical composition comprising an effective amount of a pharmacologically active compound together with a carrier therefore (including a diluent), wherein said pharmacologically active compound is selected from the group consisting of oxazole derivatives of formula (I) and pharmaceutically acceptable salts thereof.
  • the pharmaceutical compositions have activity in inhibiting the production of IL-4 in a warm-blooded animal, which may be a human.
  • the invention still further provides a method for the inhibition of the production of IL-4 in a warm-blooded animal, which may be a human, which comprises administering to said warm-blooded animal a pharmacologically effective amount of a compound having activity in inhibiting the production of IL-4, wherein said compound is selected from the group consisting of oxazole derivatives of formula (I) and pharmaceutically acceptable salts thereof.
  • the invention yet still further provides a method for the prophylaxis or treatment of a disease mediated by IL-4 in a warm-blooded animal, which may be a human, which comprises administering to said warm-blooded animal a pharmacologically effective amount of a compound having activity in inhibiting the production of IL-4, wherein said compound is selected from the group consisting of oxazole derivatives of formula (I) and pharmaceutically acceptable salts thereof.
  • said diseases are allergic diseases including asthma, atopic dermatitis, allergic rhinitis, food allergies, and systemic anaphylaxis.
  • X represents a heteroaryl group which is substituted with at least one of substituents R 1 defined above and optionally being further substituted with at least one of Substituents ⁇
  • Y represents a heteroaryl group which is optionally substituted with from 1 to 5 substituents R 3 defined above, or R 3 represents a heteroaryl group
  • R 6 or R 7 represents a heteroaryl group which is attached to the nitrogen atom of the group -NR 6 R 7 via a ring carbon atom thereof and which is optionally substituted with at least one substituent selected from Substituents ⁇ defined above, or Substituent ⁇ represents an optionally substituted heteroaryl group, or Substituent ⁇ or Substituent ⁇ represents a heteroaryl group
  • said heteroaryl groups are 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms.
  • heteroaryl groups include furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl groups.
  • 5- or 6-membered aromatic heterocyclyl groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms examples of which include furyl, thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl groups, of which we particularly prefer thiophenyl, imidazolyl, pyridinyl, pyrazolyl, thiazolyl and isoxazolyl.
  • heteroaryl groups defined and exemplified above may be fused with an aryl group defined above.
  • fused heteroaryl group examples include benzothiazolyl groups.
  • R 6 or R 7 represents a heteroaryl group which is attached to the nitrogen atom of the group -NR 6 R 7 via a ring carbon atom thereof
  • 5- or 6-membered aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are preferred and thiazol-2-yl, pyrazol-3-yl, isoxazol-3-yl and thiophen-2-yl groups are particularly preferred.
  • R 6 or R 7 represents a heteroaryl group which is substituted with at least one substituent selected from Substituents ⁇ defined above and which is attached to the nitrogen atom of the group -NR 6 R 7 via a ring carbon atom thereof
  • 5- or 6-membered aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms which are substituted with from 1 to 3 of Substituents ⁇ are preferred and 5- or 6-membered aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms which are substituted with 1 or 2 of Substituents ⁇ are particularly preferred.
  • substituted heteroaryl groups examples include 2-ethyl-2H-pyrazol-3-yl, 5- methylisoxazol-3-yl, 2-ethoxycarbonyl-4-methylthiophen-2-yl and 2- methoxycarbonylthiophen-2-yl groups.
  • Substituent ⁇ or Substituent ⁇ represents a heteroaryl group, 5- or 6-membered aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are preferred and thiazolyl, imidazolyl, pyridinyl and thiophenyl groups are particularly preferred.
  • Substituent ⁇ represents a heteroaryl group which is substituted with at least one substituent selected from the group consisting of lower alkyl groups defined above and alkoxycarbonyl groups defined above
  • substituents selected from the group consisting of lower alkyl groups defined above and alkoxycarbonyl groups defined above
  • Examples of such groups include 2-methoxycarbonyl-4- methylthiophen-3-yl and 2-ethylimidazol-l-yl groups.
  • R 3 or Substituent ⁇ represents a heteroaryl group
  • 5- or 6-membered aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are preferred and thiazolyl, imidazolyl and thiophenyl groups are particularly preferred.
  • R 2 represents a group of formula -NR 6 R 7 wherein R 6 and R 7 together with the nitrogen atom to which they are attached represent an optionally substituted heteroaryl group
  • said heteroaryl groups are 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, wherein at least one of said heteroatoms is a nitrogen atom.
  • Unsubstituted 5- or 6-membered aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms of which at least one is a nitrogen atom are preferred and pyrrolyl, pyrazolyl and imidazolyl groups are particularly preferred.
  • the heteroaryl groups may optionally be fused with an aryl group as defined above.
  • X represents a heterocycyl group which is substituted with at least one of substituents R 1 defined above and optionally substituted with at least one of substituents ⁇
  • Y represents a heterocyclyl group which is optionally substituted with from 1 to 5 substituents R 3 defined above, or R 3 represents a heterocyclyl group
  • R or R 7 represents a heterocyclyl group which is attached to the nitrogen atom of the group -NR 6 R 7 via a ring carbon atom thereof and which is optionally substituted with at least one substituent selected from Substituents ⁇ defined above, or Substituent ⁇ represents an optionally substituted heterocyclyl group, or Substituent ⁇ represents a heterocyclyl group, or the optional substituent on the lower alkyl group which may be an optional substituent on the heterocyclyl or heteroaryl group formed from the group of formula -NR 6 R 7 by R 6 and R 7 together with the nitrogen atom to which they are attached, said heterocyclyl group
  • heterocyclyl group examples include azetidinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, oxazolidinyl, thiazolidinyl, tetrahdrofuranyl, dioxanyl, piperidinyl, tetrahydropyridyl, dihydropyridyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperidyl, 2,5-dihydropyrrolyl, decahydroquinolinyl, quinuclidinyl, quinuclidienyl, octahydroindolizinyl, hexahydroindolizinyl, octahydroquinolizinyl, hexahydroquinolizinyl, hexahydroquinolizinyl,
  • heterocyclyl groups defined and exemplified above may be fused with an aryl group as defined above.
  • Examples of such a fused heterocyclyl group include 3,4-dihydro- 2H-quinolinyl.
  • heterocyclyl groups defined and exemplified above may also be fused with a cycloalkyl group as defined above.
  • fused heterocyclyl group examples include Decahydroquinolinyl.
  • R 6 or R 7 represents a heterocyclyl group which is attached to the nitrogen atom of the group -NR 6 R 7 via a ring carbon atom thereof
  • 4- to 7-membered non-aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are preferred and 5- or 6-membered non- aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are most preferred.
  • Examples of such groups include piperidinyl, piperazinyl and tetrahydrofuranyl groups.
  • R 6 or R 7 represents a heterocyclyl group which is substituted with at least one substituent selected from Substituents ⁇ defined above and which is attached to the nitrogen atom of the group -NR 6 R 7 via a ring carbon atom thereof
  • 4- to 7-membered non-aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms which are substituted with 1 or 2 of Substituents ⁇ are preferred and 5- or 6-membered non-aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms which are substituted with 1 or 2 of Substituents ⁇ are most preferred.
  • Examples of such groups include l-ethoxycarbonylpiperidin-4-yl, 4- methylpiperazin-2-yl and 3-methyl-tetrahydrofuran-2-yl groups.
  • R 6 and R 7 represents a heterocyclyl group which is fused with a cycloalkyl group
  • 4- to 7-membered non-aromatic heterocyclic groups containing from 1 to 3 heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms fused with a cycloalkyl group having from 3 to 7 carbon atoms are preferred
  • 5- to 6- membered non-aromatic heterocyclic groups containing from 1 or 2 heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms fused with a cycloalkyl group having from 5 to 6 carbon atoms are more preferred and 6-membered non- aromatic heterocyclic groups containing one nitrogen atom fused with a cyclohexyl group are most preferred.
  • Substituent a represents a heterocyclyl group
  • 4- to 7-membered non-aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are preferred and 5- or 6-membered non- aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are most preferred.
  • Examples of such groups include morpholinyl, tetrahydrofuranyl, pyrrolidinyl and piperazinyl groups.
  • Substituent ⁇ represents a heterocyclyl group which is substituted with at least one lower alkyl group defined above
  • 4- to 7-membered non-aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms which are substituted with 1 or 2 lower alkyl groups are preferred and and 5- or 6-membered non-aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms which are substituted with 1 or 2 lower alkyl groups are most preferred.
  • Examples of such groups include 4-methylpiperazinyl and 4-ethylpiperidinyl groups.
  • R 3 or Substituent ⁇ represents a heterocyclyl group
  • 4- to 7-membered non- aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are preferred and 5- or 6- membered non-aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are most preferred.
  • Examples of such groups include piperidinyl, tetrahydrofuranyl, pyrrolidinyl and piperazinyl groups.
  • R 2 represents a group of formula -NR 6 R 7 wherein R 6 and R 7 together with the nitrogen atom to which they are attached represent a heteroaryl or heterocyclyl group which is substituted with a lower alkyl group which is itself substituted with a heterocyclyl group
  • said heterocyclyl group which is a substituent on said alkyl group is preferably a 4- to 7- membered non-aromatic heterocyclic group containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, and most preferably a 5- or 6-membered non-aromatic heterocyclic group containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, examples of which include morpholinyl, thiomorpholinyl and piperidinyl groups.
  • R 2 represents a group of formula -NR 6 R 7 wherein R 6 and R 7 together with the nitrogen atom to which they are attached represent a heterocyclyl group
  • said heterocyclyl group is a 4- to 10-membered non-aromatic heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, wherein at least one of said heteroatoms is a nitrogen atom.
  • Said heterocyclyl group is preferably a 4- to 7-membered non-aromatic heterocyclic group containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, and most preferably a 5- or 6-membered non-aromatic heterocyclic group containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms.
  • Examples of such groups include thiazolidin-3-yl, pyrrolidin-1-yl, pyrrolin- l-yl, piperidin-1-yl, piperazin-1-yl, morpholin-4-yl, thiomorpholin-1-yl, 2,5-dihydropyrrol-l- yl and decahydroquinolin-1-yl groups.
  • R 2 represents a group of formula -NR 6 R 7 wherein R 6 and R 7 together with the nitrogen atom to which they are attached represent a substituted heterocyclyl group
  • said heterocyclyl group is a 4- to 10-membered non-aromatic heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, wherein at least one of said heteroatoms is a nitrogen atom and in which said group is substituted with at least one substituent selected from the group consisting of lower alkyl groups defined above which are unsubstituted or are substituted with at least one substituent selected from the group consisting of heterocyclyl groups defined above and groups of formula -NR 4 R 5 wherein R 4 and R 5 are as defined above, aryl groups defined above which are unsubstituted or are substituted with at least one substituent selected from Substituents ⁇ defined above, aralkyl groups defined above, carboxy groups, and alkoxycarbonyl
  • it is a 4- to 7-membered non-aromatic heterocyclic group containing 1 or 2 heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, wherein at least one of said heteroatoms is a nitrogen atom and in which said group is substituted with 1 or 2 of the above substituents, and most preferably a 5- or 6-membered non-aromatic heterocyclic group containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, wherein at least one of said heteroatoms is a nitrogen atom and in which said group is substituted with 1 or 2 of the above substituents.
  • Examples of such groups include 4-methylpiperidin-l-yl, 2,6-dimethyl-morpholin-4- yl, 4-methylpiperazin-l-yl, 4-(2-dimethylaminoethyl)-piperazin-l-yl, 4-[2-(morpholin-4- yl)ethyl]piperazin-l-yl, 4-phenylpiperazin-l-yl, 4-(2-morpholin-4-yl-ethyl)piperazin-l-yl, 4- (3 -trifluoromethylphenyl)piperazin- 1 -yl, 4-(2-methoxyphenyl)-piperazin- 1 -yl, 4- benzylpiperazin-1-yl and 4-ethoxycarbonylpiperidin-l-yl groups.
  • Substituent ⁇ , Substituent ⁇ or Substituent ⁇ represents a lower alkyl group, or R or R represents a lower alkyl group which may optionally be substituted with at least one substituent selected from Substituents ⁇ defined above, or R 2 is a cycloalkyl group as defined above which is substituted with a lower alkyl group, or R 2 represents a group of formula -NR R 7 wherein R 6 and R 7 together with the nitrogen atom to which they are attached represent a heteroaryl or heterocyclyl group as defined above which is substituted with a lower alkyl group, or Substituent ⁇ is a heterocyclyl or heteroaryl group as defined above which is substituted with a lower alkyl group, said lower alkyl group is a straight or branched alkyl group having from 1 to 6 carbon atoms.
  • Examples of said lower alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, s-butyl, tert-butyl, n- pentyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, n-hexyl, isohexyl, 4- methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl, 2,2- dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl and 2-ethylbutyl groups. Of these groups, methyl, ethyl, n-propyl, tert-butyl 1-methylbutyl and 1-ethylpropyl groups are more preferred.
  • R 3 , R 4 , R 5 or Substituent ⁇ represents an alkylcarbonyl group
  • said group is a carbonyl group which is substituted with a lower alkyl group as defined and exemplified above.
  • alkylcarbonyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, pentanoyl, pivaloyl, valeryl and isovaleryl groups, of which acetyl groups are preferred.
  • R 3 , R 4 , R 5 or Substituent ⁇ represents an aryl group
  • R 4 or R 5 represents alkenylcarbonyl group which is substituted with aryl group
  • R 6 or R 7 represents an aryl group which is optionally substituted with at least one of Substituents ⁇
  • Substituent ⁇ is an aryl group which is optionally substituted with at least one alkoxy group
  • R 2 represents a group of formula -NR 6 R 7 wherein R 6 and R 7 together with the nitrogen atom to which they are attached represent a heterocyclyl or heteroaryl group which is substituted with an aryl group which is itself optionally substituted with at least one of Substituents ⁇
  • R 6 or R 7 represents alkenyl carbonyl group which is substituted with aryl group
  • X, Y, R 6 or R 7 represents a heterocyclyl or heteroaryl group which is fused with an aryl group
  • R 2 represents a group
  • aryl group has from 6 to 10 carbon atoms, and examples include phenyl, naphthyl, phenanthryl and anthracenyl groups. Of these, we prefer phenyl and naphthyl groups, most preferably phenyl groups.
  • aryl groups defined and exemplified above may optionally be fused with a cycloalkyl group as defined above and exemplified below or a heterocyclyl group as defined and exemplified above.
  • R 3 , R 4 , R 5 or Substituent ⁇ represents an aryl group, phenyl groups are preferred.
  • R 6 or R 7 represents an aryl group
  • phenyl and naphthalenyl groups are preferred.
  • R 6 or R 7 represents an aryl group which is substituted with at least one of Substituents ⁇
  • aromatic hydrocarbon groups having from 6 to 14 carbon atoms in one or more rings which are substituted with 1 or 2 of Substituents ⁇ are preferred
  • phenyl and naphthalenyl groups which are substituted with 1 or 2 of Substituents ⁇ are more preferred
  • phenyl groups which are substituted with 1 or 2 of Substituents ⁇ are most preferred.
  • Examples of such groups include 2-, 3-, 4-, 5- and 6-methylphenyl, 2- ,3-, 4-, 5- and 6- ethylphenyl, 2-, 3-, 4-, 5- and 6-methoxyphenyl, 2-, 3-, 4-, 5- and 6-ethoxyphenyl, 2-, 3-, 4-, 5- and 6-methylsulfanylphenyl, 2 ⁇ , 3-, 4-, 5- and 6-trifluoromethylphenyl, 2-, 3-, 4-, 5- and 6- chlorophenyl, 2-, 3-, 4-, 5- and 6-acetylphenyl, biphenyl-2-yl, biphenyl-3-yl, 2-, 3-, 4-, 5- and 6-benzyIphenyl, 2-, 3-, 4-, 5- and 6-benzyloxyphenyl, 2-, 3-, 4-, 5- and 6-(piperidin-l- yl)phenyl, 2,5-dimethoxy-phenyl, 3-methoxy-5-trifluoromethylphenyl, 2-methoxy-5- methylphenyl
  • Substituent ⁇ represents an aryl group which is optionally substituted with at least one alkoxy group as defined above, phenyl groups which are optionally substituted with 1 or 2 alkoxy groups are preferred, examples of which include phenyl and 4- methoxyphenyl groups.
  • X, Y, R 6 or R 7 represents a heterocyclyl or heteroaryl group which is fused with an aryl group said aryl group preferably has from 6 to 10 carbon atoms, and is most preferably a phenyl group.
  • R 2 represents a group of formula -NR 6 R 7 wherein R 6 and R 7 together with the nitrogen atom to which they are attached represent a heterocyclyl or heteroaryl group which is fused with an aryl group, said aryl group preferably has from 6 to 10 carbon atoms, and is most preferably a phenyl group.
  • R 2 examples include 2,3- dihydrobenzo[l ,4]-dioxin-6-yl groups.
  • Substituent ⁇ , Substituent ⁇ , Substituent ⁇ or Substituent ⁇ represents an alkoxy group
  • R 6 or R 7 represents an aralkyl group as defined above which is substituted with an alkoxy group
  • Substituent ⁇ represents an aryl group which is substituted with an alkoxy group, said alkoxy group is a lower alkyl group as defined and exemplified above which is bonded to an oxygen atom.
  • the alkoxy groups are preferably straight or branched alkoxy groups having 1 to 4 carbon atoms, more preferably methoxy, ethoxy, propoxy, isopropoxy or butoxy groups, and particularly preferably methoxy or ethoxy groups.
  • R 6 or R 7 represents a lower alkenyl group
  • said lower alkenyl group is a straight or branched alkenyl group having from 2 to 6 carbon atoms, examples of which include vinyl, allyl, l-methyl-2-propenyl, 2-methyl-2-propenyl, 2-ethyl-2-propenyl, 2- butenyl, l-methyl-2-butenyl, 2-methyl-2-butenyl, l-ethyl-2-butenyl, 3-butenyl, l-methyl-3- butenyl, 2-methy 1-3 -butenyl, 1-ethy 1-3 -butenyl, 2-pentenyl, l-methyl-2-pentenyl, 2-methyl-2- pentenyl, 3-pentenyl, l-methyl-3-pentenyl, 2-methyl-3-pentenyl, 4-pentenyl, l-methyl-4- pentenyl, 2-methyl-4-pentenyl, 2-hexeny
  • Alkenyl groups having from 2 to 4 carbon atoms are preferred, alkenyl groups having 2 or 3 carbon atoms are more preferred and allyl groups are most preferred.
  • Substituent ⁇ or Substituent ⁇ represents a cycloalkyl group or R 6 or R 7 represents a cycloalkyl group which may optionally be substituted with a lower alkyl group as defined and exemplified above
  • said cycloalkyl group is a cycloalkyl group having from 3 to 7 carbon atoms, examples of which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptanyl groups which, for R 6 or R 7 , may optionally be substituted with 1 or 2 lower alkyl groups.
  • cycloalkyl groups having from 3 to 6 carbon atoms are preferred for Susbtituents ⁇ or Substituent ⁇ and cyclopropyl groups are particularly preferred, while cycloalkyl groups having from 3 to 6 carbon atoms which are optionally substituted with an alkyl group having from 1 to 4 carbon atoms are preferred for R 6 or R 7 and cyclobutyl, cyclohexyl and 2-methylcyclohexyl groups are particularly preferred.
  • the cycloalkyl group may optionally be fused with an aryl group as defined and exemplified above, examples of which include 1,2,3,4-tetrahydronaphthalen-l-yl groups.
  • R 3 or Substituent ⁇ represents an aralkyl group
  • R 6 or R 7 represents an aralkyl group which is optionally substituted with at least one alkoxy group or haloalkyl group
  • R 2 represents a group of formula -NR 6 R 7 wherein R 6 and R 7 together with the nitrogen atom to which they are attached represents a heterocyclyl or heteroaryl group which is substituted with an aralkyl group, said aralkyl group is a lower alkyl group as defined and exemplified above which is substituted with at least one aryl group as defined and exemplified above.
  • aralkyl groups examples include benzyl, phenanthrenylmethyl, anthracenylmethyl, ⁇ -naphthylmethyl, ⁇ -naphthylmethyl, diphenylmethyl, triphenylmethyl, ⁇ -naphthyldiphenylmethyl, 9-anthrylmethyl, piperonyl, 1-phenethyl, 2-phenethyl, 1- naphthylethyl, 2-naphthylethyl, 1-phenylpropyl, 2-phenylpropyl,
  • R 3 or Substituent ⁇ represents an aralkyl group
  • alkyl groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 phenyl groups are preferred and benzyl groups are most preferred.
  • R 6 or R 7 represents an aralkyl group
  • alkyl groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 phenyl groups are preferred and benzyl, diphenylmethyl, 3, 3 -diphenylpropyl and 2-phenethyl groups are most preferred.
  • R 6 or R 7 represents an aralkyl group which is substituted with at least one substituent selected from alkoxy groups as defined and exemplified above and haloalkyl groups as defined above and exemplified below
  • alkyl groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 phenyl groups which are substituted with 1 or 2 substituents selected from alkoxy groups and haloalkyl groups are preferred and alkyl groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 phenyl groups which are substituted with 1 or 2 substituents selected from alkoxy groups having from 1 to 4 carbon atoms and haloalkyl groups having from 1 to 4 carbon atoms are more preferred, examples of which include 2-trifluoromethylbenzyl, 3,5-bis-trifluoromethyl-benzyl, 2-methoxybenzyl, 2- (2-methoxyphenyl)ethyl, 2-(3-methoxyphenyl)ethyl, 2-(
  • aryl moieties of the aralkyl groups above may be fused with a cycloalkyl group as defined and exemplified above or a heterocyclyl group as defined and exemplified above, said fused aralkyl groups including benzo[l,3]dioxol-5-ylmethyl groups.
  • Substituent ⁇ or Substituent ⁇ represents a haloalkyl group
  • R 6 or R 7 represents an aralkyl group as defined above which is substituted with a haloallcyl group
  • said haloalkyl group is a lower alkyl group as defined and exemplified above which is substituted with at least one halogen atom as exemplified below.
  • Haloalkyl groups having from 1 to 4 carbon atoms are preferred, trifluoromethyl, trichloromethyl, difluoromethyl, dichloromethyl, dibromomethyl, fiuoromethyl, 2,2,2-trichloroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl, 2- chloroethyl, 2-fluoroethyl and 2,2-dibromoethyl groups are more preferred, trifluoromethyl, trichloromethyl, difluoromethyl and fluoromethyl groups are still more preferred, and trifluoromethyl groups are most preferred.
  • Substituent ⁇ and Substituent ⁇ represents an alkoxycarbonyl group
  • R 2 represents a group of formula -NR 6 R 7 wherein R 6 and R 7 together with the nitrogen atom to which they are attached represent a heterocyclyl or heteroaryl group as defined and exemplified above which is substituted with an alkoxycarbonyl group
  • Substituent ⁇ represents a heteroaryl group as defined and exemplifed above which is substituted with an alkoxycarbonyl group
  • said alkoxycarbonyl group is a carbonyl group which is substituted with an alkoxy group as defined and exemplified above.
  • Examples of such groups include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, s-butoxycarbonyl, tert- butoxycarbonyl and isobutoxycarbonyl groups, of which methoxycarbonyl and ethoxycarbonyl groups are preferred.
  • Substituent ⁇ represents an arylamino group
  • this is an amino group which is substituted with an aryl group as defined and exemplified above, examples of which include phenylamino groups.
  • R 3 or Substituent ⁇ represents an alkylthio group
  • said alkylthio group is a lower alkyl group as defined and exemplified above which is bonded to a sulfur atom.
  • the alkylthio groups preferably have from 1 to 4 carbon atoms, and are more preferably selected from the group consisting of methylthio and ethylthio groups.
  • halogen atoms in the definition of R 3 and Substituent group ⁇ or Substituent group ⁇ include fluorine, chlorine, bromine and iodine atoms, of which fluorine and chlorine atoms are preferred and chlorine atoms are most preferred.
  • R 3 or Substituent ⁇ represents an aralkyloxy group
  • said aralkyloxy group is an alkoxy group as defined and exemplified above which is substituted with at least one aryl group as defined and exemplified above, examples of which include benzyloxy groups.
  • Substituent ⁇ represents an aryloxy group
  • said aryloxy group is an aryl group as defined and exemplified above which is bonded to an oxygen atom.
  • the aryloxy groups are preferably phenyloxy group.
  • Substituent ⁇ represents an alkylcarbonyloxy group
  • said alkylcarbonyloxy group is an alkylcarbonyl groupsas defined and exemplified above which is bonded to an oxygen atom.
  • the alkylcarbonyl groups are preferably acetyloxy group.
  • R 4 or R 5 represents an arylcarbonyl group
  • said arylcarbonyl group is a carbonyl group which is substituted with an aryl group as defined and exemplified above.
  • the arylcarbonyl groups are preferably benzoyl group.
  • R 4 or R 5 represents a heteroarylcarbonyl group
  • said heteroarylcarbonyl group is a carbonyl group which is substituted with a heteroaryl group as defined and exemplified above.
  • the heteroarylcarbonyl groups are preferably furylcarbonyl, thienylcarbonyl and pyridylcarbonyl groups.
  • R 4 or R 5 represents a cycloalkylcarbonyl group
  • said cycloalkylcarbonyl group is a carbonyl groups which are substituted with a cycloalkyl group as defined and exemplified above.
  • the cycloalkylcarbonyl groups are preferably cycloalkyl groups having from 3 to 6 carbon atoms.
  • R 4 or R 5 represents an alkenylcarbonyl group which may be substituted with aryl group
  • said alkenylcarbonyl group is carbonyl group which is substituted with an alkenyl group as defined and exemplified above.
  • the alkenylcarbonyl groups are preferably an alkenylcarbonyl groups having from 3 to 5 carbon atoms which may be substituted with aryl group, more preferably an alkenylcarbonyl groups having 3 or 4 carbon atoms which may be substituted with phenyl or naphthyl group, and most preferably an allyl groups which may be substituted with phenyl group.
  • the compound of formula (I) of the present invention have a basic group, such as an amino group
  • the compound can be converted to a salt by reacting it with an acid
  • the compounds of formula (I) of the present invention have an acidic group, such as a carboxy group
  • the compound can be converted to a salt by reacting it with a base.
  • the compounds of the present invention encompass such salts.
  • said salts are to be used for a therapeutic use, they must be pharmacologically acceptable, i.e. on administration of said salt to the body of a live mammal they must have a similar activity to the compound of formula (I) and have a similar toxicity.
  • Preferred examples of the salts formed with a basic group present in the compound of formula (I) of the present invention include inorganic acid salts such as hydrohalogenated acid salts (e.g. hydrochlorides, hydrobromides and hydroiodides), nitrates, perchlorates, sulfates and phosphates; organic acid salts such as lower alkanesulfonates in which the lower alkyl moiety thereof is as defined above (e.g. methanesulfonates, trifluoromethanesulfonates and ethanesulfonates), arylsulfonates in which the aryl moiety thereof is as defined above (e.g.
  • benzenesulfonate or p-toluenesulfonate acetates, malates, fumarates, succinates, citrates, ascorbates, tartrates, oxalates and maleates; and amino acid salts such as glycine salts, lysine salts, arginine salts, ornithine salts, glutamates and aspartates.
  • Preferred example of the salts formed with an acidic group present in the compound of formula (I) of the present invention include metal salts such as alkali metal salts (e.g. sodium salts, potassium salts and lithium salts), alkali earth metal salts (e.g. calcium salts and magnesium salts), aluminum salts and iron salts; amine salts such as inorganic amine salts (e.g. ammonium salts) and organic amine salts (e.g.
  • t-octylamine salts dibenzylamine salts, morpholine salts, glucosamine salts, phenylglycinealkyl ester salts, ethylenediamine salts, N- methylglucamine salts, guanidine salts, diethylamine salts, triethylamine salts, dicyclohexylamine salts, N,N'-dibenzylethylenediamine salts, chloroprocaine salts, procaine salts, diethanolamine salts, N-benzylphenethylamine salts, piperazine salts, tetramethylammonium salts and tris(hydroxymethyl)aminomethane salts; and amino acid salts such as glycine salts, lysine salts, arginine salts, ornithine salts, glutamates and aspartates.
  • amino acid salts such as glycine salts, lysine salts, arginine
  • the compounds of formula (I) of the present invention can sometimes take up water upon exposure to the atmosphere or when recrystallized to absorb water or to form a hydrate and such hydrates are also included within the scope of the present invention. Additionally, certain other solvents may be taken up by the compounds of the present invention to produce solvates, which also form a part of the present invention.
  • the compounds of formula (I) of the present invention can sometimes exist in the form of geometrical isomers (cis and trans isomers) and, where said compounds contain one or more asymmetric centres, optical isomers.
  • each of said isomers and mixture of said isomers are depicted by a single formula, i.e. the formula (I). Accordingly, the present invention covers both the individual isomers and mixtures thereof in any proportion, including racemic mixtures.
  • Preferred classes of compounds of the present invention are those compounds of formula (I) and pharmacologically acceptable salts thereof wherein:
  • X represents a phenyl group which is substituted with 1 of substituents R 1 or X represents a pyridine group or a pyrimidine group;
  • X represents a phenyl group which is substituted with 1 of substituents R 1 , wherein R 1 is selected from the group consisting of nitro groups and groups of formula - NR 4 R 5 wherein R 4 andR 5 are the same or different and each is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 4 carbon atoms, alkylcarbonyl groups the alkyl moiety thereof having from 1 to 4 carbon atoms and aryl groups having from 6 to 10 carbon atoms or X represents a pyridine group;
  • X represents a phenyl group which is substituted with a group of formula -NR 4 R 5 wherein R 4 andR 5 are the same or different and each is selected from the group consisting of hydrogen atoms, methyl groups, ethyl groups, acetyl groups and phenyl groups or X represents a pyridine group;
  • X represents a phenyl group which is substituted with a substituent selected from the group consisting of amino, methylamino, dimethylamino and acetylamino groups or X represents a pyridine group;
  • X is selected from the group consisting of 4-aminophenyl, 4-acetylamino and 4-dimethylamino groups;
  • Y represents a phenyl group which is optionally substituted with 1 or 2 of substituents R 3 ;
  • Y represents a phenyl group which is optionally substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, haloallcyl groups having from 1 to 4 carbon atoms and phenyl groups;
  • Y represents a phenyl group which is substituted with a substituent selected from the group consisting of methyl, ethyl, tert-butyl and trifluoromethyl groups; (9) Y represents a 4-tert-butylphenyl group or a 4-trifluoromethylphenyl group;
  • R 2 is selected from the group consisting of hydroxy groups, alkoxy groups having from 1 to 6 carbon atoms and groups of formula -NR 6 R 7 wherein R 6 and R 7 are the same or different and each is selected from the group consisting of: hydrogen atoms; alkyl groups having from 1 to 6 carbon atoms which are optionally substituted with 1 or 2 of Substituents ⁇ 1 defined below; alkenyl groups having from 2 to 4 carbon atoms; cycloalkyl groups having from 3 to 6 carbon atoms which are optionally substituted with an alkyl group having from 1 to 4 carbon atoms, said cycloalkyl groups optionally being fused with an aryl group having from 6 to 10 carbon atoms; groups of formula -NR 4 R 5 wherein R 4 andR 5 are the same or different and each is selected from the group consisting of hydrogen atoms and aryl groups having from 6 to 10 carbon atoms; aryl groups having from 6 to 10 carbon atoms which are optionally substituted with
  • heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heterocyclyl groups optionally being substituted with 1 or 2 of Substituents ⁇ 1 defined below;
  • heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heteroaryl groups optionally being substituted with 1 or 2 of Substituents ⁇ 1 defined below and further optionally being fused with an aryl group having from 6 to 10 carbon atoms; or R 6 and R 7 together with the nitrogen atom to which they are attached represent a 4- to 7-membered heterocyclyl group or a 5- or 6-membered heteroaryl group, said heterocyclyl and heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, said heterocyclyl and heteroaryl groups optionally being substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to' 4 carbon atoms which are optionally substituted with 1 or 2 substituents selected from the group consisting of groups of formula -NR 4 R 5 wherein R 4 andR 5
  • Substituents ⁇ 1 are selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms, cycloalkyl groups having from 3 to 6 carbon atoms, 4- to 7-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with 1 or 2 alkyl groups having from 1 to 4 carbon atoms, and 5- or 6-membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms and alkoxycarbonyl groups the alkoxy moiety thereof having from 1 to 4 carbon atoms;
  • Substituents ⁇ 1 are selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, alkylthio groups having from 1 to 4 carbon atoms, haloalkyl groups having from 1 to 4 carbon atoms, halogen atoms, alkylcarbonyl groups the alkyl moiety thereof having from 1 to 4 carbon atoms, aryl groups having from 6 to 10 carbon atoms which are unsubstituted or are substituted with 1 or 2 alkoxy groups having from 1 to 4 carbon atoms, alkyl groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 aryl groups having from 6 to 10 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 aryl groups having from 6 to 10 carbon atoms, 4- to 7-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur
  • Substituents ⁇ 1 are selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, carboxy groups and alkoxycarbonyl groups the alkoxy moiety thereof having from 1 to 4 carbon atoms;
  • Substituents ⁇ 1 are selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms and haloalkyl groups having from 1 to 4 carbon atoms;
  • R 2 is selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms and groups of formula -NR 6 R 7 wherein R 6 and R 7 are the same or different and each is selected from the group consisting of: hydrogen atoms; alkyl groups having from 1 to 6 carbon atoms which are optionally substituted with 1 or 2 of Substituents ⁇ 2 defined below; alkenyl groups having from 2 to 4 carbon atoms; cycloalkyl groups having from 4 to 6 carbon atoms which are optionally substituted with an alkyl group having from 1 to 4 carbon atoms, said cycloalkyl groups optionally being fused with a phenyl group; groups of formula -NR 4 R 5 wherein R 4 andR 5 are the same or different and each is selected from the group consisting of hydrogen atoms and phenyl groups; aryl groups having from 6 to 10 carbon atoms which are optionally substituted with 1 or 2 of Substituents ⁇ 2 defined below and which are further
  • heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heteroaryl groups optionally being substituted with 1 or 2 of Substituents ⁇ 2 defined below and further optionally being fused with a phenyl group;
  • R 6 and R 7 together with the nitrogen atom to which they are attached represent a 5- or 6-membered heterocyclyl or heteroaryl group, said heterocyclyl and heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, said heterocyclyl and heteroaryl groups optionally being substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms which are optionally substituted with a group of formula -NR 4 R 5 wherein R 4 and R 5 are the same or different and each is an alkyl group having from 1 to 4 carbon atoms, or a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, aryl groups having from 6 to 10 carbon atoms which are optionally substituted with a Substituent ⁇ 2 defined below, alkyl groups having from 1 to 4 carbon
  • Substituents ⁇ 2 are selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms, cyclopropyl groups, cyclobutyl groups, 5- or 6-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with an alkyl group having from 1 to 4 carbon atoms, and 5- or 6-membered heteroaryl groups having 1 or 2 ' heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms and alkoxycarbonyl groups the alkoxy moiety thereof having from 1 to 4 carbon atoms;
  • Substituents ⁇ 2 are selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, alkylthio groups having from 1 to 4 carbon atoms, haloalkyl groups having from 1 to 4 carbon atoms, fluorine atoms, chlorine atoms, alkylcarbonyl groups the alkyl moiety thereof having from 1 to 4 carbon atoms, aryl groups having from 6 to 10 carbon atoms which are unsubstituted or are substituted with an alkoxy group having from 1 to 4 carbon atoms, alkyl groups having from
  • Substituents ⁇ 2 are selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms and alkoxycarbonyl groups the alkoxy moiety thereof having from 1 to 4 carbon atoms;
  • Substituents ⁇ 1 are selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms and haloalkyl groups having from 1 to 4 carbon atoms;
  • R 2 is selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms and groups of formula -NR 6 R 7 wherein R 6 and R 7 are the same or different and each is selected from the group consisting of: hydrogen atoms; alkyl groups having from 1 to 6 carbon atoms which are optionally substituted with a Substituent ⁇ 3 defined below; allyl groups; cycloalkyl groups having from 4 to 6 carbon atoms which are optionally substituted with a methyl or ethyl group, said cycloalkyl groups optionally being fused with a phenyl group; phenylhydrazido groups; phenyl and naphthyl groups and phenyl groups which are optionally substituted with 1 or 2 of Substituents ⁇ 3 defined below and which are further optionally fused with a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms; alkyl
  • phenyl groups and benzyl and phenethyl groups which are substituted with 1 or 2 substituents selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms and haloalkyl groups having from 1 to 4 carbon atoms, the phenyl groups of these aralkyl groups optionally further being fused with a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms;
  • heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heterocyclyl groups optionally being substituted with a methoxycarbonyl or ethoxycarbonyl group;
  • 5- or 6- membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heteroaryl groups optionally being substituted with 1 or 2 of Substituents ⁇ 2 defined above and further optionally being fused with a phenyl group; or R 6 and R 7 together with the nitrogen atom to which they are attached represent a 5- or 6-membered heteroaryl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, or a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, said heterocyclyl group optionally being substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms which are optionally substituted with a group of formula -NR 4 R 5 wherein R
  • Substituents ⁇ 3 are selected from the group consisting of methoxy groups, ethoxy groups, cyclopropyl groups, cyclobutyl groups, 5- or 6-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with a methyl or ethyl group, and 5- or 6- membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, methoxycarbonyl groups and ethoxycarbonyl groups; and
  • Substituents ⁇ 3 are selected from the group consisting of methyl groups, ethyl groups, methoxy groups, ethoxy groups, methylthio groups, ethylthio groups, methyl or ethyl groups which are substituted with from 1 to 3 fluorine or chlorine atoms, fluorine atoms, chlorine atoms, acetyl groups, propionyl groups, phenyl groups which are unsubstituted or are substituted with a methoxy or ethoxy group, benzyl groups, benzyloxy and 5- or 6-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms;
  • R is selected from the group consisting of methoxy groups, ethoxy groups and groups of formula -NR 6 R 7 wherein R 6 and R 7 are the same or different and each is selected from the group consisting of: hydrogen atoms; methyl, ethyl, 1-methylbutyl and 1-ethylpropyl groups, methyl, ethyl and propyl groups substituted with a Substituent ⁇ 4 defined below; allyl groups; cyclobutyl and cyclohexyl groups which are optionally substituted with a methyl group, said cyclobutyl and cyclohexyl groups optionally being fused with a phenyl group; phenylhydrazido groups; phenyl and naphthyl groups and phenyl groups which are optionally substituted with 1 or 2 of Substituents ⁇ 4 defined below and which are further optionally fused with a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms
  • heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen and oxygen atoms, said heterocyclyl groups optionally being substituted with a methoxycarbonyl or ethoxycarbonyl group;
  • heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heteroaryl groups optionally being substituted with 1 or 2 substituents selected from the group consisting of methyl, ethyl, methoxycarbonyl and ethoxycarbonyl groups and said heteroaryl groups further optionally being fused with a phenyl group;
  • nitrogen atom to which they are attached represent a 5- or 6-membered heteroaryl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, or a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, said heterocyclyl group optionally being substituted with 1 or 2 substituents selected from the group consisting of methyl and ethyl groups which are optionally substituted with a dimethylamino group or a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen and oxygen atoms, phenyl groups which are optionally substituted with a substituent selected from the group consisting of methoxy, ethoxy and trifluoromethyl groups, benzyl groups, and methoxycarbonyl and ethoxy
  • Substituents ⁇ 4 are selected from the group consisting of methoxy groups, cyclopropyl groups, 5- or 6-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen and oxygen atoms which are unsubstituted or are substituted with a methyl group, and 5- or 6-membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen and sulfur atoms which are unsubstituted or are substituted with 1 or 2 substituents selected from the group consisting of methyl groups and methoxycarbonyl groups; and
  • Substituents ⁇ 4 are selected from the group consisting of methyl groups, methoxy groups, ethoxy groups, trifluoromethyl groups, methylthio groups, chlorine atoms, acetyl groups, phenyl groups which are unsubstituted or are substituted with a methoxy group, benzyl groups, benzyloxy groups and 5- or 6-membered heterocyclyl groups having 1 or 2 nitrogen heteroatoms; (14) R 2 is selected from the group consisting of ethoxy groups and groups of formula -NR 6 R 7 wherein R 6 and R 7 are the same or different and each is selected from the group consisting of: hydrogen atoms; methyl, ethyl, 1-methylbutyl and 1-ethylpropyl groups, 2-methoxyethyl, cyclopropylmethyl, 3-(morpholin-4-yl)propyl, tetrahydrofuran-2- ylmethyl, 2-(pyrrolidin-l-yl)eth
  • 2,3-dihydrobenzo[l ,4]dioxin-6-yl groups benzyl, diphenylmethyl and 3, 3 -diphenylpropyl groups; 2-trifluoromethylbenzyl, 3,5-bis-trifluoromethylbenzyl, 2-methoxybenzyl, 2-(2- methoxyphenyl)ethyl, 2-(3-methoxyphenyl)ethyl, 2-(4-methoxyphenyl)ethyl and 2,6- dimethoxybenzyl groups; benzofl ,3]dioxol-5-ylmethyl groups, 1 -ethoxycarbonylpiperidin-4-yl groups; thiazol-2-yI groups;
  • R 2 is selected from the group consisting of ethoxy groups and groups of formula -NR 6 R 7 wherein R 6 and R 7 are the same or different and each is selected from the group consisting of: hydrogen atoms, methyl groups, thiophen-2-ylmethyl groups, cyclobutyl groups, phenyl groups, naphthyl groups, 2-methoxyphenyl groups, 4-methoxyphenyl groups, 3-ethoxyphenyl groups, 3-methylsulfanylphenyl groups, 4-chlorophenyl groups, biphenyl-2- yl groups, 3-benzyloxyphenyl groups, 4-(piperidin-l-yl)phenyl groups, 2,5-dimethoxyphenyl groups, 3 -methoxy-5 -trifluoromethylphenyl groups, 2-methoxy-5-methylphenyl groups, 2- trifluoromethylbenzyl groups, l-ethoxycarbonylpiperidin-4-yl groups, thiazol-2-yl
  • More preferred classes of compounds of the present invention are those compounds of formula (I) and pharmacologically acceptable salts thereof wherein:
  • X is as defined in (1) above, Y is as defined in (6) above and R 2 is as defined in (10) above;
  • Particularly preferred compounds of the present invention are those compounds of formula (I) and pharmacologically acceptable salts thereof selected from the group consisting of:
  • the compounds of formula (I) and pharmacologically acceptable salts thereof of the present invention can be prepared according to a variety of processes well known in the art for the preparation of compounds of this type, for example as described in the following methods A to F below.
  • X a represents a substituent selected from the group consisting of phenyl groups, heteroaryl groups as defined above and heterocyclyl groups as defined above, in which said substituent is substituted with a nitro group or X a represents a pyridine group or a pyrimidine group; Yis as defined above; R 2a represents an alkyl group having from 1 to 6 carbon atoms; and L 1 and L 2 are leaving groups.
  • the leaving group L 1 is a group which is capable of leaving as a nucleophilic residue.
  • examples include halogen atoms such as fluorine, chlorine, bromine and iodine, trihalogenomethyloxy groups such as trichloromethoxy, lower alkanesulfonyloxy groups such as methanesulfonyloxy and ethanesulfonyloxy groups, lower halogeno allcane sulfonyloxy groups such as trifluoromethanesulfonyloxy and pentafluoroethanesulfonyloxy groups, and arylsulfonyloxy groups such as benzenesulfonyloxy, p-toluenesulfonyloxy and p- nitrobenzenesulfonyloxy groups.
  • halogen atoms are preferred, and chlorine atoms are particularly preferred.
  • the reaction is preferably performed in the presence of an organic base as a catalyst, e.g. triethylamine.
  • the reaction is normally and preferably effected in the presence of a solvent.
  • a solvent there is no particular restriction on the solvent used, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent.
  • suitable solvents include: halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and dichloroethane; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane; aprotic polar solvents such as dimethylformamide, dimethylacetamide and dimethylsulfoxide; nitriles such as acetonitrile; esters such as methyl acetate and ethyl acetate; aromatic hydrocarbons such as benzene, toluene and xylene; aliphatic hydrocarbons such as pentane, hexane and heptane;
  • the reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention.
  • the preferred reaction temperature will depend upon such factors as the nature of the solvent, and the starting material or reagent used. However, in general, we find it convenient to carry out the reaction at a temperature of from -78°C to 100°C, more preferably from -78°C to room temperature, and most preferably at 0°C to room temeperature.
  • the time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 10 minutes to 24 hours, more preferably from 1 hour to 20 hours, and most preferably from 1 to 5 hours will usually suffice.
  • Lawesson's reagent as a thiating reagent is well-known in the field of synthetic organic chemistry [see, for example, Bull. Soc. Chim. Belg., 87, 223, 229, 299, 525 (1978); Synthesis, 941 (1979); and Tetrahedron, 35, 2433 (1979)] and this step can be performed in conventional manner.
  • This step involves reaction of the compound of formula (V), produced in Step A2 above, with trimethyloxonium tetrafluoroborate to give a compound of formula (VI) in which the thioamide moiety has been converted to a methylsulfanylmethylenimino moiety.
  • trimethyloxonium tetrafluoroborate to effect this conversion is well-known in the field of synthetic organic chemistry and the reaction can be performed using these well- known techniques [see, for example, Yokoyama et al., Synthesis, 1994, 1467-1470; Gompper et al., Angew. Chem., 95(9), 1983, 727-729; Casadei et al., Synth.
  • the reaction is normally and preferably effected in the presence of a solvent.
  • a solvent there is no particular restriction on the solvent used, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent.
  • suitable solvents include: halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and dichloroethane; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane; aprotic polar solvents such as dimethylformamide, dimethylacetamide and dimethylsulfoxide; nitriles such as acetonitrile; esters such as methyl acetate and ethyl acetate; aromatic hydrocarbons such as benzene, toluene and xylene; aliphatic hydrocarbons such as pentane, hexane and heptane;
  • the reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention.
  • the preferred reaction temperature will depend upon such factors as the nature of the solvent, and the starting material or reagent used. However, in general, we find it convenient to carry out the reaction at a temperature of from -78°C to 100°C, more preferably from -78°C to room temperature, and most preferably at 0°C to room temeperature.
  • the time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 10 minutes to 24 hours, more preferably from 1 hour to 20 hours, and most preferably from 1 to 5 hours will usually suffice.
  • This step involves reaction of the compound of formula (NI), prepared as described in Step A3 above, with a compound of formula (VII), in which X a and L 2 are as defined above, in the presence of a base to give the desired oxazole derivative of formula (la) of the present invention, in which Y, X a and R 2 are as defined above.
  • This reaction involves reaction of the compound of formula (VI) with the compound of formula (VII) via enolised intermediates in which the leaving group L 2 is first eliminated and then cyclisation takes place to give the compound of formula (la).
  • the leaving group L 2 is a group which is capable of leaving as a nucleophilic residue, examples of which are as given for L 1 above. Halogen atoms are preferred and chlorine atoms are particularly preferred.
  • the base used can be any which is typically used in such reactions, examples of which include organic bases such as organic amines, and triethylamine is particularly preferred.
  • the reaction is normally and preferably effected in the presence of a solvent.
  • a solvent there is no particular restriction on the solvent used, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent.
  • suitable solvents include: halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and dichloroethane; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane; aprotic polar solvents such as dimethylformamide, dimethylacetamide and dimethylsulfoxide; nitriles such as acetonitrile; esters such as methyl acetate and ethyl acetate; aromatic hydrocarbons such as benzene, toluene and xylene; aliphatic hydrocarbons such as pentane, hexane and heptane;
  • the reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention.
  • the preferred reaction temperature will depend upon such factors as the nature of the solvent, and the starting material or reagent used. However, in general, we find it convenient to carry out the reaction at a temperature of from -78°C to 100°C, more preferably from 0°C to 100°C, and most preferably at 0°C to room temeperature.
  • the time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 10 minutes to 24 hours, more preferably from 1 hour to 20 hours, and most preferably from 5 to 10 hours will usually suffice.
  • Y, X and R 2a are as defined above, R 6 and R 7a are the same as R 6 and R 7 defined above or are a protected version thereof in which a functional group present therein is protected by a protecting group and X represents a substituent selected from the group consisting of phenyl groups, heteroaryl groups as defined above and heterocyclyl groups as defined above, in which said substituent is substituted with an amino group.
  • This step involves hydrolysis of the ester group CO 2 R 2a present in the compound of formula (la), prepared as described in Step A4 above, to give a compound of formula (lb) of the present invention.
  • the hydrolysis of an ester to give a free carboxyl group is well-known in the field of synthetic organic chemistry and can be performed using well- known techniques.
  • the hydrolysis reaction can be performed in the presence of a base or an acid.
  • the acid include hydrochloric acid, sulfuric acid, phosphoric acid and hydrobromic acid; where a base is used, it is not particularly limited, provided that it does not affect other parts of the compound, and preferred examples include alkali metal carbonates such as sodium carbonate and potassium carbonate, alkali metal hydroxides such as sodium hydroxide and potassium hydroxide or a cone, ammonia-methanol solution. Alkali metal hydroxides are particularly preferred.
  • the solvent employable here is not particularly limited, provided that it is one usually used in hydrolysis reactions and does not inhibit the reaction, and preferred examples thereof include alcohols, e.g. methanol, ethanol or n-propanol, or ethers, e.g. tetrahydrofuran or dioxane, or mixtures thereof. Where an alkali metal hydroxide is employed, alcohols such as methanol or ethanol or mixtures thereof with an ether such as tetrahydrofuran are particularly preferred.
  • reaction temperature and time vary depending on the starting material, the solvent, the reagent used, etc. and are not particularly limited, the reaction is usually carried out at a temperature of from 0°C to 150°C, preferably room temperature to 100°C, for a period of from 30 minutes to 10 hours and preferably from 1 to 5 hours.
  • This step involves reaction of the compound of formula (lb) of the present invention, prepared as described in Step Bl above, with an amine of formula R 6a R 7a NH, wherein R 6 andR 7a are as defined above to give an amide of formula (Ic) of the present invention.
  • This conversion of a carboxylic acid to an amide by reaction with an amine is well-known in the field of synthetic organic chemistry and can be performed using any of the well-known techniques.
  • the carboxylic acid of formula (lb) can be reacted with the amine of formula R 6 R 7 NH in the presence of an amidation catalyst such as 2-chloro-l,3- dimethyl-2-imidazolinium chloride.
  • solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane; aprotic polar solvents such as dimethylformamide, dimethylacetamide and dimethyl sulfoxide; nitriles such as acetonitrile; esters such as methyl acetate and ethyl acetate; aromatic hydrocarbons such as benzene, toluene and xylene; aromatic heterocyclic compounds such as pyridine; and aliphatic hydrocarbons such as pentane, hexane and heptane; and mixtures thereof.
  • Aromatic heterocyclic compounds such as pyridine and nitriles such as acetonitrile, and mixtures thereof are particularly preferred.
  • reaction temperature and time vary depending on the starting material, the solvent, the reagent used, etc. and are not particularly limited, the reaction is usually carried out at a temperature of from 0°C to 150°C, preferably room temperature to 100°C, for a period of from 30 minutes to 30 hours and preferably from 1 to 24 hours.
  • This step involves reduction of the nitro group present in the substituent X a in the compound of formula (Ic), prepared as described in Step B2 above, to an amino group to give a compound of formula (Id).
  • This reduction reaction can be performed according using any conventional technique for the conversion of a nitro group to an amino group, e.g. hydrogenation in the presence of a hydrogenation catalyst such as palladium on activated carbon.
  • a hydrogenation catalyst such as palladium on activated carbon.
  • the reaction is usually and preferably performed in the presence of a solvent.
  • a solvent there is no particular restriction on the solvent used, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent.
  • suitable solvents include: ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane; aprotic polar solvents such as dimethylformamide, dimethylacetamide and dimethyl sulfoxide; nitriles such as acetonitrile; esters such as methyl acetate and ethyl acetate; aromatic hydrocarbons such as benzene, toluene and xylene; and aliphatic hydrocarbons such as pentane, hexane and heptane; and mixtures thereof.
  • Esters such as methyl acetate and ethyl acetate are particularly preferred.
  • reaction temperature and time vary depending on the starting material, the solvent, the reagent used, etc. and are not particularly limited, the reaction is usually carried out at a temperature of from 0°C to 100°C, preferably 0°C to room temperature, for a period of from 30 minutes to 30 hours and preferably from 1 to 24 hours.
  • X a , X b , Y, R 2a , R 6a andR 7a are as defined above and X c represents a substituent selected from the group consisting of phenyl groups, heteroaryl groups as defined above and heterocyclyl groups as defined above, in which said substituent is substituted with a group of formula -NHR 10 wherein R 10 represents a lower alkyl group as defined above or an aryl group as defined above.
  • the amino group of X b is to be converted to a monoalkylamino group
  • this can be performed using any technique known in synthetic organic chemistry for such a reaction.
  • the compound of formula (le) can be reacted with a trialkyloxonium tetrafluoroborate.
  • the reaction is normally and preferably effected in the presence of a solvent. There is no particular restriction on the solvent used, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent.
  • Suitable solvents include: halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and dichloroethane; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane; aprotic polar solvents such as dimethylformamide, dimethylacetamide and dimethylsulfoxide; nitriles such as acetonitrile; esters such as methyl acetate and ethyl acetate; aromatic hydrocarbons such as benzene, toluene and xylene; aliphatic hydrocarbons such as pentane, hexane and heptane; and mixtures thereof. Of these, we prefer halogenated hydrocarbons and particularly prefer dichloromethane.
  • halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and dichloroethane
  • ethers such
  • the reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention.
  • the preferred reaction temperature will depend upon such factors as the nature of the solvent, and the starting material or reagent used. However, in general, we find it convenient to carry out the reaction at a temperature of from -78°C to 100°C, more preferably from 0°C to 100°C, and most preferably at 0°C to room temperature.
  • the time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 10 minutes to 24 hours, more preferably from 1 hour to 20 hours, and most preferably from 1 to 5 hours will usually suffice.
  • An alternative for conversion of the amino group of X b to a monoalkylamino group involves reaction of the compound of formula (le) with a lcetone of formula R 8 R 9 CO, wherein R 8 and R 9 are the same or different and each represents an alkyl group having from 1 to 3 carbon atoms, provided that R 8 and R 9 do not both represent a propyl group, to give an imine intermediate which is then reduced to give a compound of formula (If) in which the group of formula -NHR 10 is a branched monoalkylamino group.
  • This is a standard technique in synthetic organic chemistry and can be performed using any technique known for such a reaction [see, for example, Horner et al., Can. J. Chem.
  • amino group of X b is to be converted to a monoarylamino group
  • this can be performed using any technique known in synthetic organic chemistry for such a reaction.
  • suitable techniques are described in Rivas et al., Tetrahedron, Asymmetry, 11, 8, 2000, 1703; Swamy et al., Bioorg. Med. Chem. Lett., 10, 4, 2000, 361; Edmondson et al., Org. Lett., 2, 8, 2000, 1109; Mugrage et al., 41, 13, 2000, 2047; and Prashad et al., J. Org. Chem., 65, 8, 2000, 2612.
  • This step involves hydrolysis of the ester group CO 2 R 2a present in the compound of formula (If), prepared as described in Step C2 above, to give a compound of formula (Ig) of the present invention.
  • This hydrolysis step is performed in a similar manner to that described in Step Bl above.
  • This step involves reaction of the compound of formula (Ig) of the present invention, prepared as described in Step C3 above, with an amine of formula R 6a R 7a NH, wherein R 6a andR 7a are as defined above to give an amide of formula (Ih) of the present invention.
  • This step is performed in a similar manner to that described in Step B2 above.
  • X b , Y, R 2a , R 6a and R 7a are as defined above and X d represents a substituent selected from the group consisting of phenyl groups, heteroaryl groups as defined above and heterocyclyl groups as defined above, in which said substituent is substituted with a group of formula -N(R 12 ) 2 wherein each R 2 is the same or different and represents a lower alkyl group as defined above or an aryl group as defined above.
  • This step involves reaction of a compound of formula (le), prepared as described in Step CI above, with a dialkylating or diarylating reagent to give a compound of formula (Ii) in which the amino group of the moiety X b has been converted to a dialkylamino group or diarylamino group of formula -N(R 12 ) 2 .
  • the amino group of X is to be converted to a dialkylamino group
  • this can be performed using any technique known in synthetic organic chemistry for such a reaction.
  • the compound of formula (le) can be reacted with an aldehyde of formula R ⁇ CHO where R 11 is a hydrogen atom or an alkyl group having from 1 to 5 carbon atoms followed by catalytic reduction of the imino groups thus formed to give the desired dialkylamino compound.
  • R 11 is a hydrogen atom or an alkyl group having from 1 to 5 carbon atoms
  • an alcoholic solution of the compound of formula (le) can be reacted with formaldehyde and hydrogen in the presence of a hydrogenation catalyst such as palladium on activated carbon to give a compound of formula (Ii) in which the amino group of the moiety X b has been converted to a dimethylamino group.
  • a hydrogenation catalyst such as palladium on activated carbon
  • the amino group of the substituent X b in the compound of formula (le) is to be converted to a dialkylamino group
  • this can be performed by reacting the compound of formula (le) with a group of formula R 13 -L 4 wherein R 13 is a lower alkyl group as defined above and L 4 is a group which is capable of leaving as a nucleophilic residue, examples of which are as given for L above.
  • R 13 is a lower alkyl group as defined above
  • L 4 is a group which is capable of leaving as a nucleophilic residue, examples of which are as given for L above.
  • This step involves hydrolysis of the ester group CO 2 R 2a present in the compound of formula (Ii), prepared as described in Step Dl above, to give a compound of formula (Ij) of the present invention.
  • This hydrolysis step is performed in a similar manner to that described in Step B 1 above.
  • This step involves reaction of the compound of formula (Ij) of the present invention, prepared as described in Step D2 above, with an amine of formula R 6a R 7a NH, wherein R 6a an R 7a are as defined above to give an amide of formula (Ik) of the present invention.
  • This step is performed in a similar manner to that described in Step B2 above.
  • X b , Y, R 2a , R 6a andR 7 are as defined above and X e represents a substituent selected from the group consisting of phenyl groups, heteroaryl groups as defined above and heterocyclyl groups as defined above, in which said substituent is substituted with a group of formula -NHCOR 14 wherein R 14 is a lower alkyl group as defined above, aryl group as defined above, heteroaryl group as defined above or cycloalkyl group as defined above and L 3 is a leaving group.
  • Step El involves reaction of a compound of formula (le), prepared as described in Step CI above, with an acylating agent of formula R 14 COL 3 to give a compound of formula (II) in which the amino group of the moiety X b has been converted to an acylamino group of formula -NHCOR 14 .
  • L 3 is a group which is capable of leaving as a nucleophilic residue, examples of which are as given for L 1 above.
  • L 3 is a halogen atom, and most preferably a chlorine atom.
  • the reaction is performed in the presence of an organic amine as a catalyst, e.g. pyridine.
  • an organic amine as a catalyst, e.g. pyridine.
  • the reaction is normally and preferably effected in the presence of a solvent.
  • a solvent there is no particular restriction on the solvent used, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent.
  • suitable solvents include: halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and dichloroethane; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane; aprotic polar solvents such as dimethylformamide, dimethylacetamide and dimethylsulfoxide; nitriles such as acetonitrile; hydrocarbons such as benzene, toluene and xylene; aliphatic hydrocarbons such as pentane, hexane and heptane; and mixtures thereof.
  • halogenated hydrocarbons such as dichloromethan
  • reaction temperature is not critical to the invention.
  • the preferred reaction temperature will depend upon such factors as the nature of the solvent, and the starting material or reagent used. However, in general, we find it convenient to carry out the reaction at a temperature of from -78°C to 100°C, more preferably from 0°C to 100°C, and most preferably at 0°C to room temperature.
  • the time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 10 minutes to 24 hours, more preferably from 30 minutes to 5 hours, and most preferably from 30 minutes to 5 hours will usually suffice.
  • This step involves hydrolysis of the ester group CO 2 R 2 present in the compound of formula (II), prepared as described in Step El above, to give a compound of formula (Im) of the present invention.
  • This hydrolysis step is performed in a similar manner to that described in Step Bl above.
  • This step involves reaction of the compound of formula (Im) of the present invention, prepared as described in Step E2 above, with an amine of formula R 6a R 7a NH, wherein R 6 andR 7a are as defined above to give an amide of formula (In) of the present invention.
  • This step is performed in a similar manner to that described in Step B2 above.
  • Method F provides alternative routes for the production of compounds of formulae (Ih), (Ik) and (In) using a compound of formula (Id), prepared as described in Step B3 above, as a starting material.
  • X b , X c , X d , X e , Y, R 6a , R 7a , L 3 and R 14 are as defined above.
  • Step FI This involves reaction of the compound of formula (Id), prepared as described in Step B3 above, with a monoalkylating or monoarylating reagent to give a compound of formula (Ih) in which the amino group of the moiety X b has been converted to a monoalkylamino group or monoarylamino group of formula -NHR 10 wherein R 10 is as defined above.
  • This monoalkylating or monoarylating step is performed in a similar manner to that described in Step C2 above.
  • This step involves reaction of a compound of formula (Id), prepared as described in Step B3 above, with an acylating agent of formula R 14 COL 3 , wherein R 14 and L 3 are as defined above, to give a compound of formula (In) in which the amino group of the moiety X b has been converted to an acylamino group of formula -NHCOR 14 .
  • This acylating step is performed in a similar manner to that described in Step El above.
  • This step involves reaction of a compound of formula (Id), prepared as described in Step B3 above, with a dialkylating or diarylating reagent to give a compound of formula (Ik) in which the amino group of the moiety X b has been converted to a dialkylamino group or diarylamino group of formula -N(R 12 ) 2 wherein R 12 is as defined above.
  • This dialkylating or diarylating step is performed in a similar manner to that described in Step Dl above.
  • R 6a and/or R 7a in the compounds of formula (Ic), (Id), (Ih), (Ik) and (In) produced in Methods B to F above are protected versions of R 6a and/or R 7a , the protecting groups can be removed at any point after introduction of the moiety
  • the protecting groups used are ones in which a functional group (for example, an amino group) is modified by the addition of a protecting group using conventional techniques well-known in the art (see, for example, "Protective Groups in Organic Synthesis, Second Edition, Theodora W. Greene and Peter G.M. Wuts, 1991, John Wiley & Sons, Inc.).
  • the protecting group is a protecting group which is removable by a chemical process such as hydrolysis, hydrogenolysis, electrolysis or photolysis.
  • reaction mixture for example, it can be obtained by neutralizing the reaction mixture as needed, removing insoluble matters by filtration, if any are present, adding organic solvents which are not miscible with each other, such as water and ethyl acetate, washing with water or the like, separating the organic layer containing the desired compound, drying it over anhydrous magnesium sulfate or the like and then distilling off the solvent.
  • organic solvents which are not miscible with each other, such as water and ethyl acetate, washing with water or the like, separating the organic layer containing the desired compound, drying it over anhydrous magnesium sulfate or the like and then distilling off the solvent.
  • the desired compound thus obtained can be isolated and purified by using a conventional method such as recrystallization or reprecipitation or by a chromatographic method.
  • chromatography include adsorption column chromatography using a carrier such as silica gel, alumina or magnesium-silica gel type Florisil, chromatography using a synthetic adsorbent, for example, partition column chromatography using a carrier such as Sephadex LH-20 (product of Pharmacia), Amberlite XAD-11 (product of Rohm & Haas) or Diaion HP-20 (product of Mitsubishi Chemical), ion exchange chromatography and normal-phase-reverse-phase column chromatography (high- performance liquid chromatography) using a silica gel or alkylated silica gel, e.g.
  • Prontosil Prep 2005 ® (product of Bischoff, Inc) and ZORBAX ® SB-C-8 columns (product of Hewlett- Packard, Inc.). If necessary, two or more of these techniques can be used in combination to isolate and purify the desired compound.
  • the oxazole derivatives of formula (I) and pharmacologically acceptable salts thereof of the present invention show excellent activity in inhibiting the production of IL-4 in warm-blooded animals, which may be humans. Consequently, they are effective as a medicament, particularly as an agent for the prophylaxis or treatment of diseases mediated by IL-4 in warm-blooded animals.
  • said diseases are allergic diseases including asthma, atopic dermatitis, allergic rhinitis, food allergies, and systemic anaphylaxis.
  • the compounds of formula (I) and pharmacologically acceptable salts thereof according to the present invention can be administered by a number of different routes.
  • these administration routes include oral administration in the form of tablets, capsules, granules, powders or syrups and parenteral administration in the form of injections or suppositories.
  • Such formulations can be prepared in a known manner by using additives such as an excipients, lubricants, binders, disintegrators, stabilizers, corrigents and diluents.
  • excipients examples include: organic excipients, examples of which include sugar derivatives such as lactose, sucrose, dextrose, mannitol and sorbitol, starch derivatives such as corn starch, potato starch, ⁇ -starch, dextrin and carboxymethyl starch, cellulose derivatives such as crystalline cellulose, low-substituted hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, calcium carboxymethylcellulose and sodium internally-crosslinked carboxymethyl-cellulose, gum arabic, dextran and pullulan; and inorganic excipients, examples of which include silicate derivatives such as soft silicic acid anhydride, synthetic aluminum silicate and magnesium aluminometasilicate, phosphates such as calcium phosphate, carbonates such as calcium carbonate, and sulfates such as calcium sulfate.
  • organic excipients examples of which include sugar derivatives such as lactose, sucrose, dextrose,
  • Suitable lubricants include: stearic acid; metal salts of stearic acid such as calcium stearate and magnesium stearate; talc; colloidal silica; waxes such as bee gum and spermaceti; boric acid; adipic acid; sulfates such as sodium sulfate; glycol; fixmaric acid; sodium benzoate; DL-leucine; sodium salts of an aliphatic acid; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; silicic acid derivatives such as silicic anhydride and silicic acid hydrate; and starch derivatives exemplified above as examples of suitable excipients.
  • Suitable binders include poly inylpyrrolidone, Macrogol and compounds similar to those exemplified above as suitable excipients.
  • suitable disintegrators include compounds similar to those exemplified above as suitable excipients and chemically modified starch or cellulose derivatives such as sodium cross carmellose, sodium carboxymethyl starch and crosslinked polyvinylpyrrolidone.
  • Suitable stabilizers include: paraoxybenzoate esters such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; phenol derivatives such as phenol and cresol; thimerosal; dehydroacetic acid; and sorbic acid.
  • suitable corrigents include sweeteners, acidifiers and flavors commonly employed for this purpose.
  • the dose of the compound of formula (I) or a pharmacologically acceptable salt thereof according to the present invention will vary depending on a variety of factors including the condition to be treated, the age of the patient and the administration route. When administered orally, it is administered to an adult (e.g.
  • an adult human in an amount of 0.1 mg (preferably 0.5 mg) a day as a lower limit and 2000 mg (preferably 500 mg) a day as an upper limit. It can be administered in from one to several portions depending on the condition of the patient.
  • it When administered intravenously, it is administered to an adult in an amount of 0.01 mg (preferably 0.05 mg) a day as a lower limit and 200 mg (preferably 50 mg) a day as an upper limit. It can be administered in from one to several portions depending on the condition of the patient.
  • HPLC high pressure liquid chromatography
  • the 3.5 minute elution method was performed at a flow-rate of 40 ml/min and utilized a linear gradient profile (85% water/15% acetonitrile/0.1% TFA -5% water/95%, acetonitrile/0.1% TFA).
  • the title compound was prepared from ethyl [[[l-(biphenyl-2-yl)-l-methylsulfanyl]- methylidene]amino]acetate, prepared as described in Reference Example 7 below, in a manner analogous to Example 1 above.
  • Ebe title compound was prepared from ethyl ff(l-meth ⁇ lsulfanyl-l- phenyl)methylidene] -amino] acetate, prepared as described in Reference Example 8 below, in a manner analogous to Example 1 above.
  • the title compound was prepared from ethyl [[[l-(4-tert-butylphenyl)-l- methylsulfanyl]-methylidene] amino] acetate, prepared as described in Reference Example 6 below, and 3-nitro-benzoyl chloride in a manner analogous to Example 1 above.
  • Formaldehyde (37% aqueous solution) (1 ml) was added to a solution of ⁇ -(thiazol-2- yl)-5-(4-aminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxamide (0.48 mmol, 0.2 g), prepared as described in Example 7 above, and 10% palladium on activated carbon (0.1 mmol, 0.1 g) in 95% ethanol (5 ml).
  • the reaction mixture was placed onto a Parr shaker at 379.2 kPa of hydrogen for 4 days. The solvent was then removed in vacuo and the residue partitioned between chloroform (20 ml) and water (10 ml).
  • the title compound was prepared from ethyl 5-(4-nitrophenyl)-2-phenyloxazole-4- carboxylate, prepared as described in Example 3 above, in a manner analogous to Example 10 above.
  • Ethyl 5-(4-aminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylate (626 mg, 1.72 mmol), prepared as described in Example 9 above, was dissolved in dichloromethane (13 ml). Trimethyloxonium tetrafluoroborate (305 mg, 2.06 mmol) was added and the resulting reaction mixture was stirred for 2 hours at room temperature. At the end of this time, the reaction mixture was diluted with dichloromethane (30 ml) and the organic layer washed with sodium hydrogencarbonate and brine.
  • Formaldehyde (37% aqueous solution) (1 ml) was added to a suspension of ethyl 5- (4-aminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylate (1 mmol, 0.36 g), prepared as described in Example 9 above, and 10% palladium on activated carbon (0.1 mmol, 0.1 g) in 95% ethanol (5 ml).
  • the reaction vessel was fitted to a Parr apparatus and shaken at 379.2 kPa (hydrogen atmosphere) for 4 days. The solvent was then removed in vacuo and the residue partitioned between chloroform (20 ml) and water (10 ml).
  • the title compound was prepared from ethyl 5-(4-aminophenyl)-2-phenyloxazole-4- carboxylate, prepared as described in Example 12 above, in a manner analogous to Example 15 above.
  • the title compound was prepared from ethyl 5-(3-aminophenyl)-2-(4-tert- butylphenyl)-oxazole-4-carboxylate, prepared as described in Example 10 above, in a manner analogous to Example 15 above.
  • the title compound was prepared from ethyl 5-(4-aminophenyl)-2-(biphenyl-2-yl)- oxazole-4-carboxylate, prepared as described in Example 11 above, in a manner analogous to Example 15 above.
  • the title compound was prepared from ethyl 2-(biphenyl-2-yl)-5-(4-dimethylamino- phenyl)oxazole-4-carboxylate, prepared as described in Example 18 above, in a manner analogous to Example 14 above.
  • the title compound was prepared from ethyl 5-(4-aminophenyl)-2-phenyloxazole-4- carboxylate, prepared as described in Example 16 above, in a manner analogous to Example 14 above.
  • reaction mixture was diluted with dichloromethane (150 ml), washed with 2M hydrochloric acid solution (2 x 100 ml) and brine (100 ml), and then dried over sodium sulfate. Removal of the solvent in vacuo provided the title compound (8.8 g, 90 %) as a yellow solid.
  • Example 26 The title compound was prepared in analogous manner to Example 26, using 3- (morpholin-4-yl)propylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butyl- phenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using thiazolidine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylaminophenyl)-oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyI)-2-(4-tert-butyI ⁇ henyl)oxazole-4-carboxyIic acid.
  • the title compound was prepared in analogous manner to Example 26, using ethyl piperidin-4-ylcarboxylate instead of 2-trifluoromethylbenzylamine and 2-(4-t ⁇ rt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using cyclobutylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using tetrahydrofuran-2-ylmethylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butyl-phenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using N- methylphenylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 2- methoxyethylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using pyrrolidine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5-(4- dimethylamino-phenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 1-ethyl- propylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using benzo[l,3]dioxol-5-ylmethylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 3- (imidazol-l-yl)propylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 2- methyl-cyclohexylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)- 5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using N- cyclopropyl-N-propylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 2,5- dihydropyrrole instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using thiomorpholine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 4- methylpiperidine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 4- benzylpiperazine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 2- (pyrrolidin-l-yl)ethylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using thiophen-2-ylmethylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 4- phenylpiperazine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using allylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylamino-phenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 2,6- dimethylmorpholine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5- (4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using N- methyl-4-chlorophenylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tg7-t- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 1,2,3,4- tetrahydronaphthalen-1-ylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using (2-ethyl- 2H-pyrazol-3-yl)amine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)- 5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using N- methyl-4-methoxyphenylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 4-(3- trifluoromethylphenyl)piperazine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using N-ethyl- (benzo[l,3]dioxol-5-yI)amine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylammophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 4-(2- methoxyphenyl)piperazine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5 -(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 3- ethoxyphenylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylaminophenyl)oxazoIe-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 2-(3- methoxyphenyl)ethylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 3,5-bis- trifluoromethylbenzylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 3,4- dihydro-2H-quinoline instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5- (4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 2-(4- tgrt-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert- butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using (2,3- dihydrobenzo[l,4]dioxin-6-yl)amine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5 -(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using pyridin- 4-ylmethylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 3-(4- methylpiperazin-l-yl)propylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5 -(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 3- methyl-sulfanylphenylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 4- (piperidin-l-yl)phenylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 4- methoxy-phenylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5- (4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using propylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5-(4- dimethylamino-phenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
  • the title compound was prepared in analogous manner to Example 26, using 2-(2- methoxyphenyl)ethylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tg7 - butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel oxazole derivatives which have activity in inhibiting inflammatory cytokines, particularly IL-4, pharmaceutical compositions comprising said oxazole derivatives and methods of prophylaxis and treatment of diseases mediated by cytokines, particularly allergic diseases.

Description

OXAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS CYTOKINE INHIBITORS
Background to the Invention
The present invention relates to novel oxazole derivatives which have activity in inhibiting inflammatory cytokines, particularly IL-4, to pharmaceutical compositions comprising said oxazole derivatives and to methods of prophylaxis and treatment of diseases mediated by cytokines, particularly allergic diseases.
Subsets of helper T cells can be functionally defined by their patterns of cytokine production as T helper cell type 1 (Thl) and T helper cell type 2 (Th2) in mice and humans (J. Immunol., 136, 2348-2357, 1986; Annu. Rev. Immunol., 12, 227-257, 1994; and Immunol. Today, 17, 138-146, 1996). Cell-mediated immune responses are mainly mediated by the Thl subset of T cells, which produce interferon-γ (IFN-γ), interIeukin-2 (IL-2), and tumor necrosis factor-β (TNF-β). In contrast, Th2 cells are defined by their activity to secrete interleukin-4 (IL-4), interleukin-5 (IL-5), inter leukin- 10 (IL-10), and interleukin-13 (IL-13), which are important in antibody-mediated immune responses.
IFN-γ produced by Thl cells facilitates Thl function and suppresses differentiation and function of Th2 cells. IL-4 and IL-10 produced by Th2 cells enhance differentiation and function of Th2 cells and suppress differentiation of Thl cells (J. Immunol., 136, 2348-2357, 1986; Immunol. Today, 13, 379-381, 1992; Journal of Immunology, 159, 4686-4692, 1997; and Interferon Cytokine Res., 19, 1265-70, 1999). This therefore suggests that balanced function of Thl and Th2 cells is important for maintenance of immunity, and that abnormal bias of Thl/Th2 subsets is associated with the onset and progression of allergic diseases or autoimmune diseases (Science, 260, 547-549, 1993; Immunol. Today, 16, 34-38, 1995; and Nature, 383, 787-797, 1996).
It is generally accepted that IL-4 is an IgE class switching factor for B cells and an autocrine mitogenic factor for Th2 cells, and that IL-5 plays an important role in the regulation of eosinophil differentiation, migration and function (J. Immunol., 158, 3539- 3544, 1991; J. Exp. Med., 173, 775-778, 1991; Am. J. Respir. Cell Mol. Biol., 12, 477-487, 1995; and Cytokine, 11, 783-788, 1999). Therefore, Th2 cells are clearly important in the pathogenesis of allergic inflammatory responses as well as IgE synthesis. The importance of IL-4 and IL-5 in allergic diseases is also supported by evidence (Nature, 362, 245-247, 1993; J. Exp. Med., 183, 195-201, 1996; J. Asthma, 34, 195-201, 1997; and Immunity, 11, 473-482, 1999) demonstrating that neutralization of these cytokines by antibodies administered in allergic disease models suppressed eosinophil infiltration in the airways, and that IL-4- or IL- 5 -deficient mice exhibited non-susceptibility to allergic responses. Based on this evidence, it is expected that inhibitors of Th2 cytokines such as IL-4 or IL-5 could suppress abnormal Th2 dominance, IgE production, and eosinophil infiltration and that they could, as a result, act as anti-allergic agents for the treatment or prophylaxis of allergic diseases.
Previously, steroids, cyclosporin A and FK-506 have been clinically used as antiallergic agents. These strongly suppress disease severity in some patients. However, the often severe side effects associated with the use of steroids (such as gastrointestinal problems, water retention and osteoporosis) are a significant problem making their long-term administration to patients with allergic diseases undesirable. Cyclosporin A and FK-506 have powerful anti-allergic properties but they show little selectivity in inhibition of Th2- cytokine production, also inhibiting Thl -cytokines. This leads to non-specific suppression of immune functions causing a number of problems, the most significant of which is increased susceptibility to infections.
It would therefore be highly desirable if selective inhibitors of Th2 cytokines such as IL-4 and IL-5 could be found as they would be likely to act as better anti-allergic agents with greater specificity and fewer side effects, making them useful in the treatment and prophylaxis of allergic diseases including asthma, atopic dermatitis, allergic rhinitis, food allergies, and systemic anaphylaxis.
WO-A-99/33827 discloses imidazole derivatives that are said to show some specificity in inhibiting IL-4 and IL-5 production. There is a need, however, for compounds having good activity in inhibiting the production of IL-4 alone with greater specificity and lower toxicity.
Brief Summary of the Invention
It is an object of the present invention to provide novel compounds having specific activity against the production of IL-4, said compounds having a low toxicity. It is a further object of the present invention to provide compositions having activity in inhibiting the production of IL-4 and methods using said compounds.
Thus, the present invention provides in a first aspect a compound of formula (I):
wherein:
Figure imgf000004_0001
CO X represents a substituent selected from the group consisting of phenyl groups, heteroaryl groups defined below and heterocyclyl groups defined below, said substituent X being substituted with at least one of substituents R1 defined below and optionally further being substituted with at least one of Substituents β defined below, said heteroaryl groups and heterocyclyl groups optionally further being fused with an aryl group defined below or
X represents a pyridine group or a pyrimidine group;
Y represents a substituent selected from the group consisting of phenyl groups, heteroaryl groups defined below and heterocyclyl groups defined below, said substituent Y optionally being substituted with from 1 to 5 substituents R3 defined below, said heteroaryl groups and heterocyclyl groups optionally further being fused with an aryl group defined below;
R1 represents a nitro group or a group of formula -NR4R5 wherein R4 and R5 are the same or different and each is selected from the group consisting of hydrogen atoms, lower alkyl groups defined below, alkoxy groups defined below, alkylcarbonyl groups defined below which are unsubstituted or are substituted with at least one substituent selected from Substituents ε defined below, aryl groups defined below, arylcarbonyl groups defined below which are unsubstituted or are substituted with at least one substituent selected from Substituents δ defined below, heteroarylcarbonyl groups defined below, cycloalkylcarbonyl groups defined below and alkenylcarbonyl groups defined below which are unsubstituted or are substituted with aryl group(s); R2 represents a substituent selected from the group consisting of hydroxy groups, alkoxy groups defined below and groups of formula -NR6R7 wherein R6 and R7 are the same or different and each is selected from the group consisting of: hydrogen atoms; lower alkyl groups defined below which are unsubstituted or are substituted with at least one substituent selected from Substituents α defined below; lower alkenyl groups defined below; cycloalkyl groups defined below which are unsubstituted or are substituted with at least one lower alkyl group defined below, said cycloalkyl groups optionally being fused with an aryl group as defined below; groups of formula -NR4R5 wherein R4 and R5 are as defined above; aryl groups defined below which are unsubstituted or are substituted with at least one substituent selected from Substituents β defined below; aralkyl groups defined below which are unsubstituted or are substituted with at least one substituent selected from the group consisting of alkoxy groups defined below, haloalkyl groups defined below and aryl groups defined below; heterocyclyl groups defined below which are attached to the nitrogen atom of the group -NR6R7 via a ring carbon atom thereof and which are unsubstituted or are substituted with at least one substituent selected from Substituents γ defined below, said heterocyclyl groups further optionally being fused with an aryl defined below; and heteroaryl groups defined below which are attached to the nitrogen atom of the group -NR6R7 via a ring carbon atom thereof and which are unsubstituted or are substituted with at least one substituent selected from Substituents γ defined below, or
R6 and R7 together with the nitrogen atom to which they are attached represent a heterocyclyl group defined below or a heteroaryl group defined below, said groups being unsubstituted or substituted with at least one substituent selected from the group consisting of lower alkyl groups which are unsubstituted or are substituted with at least one substituent selected from the group consisting of groups of formula -NR4R5 wherein R4 and R5 are as defined above and heterocyclyl groups defined below, aryl groups defined below which are unsubstituted or are substituted with at least one substituent selected from Substituents δ defined below, aralkyl groups defined below, carboxy groups, and alkoxycarbonyl groups defined below, said heterocyclyl and heteroaryl groups further optionally being fused with an aryl group defined below;
R3 represents a substituent selected from the group consisting of lower alkyl groups defined below, alkoxy groups defined below, alkylthio groups defined below, haloalkyl groups defined below, halogen atoms, alkylcarbonyl groups defined below, aryl groups defined below which are unsubstituted or are substituted with at least one alkoxy group defined below, aralkyl groups defined below, aralkyloxy groups defined below, heterocyclyl groups defined below and heteroaryl groups defined below; and
Substituents α are selected from the group consisting of alkoxy groups defined below, cycloalkyl groups defined below, arylamino groups defined below, heterocyclyl groups defined below which are unsubstituted or are substituted with at least one lower alkyl group defined below, and heteroaryl groups defined below which are unsubstituted or are substituted with at least one substituent selected from the group consisting of lower alkyl groups defined below and alkoxycarbonyl groups defined below;
Substituents β are selected from the group consisting of lower alkyl groups defined below, alkoxy groups defined below, alkylthio groups defined below, haloalkyl groups defined below, halogen atoms, alkylcarbonyl groups defined below, aryl groups defined below which are unsubstituted or are substituted with at least one alkoxy group defined below, aralkyl groups defined below, aralkyloxy groups defined below, heterocyclyl groups defined below and heteroaryl groups defined below;
Substituents γ are selected from the group consisting of lower alkyl groups defined below, carboxy groups and alkoxycarbonyl groups defined below;
Substituents δ are selected from the group consisting of lower alkyl groups defined below, haloalkyl groups defined below and alkoxy groups defined below;
Substituents ε are selected from the group consisting of alkoxy groups defined below, halogen atoms, aryl groups defined below, aryloxy groups defined below, cycloalkyl groups defined below, alkylcarbonyloxy groups defined below j alkoxycarbonyl groups defined below, hetero aryl groups defined below; or a pharmacologically acceptable salt thereof;
said lower alkyl groups referred to above are straight or branched alkyl groups having from 1 to 6 carbon atoms; said aryl groups referred to above are aromatic hydrocarbon groups having from 6 to 14 carbon atoms in one or more rings, said aromatic hydrocarbon groups optionally being fused with a cycloalkyl group as defined below or a heterocyclyl group as defined below; said alkoxy groups referred to above are lower alkyl groups as defined above which are bonded to an oxygen atom; said cycloalkyl groups referred to above are cycloalkyl groups having from 3 to 7 carbon atoms; said arylamino groups referred to above are amino groups which are substituted with an aryl group as defined above; said heterocyclyl groups referred to above are non-aromatic heterocyclic groups having from 4 to 10 ring atoms in one or more rings, at least one of said ring atoms being a heteroatom selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms; said heteroaryl groups referred to above are 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms; said lower alkenyl groups referred to above are straight or branched alkenyl groups having from 2 to 6 carbon atoms; said aralkyl groups referred to above are lower alkyl groups as defined above which are substituted with at least one aryl group as defined above; said alkoxycarbonyl groups referred to above are carbonyl groups which are substituted with an alkoxy group as defined above; said haloalkyl groups referred to above are lower alkyl groups as defined above which are substituted with at least one halogen atom; said alkylthio groups referred to above are lower alkyl groups as defined above which are bonded to a sulfur atom; said alkylcarbonyl groups referred to above are carbonyl groups which are substituted with a lower alkyl group as defined above; said aralkyloxy groups referred to above are alkoxy groups as defined above which are substituted with at least one aryl group as defined above; said aryloxy groups referred to above are aryl groups as defined above which are bonded to an oxygen atom; said alkylcarbonyloxy groups referred to above are alkylcarbonyl groups as defined above which are bonded to an oxygen atom; said cycloalkylcarbonyl groups referred to above are carbonyl groups which are substituted with an cycloalkyl group as defined above; said arylcarbonyl groups referred to above are carbonyl groups which are substituted with an aryl group as defined above; said heteroarylcarbonyl groups referred to above are carbonyl groups which are substituted with an heteroaryl group as defined above; said alkenylcarbonyl groups referred to above are carbonyl groups which are substituted with an alkenyl group as defined above;
The invention further provides a pharmaceutical composition comprising an effective amount of a pharmacologically active compound together with a carrier therefore (including a diluent), wherein said pharmacologically active compound is selected from the group consisting of oxazole derivatives of formula (I) and pharmaceutically acceptable salts thereof. Preferably, the pharmaceutical compositions have activity in inhibiting the production of IL-4 in a warm-blooded animal, which may be a human.
The invention still further provides a method for the inhibition of the production of IL-4 in a warm-blooded animal, which may be a human, which comprises administering to said warm-blooded animal a pharmacologically effective amount of a compound having activity in inhibiting the production of IL-4, wherein said compound is selected from the group consisting of oxazole derivatives of formula (I) and pharmaceutically acceptable salts thereof.
The invention yet still further provides a method for the prophylaxis or treatment of a disease mediated by IL-4 in a warm-blooded animal, which may be a human, which comprises administering to said warm-blooded animal a pharmacologically effective amount of a compound having activity in inhibiting the production of IL-4, wherein said compound is selected from the group consisting of oxazole derivatives of formula (I) and pharmaceutically acceptable salts thereof. In particular, said diseases are allergic diseases including asthma, atopic dermatitis, allergic rhinitis, food allergies, and systemic anaphylaxis. Detailed Description of the Invention
Where X represents a heteroaryl group which is substituted with at least one of substituents R1 defined above and optionally being further substituted with at least one of Substituents β, or Y represents a heteroaryl group which is optionally substituted with from 1 to 5 substituents R3 defined above, or R3 represents a heteroaryl group, or R6 or R7 represents a heteroaryl group which is attached to the nitrogen atom of the group -NR6R7 via a ring carbon atom thereof and which is optionally substituted with at least one substituent selected from Substituents γ defined above, or Substituent α represents an optionally substituted heteroaryl group, or Substituent β or Substituent ε represents a heteroaryl group, said heteroaryl groups are 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms.
Examples of such heteroaryl groups include furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl groups. We prefer 5- or 6-membered aromatic heterocyclyl groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, examples of which include furyl, thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl groups, of which we particularly prefer thiophenyl, imidazolyl, pyridinyl, pyrazolyl, thiazolyl and isoxazolyl.
The heteroaryl groups defined and exemplified above may be fused with an aryl group defined above. Examples of such a fused heteroaryl group include benzothiazolyl groups.
Where R6 or R7 represents a heteroaryl group which is attached to the nitrogen atom of the group -NR6R7 via a ring carbon atom thereof, 5- or 6-membered aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are preferred and thiazol-2-yl, pyrazol-3-yl, isoxazol-3-yl and thiophen-2-yl groups are particularly preferred.
Where R6 or R7 represents a heteroaryl group which is substituted with at least one substituent selected from Substituents γ defined above and which is attached to the nitrogen atom of the group -NR6R7 via a ring carbon atom thereof, 5- or 6-membered aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms which are substituted with from 1 to 3 of Substituents γ are preferred and 5- or 6-membered aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms which are substituted with 1 or 2 of Substituents γ are particularly preferred. Examples of such substituted heteroaryl groups include 2-ethyl-2H-pyrazol-3-yl, 5- methylisoxazol-3-yl, 2-ethoxycarbonyl-4-methylthiophen-2-yl and 2- methoxycarbonylthiophen-2-yl groups.
Where Substituent α or Substituent ε represents a heteroaryl group, 5- or 6-membered aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are preferred and thiazolyl, imidazolyl, pyridinyl and thiophenyl groups are particularly preferred.
Where Substituent α represents a heteroaryl group which is substituted with at least one substituent selected from the group consisting of lower alkyl groups defined above and alkoxycarbonyl groups defined above, 5- or 6-membered aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms which are substituted by 1 or 2 substituents selected from the group consisting of lower alkyl groups defined above and alkoxycarbonyl groups defined above are preferred. Examples of such groups include 2-methoxycarbonyl-4- methylthiophen-3-yl and 2-ethylimidazol-l-yl groups.
Where R3 or Substituent β represents a heteroaryl group, 5- or 6-membered aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are preferred and thiazolyl, imidazolyl and thiophenyl groups are particularly preferred.
Where R2 represents a group of formula -NR6R7 wherein R6 and R7 together with the nitrogen atom to which they are attached represent an optionally substituted heteroaryl group, said heteroaryl groups are 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, wherein at least one of said heteroatoms is a nitrogen atom. Unsubstituted 5- or 6-membered aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms of which at least one is a nitrogen atom are preferred and pyrrolyl, pyrazolyl and imidazolyl groups are particularly preferred. The heteroaryl groups may optionally be fused with an aryl group as defined above.
Where X represents a heterocycyl group which is substituted with at least one of substituents R1 defined above and optionally substituted with at least one of substituents β, or Y represents a heterocyclyl group which is optionally substituted with from 1 to 5 substituents R3 defined above, or R3 represents a heterocyclyl group, or R or R7 represents a heterocyclyl group which is attached to the nitrogen atom of the group -NR6R7 via a ring carbon atom thereof and which is optionally substituted with at least one substituent selected from Substituents γ defined above, or Substituent α represents an optionally substituted heterocyclyl group, or Substituent β represents a heterocyclyl group, or the optional substituent on the lower alkyl group which may be an optional substituent on the heterocyclyl or heteroaryl group formed from the group of formula -NR6R7 by R6 and R7 together with the nitrogen atom to which they are attached, said heterocyclyl group is a non-aromatic heterocyclic group having from 4 to 10 ring atoms in one or more rings, at least one of said ring atoms being a heteroatom selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms. It is preferably a 4- to 10-membered non-aromatic heterocyclic group containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, more preferably it is a 4- to 7-membered non-aromatic heterocyclic group containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms and most preferably it is a 5- or 6-membered non-aromatic heterocyclic group containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms.
Examples of such a heterocyclyl group include azetidinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, oxazolidinyl, thiazolidinyl, tetrahdrofuranyl, dioxanyl, piperidinyl, tetrahydropyridyl, dihydropyridyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperidyl, 2,5-dihydropyrrolyl, decahydroquinolinyl, quinuclidinyl, quinuclidienyl, octahydroindolizinyl, hexahydroindolizinyl, octahydroquinolizinyl, hexahydroquinolizinyl,
8-azabicyclo[3.2. l]octanyl, 8-azabicyclo[3.2. l]octenyl, 9-azabicyclo[3.3. l]nonanyl and 9-azabicyclo[3.3.1]nonenyl groups, of which pyrrolidinyl, pyrrolinyl, thiazolidinyl, tetrahydrofuranyl, dioxanyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 2,5- dihydropyrrolyl and decahydroquinolinyl groups are more preferred, and pyrrolidinyl, thiazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl and morpholinyl groups are most preferred.
The heterocyclyl groups defined and exemplified above may be fused with an aryl group as defined above. Examples of such a fused heterocyclyl group include 3,4-dihydro- 2H-quinolinyl.
The heterocyclyl groups defined and exemplified above may also be fused with a cycloalkyl group as defined above. Examples of such a fused heterocyclyl group include Decahydroquinolinyl.
Where R6 or R7 represents a heterocyclyl group which is attached to the nitrogen atom of the group -NR6R7 via a ring carbon atom thereof, 4- to 7-membered non-aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are preferred and 5- or 6-membered non- aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are most preferred. Examples of such groups include piperidinyl, piperazinyl and tetrahydrofuranyl groups.
Where R6 or R7 represents a heterocyclyl group which is substituted with at least one substituent selected from Substituents γ defined above and which is attached to the nitrogen atom of the group -NR6R7 via a ring carbon atom thereof, 4- to 7-membered non-aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms which are substituted with 1 or 2 of Substituents γ are preferred and 5- or 6-membered non-aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms which are substituted with 1 or 2 of Substituents γ are most preferred. Examples of such groups include l-ethoxycarbonylpiperidin-4-yl, 4- methylpiperazin-2-yl and 3-methyl-tetrahydrofuran-2-yl groups.
Where R6 and R7 represents a heterocyclyl group which is fused with a cycloalkyl group, 4- to 7-membered non-aromatic heterocyclic groups containing from 1 to 3 heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms fused with a cycloalkyl group having from 3 to 7 carbon atoms are preferred, 5- to 6- membered non-aromatic heterocyclic groups containing from 1 or 2 heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms fused with a cycloalkyl group having from 5 to 6 carbon atoms are more preferred and 6-membered non- aromatic heterocyclic groups containing one nitrogen atom fused with a cyclohexyl group are most preferred.
Where Substituent a represents a heterocyclyl group, 4- to 7-membered non-aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are preferred and 5- or 6-membered non- aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are most preferred. Examples of such groups include morpholinyl, tetrahydrofuranyl, pyrrolidinyl and piperazinyl groups.
Where Substituent α represents a heterocyclyl group which is substituted with at least one lower alkyl group defined above, 4- to 7-membered non-aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms which are substituted with 1 or 2 lower alkyl groups are preferred and and 5- or 6-membered non-aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms which are substituted with 1 or 2 lower alkyl groups are most preferred. Examples of such groups include 4-methylpiperazinyl and 4-ethylpiperidinyl groups.
Where R3 or Substituent β represents a heterocyclyl group, 4- to 7-membered non- aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are preferred and 5- or 6- membered non-aromatic heterocyclic groups containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms are most preferred. Examples of such groups include piperidinyl, tetrahydrofuranyl, pyrrolidinyl and piperazinyl groups.
Where R2 represents a group of formula -NR6R7 wherein R6 and R7 together with the nitrogen atom to which they are attached represent a heteroaryl or heterocyclyl group which is substituted with a lower alkyl group which is itself substituted with a heterocyclyl group, said heterocyclyl group which is a substituent on said alkyl group is preferably a 4- to 7- membered non-aromatic heterocyclic group containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, and most preferably a 5- or 6-membered non-aromatic heterocyclic group containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, examples of which include morpholinyl, thiomorpholinyl and piperidinyl groups.
Where R2 represents a group of formula -NR6R7 wherein R6 and R7 together with the nitrogen atom to which they are attached represent a heterocyclyl group, said heterocyclyl group is a 4- to 10-membered non-aromatic heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, wherein at least one of said heteroatoms is a nitrogen atom. Said heterocyclyl group is preferably a 4- to 7-membered non-aromatic heterocyclic group containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, and most preferably a 5- or 6-membered non-aromatic heterocyclic group containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms. Examples of such groups include thiazolidin-3-yl, pyrrolidin-1-yl, pyrrolin- l-yl, piperidin-1-yl, piperazin-1-yl, morpholin-4-yl, thiomorpholin-1-yl, 2,5-dihydropyrrol-l- yl and decahydroquinolin-1-yl groups.
Where R2 represents a group of formula -NR6R7 wherein R6 and R7 together with the nitrogen atom to which they are attached represent a substituted heterocyclyl group, said heterocyclyl group is a 4- to 10-membered non-aromatic heterocyclic group containing from 1 to 3 heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, wherein at least one of said heteroatoms is a nitrogen atom and in which said group is substituted with at least one substituent selected from the group consisting of lower alkyl groups defined above which are unsubstituted or are substituted with at least one substituent selected from the group consisting of heterocyclyl groups defined above and groups of formula -NR4R5 wherein R4 and R5 are as defined above, aryl groups defined above which are unsubstituted or are substituted with at least one substituent selected from Substituents δ defined above, aralkyl groups defined above, carboxy groups, and alkoxycarbonyl groups defined above. Preferably, it is a 4- to 7-membered non-aromatic heterocyclic group containing 1 or 2 heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, wherein at least one of said heteroatoms is a nitrogen atom and in which said group is substituted with 1 or 2 of the above substituents, and most preferably a 5- or 6-membered non-aromatic heterocyclic group containing one or two heteroatoms selected from the group consisting of sulfur atoms, oxygen atoms and nitrogen atoms, wherein at least one of said heteroatoms is a nitrogen atom and in which said group is substituted with 1 or 2 of the above substituents.
Examples of such groups include 4-methylpiperidin-l-yl, 2,6-dimethyl-morpholin-4- yl, 4-methylpiperazin-l-yl, 4-(2-dimethylaminoethyl)-piperazin-l-yl, 4-[2-(morpholin-4- yl)ethyl]piperazin-l-yl, 4-phenylpiperazin-l-yl, 4-(2-morpholin-4-yl-ethyl)piperazin-l-yl, 4- (3 -trifluoromethylphenyl)piperazin- 1 -yl, 4-(2-methoxyphenyl)-piperazin- 1 -yl, 4- benzylpiperazin-1-yl and 4-ethoxycarbonylpiperidin-l-yl groups.
Where R3, R4, R5, Substituent β, Substituent γ or Substituent δ represents a lower alkyl group, or R or R represents a lower alkyl group which may optionally be substituted with at least one substituent selected from Substituents α defined above, or R2 is a cycloalkyl group as defined above which is substituted with a lower alkyl group, or R2 represents a group of formula -NR R7 wherein R6 and R7 together with the nitrogen atom to which they are attached represent a heteroaryl or heterocyclyl group as defined above which is substituted with a lower alkyl group, or Substituent α is a heterocyclyl or heteroaryl group as defined above which is substituted with a lower alkyl group, said lower alkyl group is a straight or branched alkyl group having from 1 to 6 carbon atoms. Examples of said lower alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, s-butyl, tert-butyl, n- pentyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, n-hexyl, isohexyl, 4- methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl, 2,2- dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl and 2-ethylbutyl groups. Of these groups, methyl, ethyl, n-propyl, tert-butyl 1-methylbutyl and 1-ethylpropyl groups are more preferred.
Where R3, R4, R5 or Substituent β represents an alkylcarbonyl group, said group is a carbonyl group which is substituted with a lower alkyl group as defined and exemplified above. Examples of these alkylcarbonyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, pentanoyl, pivaloyl, valeryl and isovaleryl groups, of which acetyl groups are preferred.
Where R3, R4, R5 or Substituent ε represents an aryl group, or R4 or R5 represents alkenylcarbonyl group which is substituted with aryl group, or R6 or R7 represents an aryl group which is optionally substituted with at least one of Substituents β, or Substituent β is an aryl group which is optionally substituted with at least one alkoxy group, or R2 represents a group of formula -NR6R7 wherein R6 and R7 together with the nitrogen atom to which they are attached represent a heterocyclyl or heteroaryl group which is substituted with an aryl group which is itself optionally substituted with at least one of Substituents δ, R6 or R7 represents alkenyl carbonyl group which is substituted with aryl group, or X, Y, R6 or R7 represents a heterocyclyl or heteroaryl group which is fused with an aryl group, or R2 represents a group of formula -NR6R7 wherein R6 and R7 together with the nitrogen atom to which they are attached represent a heterocyclyl or heteroaryl group which is fused with an aryl group, said aryl group is an aromatic hydrocarbon group having from 6 to 14 carbon atoms in one or more rings. Preferably said aryl group has from 6 to 10 carbon atoms, and examples include phenyl, naphthyl, phenanthryl and anthracenyl groups. Of these, we prefer phenyl and naphthyl groups, most preferably phenyl groups.
The aryl groups defined and exemplified above may optionally be fused with a cycloalkyl group as defined above and exemplified below or a heterocyclyl group as defined and exemplified above.
Where R3, R4, R5 or Substituent ε represents an aryl group, phenyl groups are preferred.
Where R6 or R7 represents an aryl group, phenyl and naphthalenyl groups are preferred.
Where R6 or R7 represents an aryl group which is substituted with at least one of Substituents β, aromatic hydrocarbon groups having from 6 to 14 carbon atoms in one or more rings which are substituted with 1 or 2 of Substituents β are preferred, phenyl and naphthalenyl groups which are substituted with 1 or 2 of Substituents β are more preferred, and phenyl groups which are substituted with 1 or 2 of Substituents β are most preferred. Examples of such groups include 2-, 3-, 4-, 5- and 6-methylphenyl, 2- ,3-, 4-, 5- and 6- ethylphenyl, 2-, 3-, 4-, 5- and 6-methoxyphenyl, 2-, 3-, 4-, 5- and 6-ethoxyphenyl, 2-, 3-, 4-, 5- and 6-methylsulfanylphenyl, 2~, 3-, 4-, 5- and 6-trifluoromethylphenyl, 2-, 3-, 4-, 5- and 6- chlorophenyl, 2-, 3-, 4-, 5- and 6-acetylphenyl, biphenyl-2-yl, biphenyl-3-yl, 2-, 3-, 4-, 5- and 6-benzyIphenyl, 2-, 3-, 4-, 5- and 6-benzyloxyphenyl, 2-, 3-, 4-, 5- and 6-(piperidin-l- yl)phenyl, 2,5-dimethoxy-phenyl, 3-methoxy-5-trifluoromethylphenyl, 2-methoxy-5- methylphenyl, 3,5-bis-trifluoromethylphenyl and 4-methoxybiphenyl-3-yl groups. Where Substituent β represents an aryl group which is optionally substituted with at least one alkoxy group as defined above, phenyl groups which are optionally substituted with 1 or 2 alkoxy groups are preferred, examples of which include phenyl and 4- methoxyphenyl groups.
Where X, Y, R6 or R7 represents a heterocyclyl or heteroaryl group which is fused with an aryl group said aryl group preferably has from 6 to 10 carbon atoms, and is most preferably a phenyl group.
Where R2 represents a group of formula -NR6R7 wherein R6 and R7 together with the nitrogen atom to which they are attached represent a heterocyclyl or heteroaryl group which is fused with an aryl group, said aryl group preferably has from 6 to 10 carbon atoms, and is most preferably a phenyl group. Examples of such a substituent R2 include 2,3- dihydrobenzo[l ,4]-dioxin-6-yl groups.
Where R2, R3, R4, R5, Substituent α, Substituent β, Substituent δ or Substituent ε represents an alkoxy group, or R6 or R7 represents an aralkyl group as defined above which is substituted with an alkoxy group, or Substituent β represents an aryl group which is substituted with an alkoxy group, said alkoxy group is a lower alkyl group as defined and exemplified above which is bonded to an oxygen atom. The alkoxy groups are preferably straight or branched alkoxy groups having 1 to 4 carbon atoms, more preferably methoxy, ethoxy, propoxy, isopropoxy or butoxy groups, and particularly preferably methoxy or ethoxy groups.
Where R6 or R7 represents a lower alkenyl group, said lower alkenyl group is a straight or branched alkenyl group having from 2 to 6 carbon atoms, examples of which include vinyl, allyl, l-methyl-2-propenyl, 2-methyl-2-propenyl, 2-ethyl-2-propenyl, 2- butenyl, l-methyl-2-butenyl, 2-methyl-2-butenyl, l-ethyl-2-butenyl, 3-butenyl, l-methyl-3- butenyl, 2-methy 1-3 -butenyl, 1-ethy 1-3 -butenyl, 2-pentenyl, l-methyl-2-pentenyl, 2-methyl-2- pentenyl, 3-pentenyl, l-methyl-3-pentenyl, 2-methyl-3-pentenyl, 4-pentenyl, l-methyl-4- pentenyl, 2-methyl-4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl and 5-hexenyl groups. Alkenyl groups having from 2 to 4 carbon atoms are preferred, alkenyl groups having 2 or 3 carbon atoms are more preferred and allyl groups are most preferred. Where Substituent α or Substituent ε represents a cycloalkyl group or R6 or R7 represents a cycloalkyl group which may optionally be substituted with a lower alkyl group as defined and exemplified above, said cycloalkyl group is a cycloalkyl group having from 3 to 7 carbon atoms, examples of which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptanyl groups which, for R6 or R7, may optionally be substituted with 1 or 2 lower alkyl groups. Of these, cycloalkyl groups having from 3 to 6 carbon atoms are preferred for Susbtituents α or Substituent ε and cyclopropyl groups are particularly preferred, while cycloalkyl groups having from 3 to 6 carbon atoms which are optionally substituted with an alkyl group having from 1 to 4 carbon atoms are preferred for R6 or R7 and cyclobutyl, cyclohexyl and 2-methylcyclohexyl groups are particularly preferred. In the case of R6 or R7, the cycloalkyl group may optionally be fused with an aryl group as defined and exemplified above, examples of which include 1,2,3,4-tetrahydronaphthalen-l-yl groups.
Where R3 or Substituent β represents an aralkyl group, or R6 or R7 represents an aralkyl group which is optionally substituted with at least one alkoxy group or haloalkyl group, or R2 represents a group of formula -NR6R7 wherein R6 and R7 together with the nitrogen atom to which they are attached represents a heterocyclyl or heteroaryl group which is substituted with an aralkyl group, said aralkyl group is a lower alkyl group as defined and exemplified above which is substituted with at least one aryl group as defined and exemplified above.
Examples of said aralkyl groups include benzyl, phenanthrenylmethyl, anthracenylmethyl, α-naphthylmethyl, β-naphthylmethyl, diphenylmethyl, triphenylmethyl, α-naphthyldiphenylmethyl, 9-anthrylmethyl, piperonyl, 1-phenethyl, 2-phenethyl, 1- naphthylethyl, 2-naphthylethyl, 1-phenylpropyl, 2-phenylpropyl,
3-phenylpropyl, 3,3-diphenylpropyl, 1-naphthylpropyl, 2-naphthylpropyl, 3-naphthyl- propyl, 1-phenylbutyl, 2-phenylbutyl, 3-phenylbutyl, 4-phenylbutyl, 1-naphthylbutyl,
2-naphthylbutyl, 3-naphthylbutyl, 4-naphthylbutyl, 1-phenylpentyl, 2-phenylpentyl, 3-phenylpentyl, 4-phenylpentyl, 5-phenylpentyl, 1-naphthylpentyl, 2-naphthylpentyl, 3-naphthylpentyl, 4-naphthylpentyl, 5-naphthylpentyl, 1-phenylhexyl, 2-phenylhexyl, 3-phenylhexyl, 4-phenylhexyl, 5-phenylhexyl, 6-phenylhexyl, 1-naphthylhexyl, 2-naphthylhexyl, 3-naphthylhexyl, 4-naphthylhexyl, 5-naphthylhexyl and 6-naphthyl- hexyl groups, of which benzyl, phenanthrenylmethyl, anthracenylmethyl, α-naphthyl-methyl, β-naphthylmethyl, diphenylmethyl, triphenylmethyl, 9-anthrylmethyl, piperonyl, 1- phenethyl, 2-phenethyl, 1-phenylpropyl, 2-phenylpropyl, 3-phenylpropyl, 3,3- diphenylpropyl, 1-phenylbutyl, 2-phenylbutyl, 3-phenylbutyl and 4-phenylbutyl groups are preferred and benzyl, diphenylmethyl, 2-phenethyl and 3, 3 -diphenylpropyl groups are most preferred.
Where R3 or Substituent β represents an aralkyl group, alkyl groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 phenyl groups are preferred and benzyl groups are most preferred.
Where R6 or R7 represents an aralkyl group, alkyl groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 phenyl groups are preferred and benzyl, diphenylmethyl, 3, 3 -diphenylpropyl and 2-phenethyl groups are most preferred.
Where R6 or R7 represents an aralkyl group which is substituted with at least one substituent selected from alkoxy groups as defined and exemplified above and haloalkyl groups as defined above and exemplified below, alkyl groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 phenyl groups which are substituted with 1 or 2 substituents selected from alkoxy groups and haloalkyl groups are preferred and alkyl groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 phenyl groups which are substituted with 1 or 2 substituents selected from alkoxy groups having from 1 to 4 carbon atoms and haloalkyl groups having from 1 to 4 carbon atoms are more preferred, examples of which include 2-trifluoromethylbenzyl, 3,5-bis-trifluoromethyl-benzyl, 2-methoxybenzyl, 2- (2-methoxyphenyl)ethyl, 2-(3-methoxyphenyl)ethyl, 2-(4-methoxyphenyl)ethyl and 2,6- dimethoxybenzyl groups.
The aryl moieties of the aralkyl groups above may be fused with a cycloalkyl group as defined and exemplified above or a heterocyclyl group as defined and exemplified above, said fused aralkyl groups including benzo[l,3]dioxol-5-ylmethyl groups.
Where R3, Substituent β or Substituent δ represents a haloalkyl group, or R6 or R7 represents an aralkyl group as defined above which is substituted with a haloallcyl group, said haloalkyl group is a lower alkyl group as defined and exemplified above which is substituted with at least one halogen atom as exemplified below. Haloalkyl groups having from 1 to 4 carbon atoms are preferred, trifluoromethyl, trichloromethyl, difluoromethyl, dichloromethyl, dibromomethyl, fiuoromethyl, 2,2,2-trichloroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl, 2- chloroethyl, 2-fluoroethyl and 2,2-dibromoethyl groups are more preferred, trifluoromethyl, trichloromethyl, difluoromethyl and fluoromethyl groups are still more preferred, and trifluoromethyl groups are most preferred.
Where Substituent γ and Substituent ε represents an alkoxycarbonyl group, or R2 represents a group of formula -NR6R7 wherein R6 and R7 together with the nitrogen atom to which they are attached represent a heterocyclyl or heteroaryl group as defined and exemplified above which is substituted with an alkoxycarbonyl group, or Substituent α represents a heteroaryl group as defined and exemplifed above which is substituted with an alkoxycarbonyl group, said alkoxycarbonyl group is a carbonyl group which is substituted with an alkoxy group as defined and exemplified above. Examples of such groups include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, s-butoxycarbonyl, tert- butoxycarbonyl and isobutoxycarbonyl groups, of which methoxycarbonyl and ethoxycarbonyl groups are preferred.
Where Substituent α represents an arylamino group, this is an amino group which is substituted with an aryl group as defined and exemplified above, examples of which include phenylamino groups.
Where R3 or Substituent β represents an alkylthio group, said alkylthio group is a lower alkyl group as defined and exemplified above which is bonded to a sulfur atom.
The alkylthio groups preferably have from 1 to 4 carbon atoms, and are more preferably selected from the group consisting of methylthio and ethylthio groups.
The halogen atoms in the definition of R3 and Substituent group β or Substituent group ε include fluorine, chlorine, bromine and iodine atoms, of which fluorine and chlorine atoms are preferred and chlorine atoms are most preferred.
Where R3 or Substituent β represents an aralkyloxy group, said aralkyloxy group is an alkoxy group as defined and exemplified above which is substituted with at least one aryl group as defined and exemplified above, examples of which include benzyloxy groups.
Where Substituent ε represents an aryloxy group, said aryloxy group is an aryl group as defined and exemplified above which is bonded to an oxygen atom. The aryloxy groups are preferably phenyloxy group. Where Substituent ε represents an alkylcarbonyloxy group, said alkylcarbonyloxy group is an alkylcarbonyl groupsas defined and exemplified above which is bonded to an oxygen atom. The alkylcarbonyl groups are preferably acetyloxy group.
Where R4 or R5 represents an arylcarbonyl group, said arylcarbonyl group is a carbonyl group which is substituted with an aryl group as defined and exemplified above. The arylcarbonyl groups are preferably benzoyl group.
Where R4 or R5 represents a heteroarylcarbonyl group, said heteroarylcarbonyl group is a carbonyl group which is substituted with a heteroaryl group as defined and exemplified above. The heteroarylcarbonyl groups are preferably furylcarbonyl, thienylcarbonyl and pyridylcarbonyl groups.
Where R4 or R5 represents a cycloalkylcarbonyl group, said cycloalkylcarbonyl group is a carbonyl groups which are substituted with a cycloalkyl group as defined and exemplified above. The cycloalkylcarbonyl groups are preferably cycloalkyl groups having from 3 to 6 carbon atoms.
Where R4 or R5 represents an alkenylcarbonyl group which may be substituted with aryl group, said alkenylcarbonyl group is carbonyl group which is substituted with an alkenyl group as defined and exemplified above. The alkenylcarbonyl groups are preferably an alkenylcarbonyl groups having from 3 to 5 carbon atoms which may be substituted with aryl group, more preferably an alkenylcarbonyl groups having 3 or 4 carbon atoms which may be substituted with phenyl or naphthyl group, and most preferably an allyl groups which may be substituted with phenyl group.
Where the compounds of formula (I) of the present invention have a basic group, such as an amino group, the compound can be converted to a salt by reacting it with an acid, and in the case where the compounds of formula (I) of the present invention have an acidic group, such as a carboxy group, the compound can be converted to a salt by reacting it with a base. The compounds of the present invention encompass such salts. Where said salts are to be used for a therapeutic use, they must be pharmacologically acceptable, i.e. on administration of said salt to the body of a live mammal they must have a similar activity to the compound of formula (I) and have a similar toxicity. Preferred examples of the salts formed with a basic group present in the compound of formula (I) of the present invention include inorganic acid salts such as hydrohalogenated acid salts (e.g. hydrochlorides, hydrobromides and hydroiodides), nitrates, perchlorates, sulfates and phosphates; organic acid salts such as lower alkanesulfonates in which the lower alkyl moiety thereof is as defined above (e.g. methanesulfonates, trifluoromethanesulfonates and ethanesulfonates), arylsulfonates in which the aryl moiety thereof is as defined above (e.g. benzenesulfonate or p-toluenesulfonate), acetates, malates, fumarates, succinates, citrates, ascorbates, tartrates, oxalates and maleates; and amino acid salts such as glycine salts, lysine salts, arginine salts, ornithine salts, glutamates and aspartates.
Preferred example of the salts formed with an acidic group present in the compound of formula (I) of the present invention include metal salts such as alkali metal salts (e.g. sodium salts, potassium salts and lithium salts), alkali earth metal salts (e.g. calcium salts and magnesium salts), aluminum salts and iron salts; amine salts such as inorganic amine salts (e.g. ammonium salts) and organic amine salts (e.g. t-octylamine salts, dibenzylamine salts, morpholine salts, glucosamine salts, phenylglycinealkyl ester salts, ethylenediamine salts, N- methylglucamine salts, guanidine salts, diethylamine salts, triethylamine salts, dicyclohexylamine salts, N,N'-dibenzylethylenediamine salts, chloroprocaine salts, procaine salts, diethanolamine salts, N-benzylphenethylamine salts, piperazine salts, tetramethylammonium salts and tris(hydroxymethyl)aminomethane salts; and amino acid salts such as glycine salts, lysine salts, arginine salts, ornithine salts, glutamates and aspartates.
The compounds of formula (I) of the present invention can sometimes take up water upon exposure to the atmosphere or when recrystallized to absorb water or to form a hydrate and such hydrates are also included within the scope of the present invention. Additionally, certain other solvents may be taken up by the compounds of the present invention to produce solvates, which also form a part of the present invention.
The compounds of formula (I) of the present invention can sometimes exist in the form of geometrical isomers (cis and trans isomers) and, where said compounds contain one or more asymmetric centres, optical isomers. For the compounds of the present invention, each of said isomers and mixture of said isomers are depicted by a single formula, i.e. the formula (I). Accordingly, the present invention covers both the individual isomers and mixtures thereof in any proportion, including racemic mixtures. Preferred classes of compounds of the present invention are those compounds of formula (I) and pharmacologically acceptable salts thereof wherein:
(1) X represents a phenyl group which is substituted with 1 of substituents R1 or X represents a pyridine group or a pyrimidine group;
(2) X represents a phenyl group which is substituted with 1 of substituents R1, wherein R1 is selected from the group consisting of nitro groups and groups of formula - NR4R5 wherein R4 andR5 are the same or different and each is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 4 carbon atoms, alkylcarbonyl groups the alkyl moiety thereof having from 1 to 4 carbon atoms and aryl groups having from 6 to 10 carbon atoms or X represents a pyridine group;
(3) X represents a phenyl group which is substituted with a group of formula -NR4R5 wherein R4 andR5 are the same or different and each is selected from the group consisting of hydrogen atoms, methyl groups, ethyl groups, acetyl groups and phenyl groups or X represents a pyridine group;
(4) X represents a phenyl group which is substituted with a substituent selected from the group consisting of amino, methylamino, dimethylamino and acetylamino groups or X represents a pyridine group;
(5) X is selected from the group consisting of 4-aminophenyl, 4-acetylamino and 4-dimethylamino groups;
(6) Y represents a phenyl group which is optionally substituted with 1 or 2 of substituents R3;
(7) Y represents a phenyl group which is optionally substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, haloallcyl groups having from 1 to 4 carbon atoms and phenyl groups;
(8) Y represents a phenyl group which is substituted with a substituent selected from the group consisting of methyl, ethyl, tert-butyl and trifluoromethyl groups; (9) Y represents a 4-tert-butylphenyl group or a 4-trifluoromethylphenyl group;
(10) R2 is selected from the group consisting of hydroxy groups, alkoxy groups having from 1 to 6 carbon atoms and groups of formula -NR6R7 wherein R6 and R7 are the same or different and each is selected from the group consisting of: hydrogen atoms; alkyl groups having from 1 to 6 carbon atoms which are optionally substituted with 1 or 2 of Substituents α1 defined below; alkenyl groups having from 2 to 4 carbon atoms; cycloalkyl groups having from 3 to 6 carbon atoms which are optionally substituted with an alkyl group having from 1 to 4 carbon atoms, said cycloalkyl groups optionally being fused with an aryl group having from 6 to 10 carbon atoms; groups of formula -NR4R5 wherein R4andR5 are the same or different and each is selected from the group consisting of hydrogen atoms and aryl groups having from 6 to 10 carbon atoms; aryl groups having from 6 to 10 carbon atoms which are optionally substituted with 1 or 2 of Substituents β1 defined below and which are further optionally fused with a 4- to 7-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms; alkyl groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 aryl groups having from 6 to 10 carbon atoms, said aryl groups optionally being substituted with 1 or 2 substituents selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms and haloalkyl groups having from 1 to 4 carbon atoms, said aryl groups optionally being fused with a 4- to 7- membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms;
4- to 7- membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heterocyclyl groups optionally being substituted with 1 or 2 of Substituents γ1 defined below;
5- or 6- membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heteroaryl groups optionally being substituted with 1 or 2 of Substituents γ1 defined below and further optionally being fused with an aryl group having from 6 to 10 carbon atoms; or R6 and R7 together with the nitrogen atom to which they are attached represent a 4- to 7-membered heterocyclyl group or a 5- or 6-membered heteroaryl group, said heterocyclyl and heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, said heterocyclyl and heteroaryl groups optionally being substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to' 4 carbon atoms which are optionally substituted with 1 or 2 substituents selected from the group consisting of groups of formula -NR4R5 wherein R4 andR5 are the same or different and each is selected from the group consisting of hydrogen atoms and alkyl groups having from 1 to 4 carbon atoms, and 4- to 7-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, aryl groups having from 6 to 10 carbon atoms which are optionally substituted with 1 or 2 of Substituents δ1 defined below, alkyl groups having from 1 to 4 carbon atoms which are substituted with an aryl group having from 6 to 10 carbon atoms, and alkoxycarbonyl groups wherein the alkoxy moiety has from 1 to 4 carbon atoms, said heterocyclyl and heteroaryl groups optionally being fused with an aryl group having from 6 to 10 carbon atoms;
Substituents α1 are selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms, cycloalkyl groups having from 3 to 6 carbon atoms, 4- to 7-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with 1 or 2 alkyl groups having from 1 to 4 carbon atoms, and 5- or 6-membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms and alkoxycarbonyl groups the alkoxy moiety thereof having from 1 to 4 carbon atoms;
Substituents β1 are selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, alkylthio groups having from 1 to 4 carbon atoms, haloalkyl groups having from 1 to 4 carbon atoms, halogen atoms, alkylcarbonyl groups the alkyl moiety thereof having from 1 to 4 carbon atoms, aryl groups having from 6 to 10 carbon atoms which are unsubstituted or are substituted with 1 or 2 alkoxy groups having from 1 to 4 carbon atoms, alkyl groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 aryl groups having from 6 to 10 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 aryl groups having from 6 to 10 carbon atoms, 4- to 7-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms and 5- or 6-membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms;
Substituents γ1 are selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, carboxy groups and alkoxycarbonyl groups the alkoxy moiety thereof having from 1 to 4 carbon atoms;
Substituents δ1 are selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms and haloalkyl groups having from 1 to 4 carbon atoms;
(11) R2 is selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms and groups of formula -NR6R7 wherein R6 and R7 are the same or different and each is selected from the group consisting of: hydrogen atoms; alkyl groups having from 1 to 6 carbon atoms which are optionally substituted with 1 or 2 of Substituents α2 defined below; alkenyl groups having from 2 to 4 carbon atoms; cycloalkyl groups having from 4 to 6 carbon atoms which are optionally substituted with an alkyl group having from 1 to 4 carbon atoms, said cycloalkyl groups optionally being fused with a phenyl group; groups of formula -NR4R5 wherein R4 andR5 are the same or different and each is selected from the group consisting of hydrogen atoms and phenyl groups; aryl groups having from 6 to 10 carbon atoms which are optionally substituted with 1 or 2 of Substituents β2 defined below and which are further optionally fused with a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms; alkyl groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 phenyl groups, said phenyl groups optionally being substituted with 1 or 2 substituents selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms and haloalkyl groups having from 1 to 4 carbon atoms, said phenyl groups optionally further being fused with a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms; 5- or 6- membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heterocyclyl groups optionally being substituted with an alkoxycarbonyl group the alkoxy moiety thereof having from 1 to 4 carbon atoms;
5- or 6- membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heteroaryl groups optionally being substituted with 1 or 2 of Substituents γ2 defined below and further optionally being fused with a phenyl group;
or R6 and R7 together with the nitrogen atom to which they are attached represent a 5- or 6-membered heterocyclyl or heteroaryl group, said heterocyclyl and heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, said heterocyclyl and heteroaryl groups optionally being substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms which are optionally substituted with a group of formula -NR4R5 wherein R4 and R5 are the same or different and each is an alkyl group having from 1 to 4 carbon atoms, or a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, aryl groups having from 6 to 10 carbon atoms which are optionally substituted with a Substituent δ2 defined below, alkyl groups having from 1 to 4 carbon atoms which are substituted with a phenyl group, and alkoxycarbonyl groups wherein the alkoxy moiety has from 1 to 4 carbon atoms, said heterocyclyl and heteroaryl groups optionally being fused with a phenyl group;
Substituents α2 are selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms, cyclopropyl groups, cyclobutyl groups, 5- or 6-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with an alkyl group having from 1 to 4 carbon atoms, and 5- or 6-membered heteroaryl groups having 1 or 2'heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms and alkoxycarbonyl groups the alkoxy moiety thereof having from 1 to 4 carbon atoms;
Substituents β2 are selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, alkylthio groups having from 1 to 4 carbon atoms, haloalkyl groups having from 1 to 4 carbon atoms, fluorine atoms, chlorine atoms, alkylcarbonyl groups the alkyl moiety thereof having from 1 to 4 carbon atoms, aryl groups having from 6 to 10 carbon atoms which are unsubstituted or are substituted with an alkoxy group having from 1 to 4 carbon atoms, alkyl groups having from
1 to 4 carbon atoms which are substituted with a phenyl group, alkoxy groups having from 1 to 4 carbon atoms which are substituted with a phenyl group and 5- or 6-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms;
Substituents γ2 are selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms and alkoxycarbonyl groups the alkoxy moiety thereof having from 1 to 4 carbon atoms;
Substituents δ1 are selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms and haloalkyl groups having from 1 to 4 carbon atoms;
(12) R2 is selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms and groups of formula -NR6R7 wherein R6 and R7 are the same or different and each is selected from the group consisting of: hydrogen atoms; alkyl groups having from 1 to 6 carbon atoms which are optionally substituted with a Substituent α3 defined below; allyl groups; cycloalkyl groups having from 4 to 6 carbon atoms which are optionally substituted with a methyl or ethyl group, said cycloalkyl groups optionally being fused with a phenyl group; phenylhydrazido groups; phenyl and naphthyl groups and phenyl groups which are optionally substituted with 1 or 2 of Substituents β3 defined below and which are further optionally fused with a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms; alkyl groups having from 1 to 3 carbon atoms which are substituted with 1 or
2 phenyl groups, and benzyl and phenethyl groups which are substituted with 1 or 2 substituents selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms and haloalkyl groups having from 1 to 4 carbon atoms, the phenyl groups of these aralkyl groups optionally further being fused with a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms;
5- or 6- membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heterocyclyl groups optionally being substituted with a methoxycarbonyl or ethoxycarbonyl group;
5- or 6- membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heteroaryl groups optionally being substituted with 1 or 2 of Substituents γ2 defined above and further optionally being fused with a phenyl group; or R6 and R7 together with the nitrogen atom to which they are attached represent a 5- or 6-membered heteroaryl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, or a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, said heterocyclyl group optionally being substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms which are optionally substituted with a group of formula -NR4R5 wherein R4 and R5 are the same or different and each is a methyl or ethyl group, or a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, phenyl groups which are optionally substituted with a Substituent δ2 defined above, benzyl groups, and methoxycarbonyl and ethoxycarbonyl groups, said heterocyclyl group optionally being fused with a phenyl group;
Substituents α3 are selected from the group consisting of methoxy groups, ethoxy groups, cyclopropyl groups, cyclobutyl groups, 5- or 6-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with a methyl or ethyl group, and 5- or 6- membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, methoxycarbonyl groups and ethoxycarbonyl groups; and
Substituents β3 are selected from the group consisting of methyl groups, ethyl groups, methoxy groups, ethoxy groups, methylthio groups, ethylthio groups, methyl or ethyl groups which are substituted with from 1 to 3 fluorine or chlorine atoms, fluorine atoms, chlorine atoms, acetyl groups, propionyl groups, phenyl groups which are unsubstituted or are substituted with a methoxy or ethoxy group, benzyl groups, benzyloxy and 5- or 6-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms;
(13) R is selected from the group consisting of methoxy groups, ethoxy groups and groups of formula -NR6R7 wherein R6 and R7 are the same or different and each is selected from the group consisting of: hydrogen atoms; methyl, ethyl, 1-methylbutyl and 1-ethylpropyl groups, methyl, ethyl and propyl groups substituted with a Substituent α4 defined below; allyl groups; cyclobutyl and cyclohexyl groups which are optionally substituted with a methyl group, said cyclobutyl and cyclohexyl groups optionally being fused with a phenyl group; phenylhydrazido groups; phenyl and naphthyl groups and phenyl groups which are optionally substituted with 1 or 2 of Substituents β4 defined below and which are further optionally fused with a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen and oxygen atoms; benzyl, diphenylmethyl and 3, 3 -diphenylpropyl groups, and benzyl and phenethyl groups which are substituted with 1 or 2 substituents selected from the group consisting of methoxy, ethoxy and trifluoromethyl groups, the phenyl groups of these aralkyl groups optionally further being fused with a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms;
6- membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen and oxygen atoms, said heterocyclyl groups optionally being substituted with a methoxycarbonyl or ethoxycarbonyl group;
5- or 6- membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heteroaryl groups optionally being substituted with 1 or 2 substituents selected from the group consisting of methyl, ethyl, methoxycarbonyl and ethoxycarbonyl groups and said heteroaryl groups further optionally being fused with a phenyl group;
Figure imgf000031_0001
together with the nitrogen atom to which they are attached represent a 5- or 6-membered heteroaryl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, or a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, said heterocyclyl group optionally being substituted with 1 or 2 substituents selected from the group consisting of methyl and ethyl groups which are optionally substituted with a dimethylamino group or a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen and oxygen atoms, phenyl groups which are optionally substituted with a substituent selected from the group consisting of methoxy, ethoxy and trifluoromethyl groups, benzyl groups, and methoxycarbonyl and ethoxycarbonyl groups, said heterocyclyl group optionally being fused with a phenyl group;
Substituents α4 are selected from the group consisting of methoxy groups, cyclopropyl groups, 5- or 6-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen and oxygen atoms which are unsubstituted or are substituted with a methyl group, and 5- or 6-membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen and sulfur atoms which are unsubstituted or are substituted with 1 or 2 substituents selected from the group consisting of methyl groups and methoxycarbonyl groups; and
Substituents β4 are selected from the group consisting of methyl groups, methoxy groups, ethoxy groups, trifluoromethyl groups, methylthio groups, chlorine atoms, acetyl groups, phenyl groups which are unsubstituted or are substituted with a methoxy group, benzyl groups, benzyloxy groups and 5- or 6-membered heterocyclyl groups having 1 or 2 nitrogen heteroatoms; (14) R2 is selected from the group consisting of ethoxy groups and groups of formula -NR6R7 wherein R6 and R7 are the same or different and each is selected from the group consisting of: hydrogen atoms; methyl, ethyl, 1-methylbutyl and 1-ethylpropyl groups, 2-methoxyethyl, cyclopropylmethyl, 3-(morpholin-4-yl)propyl, tetrahydrofuran-2- ylmethyl, 2-(pyrrolidin-l-yl)ethyl, 3-(pyrrolidin-l-yl)propyl, 3-(4-methylpiperazin-l- yl)propyl, 2-methoxycarbonyl-4-methylthiophen-3 -ylmethyl, 3 -(imidazol- 1 -yl)propyl, thiophen-2-ylmethyI and pyridin-2-ylmethyl groups; allyl groups; cyclobutyl groups, 2-methylcyclohexyl groups and 1,2,3,4-tetrahydro- naphthalen-1-yl groups; phenylhydrazido groups; phenyl and naphthyl groups; 2-, 3-, 4-, 5- and 6-methylphenyl, 2-, 3-, 4-, 5- and 6-ethylphenyl, 2-, 3-, 4-, 5- and 6- methoxyphenyl, 2-, 3-, 4-, 5- and 6-ethoxyphenyl, 2-, 3-, 4-, 5- and 6-methyl-sulfanylphenyl, 2-, 3-, 4-, 5- and 6-trifluoromethylphenyl, 2-, 3-, 4-, 5- and 6-chloro-phenyl, 2-, 3-, 4-, 5- and 6-acetylphenyl, biphenyl-2-yl, biphenyl-3-yl, 2-, 3-, 4-, 5- and 6-benzylphenyl, 2-, 3-, 4-, 5- and 6-benzyloxyphenyl, 2-, 3-, 4-, 5- and 6-(piperidin-l-yl)phenyl, 2,5-dimethoxyphenyl, 3- methoxy-5 -trifluoromethylphenyl, 2-methoxy-5 -methylphenyl, 3 , 5 -bis-trifluoromethylphenyl and 4-methoxybiphenyl-3-yl groups;
2,3-dihydrobenzo[l ,4]dioxin-6-yl groups; benzyl, diphenylmethyl and 3, 3 -diphenylpropyl groups; 2-trifluoromethylbenzyl, 3,5-bis-trifluoromethylbenzyl, 2-methoxybenzyl, 2-(2- methoxyphenyl)ethyl, 2-(3-methoxyphenyl)ethyl, 2-(4-methoxyphenyl)ethyl and 2,6- dimethoxybenzyl groups; benzofl ,3]dioxol-5-ylmethyl groups, 1 -ethoxycarbonylpiperidin-4-yl groups; thiazol-2-yI groups;
2-ethyl-2H-pyrazol-3-yl, 5-methylisoxazol-3-yl, 2-ethoxycarbonyl-4-methyl- thiophen-2-yl and 2-methoxycarbonylthiophen-2-yl groups; and benzothiazol-2-yl groups; or R6 and R7 together with the nitrogen atom to which they are attached represent a substituent selected from the group consisting of thiazolidin-3-yl, pyrrolidin-l-yl, pyrrolin-l-yl, piperidin-1-yl, piperazin-1-yl, morphoIin-4-yl, thiomorpholin-l-yl, 2,5- dihydropyrrol-l-yl, decahydroquinolin-l-yl, 4-methylpiperidin-l-yl, 2,6-dimethyl-morpholin- 4-yl, 4-methylpiperazin-l-yl, 4-(2-dimethylaminoethyl)piperazin-l-yl, 4-[2-(morpholin-4- yl)ethyl]piperazin-l-yl, 4-phenylpiperazin-l-yl, 4-(2-morpholin-4-yl-ethyl)piperazin-l-yl, 4- (3 -trifluoromethy lphenyl)piperazin- 1 -yl, 4-(2-methoxyphenyl)-piperazin- 1 -yl, 4- benzylpiperazin-1-yl, 3,4-dihydro-2H-quinolin-l-yl and 4-ethoxycarbonylpiperidin-l-yl groups; and
(15) R2 is selected from the group consisting of ethoxy groups and groups of formula -NR6R7 wherein R6 and R7 are the same or different and each is selected from the group consisting of: hydrogen atoms, methyl groups, thiophen-2-ylmethyl groups, cyclobutyl groups, phenyl groups, naphthyl groups, 2-methoxyphenyl groups, 4-methoxyphenyl groups, 3-ethoxyphenyl groups, 3-methylsulfanylphenyl groups, 4-chlorophenyl groups, biphenyl-2- yl groups, 3-benzyloxyphenyl groups, 4-(piperidin-l-yl)phenyl groups, 2,5-dimethoxyphenyl groups, 3 -methoxy-5 -trifluoromethylphenyl groups, 2-methoxy-5-methylphenyl groups, 2- trifluoromethylbenzyl groups, l-ethoxycarbonylpiperidin-4-yl groups, thiazol-2-yl groups and 5-methylisoxazol-3-yl groups; or R6 and R7 together with the nitrogen atom to which they are attached represent a substituent selected from the group consisting of thiazolidin-3-yl, 3,4-dihydro-2H-quinolin-l- yl, 2,5-dihydropyrrol-l-yl, 4-phenylpiperazin-l-yl, 4-(2-methoxyphenyl)piperazin-l-yl and 4- benzylpiperazin-1-yl groups.
More preferred classes of compounds of the present invention are those compounds of formula (I) and pharmacologically acceptable salts thereof wherein:
(i) X is as defined in (1) above, Y is as defined in (6) above and R2 is as defined in (10) above;
(ii) X is as defined in (2) above, Y is as defined in (7) above and R2 is as defined in (11) above;
(iii) X is as defined in (3) above, Y is as defined in (7) above and R2 is as defined in (12) above; (iv) X is as defined in (3) above, Y is as defined in (7) above and R2 is as defined in (13) above;
(v) X is as defined in (3) above, Y is as defined in (7) above and R2 is as defined in (14) above;
(vi) ■ X is as defined in (3) above, Y is as defined in (7) above and R2 is as defined in (15) above;
(vii) X is as defined in (4) above, Y is as defined in (8) above and R2 is as defined in (13) above;
(viii) X is as defined in (4) above, Y is as defined in (8) above and R2 is as defined in (14) above;
(ix) X is as defined in (4) above, Y is as defined in (8) above and R2 is as defined in (15) above;
(x) X is as defined in (5) above, Y is as defined in (9) above and R2 is as defined in (13) above;
(xi) X is as defined in (5) above, Y is as defined in (9) above and R2 is as defined in (14) above; and
(xii) X is as defined in (5) above, Y is as defined in (9) above and R2 is as defined in (15) above.
Particularly preferred compounds of the present invention are those compounds of formula (I) and pharmacologically acceptable salts thereof selected from the group consisting of:
N-(2-trifluoromethylbenzyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)-oxazole- 4-carboxamide;
5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)-4-[(4-phenylpiperazin-l- yl)carbonyl]oxazole; N-(2-methoxy-5-methylphenyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4- carboxamide;
5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)-4-[[4-(2-methoxyphenyl)-piperazin- l-yl]carbonyl]oxazole;
N-(2,5-dimethoxyphenyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)- oxazole-4-carboxamide;
N-(naphthalen-l-yl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole- 4-carboxamide;
N-(2-methoxyphenyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole- 4-carboxamide;
N-(3-methylsulfanylphenyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)- oxazole-4-carboxamide;
N-[4-(piperidin-l-yl)phenyl]-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)- oxazole-4-carboxamide;
N-(4-methoxyphenyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole- 4-carboxamide;
N-allyl-5-(4-dimethylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4- carboxamide;
N-(2-trifluoromethylbenzyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4- carboxamide;
N-(3-methoxy-5-trifluoromethylphenyl)-5-(4-acetylaminophenyl)-2-phenyl- oxazole-4-carboxamide; and
N-cyclopropylmethyl-N-propyl-5-(4-acetylaminophenyl)-2-(4-tert- butylphenyl)-oxazole-4-carboxamide.
The compounds of formula (I) and pharmacologically acceptable salts thereof of the present invention can be prepared according to a variety of processes well known in the art for the preparation of compounds of this type, for example as described in the following methods A to F below.
Method A
Reaction Scheme A
Figure imgf000036_0001
(II) (HI)
(IV)
Figure imgf000036_0002
In the above formulae, Xa represents a substituent selected from the group consisting of phenyl groups, heteroaryl groups as defined above and heterocyclyl groups as defined above, in which said substituent is substituted with a nitro group or Xa represents a pyridine group or a pyrimidine group; Yis as defined above; R2a represents an alkyl group having from 1 to 6 carbon atoms; and L1 and L2 are leaving groups. Step Al
In this step, a glycine ester of formula (II), wherein R2a is as defined above, is reacted with a group of formula (III), wherein Y and L1 are as defined above to give an amide of formula (IV).
The leaving group L1 is a group which is capable of leaving as a nucleophilic residue. Examples include halogen atoms such as fluorine, chlorine, bromine and iodine, trihalogenomethyloxy groups such as trichloromethoxy, lower alkanesulfonyloxy groups such as methanesulfonyloxy and ethanesulfonyloxy groups, lower halogeno allcane sulfonyloxy groups such as trifluoromethanesulfonyloxy and pentafluoroethanesulfonyloxy groups, and arylsulfonyloxy groups such as benzenesulfonyloxy, p-toluenesulfonyloxy and p- nitrobenzenesulfonyloxy groups. Of these, halogen atoms are preferred, and chlorine atoms are particularly preferred.
The reaction is preferably performed in the presence of an organic base as a catalyst, e.g. triethylamine.
The reaction is normally and preferably effected in the presence of a solvent. There is no particular restriction on the solvent used, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. Examples of suitable solvents which can be used include: halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and dichloroethane; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane; aprotic polar solvents such as dimethylformamide, dimethylacetamide and dimethylsulfoxide; nitriles such as acetonitrile; esters such as methyl acetate and ethyl acetate; aromatic hydrocarbons such as benzene, toluene and xylene; aliphatic hydrocarbons such as pentane, hexane and heptane; and mixtures thereof. Of these, we prefer halogenated hydrocarbons and particularly prefer dichloromethane .
The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. The preferred reaction temperature will depend upon such factors as the nature of the solvent, and the starting material or reagent used. However, in general, we find it convenient to carry out the reaction at a temperature of from -78°C to 100°C, more preferably from -78°C to room temperature, and most preferably at 0°C to room temeperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 10 minutes to 24 hours, more preferably from 1 hour to 20 hours, and most preferably from 1 to 5 hours will usually suffice.
Step A2
This involves the reaction of the compound of formula (IV), prepared in Step Al above, with Lawesson's reagent [2,4-bis(4-methoxyphenyl)-l,3-dithia-2,4- diphosphetane-2,4-disuIfide] to give a compound of formula (V) in which the carbonyl group of the amide moiety of the compound of formula (IV) has been converted to a thiocarbonyl group.
The use of Lawesson's reagent as a thiating reagent is well-known in the field of synthetic organic chemistry [see, for example, Bull. Soc. Chim. Belg., 87, 223, 229, 299, 525 (1978); Synthesis, 941 (1979); and Tetrahedron, 35, 2433 (1979)] and this step can be performed in conventional manner.
Step A3
This step involves reaction of the compound of formula (V), produced in Step A2 above, with trimethyloxonium tetrafluoroborate to give a compound of formula (VI) in which the thioamide moiety has been converted to a methylsulfanylmethylenimino moiety. The use of trimethyloxonium tetrafluoroborate to effect this conversion is well-known in the field of synthetic organic chemistry and the reaction can be performed using these well- known techniques [see, for example, Yokoyama et al., Synthesis, 1994, 1467-1470; Gompper et al., Angew. Chem., 95(9), 1983, 727-729; Casadei et al., Synth. Commun., 13(9), 1983, 753-760; Yokoyama et al., Bull. Chem. Soc. Jpn., 67(8), 1994, 2219-2226; Kreher et al., Z. Chem., 22(7), 1982, 258-259; Tueckmantel et al., Angew. Chem., 97(7), 1985, 592-594; and Kuhn et al., Pestic. Sci.; 41(3), 1994, 279-286].
The reaction is normally and preferably effected in the presence of a solvent. There is no particular restriction on the solvent used, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. Examples of suitable solvents which can be used include: halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and dichloroethane; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane; aprotic polar solvents such as dimethylformamide, dimethylacetamide and dimethylsulfoxide; nitriles such as acetonitrile; esters such as methyl acetate and ethyl acetate; aromatic hydrocarbons such as benzene, toluene and xylene; aliphatic hydrocarbons such as pentane, hexane and heptane; and mixtures thereof. Of these, we prefer halogenated hydrocarbons and particularly prefer dichloromethane.
The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. The preferred reaction temperature will depend upon such factors as the nature of the solvent, and the starting material or reagent used. However, in general, we find it convenient to carry out the reaction at a temperature of from -78°C to 100°C, more preferably from -78°C to room temperature, and most preferably at 0°C to room temeperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 10 minutes to 24 hours, more preferably from 1 hour to 20 hours, and most preferably from 1 to 5 hours will usually suffice.
Step A4
This step involves reaction of the compound of formula (NI), prepared as described in Step A3 above, with a compound of formula (VII), in which Xa and L2 are as defined above, in the presence of a base to give the desired oxazole derivative of formula (la) of the present invention, in which Y, Xa and R2 are as defined above.
This reaction involves reaction of the compound of formula (VI) with the compound of formula (VII) via enolised intermediates in which the leaving group L2 is first eliminated and then cyclisation takes place to give the compound of formula (la). The leaving group L2 is a group which is capable of leaving as a nucleophilic residue, examples of which are as given for L1 above. Halogen atoms are preferred and chlorine atoms are particularly preferred. The base used can be any which is typically used in such reactions, examples of which include organic bases such as organic amines, and triethylamine is particularly preferred.
The reaction is normally and preferably effected in the presence of a solvent. There is no particular restriction on the solvent used, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. Examples of suitable solvents which can be used include: halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and dichloroethane; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane; aprotic polar solvents such as dimethylformamide, dimethylacetamide and dimethylsulfoxide; nitriles such as acetonitrile; esters such as methyl acetate and ethyl acetate; aromatic hydrocarbons such as benzene, toluene and xylene; aliphatic hydrocarbons such as pentane, hexane and heptane; and mixtures thereof. Of these, we prefer halogenated hydrocarbons and particularly prefer dichloromethane.
The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. The preferred reaction temperature will depend upon such factors as the nature of the solvent, and the starting material or reagent used. However, in general, we find it convenient to carry out the reaction at a temperature of from -78°C to 100°C, more preferably from 0°C to 100°C, and most preferably at 0°C to room temeperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 10 minutes to 24 hours, more preferably from 1 hour to 20 hours, and most preferably from 5 to 10 hours will usually suffice.
Method B
Reaction Scheme B
Figure imgf000041_0001
Figure imgf000041_0002
In the above formulae, Y, X and R2a are as defined above, R6 and R7a are the same as R6 and R7 defined above or are a protected version thereof in which a functional group present therein is protected by a protecting group and X represents a substituent selected from the group consisting of phenyl groups, heteroaryl groups as defined above and heterocyclyl groups as defined above, in which said substituent is substituted with an amino group.
Step Bl
This step involves hydrolysis of the ester group CO2R2a present in the compound of formula (la), prepared as described in Step A4 above, to give a compound of formula (lb) of the present invention. The hydrolysis of an ester to give a free carboxyl group is well-known in the field of synthetic organic chemistry and can be performed using well- known techniques.
More specifically, the hydrolysis reaction can be performed in the presence of a base or an acid. Examples of the acid include hydrochloric acid, sulfuric acid, phosphoric acid and hydrobromic acid; where a base is used, it is not particularly limited, provided that it does not affect other parts of the compound, and preferred examples include alkali metal carbonates such as sodium carbonate and potassium carbonate, alkali metal hydroxides such as sodium hydroxide and potassium hydroxide or a cone, ammonia-methanol solution. Alkali metal hydroxides are particularly preferred.
The solvent employable here is not particularly limited, provided that it is one usually used in hydrolysis reactions and does not inhibit the reaction, and preferred examples thereof include alcohols, e.g. methanol, ethanol or n-propanol, or ethers, e.g. tetrahydrofuran or dioxane, or mixtures thereof. Where an alkali metal hydroxide is employed, alcohols such as methanol or ethanol or mixtures thereof with an ether such as tetrahydrofuran are particularly preferred.
While the reaction temperature and time vary depending on the starting material, the solvent, the reagent used, etc. and are not particularly limited, the reaction is usually carried out at a temperature of from 0°C to 150°C, preferably room temperature to 100°C, for a period of from 30 minutes to 10 hours and preferably from 1 to 5 hours.
Step B2
This step involves reaction of the compound of formula (lb) of the present invention, prepared as described in Step Bl above, with an amine of formula R6aR7aNH, wherein R6 andR7a are as defined above to give an amide of formula (Ic) of the present invention.
This conversion of a carboxylic acid to an amide by reaction with an amine is well-known in the field of synthetic organic chemistry and can be performed using any of the well-known techniques. For example, the carboxylic acid of formula (lb) can be reacted with the amine of formula R6 R7 NH in the presence of an amidation catalyst such as 2-chloro-l,3- dimethyl-2-imidazolinium chloride.
There is no particular restriction on the solvent used, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. Examples of suitable solvents which can be used include: ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane; aprotic polar solvents such as dimethylformamide, dimethylacetamide and dimethyl sulfoxide; nitriles such as acetonitrile; esters such as methyl acetate and ethyl acetate; aromatic hydrocarbons such as benzene, toluene and xylene; aromatic heterocyclic compounds such as pyridine; and aliphatic hydrocarbons such as pentane, hexane and heptane; and mixtures thereof. Aromatic heterocyclic compounds such as pyridine and nitriles such as acetonitrile, and mixtures thereof are particularly preferred.
While the reaction temperature and time vary depending on the starting material, the solvent, the reagent used, etc. and are not particularly limited, the reaction is usually carried out at a temperature of from 0°C to 150°C, preferably room temperature to 100°C, for a period of from 30 minutes to 30 hours and preferably from 1 to 24 hours.
Step B3
This step involves reduction of the nitro group present in the substituent Xa in the compound of formula (Ic), prepared as described in Step B2 above, to an amino group to give a compound of formula (Id).
This reduction reaction can be performed according using any conventional technique for the conversion of a nitro group to an amino group, e.g. hydrogenation in the presence of a hydrogenation catalyst such as palladium on activated carbon.
The reaction is usually and preferably performed in the presence of a solvent. There is no particular restriction on the solvent used, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. Examples of suitable solvents which can be used include: ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane; aprotic polar solvents such as dimethylformamide, dimethylacetamide and dimethyl sulfoxide; nitriles such as acetonitrile; esters such as methyl acetate and ethyl acetate; aromatic hydrocarbons such as benzene, toluene and xylene; and aliphatic hydrocarbons such as pentane, hexane and heptane; and mixtures thereof. Esters such as methyl acetate and ethyl acetate are particularly preferred.
While the reaction temperature and time vary depending on the starting material, the solvent, the reagent used, etc. and are not particularly limited, the reaction is usually carried out at a temperature of from 0°C to 100°C, preferably 0°C to room temperature, for a period of from 30 minutes to 30 hours and preferably from 1 to 24 hours. Method C
Reaction Scheme C
Figure imgf000044_0001
In the above formulae, Xa, Xb, Y, R2a, R6a andR7a are as defined above and Xc represents a substituent selected from the group consisting of phenyl groups, heteroaryl groups as defined above and heterocyclyl groups as defined above, in which said substituent is substituted with a group of formula -NHR10 wherein R10 represents a lower alkyl group as defined above or an aryl group as defined above.
Step CI
This involves reduction to an amino group of the nitro substituent on the group X*in the compound of formula (la), prepared as described in Step A4 above, to give a compound of formula (le) in which Xb is as defined above. This reduction step is performed in a similar manner to that described in Step B3 above. Step C2
This involves reaction of the compound of formula (le), prepared as described in Step CI above, with a monoalkylating or monoarylating reagent to give a compound of formula (If) in which the amino group of the moiety Xb has been converted to a monoalkylamino group or monoarylamino group of formula -NHR10.
Where the amino group of Xb is to be converted to a monoalkylamino group, this can be performed using any technique known in synthetic organic chemistry for such a reaction. For example, the compound of formula (le) can be reacted with a trialkyloxonium tetrafluoroborate. The reaction is normally and preferably effected in the presence of a solvent. There is no particular restriction on the solvent used, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. Examples of suitable solvents which can be used include: halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and dichloroethane; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane; aprotic polar solvents such as dimethylformamide, dimethylacetamide and dimethylsulfoxide; nitriles such as acetonitrile; esters such as methyl acetate and ethyl acetate; aromatic hydrocarbons such as benzene, toluene and xylene; aliphatic hydrocarbons such as pentane, hexane and heptane; and mixtures thereof. Of these, we prefer halogenated hydrocarbons and particularly prefer dichloromethane.
The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. The preferred reaction temperature will depend upon such factors as the nature of the solvent, and the starting material or reagent used. However, in general, we find it convenient to carry out the reaction at a temperature of from -78°C to 100°C, more preferably from 0°C to 100°C, and most preferably at 0°C to room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 10 minutes to 24 hours, more preferably from 1 hour to 20 hours, and most preferably from 1 to 5 hours will usually suffice.
An alternative for conversion of the amino group of Xb to a monoalkylamino group involves reaction of the compound of formula (le) with a lcetone of formula R8R9CO, wherein R8 and R9 are the same or different and each represents an alkyl group having from 1 to 3 carbon atoms, provided that R8 and R9 do not both represent a propyl group, to give an imine intermediate which is then reduced to give a compound of formula (If) in which the group of formula -NHR10 is a branched monoalkylamino group. This is a standard technique in synthetic organic chemistry and can be performed using any technique known for such a reaction [see, for example, Horner et al., Can. J. Chem. 1966, 44, 315; Meiners et al., J. Org. Chem., 1958, 23, 1122; Richardson et al., J. Chem. Soc, 1962, 2758; Hamlin et al., J. Am. Chem. Soc, 1953, 75, 369; and Fry et al., J. Org. Chem. 1984, 49(25), 4877].
Where the amino group of Xb is to be converted to a monoarylamino group, this can be performed using any technique known in synthetic organic chemistry for such a reaction. For example suitable techniques are described in Rivas et al., Tetrahedron, Asymmetry, 11, 8, 2000, 1703; Swamy et al., Bioorg. Med. Chem. Lett., 10, 4, 2000, 361; Edmondson et al., Org. Lett., 2, 8, 2000, 1109; Mugrage et al., 41, 13, 2000, 2047; and Prashad et al., J. Org. Chem., 65, 8, 2000, 2612.
Step C3
This step involves hydrolysis of the ester group CO2R2a present in the compound of formula (If), prepared as described in Step C2 above, to give a compound of formula (Ig) of the present invention. This hydrolysis step is performed in a similar manner to that described in Step Bl above.
Step C4
This step involves reaction of the compound of formula (Ig) of the present invention, prepared as described in Step C3 above, with an amine of formula R6aR7aNH, wherein R6aandR7a are as defined above to give an amide of formula (Ih) of the present invention. This step is performed in a similar manner to that described in Step B2 above. Method D
Reaction Scheme D
Figure imgf000047_0001
In the above formulae, Xb, Y, R2a, R6a and R7a are as defined above and Xd represents a substituent selected from the group consisting of phenyl groups, heteroaryl groups as defined above and heterocyclyl groups as defined above, in which said substituent is substituted with a group of formula -N(R12)2 wherein each R 2 is the same or different and represents a lower alkyl group as defined above or an aryl group as defined above.
Step Dl
This step involves reaction of a compound of formula (le), prepared as described in Step CI above, with a dialkylating or diarylating reagent to give a compound of formula (Ii) in which the amino group of the moiety Xb has been converted to a dialkylamino group or diarylamino group of formula -N(R12)2.
Where the amino group of X is to be converted to a dialkylamino group, this can be performed using any technique known in synthetic organic chemistry for such a reaction. For example, the compound of formula (le) can be reacted with an aldehyde of formula RπCHO where R11 is a hydrogen atom or an alkyl group having from 1 to 5 carbon atoms followed by catalytic reduction of the imino groups thus formed to give the desired dialkylamino compound. This is a method well-known in the field of synthetic organic chemistry and can be performed using standard reaction conditions. For example, an alcoholic solution of the compound of formula (le) can be reacted with formaldehyde and hydrogen in the presence of a hydrogenation catalyst such as palladium on activated carbon to give a compound of formula (Ii) in which the amino group of the moiety Xb has been converted to a dimethylamino group.
As an alternative, where the amino group of the substituent Xb in the compound of formula (le) is to be converted to a dialkylamino group, this can be performed by reacting the compound of formula (le) with a group of formula R13-L4 wherein R13 is a lower alkyl group as defined above and L4 is a group which is capable of leaving as a nucleophilic residue, examples of which are as given for L above. This is a reaction well- known in the field of synthetic organic chemistry and can be performed using well-known techniques.
Step D2
This step involves hydrolysis of the ester group CO2R2a present in the compound of formula (Ii), prepared as described in Step Dl above, to give a compound of formula (Ij) of the present invention. This hydrolysis step is performed in a similar manner to that described in Step B 1 above.
Step D3
This step involves reaction of the compound of formula (Ij) of the present invention, prepared as described in Step D2 above, with an amine of formula R6aR7aNH, wherein R6aan R7a are as defined above to give an amide of formula (Ik) of the present invention. This step is performed in a similar manner to that described in Step B2 above.
Method E
Reaction Scheme E
Figure imgf000049_0001
In the above formulae, Xb, Y, R2a, R6aandR7 are as defined above and Xe represents a substituent selected from the group consisting of phenyl groups, heteroaryl groups as defined above and heterocyclyl groups as defined above, in which said substituent is substituted with a group of formula -NHCOR14 wherein R14 is a lower alkyl group as defined above, aryl group as defined above, heteroaryl group as defined above or cycloalkyl group as defined above and L3 is a leaving group.
Step El This step involves reaction of a compound of formula (le), prepared as described in Step CI above, with an acylating agent of formula R14COL3 to give a compound of formula (II) in which the amino group of the moiety Xb has been converted to an acylamino group of formula -NHCOR14.
This is a reaction well-known in the field of synthetic organic chemistry and can be performed using well-known techniques. L3 is a group which is capable of leaving as a nucleophilic residue, examples of which are as given for L1 above. Preferably, L3 is a halogen atom, and most preferably a chlorine atom.
Preferably, the reaction is performed in the presence of an organic amine as a catalyst, e.g. pyridine.
The reaction is normally and preferably effected in the presence of a solvent. There is no particular restriction on the solvent used, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. Examples of suitable solvents which can be used include: halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and dichloroethane; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane; aprotic polar solvents such as dimethylformamide, dimethylacetamide and dimethylsulfoxide; nitriles such as acetonitrile; hydrocarbons such as benzene, toluene and xylene; aliphatic hydrocarbons such as pentane, hexane and heptane; and mixtures thereof. Of these, we prefer halogenated hydrocarbons and particularly prefer dichloromethane.
The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. The preferred reaction temperature will depend upon such factors as the nature of the solvent, and the starting material or reagent used. However, in general, we find it convenient to carry out the reaction at a temperature of from -78°C to 100°C, more preferably from 0°C to 100°C, and most preferably at 0°C to room temperature. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 10 minutes to 24 hours, more preferably from 30 minutes to 5 hours, and most preferably from 30 minutes to 5 hours will usually suffice. Step E2
This step involves hydrolysis of the ester group CO2R2 present in the compound of formula (II), prepared as described in Step El above, to give a compound of formula (Im) of the present invention. This hydrolysis step is performed in a similar manner to that described in Step Bl above.
Step E3
This step involves reaction of the compound of formula (Im) of the present invention, prepared as described in Step E2 above, with an amine of formula R6aR7aNH, wherein R6 andR7a are as defined above to give an amide of formula (In) of the present invention. This step is performed in a similar manner to that described in Step B2 above.
Method F
Reaction Scheme F
Figure imgf000052_0001
Method F provides alternative routes for the production of compounds of formulae (Ih), (Ik) and (In) using a compound of formula (Id), prepared as described in Step B3 above, as a starting material. Xb, Xc, Xd, Xe, Y, R6a, R7a, L3 and R14 are as defined above.
Step FI This involves reaction of the compound of formula (Id), prepared as described in Step B3 above, with a monoalkylating or monoarylating reagent to give a compound of formula (Ih) in which the amino group of the moiety Xb has been converted to a monoalkylamino group or monoarylamino group of formula -NHR10 wherein R10 is as defined above. This monoalkylating or monoarylating step is performed in a similar manner to that described in Step C2 above.
Step F2
This step involves reaction of a compound of formula (Id), prepared as described in Step B3 above, with an acylating agent of formula R14COL3, wherein R14 and L3 are as defined above, to give a compound of formula (In) in which the amino group of the moiety Xb has been converted to an acylamino group of formula -NHCOR14. This acylating step is performed in a similar manner to that described in Step El above.
Step F3
This step involves reaction of a compound of formula (Id), prepared as described in Step B3 above, with a dialkylating or diarylating reagent to give a compound of formula (Ik) in which the amino group of the moiety Xb has been converted to a dialkylamino group or diarylamino group of formula -N(R12)2 wherein R12 is as defined above. This dialkylating or diarylating step is performed in a similar manner to that described in Step Dl above.
Where R6a and/or R7a in the compounds of formula (Ic), (Id), (Ih), (Ik) and (In) produced in Methods B to F above are protected versions of R6a and/or R7a, the protecting groups can be removed at any point after introduction of the moiety
-NR6 R7a according to techniques well-known in the art to give the unprotected compounds of the present invention. The protecting groups used are ones in which a functional group (for example, an amino group) is modified by the addition of a protecting group using conventional techniques well-known in the art (see, for example, "Protective Groups in Organic Synthesis, Second Edition, Theodora W. Greene and Peter G.M. Wuts, 1991, John Wiley & Sons, Inc.). The protecting group is a protecting group which is removable by a chemical process such as hydrolysis, hydrogenolysis, electrolysis or photolysis. After completion of each of the reactions described in the steps of Method A to Method F above, the desired compound may be isolated from the reaction mixture in a conventional manner. For example, it can be obtained by neutralizing the reaction mixture as needed, removing insoluble matters by filtration, if any are present, adding organic solvents which are not miscible with each other, such as water and ethyl acetate, washing with water or the like, separating the organic layer containing the desired compound, drying it over anhydrous magnesium sulfate or the like and then distilling off the solvent.
If necessary, the desired compound thus obtained can be isolated and purified by using a conventional method such as recrystallization or reprecipitation or by a chromatographic method. Examples of chromatography include adsorption column chromatography using a carrier such as silica gel, alumina or magnesium-silica gel type Florisil, chromatography using a synthetic adsorbent, for example, partition column chromatography using a carrier such as Sephadex LH-20 (product of Pharmacia), Amberlite XAD-11 (product of Rohm & Haas) or Diaion HP-20 (product of Mitsubishi Chemical), ion exchange chromatography and normal-phase-reverse-phase column chromatography (high- performance liquid chromatography) using a silica gel or alkylated silica gel, e.g. Prontosil Prep 2005® (product of Bischoff, Inc) and ZORBAX® SB-C-8 columns (product of Hewlett- Packard, Inc.). If necessary, two or more of these techniques can be used in combination to isolate and purify the desired compound.
The oxazole derivatives of formula (I) and pharmacologically acceptable salts thereof of the present invention show excellent activity in inhibiting the production of IL-4 in warm-blooded animals, which may be humans. Consequently, they are effective as a medicament, particularly as an agent for the prophylaxis or treatment of diseases mediated by IL-4 in warm-blooded animals. In particular, said diseases are allergic diseases including asthma, atopic dermatitis, allergic rhinitis, food allergies, and systemic anaphylaxis.
The compounds of formula (I) and pharmacologically acceptable salts thereof according to the present invention can be administered by a number of different routes. Examples of these administration routes include oral administration in the form of tablets, capsules, granules, powders or syrups and parenteral administration in the form of injections or suppositories. Such formulations can be prepared in a known manner by using additives such as an excipients, lubricants, binders, disintegrators, stabilizers, corrigents and diluents. Examples of suitable excipients include: organic excipients, examples of which include sugar derivatives such as lactose, sucrose, dextrose, mannitol and sorbitol, starch derivatives such as corn starch, potato starch, α-starch, dextrin and carboxymethyl starch, cellulose derivatives such as crystalline cellulose, low-substituted hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, calcium carboxymethylcellulose and sodium internally-crosslinked carboxymethyl-cellulose, gum arabic, dextran and pullulan; and inorganic excipients, examples of which include silicate derivatives such as soft silicic acid anhydride, synthetic aluminum silicate and magnesium aluminometasilicate, phosphates such as calcium phosphate, carbonates such as calcium carbonate, and sulfates such as calcium sulfate.
Examples of suitable lubricants include: stearic acid; metal salts of stearic acid such as calcium stearate and magnesium stearate; talc; colloidal silica; waxes such as bee gum and spermaceti; boric acid; adipic acid; sulfates such as sodium sulfate; glycol; fixmaric acid; sodium benzoate; DL-leucine; sodium salts of an aliphatic acid; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; silicic acid derivatives such as silicic anhydride and silicic acid hydrate; and starch derivatives exemplified above as examples of suitable excipients.
Examples of suitable binders include poly inylpyrrolidone, Macrogol and compounds similar to those exemplified above as suitable excipients.
Examples of suitable disintegrators include compounds similar to those exemplified above as suitable excipients and chemically modified starch or cellulose derivatives such as sodium cross carmellose, sodium carboxymethyl starch and crosslinked polyvinylpyrrolidone.
Examples of suitable stabilizers include: paraoxybenzoate esters such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; phenol derivatives such as phenol and cresol; thimerosal; dehydroacetic acid; and sorbic acid. Examples of suitable corrigents include sweeteners, acidifiers and flavors commonly employed for this purpose. The dose of the compound of formula (I) or a pharmacologically acceptable salt thereof according to the present invention will vary depending on a variety of factors including the condition to be treated, the age of the patient and the administration route. When administered orally, it is administered to an adult (e.g. an adult human) in an amount of 0.1 mg (preferably 0.5 mg) a day as a lower limit and 2000 mg (preferably 500 mg) a day as an upper limit. It can be administered in from one to several portions depending on the condition of the patient. When administered intravenously, it is administered to an adult in an amount of 0.01 mg (preferably 0.05 mg) a day as a lower limit and 200 mg (preferably 50 mg) a day as an upper limit. It can be administered in from one to several portions depending on the condition of the patient.
Illustrative Examples
The following examples, reference examples, formulation examples and test examples are intended to further illustrate the present invention and are not intended to limit the scope of the invention in any way.
In the following examples and reference examples, all high pressure liquid chromatography (HPLC) analyses were performed using a Hewlett-Packard ZORBAX® SB- C-8 column (4.6 mm x 30 mm). The 2.5 minute elution method was performed at a flow-rate of 3.0 ml/min and utilized a linear gradient profile (85% water/15% acetonitrile/0.1% TFA -5% water/95% acetonitrile/0.1% TFA). All HPLC purifications were performed using a Bischoff Prontosil Prep 2005® 120-10-C-18-SH column (50 mm x 20 mm). The 3.5 minute elution method was performed at a flow-rate of 40 ml/min and utilized a linear gradient profile (85% water/15% acetonitrile/0.1% TFA -5% water/95%, acetonitrile/0.1% TFA). Examples
Example 1
Ethyl 2-(4-tert-butylphenyl)-5-(4-nitrophenyl)oxazole-4-carboxylate
Figure imgf000057_0001
4-Nitrobenzoyl chloride (64 mmol, 11.8 g) and triethylamine (64 mmol, 8.9 ml) were added to a solution of ethyl [[[l-(4-tert-butylphenyl)-l-methylsulfanyl]methylidene]- aminojacetate (19.8 mmol, 5.8 g), prepared as described in Reference Example 6 below, in dichloromethane (200 ml) and the reaction was stirred for 8 hours at room temperature. At the end of this time, the solvent was removed in vacuo and the crude residue partitioned between diethyl ether (150 ml) and 2M hydrochloric acid solution (100 ml). The organic layer was washed with water (100 ml) and brine (100 ml), dried over sodium sulfate and the solvent removed in vacuo. The resulting residue was subjected to flash chromatography (12.5 % ethyl acetate/hexanes) to provide the title compound as a yellow solid (5.2 g, 67%).
^-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
8.36 (multiplet, 4H);
8.05 (doublet, J = 10 Hz, 2H);
7.56 (doublet, J = 10 Hz, 2H); 4.48 (quartet, J = 7.2 Hz, 2H);
1.43 (triplet, J = 7.2 Hz, 3H);
1.38 (singlet, 9H).
HPLC: Retention time = 1.59 min.
Mass Spectrum (ES+, m/z): 395 (M+H)+.
Example 2
Ethyl 2-(biphenyl-2-yl)-5-(4-nitrophenyl)oxazole-4-carboxylate
Figure imgf000058_0001
The title compound was prepared from ethyl [[[l-(biphenyl-2-yl)-l-methylsulfanyl]- methylidene]amino]acetate, prepared as described in Reference Example 7 below, in a manner analogous to Example 1 above.
^-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm: 8.22 (doublet, J = 10 Hz, 2H); 7.88 (doublet, J = 10 Hz, 2H) 7.80 (doublet, J = 10 Hz, IH) 7.61 (multiplet, IH); 7.52 (multiplet, 2H);
7.25 (multiplet, 5H);
4.30 (quartet, 2H);
1.30 (triplet, 3H).
HPLC: Retention time = 1.43 min.
Mass Spectrum (ES+, m/z): 414 (M+H)+.
Example 3 Ethyl 5-(4-nitrophenyl)-2-phenyloxazole-4-carboxylate
Figure imgf000059_0001
Ebe title compound was prepared from ethyl ff(l-methγlsulfanyl-l- phenyl)methylidene] -amino] acetate, prepared as described in Reference Example 8 below, in a manner analogous to Example 1 above.
^-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
8.35 (multiplet, 4H);
8.12 (multiplet, 2H);
7.53 (multiplet, 3H);
4.48 (quartet, 2H);
1.45 (triplet, 3H); 1.43 (triplet, 3H).
HPLC: Retention time = 1.34 min.
Mass Spectrum (ES+, m/z): 339 (M+H)+.
Example 4 Ethyl 2-(4-tert-butylphenyl)-5-(3-nitrophenyl)oxazole-4-carboxylate
Figure imgf000060_0001
The title compound was prepared from ethyl [[[l-(4-tert-butylphenyl)-l- methylsulfanyl]-methylidene] amino] acetate, prepared as described in Reference Example 6 below, and 3-nitro-benzoyl chloride in a manner analogous to Example 1 above.
1H-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
8.96 (multiplet, IH);
8.50 (multiplet, IH);
8.35 (multiplet, IH);
8.06 (doublet, J = 10 Hz, 2H);
7.70 (triplet, IH);
7.57 (doublet, J = 10 Hz, 2H);
4.49 (quartet, 2H); 1.45 (triplet, 3H);
1.38 (singlet, 9H).
HPLC: Retention time = 1.58 min.
Mass Spectrum (ES+, m/z): 395 (M+H)+.
Example 5 2-(4-tert-Butylphenyl)-5-(4-nitrophenyl)oxazole-4-carboxylic acid
Figure imgf000061_0001
A solution of 10% aqueous sodium hydroxide (10 ml) was added to a solution of ethyl 2-(4-tert-butylphenyl)-5-(4-nitrophenyl)oxazole-4-carboxylate (4.3 mmol, 1.7 g), prepared as described in Example 1 above, in a mixture of methanol (15 ml) and tetrahydrofuran (10 ml). The resulting reaction mixture was stirred for 1 hour and a precipitate gradually formed. At the end of this time, 2M hydrochloric acid solution (50 ml) was added and stirring was continued until a uniform precipitate was obtained. Filtration of the reaction mixture provided the title compound as a yellow solid (1.52 g, 97%). ^-Nuclear Magnetic Resonance Spectrum (300 MHz, d6-DMSO) δ ppm:
8.40 (doublet, J = 10 Hz, 2H);
8.32 (doublet, J = 10 Hz, 2H);
8.05 (doublet, J = 10 Hz, 2H);
7.58 (doublet, J = 10 Hz, 2H);
1.32 (singlet, 9H).
HPLC: Retention time = 1.31 min.
Mass Spectrum (ES+, m/z): 367 (M+H)+.
Example 6
N-(thiazol-2-yl)-2-(4-tert-butylphenyl)-5-(4-nitrophenyl)oxazole-4-carboxamide
Figure imgf000062_0001
2-Chloro-l,3-dimethyl-2-imidazolinium chloride (DMC) (5.3 mmol, 0.9 g) was added to a solution of 2-(4-tert-butylphenyl)-5-(4-nitrophenyl)oxazole-4-carboxylic acid (3.6 mmol, 1.3 g), prepared as described in Example 5 above, in acetonitrile (10 ml) and pyridine (3 ml). 2-Aminothiazole (3.6 mmol, 0.36 g) was then added and the resulting reaction mixture was stirred for 2 hours at room temperature. At the end of this time, the solvent was removed in vacuo and the crude residue partitioned between chloroform (50 ml) and 2M hydrochloric acid solution (20 ml). The organic layer was washed with brine (20 ml), dried over sodium sulfate and the solvent then removed in vacuo. Flash chromatography of the resulting crude residue (20 % ethyl acetate/hexanes) provided the title compound as a yellow solid (990 mg,
Η-Nuclear Magnetic Resonance Spectrum (300 MHz, d6-DMSO) δ ppm:
12.18 (singlet, IH);
8.43 (singlet, 4H);
8.22 (doublet, J = 10 Hz, 2H);
7.60 (doublet, J = 10 Hz, 2H);
7.58 (doublet, J = 3 Hz, IH);
7.35 (doublet, J = 3 Hz, IH);
1.32 (singlet, 9H).
HPLC: Retention time = 1.61 min.
Mass Spectrum (ES+, m/z): 449 (M+H)+.
Example 7
N-(thiazol-2-yl)-5-(4-aminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxamide
Figure imgf000063_0001
10% palladium on activated carbon (0.045 mmol, 0.05 g) was added to a solution of N-(thiazol-2-yl)-2-(4-tert-butylphenyl)-5-(4-nitrophenyl)oxazole-4-carboxamide (0.45 mmol, 0.2 g), prepared as described in Example 6 above, in ethyl acetate (10 ml). The reaction mixture was placed under 101.3 kPa (1 atmosphere) of hydrogen and stirred vigorously overnight. At the end of this time, methanol (20 ml) was added and the solution was heated to dissolve the product. After filtration of the reaction mixture through a pad of Celite®, the solvent was removed in vacuo providing 188 mg (100 %) of the title compound as a yellow solid.
^-Nuclear Magnetic Resonance Spectrum (300 MHz, d6-DMSO) δ ppm:
11.60 (singlet, IH);
8.18 (doublet, J = 10 Hz, 2H);
7.83 (doublet, J = 10 Hz, 2H);
7.59 (doublet, J = 10 Hz, 2H);
7.58 (doublet, J = 3 Hz, IH);
7.35 (doublet, J = 3 Hz, IH);
6.68 (doublet, J = 10 Hz, 2H);
5.90 (singlet, 2H);
1.34 (singlet, 9H).
HPLC: Retention time = 1.33 min.
Mass Spectrum (ES+, m/z): 419 (M+H)+. Example 8
N-(thiazol-2-yl)-2-(4-tert-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000065_0001
Formaldehyde (37% aqueous solution) (1 ml) was added to a solution of Ν-(thiazol-2- yl)-5-(4-aminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxamide (0.48 mmol, 0.2 g), prepared as described in Example 7 above, and 10% palladium on activated carbon (0.1 mmol, 0.1 g) in 95% ethanol (5 ml). The reaction mixture was placed onto a Parr shaker at 379.2 kPa of hydrogen for 4 days. The solvent was then removed in vacuo and the residue partitioned between chloroform (20 ml) and water (10 ml). The organic layer was washed with brine (10 ml) and dried over sodium sulfate. Removal of the solvent in vacuo afforded a yellow residue. Flash chromatography (25% ethyl acetate/hexanes) of this crude residue provided 26.5 mg (12%) of the title compound as a yellow solid.
^-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
10.62 (singlet, IH);
8.30 (doublet, J = 9 Hz, 2H);
7.95 (doublet, J = 9 Hz, 2H)
7.55 (doublet, J = 9 Hz, 2H)
7.53 (doublet, J = 3 Hz, IH) 7.02 (doublet, J = 3 Hz, IH);
6.75 (doublet, J = 9 Hz, 2H);
3.05 (singlet, 6H);
1.38 (singlet, 9H).
HPLC: Retention time = 1.62 min.
Mass Spectrum (ES+, m/z): 447 (M+H)+.
Example 9
Ethyl 5-(4-aminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylate
Figure imgf000066_0001
10% palladium on activated carbon (0.33 mmol, 0.3 g) was added to a solution of ethyl 2-(4-tert-butylphenyl)-5-(4-nitrophenyl)oxazole-4-carboxylate (3.3 mmol, 1.3 g), prepared as described in Example 1 above, in ethyl acetate (50 ml). The reaction mixture was placed under 101.3 kPa (1 atmosphere) of hydrogen and stirred vigorously overnight. At the end of this time, methanol (20 ml) was added and the solution was heated to dissolve the product. After filtration through a pad of Celite®, the solvent was removed in vacuo providing 1.24 g (100 %) of the title compound as a yellow solid. ^-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
8.04 (doublet, J = 9 Hz, 2H);
7.95 (doublet, J = 9 Hz, 2H);
7.52 (doublet, J = 9 Hz, 2H);
6.75 (doublet, J = 9 Hz, 2H);
4.45 (quartet, 2H);
4.00 (singlet, 2H);
1.42 (triplet, 3H);
1.38 (singlet, 9H).
HPLC: Retention time = 1.32 min.
Mass Spectrum (ES+, m/z): 365 (M+H)+.
Example 10
Ethyl 5-(3-aminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylate
Figure imgf000067_0001
10 % palladium on activated carbon (0.16 mmol, 0.15 g) was added to a solution of ethyl 2-(4-tert-butylphenyl)-5-(3-nitrophenyl)oxazole-4-carboxylate (10.5 mmol, 4.15 g), prepared as described in Example 4 above, in ethyl acetate (60 ml). The reaction vessel was fitted to a Parr shaker apparatus and shaken vigorously overnight at 379.2 kPa hydrogen pressure. The reaction mixture was then filtered through a pad of Celite and the solvent was removed in vacuo to provide 1.24 g (100 %) of the title compound as a yellow solid.
^-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
8.04 (doublet, J = 9 Hz, 2H);
7.52 (multiplet, 4H);
7.26 (multiplet, IH);
6.80 (doublet of doublets, = 9 Hz, J2 = 2 Hz, IH);
4.45 (quartet, 2H);
3.88 (broad singlet, 2H);
1.42 (triplet, 3H);
1.38 (singlet, 9H).
HPLC: Retention time = 1.36 min.
Mass Spectrum (ES+, m/z): 365 (M+H)+.
Example 11
Ethyl 5-(4-aminophenyl)-2-(biphenyl-2-yl)oxazole-4-carboxylate
Figure imgf000068_0001
The title compound was prepared from ethyl 2-(biphenyl-2-yl)-5-(4- nitrophenyl)oxazole-4-carboxylate, prepared as described in Example 2 above, in a manner analogous to Example 10 above.
1H-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
7.74 (doublet, J = 9 Hz, IH);
7.57 (doublet, J = 9 Hz, 2H);
7.50 (multiplet, 3H);
7.25 (doublet, J = 9 Hz, 2H);
7.23 (multiplet, 3H);
6.60 (doublet, J = 9 Hz, 2H);
4.25 (quartet, 2H);
3.90 (broad singlet, 2H);
1.25 (triplet, 3H).
HPLC: Retention time = 1.26 min.
Mass Spectrum (ES+, m/z): 385 (M+H)+.
Example 12 Ethyl 5 -(4-aminophenyl)-2-phenyloxazole-4-carboxy late
Figure imgf000069_0001
The title compound was prepared from ethyl 5-(4-nitrophenyl)-2-phenyloxazole-4- carboxylate, prepared as described in Example 3 above, in a manner analogous to Example 10 above.
^-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
8.10 (multiplet, 2H);
7.97 (doublet, J = 9 Hz, 2H);
7.48 (multiplet, 3H);
6.75 (doublet, J = 9 Hz, 2H);
4.45 (quartet, 2H);
4.00 (broad singlet, 2H);
1.32 (triplet, 3H).
HPLC: Retention time = 1.11 min.
Mass Spectrum (ES+, m/z): 309 (M+H)+.
Example 13 Ethyl 2-(4-tert-butylphenyl)-5-(4-methylaminophenyl)oxazole-4-carboxylate
Figure imgf000071_0001
Ethyl 5-(4-aminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylate (626 mg, 1.72 mmol), prepared as described in Example 9 above, was dissolved in dichloromethane (13 ml). Trimethyloxonium tetrafluoroborate (305 mg, 2.06 mmol) was added and the resulting reaction mixture was stirred for 2 hours at room temperature. At the end of this time, the reaction mixture was diluted with dichloromethane (30 ml) and the organic layer washed with sodium hydrogencarbonate and brine. Removal of the solvent from the organic layer in vacuo yielded a crude mixture that was purified via flash chromatography (99.5:0.5 dichloromethane:methanol) to afford the title compound as a yellow solid (110 mg, 16%). Trituration with hexanes/trace ether gave a sample that was analytically pure (20 mg).
1H-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm: 8.04 (doublet, J = 9 Hz, 2H); 7.97 (doublet, J = 9 Hz, 2H); 7.51 (doublet, J = 9 Hz, 2H); 6.64 (doublet, J = 9 Hz, 2H); 4.45 (quartet, 2H);
4.20 (singlet, IH);
2.90 (singlet, 3H);
1.42 (triplet, 3H);
1.38 (singlet, 9H).
HPLC: Retention time = 1.41 min.
Mass Spectrum (ES+, m/z): 379 (M+H)+.
Example 14
2-(4-tert-butylphenyl)-5-(4-methylaminophenyl)oxazole-4-carboxylic acid
Figure imgf000072_0001
A solution of IM potassium hydroxide in ethanol (280 μl, 0.28 mmol) was added to a suspension of ethyl 2-(4-tert-butylphenyl)-5-(4-methylaminophenyl)oxazole-4-carboxylate, prepared as described in Example 13 above, in ethanol (2 ml). The reaction mixture was stirred for 6 hours at 60°C. At the end of this time, the reaction mixture was cooled to room temperature and the solvent was removed in vacuo. The resulting residue was diluted with water (10 ml). A IN hydrochloric acid solution (300 μl) was added and the suspension extracted with ethyl acetate (2 x 20 ml). The combined organic layers were washed with brine and dried over magnesium sulfate. Removal of the solvent in vacuo yielded a yellow oil that was triturated with 1 : 1 hexanes :ether to afford the title compound as a yellow solid (33 mg, 39%).
1H-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
8.22 (doublet, J = 9 Hz, 2H);
7.92 (doublet, J = 9 Hz, 2H);
7.52 (doublet, J = 9 Hz, 2H);
6.66 (doublet, J = 9 Hz, 2H);
2.92 (singlet, 3H);
1.38 (singlet, 9H).
HPLC: Retention time = 1.14 min.
Mass Spectrum (ES+, m/z): 351 (M+H)+.
Example 15 Ethyl 2-(4-tert-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylate
Figure imgf000073_0001
Formaldehyde (37% aqueous solution) (1 ml) was added to a suspension of ethyl 5- (4-aminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylate (1 mmol, 0.36 g), prepared as described in Example 9 above, and 10% palladium on activated carbon (0.1 mmol, 0.1 g) in 95% ethanol (5 ml). The reaction vessel was fitted to a Parr apparatus and shaken at 379.2 kPa (hydrogen atmosphere) for 4 days. The solvent was then removed in vacuo and the residue partitioned between chloroform (20 ml) and water (10 ml). The organic layer was washed with brine (10 ml), dried over sodium sulfate and the solvent removed. The resulting residue was subjected to flash chromatography (25% ethyl acetate/hexanes) providing 180 mg (45 %) of the title compound as a yellow solid.
^-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
8.03 (multiplet, 4H);
7.52 (doublet, J = 9 Hz, 2H);
6.75 (doublet, J = 9 Hz, 2H);
4.45 (quartet, 4H);
3.06 (singlet, 6H);
1.43 (triplet, 3H);
1.38 (singlet, 9H).
HPLC: Retention time = 1.60 min.
Mass Spectrum (ES+, m/z): 393 (M+H)+.
Example 16
Ethyl 5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxylate
Figure imgf000075_0001
The title compound was prepared from ethyl 5-(4-aminophenyl)-2-phenyloxazole-4- carboxylate, prepared as described in Example 12 above, in a manner analogous to Example 15 above.
^-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
8.10 (multiplet, 2H);
8.02 (doublet, J = 9 Hz, 2H);
7.48 (multiplet, 3H);
6.75 (doublet, J = 9 Hz, 2H);
4.45 (quartet, 2H);
3.05 (singlet, 6H);
1.42 (triplet, 3H).
HPLC: Retention time = 1.37 min.
Mass Spectrum (ES+, m/z): 337 (M+H)+. Example 17 Ethyl 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylate
Figure imgf000076_0001
The title compound was prepared from ethyl 5-(3-aminophenyl)-2-(4-tert- butylphenyl)-oxazole-4-carboxylate, prepared as described in Example 10 above, in a manner analogous to Example 15 above.
Η-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
8.04 (doublet, J = 9 Hz, 2H);
7.52 (doublet, J = 9 Hz, 2H);
7.48 (multiplet, 2H);
7.36 (multiplet, IH);
6.85 (doublet of doublets, Jj = 9 Hz, J2 = 2 Hz, IH);
4.45 (quartet, 2H);
3.02 (singlet, 6H);
1.43 (triplet, 3H);
1.36 (singlet, 9H).
HPLC: Retention time = 1.27 min. Mass Spectrum (ES+, m/z): 393 (M+H)+.
Example 18 Ethyl 2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazoIe-4-carboxylate
Figure imgf000077_0001
The title compound was prepared from ethyl 5-(4-aminophenyl)-2-(biphenyl-2-yl)- oxazole-4-carboxylate, prepared as described in Example 11 above, in a manner analogous to Example 15 above.
'H-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
7.74 (doublet of doublets, Ji = 9 Hz, J2 = 2 Hz, IH);
7.65 (doublet, J = 9 Hz, 2H);
7.52 (multiplet, 3H);
7.25 (multiplet, 5H);
7.23 (multiplet, 3H);
6.63 (doublet, J = 9 Hz, 2H);
4.25 (quartet, 2H);
3.02 (singlet, 6H); 1.25 (triplet, 3H).
HPLC: Retention time = 1.38 min.
Mass Spectrum (ES+, m/z): 413 (M+H)+.
Example 19 2-(4-tert-Butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid
Figure imgf000078_0001
An aqueous solution of IM lithium hydroxide (350 μl) was added to a solution of ethyl 2-(4-tert-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylate (0.35 mmol, 137 mg), prepared as described in Example 15 above, in methanol (2 ml) and tetrahydrofuran (1 ml). The reaction mixture was then stirred for 8 hours during which time a precipitate formed. At the end of this time, 2M hydrochloric acid solution (1ml) was added and stirring continued until the precipitate became uniform. Filtration provided 95 mg (75%) of the title compound as a yellow solid.
!H-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm: 8.26 (doublet, J = 9 Hz, 2H); 7.95 (doublet, J = 9 Hz, 2H); 7.55 (doublet, J = 9 Hz, 2H);
6.76 (doublet, J = 9 Hz, 2H);
3.08 (singlet, 6H);
1.38 (singlet, 9H).
HPLC: Retention time = 1.32 min.
Mass Spectrum (ES+, m/z): 365 (M+H)+.
Example 20 2-(4-tert-Butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid
Figure imgf000079_0001
The title compound was prepared from ethyl 2-(4-tert-butylphenyl)-5-(3- dimethylamino-phenyl)oxazole-4-carboxylate, prepared as described in Example 17, in a manner analogous to Example 14 above.
H-Nuclear Magnetic Resonance Spectrum (300 MHz, d6-DMSO) δ ppm: 8.40 (multiplet, 2H); 7.50 (multiplet, 2H) 7.35 (multiplet, 3H) 6.82 (multiplet, IH);
3.00 (singlet, 6H);
1.35 (singlet, 9H).
HPLC: Retention time = 1.36 min.
Mass Spectrum (ES+, m/z): 365 (M+H)+.
Example 21 2-(Biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid
Figure imgf000080_0001
The title compound was prepared from ethyl 2-(biphenyl-2-yl)-5-(4-dimethylamino- phenyl)oxazole-4-carboxylate, prepared as described in Example 18 above, in a manner analogous to Example 14 above.
^-Nuclear Magnetic Resonance Spectrum (300 MHz, d6-DMSO) δ ppm:
7.80 (doublet of doublets, Ji = 9 Hz, J2 = 2 Hz, IH);
7.55 (multiplet, IH);
7.47 (multiplet, 2H);
7.40 (doublet, J = 9 Hz, 2H); 7.26 (multiplet, 5H);
6.66 (doublet, J = 9 Hz, 2H);
2.93 (singlet, 6H).
HPLC: Retention time = 1.11 min.
Mass Spectrum (ES+, m/z): 385 (M+H)+.
Example 22 5 -(4-Dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid
Figure imgf000081_0001
The title compound was prepared from ethyl 5-(4-aminophenyl)-2-phenyloxazole-4- carboxylate, prepared as described in Example 16 above, in a manner analogous to Example 14 above.
^-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
8.30 (doublet of doublets, Jx = 9 Hz, J2 = 2 Hz, 2H);
7.96 (doublet, J = 9 Hz, 2H);
7.49 (multiplet, 3H);
6.76 (doublet, J = 9 Hz, 2H);
3.07 (singlet, 6H). HPLC: Retention time = 0.94 min. Mass Spectrum (ES+, m/z): 309 (M+H)+.
Example 23 N-(thiazol-2-yl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxamide
Figure imgf000082_0001
Ν-(thiazol-2-yl)-5-(4-aminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxamide (0.25 mmol, 100 mg), prepared as described in Example 7 above, was dissolved in pyridine (1 ml). Acetyl chloride (0.27 mmol, 21 mg, 19 μl) was added and the reaction mixture was stirred overnight at room temperature. At the end of this time, the solvent was removed in vacuo. Flash column cliromatography (25% ethyl acetate/hexanes) provided 30 mg (27%) of the title compound as a tan solid.
^-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
10.60 (singlet, IH);
8.29 (doublet of doublets, Ji = 8 Hz, J2 = 2 Hz, 2H);
8.06 (doublet, J = 8 Hz, 2H); 7.70 (doublet, J = 9 Hz, 2H);
7.55 (multiplet, 3H);
7.48 (singlet, IH);
7.04 (doublet of doublets, J1 = 4 Hz, J2 = 1 Hz, IH);
2.22 (singlet, 3H);
1.38 (singlet, 9H).
HPLC: Retention time = 1.42 min.
Mass Spectrum (ES+, m/z): 461 (M+H)+.
Example 24
Figure imgf000083_0001
Ethyl 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylate
Pyridine (125 mmol, 10 ml) was added to a solution of ethyl 5-(4-aminophenyl)-2-(4- tert-butylphenyl)oxazole-4-carboxylate (24.2 mmol, 8.8 g), prepared as described in Example 9 above, in dichloromethane (150 ml) and the reaction was cooled to 0°C. Acetyl chloride (48.4 mmol, 3.4 ml) was added dropwise to the cooled mixture and the reaction mixture was then stirred for 1 hour. At the end of this time, the reaction mixture was diluted with dichloromethane (150 ml), washed with 2M hydrochloric acid solution (2 x 100 ml) and brine (100 ml), and then dried over sodium sulfate. Removal of the solvent in vacuo provided the title compound (8.8 g, 90 %) as a yellow solid.
1 H-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
8.10 (doublet, J = 9 Hz, 2H);
8.05 (doublet, J = 9 Hz, 2H);
7.67 (doublet, J = 9 Hz, 2H);
7.55 (doublet, J = 9 Hz, 2H);
4.45 (quartet, J = 9 Hz, 2H);
2.20 (singlet, 3H);
1.42 (triplet, J = 9 Hz, 3H);
1.38 (singlet, 9H).
HPLC: Retention time = 1.36 min.
Mass Spectrum (ES+, m/z): 407 (M+H)+.
Example 25 5-(4-Acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid
Figure imgf000084_0001
10 % sodium hydroxide (75 ml) was added to a solution of ethyl 5-(4-acetylamino- phenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylate (21.8 mmol, 8.8 g), prepared as described in Example 24 above, in methanol (100 ml) and tetrahydrofuran (75 ml). The reaction mixture was then stirred for 4 hours upon which a yellow precipitate formed. The solvent was removed in vacuo and the crude residue partitioned between ethyl acetate (200 ml) and 2M hydrochloric acid solution (200 ml). The organic layer was washed with brine (100 ml), dried over sodium sulfate and the solvent was then removed in vacuo providing the title compound (5.9g, 72 %) as a yellow solid.
1 H-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
8.25 (doublet, J = 8.7 Hz, 2H);
8.09 (doublet, J = 8.7 Hz, 2H);
7.70 (doublet, J = 8.4 Hz, 2H);
7.55 (doublet, J = 8.7 Hz, 2H);
2.25 (singlet, 3H);
1.38 (singlet, 9H).
HPLC: Retention time = 1.17 min.
Mass Spectrum (ES+, m/z): 379 (M+H)+.
Example 26 N-(2-trifluoromethylbenzyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide
Figure imgf000086_0001
A solution of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 25 above, in a 4:1 by volume mixture of acetonitrile and pyridine (800 μl, 0.125M, 100 μmol) was added to a 2-dram reaction vial. A solution of 2-chloro-l,3-dimethylimidazolinium chloride (DMC) in a 4:1 by volume mixture of acetonitrile and pyridine (800 μl, 0.25M, 200 μmol) was added followed by the addition of a solution of 2-trifluoromethylbenzylamine in CH3CN (400 μl, 0.25M, 100 μmol). The reaction was allowed to stand for 4 hours at room temperature. The solvent was removed in vacuo and the crude material submitted for HPLC purification.
^-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
8.25 (doublet, J = 8.4 Hz, 2H); 8.03 (doublet, J = 8.7 Hz, 2H); 7.78 (triplet, J = 6.6 Hz, IH); 7.65 (multiplet, 4H);
7.52 (multiplet, 3H);
7.37 (triplet, J = 7.5 Hz, 2H);
7.26 (singlet, IH);
4.85 (doublet, J = 6.3 Hz, 2H); 2.20 (singlet, 3H);
1.34 (singlet, 9H).
HPLC: Retention time = 1.68 min.
Mass Spectrum (ES+, m/z): 536 (M+H)+.
Example 27 N-[3-(morpholin-4-yl)propyl]-2-(4-tert-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000087_0001
The title compound was prepared in analogous manner to Example 26, using 3- (morpholin-4-yl)propylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butyl- phenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.10 min. Mass Spectrum (ES+, m/z): 491 (M+H)+. Example 28 2-(4-tert-butylphenγl)-5-(4-dimethylaminophenyl)-4-('thiazolidin-3- γlcarbonyl) oxazole
Figure imgf000088_0001
The title compound was prepared in analogous manner to Example 26, using thiazolidine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylaminophenyl)-oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyI)-2-(4-tert-butyIρhenyl)oxazole-4-carboxyIic acid.
HPLC: Retention time = 1.62 min. Mass Spectrum (ES+, m/z): 436 (M+H)+.
Example 29 2-(4-tgrt-Butylphenyl)-5-(4-dimethylaminophenyl)-4-[[4-(2-ethoxycarbonyl)piperidine]- carbonylloxazole
Figure imgf000089_0001
The title compound was prepared in analogous manner to Example 26, using ethyl piperidin-4-ylcarboxylate instead of 2-trifluoromethylbenzylamine and 2-(4-tβrt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.61 min. Mass Spectrum (ES+, m/z): 504 (M+H)+.
Example 30 N-cyclobutγl-2-(4-tQYt-butγlphenyl)-5-(4-dimethylaminophenγl)oxazole-4- carboxamide
Figure imgf000090_0001
The title compound was prepared in analogous manner to Example 26, using cyclobutylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.76 min. Mass Spectrum (ES+, m/z): 418 (M+H)+.
Example 31 N-(tetrahydrofuran-2-γlmethγl)-2-(4-tert-butylphenγl)-5-(4- dimethγlaminophenγl)oxazole-4-carboxamide
Figure imgf000090_0002
The title compound was prepared in analogous manner to Example 26, using tetrahydrofuran-2-ylmethylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butyl-phenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.68 min. Mass Spectrum (ES+, m/z): 448 (M+H)+.
Example 32 ~N-(2-methoxγbenzγl)-2-(4-tert-butylphenγl)-5-(4-dimethγlaminophenγl)oxazole-4- carboxamide
Figure imgf000091_0001
The title compound was prepared in analogous manner to Example 26, using 2- methoxybenzylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5- (4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-fert-butylρhenyl)oxazole-4-carboxylic acid. HPLC: Retention time = 1.79 min. Mass Spectrum (ES+, m/z): 484 (M+H)+.
Example 33 Υ-Methyl- -phenγl~2-(4-tert-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000092_0001
The title compound was prepared in analogous manner to Example 26, using N- methylphenylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.65 min. Mass Spectrum (ES+, m/z): 454 (M+H)+. Example 34 l^-(2-methoxyethyl)-2-(4-tGvt-butylphenyl)-5-(4-dimethγlaminophenγl)oxazole-4- carboxamide
Figure imgf000093_0001
The title compound was prepared in analogous manner to Example 26, using 2- methoxyethylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.62 min. Mass Spectrum (ES+, m/z): 422 (M+H)+.
Example 35 2- (4-tQrt-butylphenyl) -5- (4-dimethylam inophenγl) -4-(pyrrolidin-l - γlcarbonγl) oxazole
Figure imgf000094_0001
The title compound was prepared in analogous manner to Example 26, using pyrrolidine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5-(4- dimethylamino-phenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.60 min. Mass Spectrum (ES+, m/z): 418 (M+H)+.
Example 36 N-( 1 -ethylpropyl)-2-(4-tert-butylphenyl)-5 -(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000095_0001
The title compound was prepared in analogous manner to Example 26, using 1-ethyl- propylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.82 min. Mass Spectrum (ES+, m/z): 434 (M+H)+.
Example 37 'N-(benzofl,3]dioxol-5-γlmethyi)-2- 4-teή-butylphenγl)-5-('4- dimethylaminophenγl)oxazole-4-carboxamide
Figure imgf000095_0002
The title compound was prepared in analogous manner to Example 26, using benzo[l,3]dioxol-5-ylmethylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.74 min. Mass Spectrum (ES+, m/z): 498 (M+H)+.
Example 38 N-[3-(imidazol-l-γl)propylJ-2-(4-tert-butylphenγl)-5-(4- dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000096_0001
The title compound was prepared in analogous manner to Example 26, using 3- (imidazol-l-yl)propylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.11 min. Mass Spectrum (ES+, m/z): 472 (M+H)+.
Example 39 Η-(2-methylcyclohexyl)-2-(4-t&ct-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000097_0001
The title compound was prepared in analogous manner to Example 26, using 2- methyl-cyclohexylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)- 5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.88 min. Mass Spectrum (ES+, m/z): 460 (M+H)+. Example 40 ~N-cγclopropylmethyl-~N-propγl-2-(4-tert-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000098_0001
The title compound was prepared in analogous manner to Example 26, using N- cyclopropyl-N-propylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.76 min. Mass Spectrum (ES+, m/z): 460 (M+H)+.
Example 41 W-phenyl-2-(4-tert-butylphenyl)-5-(4-dimethγlaminophenγl)oxazole-4- carbonylhydrazide
Figure imgf000099_0001
The title compound was prepared in analogous manner to Example 26, N-phenyl- hydrazine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.69 min. Mass Spectrum (ES+, m/z): 455 (M+H)+.
Example 42 2-(4-tert-Butylphenyl)-4-r(2,5-dihydropyrrol-l-yl)carbonyl]-5-(4- dimethylaminophenyl)oxazole
Figure imgf000100_0001
The title compound was prepared in analogous manner to Example 26, using 2,5- dihydropyrrole instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.62 min.
Mass Spectrum (ES+, m/z): 416 (M+H)
Example 43 2-(4-tert-Butγlphenyl)-5-(4-dimethylaminophenyl)-4-[(thiomorpholin-4- yl) carbonyl] oxazole
Figure imgf000101_0001
The title compound was prepared in analogous manner to Example 26, using thiomorpholine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.62 min. Mass Spectrum (ES+, m/z): 450 (M+H)+.
Example 44 2-(4-tQrt-Butylphenyl)-5-(4-dimethylaminophenyl)-4-f (4-methylpiperidin-l- yl) carbonyl] oxazole
Figure imgf000102_0001
The title compound was prepared in analogous manner to Example 26, using 4- methylpiperidine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.72 min. Mass Spectrum (ES+, m/z): 446 (M+H)+.
Example 45 4-f(4-Benzylpiperazin-l-yl)carbonyl]-2-(4-text-butylphenyl)-5-(4- dimethγlam inophenyl) oxazole
Figure imgf000103_0001
The title compound was prepared in analogous manner to Example 26, using 4- benzylpiperazine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.14 min. Mass Spectrum (ES+, m/z): 523 (M+H)+.
Example 46 Η-[2-(pyrrolidin-l-yl)ethyl]-2-(4-tQϊt-butylphenγl)-5-(4- dimethylaminophenγl)oxazole-4-carboxamide
Figure imgf000104_0001
The title compound was prepared in analogous manner to Example 26, using 2- (pyrrolidin-l-yl)ethylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.11 min. Mass Spectrum (ES+, m/z): 461 (M+H)+.
Example 47 'N-fthiophen-2-γlmeth\>l)-2-(4-teτLt-butylphenyl)-5-(4-dimethylaminophenyl)oxazole- 4-carboxamide
Figure imgf000105_0001
The title compound was prepared in analogous manner to Example 26, using thiophen-2-ylmethylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.74 min. Mass Spectrum (ES+, m/z): 460 (M+H)+.
Example 48 2- (4-teti-Butylphenyl) -5- (4-dimethylam inophenγl) -4-[(4-phenylpiperazin- 1 - yl) carbonyl] oxazole
Figure imgf000106_0001
The title compound was prepared in analogous manner to Example 26, using 4- phenylpiperazine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.70 min. Mass Spectrum (ES+, m/z): 509 (M+H)+.
Example 49 N-allyl-2-(4-tQrt-butγlphenγl)-5-(4-dimethγlaminophenyl)oxazole-4-carboxamide
Figure imgf000106_0002
The title compound was prepared in analogous manner to Example 26, using allylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylamino-phenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.69 min. Mass Spectrum (ES+, m/z): 404 (M+H)+.
Example 50 2-(4-tert-Butγlphenγl)-5-(4-dimethylaminophenyl)-4-[(morpholin-4- γl) carbonyl] oxazole
Figure imgf000107_0001
The title compound was prepared in analogous manner to Example 26, using morpholine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylamino-phenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid. HPLC: Retention time = 1.50 min.
Mass Spectrum (ES+, m/z): 434 (M+H)+.
Example 51 2-(4-tert-Butylphenyl)-5-(4-dimethylaminophenyl)-4-[(2,6-dimethγlmorpholin-4- yl) carbonyl] -oxazole
Figure imgf000108_0001
The title compound was prepared in analogous manner to Example 26, using 2,6- dimethylmorpholine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5- (4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.58 min. Mass Spectrum (ES+, m/z): 462 (M+H)+. Example 52 N-(4-chlorophenyl)-N-methyl-2-(4-tert-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000109_0001
The title compound was prepared in analogous manner to Example 26, using N- methyl-4-chlorophenylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tg7-t- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.72 min.
Mass Spectrum (ES+, m/z): 489, 491 (M+H)+.
Example 53 Η-(l,2,3,4-tetrahydronaphthalen-l-γl)-2-(4-text-butylphenyl)-5-(4- dimethylaminophenyl)-oxazole-4-carboxamide
Figure imgf000110_0001
The title compound was prepared in analogous manner to Example 26, using 1,2,3,4- tetrahydronaphthalen-1-ylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.91 min. Mass Spectrum (ES+, m/z): 494 (M+H)+.
Example 54 ~N-(2-ethyl-2R.-pyrazol-3-yl) -2- (4-tQrt-butylphenγl) -5- (4- dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000111_0001
The title compound was prepared in analogous manner to Example 26, using (2-ethyl- 2H-pyrazol-3-yl)amine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)- 5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
ΗPLC: Retention time = 1.69 min. Mass Spectrum (ES+, m/z): 458 (M+Η)+.
Example 55 Η-(4-methoxyphenyϊ)-: -meihyl-2-(4-tQtX-butylphenyϊ)-5-(4- dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000112_0001
The title compound was prepared in analogous manner to Example 26, using N- methyl-4-methoxyphenylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.61 min. Mass Spectrum (ES+, m/z): 484 (M+H)+
Example 56 2- (4-tβrt-Butylphenγl) -5- (4-dimethγlam inophenyl) -4-[[4-(3- trifluoromethγlphenγl)piperazin-l-γl] carbonyl] oxazole
Figure imgf000113_0001
The title compound was prepared in analogous manner to Example 26, using 4-(3- trifluoromethylphenyl)piperazine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.78 min. Mass Spectrum (ES+, m/z): 577 (M+H)+.
Example 57 ~N-(benzoπ,3]dioxol-5-yl)-'N-et}ιyl-2-(4-tert-butylphenyl)-5-(4- dimethγlaminophenyl)oxazole-4-carboxamide
Figure imgf000113_0002
The title compound was prepared in analogous manner to Example 26, using N-ethyl- (benzo[l,3]dioxol-5-yI)amine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylammophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.64 min. Mass Spectrum (ES+, m/z): 512 (M+H)+.
Example 58 2-(4-tQrt-Butylphenγl)-5-(4-dimethγlaminophenyl)-4-f[4-(2- methoxyphenyl)piperazin-l-γl] carbonyl] oxazole
Figure imgf000114_0001
The title compound was prepared in analogous manner to Example 26, using 4-(2- methoxyphenyl)piperazine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5 -(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.66 min. Mass Spectrum (ES+, m/z): 539 (M+H)+.
Example 59 ~N-(3-ethoxyphenyl)-2-(4-tert-butylphenγl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000115_0001
The title compound was prepared in analogous manner to Example 26, using 3- ethoxyphenylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5-(4- dimethylaminophenyl)oxazoIe-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.89 min. Mass Spectrum (ES+, m/z): 484 (M+H)+. Example 60 ~N-f2-C3-methoxyphenyl)ethyl]-2-(4-tert-butγlphenγl)-5-(4- dimethylaminophenγl)oxazole-4-carboxamide
Figure imgf000116_0001
The title compound was prepared in analogous manner to Example 26, using 2-(3- methoxyphenyl)ethylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.77 min. Mass Spectrum (ES+, m/z): 498 (M+H)+.
Example 61 N-(3,5-bis-trifluoromethylbenzyl)-2-(4-teγt-butγlphenγl)-5-(4- dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000117_0001
The title compound was prepared in analogous manner to Example 26, using 3,5-bis- trifluoromethylbenzylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.88 min. Mass Spectrum (ES+, m/z): 590 (M+H)+.
Example 62 2-(4-teτt-Butylphenγl)-4-[(3,4-dihydro-2H-quinolin-l-yl)carbonyl]-5-(4- dimethγlaminophenyl) -oxazole
Figure imgf000118_0001
The title compound was prepared in analogous manner to Example 26, using 3,4- dihydro-2H-quinoline instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5- (4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
ΗPLC: Retention time = 1.73 min. Mass Spectrum (ES+, m/z): 480 (M+Η)+.
Example 63 N- (2-trifluoromethylbenzyl) -2- (4-tert-butylphenγl)-5- (4- dimethylaminophenγl)oxazole-4-carboxamide
Figure imgf000119_0001
The title compound was prepared in analogous manner to Example 26, using 2-(4- tgrt-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert- butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.87 min. Mass Spectrum (ES+, m/z): 522 (M+H)+.
Example 64 Η-(2,3-dihydrobenzofl,4]dioxin-6-yl)-2-(4-tQxt-butylphenyl)-5-(4- dimethylaminophenγl)-oxazole-4-carboxamide
Figure imgf000120_0001
The title compound was prepared in analogous manner to Example 26, using (2,3- dihydrobenzo[l,4]dioxin-6-yl)amine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5 -(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.79 min. Mass Spectrum (ES+, m/z): 498 (M+H)+.
Example 65 N-(pyridin-4-ylmethyl)-2-(4-tQrt-butylphenγl)-5-(4-dimethylammophenyl)oxazole-4- carboxamide
Figure imgf000121_0001
The title compound was prepared in analogous manner to Example 26, using pyridin- 4-ylmethylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.23 min.
Mass Spectrum (ES+, m/z): 455 (M+H)+
Example 66 N-f3-(4-methylpiperazin-l-γl)propγl]-2-(4-tQrt-butylphenγl)-5-(4- dimethylaminophenyl)-oxazole-4-carboxamide
Figure imgf000122_0001
The title compound was prepared in analogous manner to Example 26, using 3-(4- methylpiperazin-l-yl)propylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5 -(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 0.93 min. Mass Spectrum (ES+, m/z): 504 (M+H)+.
Example 67 Y{-(3-methylsulfanylphenyl) -2- (4-tert-butylphenyl) -5- (4- dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000123_0001
The title compound was prepared in analogous manner to Example 26, using 3- methyl-sulfanylphenylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.87 min. Mass Spectrum (ES+, m/z): 486 (M+H)+.
Example 68 N- (4-piperidin-l -ylphenyl) -2-(4-tert-butγlphenγl) -5- (4- dimethγlaminophenγl)oxazole-4-carboxamide
Figure imgf000124_0001
The title compound was prepared in analogous manner to Example 26, using 4- (piperidin-l-yl)phenylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert- butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.37 min. Mass Spectrum (ES+, m/z): 523 (M+H)+.
Example 69 N-(4-methoxyphenyl)-2-(4-tert-butylphenγl)-5-('4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000125_0001
The title compound was prepared in analogous manner to Example 26, using 4- methoxy-phenylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tgrt-butylphenyl)-5- (4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.79 min. Mass Spectrum (ES+, m/z): 470 (M+H)+.
Example 70 ll-propy!-2-(4-tert-butylphenyl)-5-(4-dimethylammophenyl)oxazole-4-carboxamide
Figure imgf000125_0002
The title compound was prepared in analogous manner to Example 26, using propylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tert-butylphenyl)-5-(4- dimethylamino-phenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid.
HPLC: Retention time = 1.72 min. Mass Spectrum (ES+, m/z): 406 (M+H)+.
Example 71 -[2-(2-methoxyphenyl)ethyll-2-(4-t5Xt-butylphenyl)-5-(4- dimethγlaminophenyl)oxazole-4-carboxamide
Figure imgf000126_0001
The title compound was prepared in analogous manner to Example 26, using 2-(2- methoxyphenyl)ethylamine instead of 2-trifluoromethylbenzylamine and 2-(4-tg7 - butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, instead of 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxylic acid.
HPLC: Retention time = 1.81 min. Mass Spectrum (ES+, m/z): 498 (M+H)+. Example 72 ~N-(4-acetylphenyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide
Figure imgf000127_0001
The title compound was prepared in analogous manner to Example 26, using 4- acetylphenylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.57 min. Mass Spectrum (ES+, m/z): 496 (M+H)+.
Example 73 ^-f3-(morpholin-4-γl)propyl]-5-(4-acetylaminophenyl)-2-(4-tQrt- butylphenyl)oxazole-4-carboxamide
Figure imgf000128_0001
The title compound was prepared in analogous manner to Example 26, using 3- (morpholin-4-yl)propylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 0.89 min. Mass Spectrum (ES+, m/z): 505 (M+H)+.
Example 74 5-(4-Acetylaminophenyl)-2-(4-ttrt-butylphenyl)-4-f(thiazolidin-3- γl) carbonyl] oxazole
Figure imgf000128_0002
The title compound was prepared in analogous manner to Example 26, using thiazolidine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.36 min. Mass Spectrum (ES+, m/z): 450 (M+H)+.
Example 75 5-(4-Acetylaminophenγl)-2-(4-tert-butylphenγl)-4-[[4-(ethoxycarbonyl)piperidin-l- γl] carbonyl] oxazole
Figure imgf000129_0001
The title compound was prepared in analogous manner to Example 26, using 4- (ethoxycarbonyl)piperidine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.37 min. Mass Spectrum (ES+, m/z): 518 (M+H)+.
Example 76 ~N-cyclobutyl-5-(4-acetylaminophenγl)-2-(4-teή-butylphenγl)oxazole-4-carboxamide
Figure imgf000130_0001
The title compound was prepared in analogous manner to Example 26, using cyclobutylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.50 min. Mass Spectrum (ES+, m/z): 432 (M+H)+.
Example 77 ~N-(tetrahydrofuran-2-γlmethyl)-5-(4-acetylaminophenyl)-2-(4-tert- butylphenγl)oxazole-4-carboxamide
Figure imgf000131_0001
The title compound was prepared in analogous manner to Example 26, using tetrahydrofuran-2-ylmethylamine instead of 2-trifluoromethylbenzylamine .
HPLC: Retention time = 1.41 min. Mass Spectrum (ES+, m/z): 462 (M+H)+.
Example 78 Η-(2-methoxγbenzyl)-5-(4-acetylaminophenyl)-2-(4-tQxX-butylphenyl)oxazole-4- carboxamide
Figure imgf000131_0002
The title compound was prepared in analogous manner to Example 26, using 2- methoxybenzylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.58 min. Mass Spectrum (ES+, m/z): 498 (M+H)+.
Example 79 lj-f(2-methoxγcarbonyl)thiophen-3-γl]-5-(4-Acetylaminophenyl)-2-(4-tQYt- butylphenyl) oxazole-4-carboxam ide
Figure imgf000132_0001
The title compound was prepared in analogous manner to Example 26, using 2- (methoxycarbonyl)thiophen-3-ylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.71 min. Mass Spectrum (ES+, m/z): 518 (M+H)+. Example 80 ~N-(biphenyl-2-γl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenγl)oxazole-4- carboxamide
Figure imgf000133_0001
The title compound was prepared in analogous manner to Example 26, using biphenyl-2-ylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.82 min. Mass Spectrum (ES+, m/z): 530 (M+H)+.
Example 81 'N-methyl-'N-phenyl-5-(4-acetγlaminophenγl)-2-(4-tert-butylphenγl)oxazole-4- carboxamide
Figure imgf000134_0001
The title compound was prepared in analogous manner to Example 26, using N- methyl phenylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.41 min. Mass Spectrum (ES+, m/z): 468 (M+H)+.
Example 82 N- (2-methoxyethyl) -5- (4-acetγlaminophenγl) -2- (4-tert-butγlphenγl) oxazole-4- carboxamide
Figure imgf000134_0002
The title compound was prepared in analogous manner to Example 26, using 2- methoxyethylamine instead of 2-trifluoromethylbenzylamine. HPLC: Retention time = 1.35 min. Mass Spectrum (ES+, m/z): 436 (M+H)+.
Example 83 5-(4-Acetylaminophenγl)-2-(4-tβrt-butylphenγl)-4-f(pyrrolidin-l- yl) carbonyl] oxazole
Figure imgf000135_0001
The title compound was prepared in analogous manner to Example 26, using pyrrolidine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.31 min. Mass Spectrum (ES+, m/z): 432 (M+H)+.
Example 84 ~N-(l-ethγlpropyl)-5-(4-acetylaminophenγl)-2-(4-tert-butγlphenyl)oxazole-4- carboxamide
Figure imgf000136_0001
The title compound was prepared in analogous manner to Example 26, using 1-ethylpropylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.61 min. Mass Spectrum (ES+, m/z): 447 (M+H)+.
Example 85 N-(benzofl,3]dioxol-5-γlmethyl)-5-(4-acetylaminophenyl)-2-(4-tert- butylphenyl)oxazole-4-carboxamide
Figure imgf000136_0002
The title compound was prepared in analogous manner to Example 26, using benzo[l,3]dioxol-5-ylmethylamine instead of 2-trifluoromethylbenzylamine. HPLC: Retention time = 1.51 min. Mass Spectrum (ES+, m/z): 512 (M+H)+.
Example 86 N-[3-(imidazol-l-γl)propyl]-5-(4-acetylaminophenyl)-2-(4-tQrt-butylphenyl)oxazole- 4-carboxamide
Figure imgf000137_0001
The title compound was prepared in analogous manner to Example 26, using 3- (imidazol- 1 -yl)propylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 0.89 min. Mass Spectrum (ES+, m/z): 486 (M+H)+.
Example 87 Η-benzhydryl-5-(4-acetylaminophenyl)-2-(4-tQrt-butylphenyl)oxazole-4- carboxamide
Figure imgf000138_0001
The title compound was prepared in analogous manner to Example 26, benzhydrylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.72 min. Mass Spectrum (ES+, m/z): 544 (M+H)+.
Example 88 N'-phenyl-5-(4-acetylaminophenyl)-2-(4-tGύ.-butylphenγl)oxazole-4- carbonylhγdrazide
Figure imgf000139_0001
The title compound was prepared in analogous manner to Example 26, using N- phenylhydrazine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.47 min. Mass Spectrum (ES+, m/z): 469 (M+H)+.
Example 89 5-(4-Acetylaminophenγl)-2-(4-teγt-butylphenγl)-4-f(2,5-dihydropyrrol-l- yl)carbonyl] oxazole
Figure imgf000140_0001
The title compound was prepared in analogous manner to Example 26, using 2,5- dihydropyrrole instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.35 min. Mass Spectrum (ES+, m/z): 430 (M+H)+.
Example 90 5-(4-Acetylaminophenyl)-2-(4-teή-butylphenyl)-4-[(thiomorpholin-4- yl) carbonyl] oxazole
Figure imgf000140_0002
The title compound was prepared in analogous manner to Example 26, using thiomorpholine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.36 min. Mass Spectrum (ES+, m/z): 464 (M+H)+.
Example 91 5-(4-Acetylaminophenyl)-2-(4-tert-butylphenyl)-4-f (4-methylpiperidin-l- yl) carbonyl] oxazole
Figure imgf000141_0001
The title compound was prepared in analogous manner to Example 26, 4- methylpiperidine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.45 min. Mass Spectrum (ES+, m/z): 460 (M+H)+. Example 92 5-(4-Acetylaminophenyl)-4-f(4-benzylpiperazin-l-γl)carbonyl]-2-(4-tert- butylphenyl) oxazole
Figure imgf000142_0001
The title compound was prepared in analogous manner to Example 26, 4-benzyl- piperazine instead of 2-trifluoromethylbenzylamine. HPLC: Retention time = 0.94 min. Mass Spectrum (ES+, m/z): 537 (M+H)+.
Example 93 N-f2-(pyrrolidm-l-γl)ethyl]-5-(4-acetylaminophenγl)-2-(4-tert-butylphenyl)oxazole- 4-carboxamide
Figure imgf000143_0001
The title compound was prepared in analogous manner to Example 26, 2-(pyrrolidin- l-yl)ethylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 0.91 min. Mass Spectrum (ES+, m/z): 475 (M+H)+.
Example 94 ~N-(thiophen-2-ylmethyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenγl)oxazole-4- carboxamide
Figure imgf000143_0002
The title compound was prepared in analogous manner to Example 26, using thiophen-2-ylmethylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.51 min. Mass Spectrum (ES+, m/z): 474 (M+H)+.
Example 95 5-(4-Acetγlaminophenyl)-2-(4-tert-butylphenγl)-4-f(4-phenγlpiperazin-l- yl) carbonyl] oxazole
Figure imgf000144_0001
The title compound was prepared in analogous manner to Example 26, using 4- phenylpiperazine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.46 min. Mass Spectrum (ES+, m/z): 523 (M+H)+. Example 96 Η-allyl-5-(4-acetylaminophenyl)-2-(4-tQxt-butylphenyl)oxazole-4-carboxamide
Figure imgf000145_0001
The title compound was prepared in analogous manner to Example 26, using allylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.43 min. Mass Spectrum (ES+, m/z): 418 (M+H)+.
Example 97 5-(4-Acetylaminophenγl)-2-(4-tert-butylphenγl)-4-[(morpholin-4- γl) carbonyl] oxazole
Figure imgf000146_0001
The title compound was prepared in analogous manner to Example 26, using morpholine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.21 min. Mass Spectrum (ES+, m/z): 448 (M+H)+.
Example 98 5-(4-Acetylaminophenyl)-2-(4-tert-butylphenγl)-4-f(2,6-dimethγlmorpholin-4- γl) carbonyl] -oxazole
Figure imgf000146_0002
The title compound was prepared in analogous manner to Example 26, using 2,6- dimethylmorpholine instead of 2-trifluoromethylbenzylamine. HPLC: Retention time = 1.31 min. Mass Spectrum (ES+, m/z): 476 (M+H)+.
Example 99 Y\-(4-chlorophenyl)-~N-methyl-5-(4-acetylaminophenγl)-2-(4-t&xt- butylphenyl)oxazole-4-carboxamide
Figure imgf000147_0001
The title compound was prepared in analogous manner to Example 26, using N- methyl-4-chlorophenylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.49 min.
Mass Spectrum (ES+, m/z): 503, 505 (M+H)+.
Example 100 N-(l,2,3,4-tetrahydronaphthalen-l-γl)-5-(4-acetylammophenγl)-2-(4-teή- butylphenyl) oxazole-4-carboxam ide
Figure imgf000148_0001
The title compound was prepared in analogous manner to Example 26, using (1,2,3,4- tettahydronaphthalen-1 -yl)amine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.71 min. Mass Spectrum (ES+, m/z): 508 (M+H)+.
Example 101 N-(2-ethyl-2H-pyrazol-3-yl)-5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxamide
Figure imgf000149_0001
The title compound was prepared in analogous manner to Example 26, using (2-ethyl- 2H-pyrazol-3-yl)amine instead of 2-trifluoromethylbenzylamine.
ΗPLC: Retention time = 1.41 min. Mass Spectrum (ES+, m/z): 472 (M+Η)+.
Example 102
N-(4-methoxyphenyl)-N-methyl-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole- 4-carboxamide
Figure imgf000149_0002
The title compound was prepared in analogous manner to Example 26, using N- methyl-4-methoxyphenylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.38 min. Mass Spectrum (ES+, m/z): 498 (M+H)+. Example 103 5-(4-Acetylaminophenyl)-2-(4-tgrt-butylphenyl)-4-r[4-(3-trifluoromethylphenyl)piperazin-l- yl] carbonyl] oxazole
Figure imgf000150_0001
The title compound was prepared in analogous manner to Example 26, using 4-(3- trifluoromethylphenyl)piperazine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.58 min. Mass Spectrum (ES+, m/z): 591 (M+H)+.
Example 104 N-(benzori,3]dioxol-5-yl)-N-ethyl-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide
Figure imgf000150_0002
The title compound was prepared in analogous manner to Example 26, using N- methyl-N-(benzo[l,3]dioxol-5-yl)amine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.42 min. Mass Spectrum (ES+, m/z): 526 (M+H)+.
Example 105 5-(4-Acetylaminophenyl)-2-(4-tgrt-butylphenyl)-4-[[4-(2-methoxyphenyl)piperazin-l- yl]carbonyl]oxazole
Figure imgf000151_0001
The title compound was prepared in analogous manner to Example 26, using 4-(2- methoxyphenyl)piperazine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.42 min. Mass Spectrum (ES+, m/z): 553 (M+H)+.
Example 106 N-(3-ethoxyphenyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxamide
Figure imgf000152_0001
The title compound was prepared in analogous manner to Example 26, using 3- ethoxyphenylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.66 min. Mass Spectrum (ES+, m/z): 498 (M+H)+.
Example 107 N-(3,5-bis-trifluoromethylphenyl)-5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxamide
Figure imgf000152_0002
The title compound was prepared in analogous manner to Example 26, using 3,5-bis- trifluoromethylphenylamine instead of 2-trifluoromethylbenzylamine. HPLC: Retention time = 1.84 min. Mass Spectrum (ES+, m/z): 590 (M+H)+.
Example 108 N-r2-(3-methoxyphenyl)ethyl]-5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxamide
Figure imgf000153_0001
The title compound was prepared in analogous manner to Example 26,. using 2-(3- methoxyphenyl)ethylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.56 min. Mass Spectrum (ES+, m/z): 512 (M+H)+.
Example 109 N-(3,5-bis-trifluoromethylbenzyl)-5-(4-acetylaminophenyl)-2-(4-te7-t-butylphenyl)oxazole-4- carboxamide
Figure imgf000154_0001
The title compound was prepared in analogous manner to Example 26, using 3,5-bis- trifluoromethylbenzylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.71 min. Mass Spectrum (ES+, m/z): 604 (M+H)+.
Example 110 N-(benzothiazol-2-yl)-5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxamide
Figure imgf000154_0002
The title compound was prepared in analogous manner to Example 26, using benzothiazol-2-ylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.67 min. Mass Spectrum (ES+, m/z): 511 (M+H)+. Example 111 N-(l-ethoxycarbonylpiperidin-4-yl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole- 4-carboxamide
Figure imgf000155_0001
The title compound was prepared in analogous manner to Example 26, using (1- ethoxycarbonylpiρeridin-4-yl)amine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.45 min. Mass Spectrum (ES+, m/z): 533 (M+H)+.
Example 112 5-(4-Acetylaminophenyl)-2-(4-tg7 -butylphenyl)-4-(3,4-dihydro-2H-quinolin-l-ylcarbonyl)- oxazole
Figure imgf000155_0002
The title compound was prepared in analogous manner to Example 26, using 3,4- dihydro-2H-quinoline instead of 2-trifluoromethylbenzylamine. HPLC: Retention time = 1.50 min. Mass Spectrum (ES+, m/z): 494 (M+H)+.
Example 113 N-(2-methoxy-5-methylphenyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide
Figure imgf000156_0001
The title compound was prepared in analogous manner to Example 26, using 2- methoxy-5-methylphenylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.74 min. Mass Spectrum (ES+, m/z): 498 (M+H)+.
Example 114 N-(2,5-dimethoxyphenyl)-5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxamide
Figure imgf000157_0001
The title compound was prepared in analogous manner to Example 26, using 2,5- dimethoxyphenylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.66 min. Mass Spectrum (ES+, m/z): 514 (M+H)+.
Example 115 N-(biphenyl-4-yl)-5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxamide
Figure imgf000157_0002
The title compound was prepared in analogous manner to Example 26, using biphenyl-4-ylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.76 min. Mass Spectrum (ES+, m/z): 530 (M+H)+.
Example 116 N-(2-acetylphenyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxamide
Figure imgf000158_0001
The title compound was prepared in analogous manner to Example 26, using 2- acetylphenylamine instead of 2-trifiuoromethylbenzylamine.
HPLC: Retention time = 1.66 min. Mass Spectrum (ES+, m/z): 496 (M+H)+.
Example 117 N-(2,6-dimethoxybenzyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide
Figure imgf000158_0002
The title compound was prepared in analogous manner to Example 26, using 2,6- dimethoxybenzylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.59 min. Mass Spectrum (ES+, m/z): 528 (M+H)+. Example 118 N-(2-methoxycarbonyl-4-methylthiophene-3-yl)-5-(4-acetylaminophenyl)-2-(4-tgrt- butylphenyl)-oxazole-4-carboxamide
Figure imgf000159_0001
The title compound was prepared in analogous manner to Example 26, using (2- methoxycarbonyl-4-methylthiophene-3-yl)amine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.65 min. Mass Spectrum (ES+, m/z): 532 (M+H)+.
Example 119
N-[3-(pyrrolidin-: l-yl)propyl]-_ >-(4- -acetylaminophenyl)-2-(4- tert-butylphenyl)oxazole-4' carboxamide
Figure imgf000159_0002
The title compound was prepared in analogous manner to Example 26, using 3- (pyrrolidin-l-yl)propylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 0.92 min. Mass Spectrum (ES+, m/z): 489 (M+H)+.
Example 120 N-(3 -methoxy-5 -trifluoromethylphenyl)-5 -(4-acetylaminophenyl)-2-(4-tgrt- butylphenyl)oxazole-4-carboxamide
Figure imgf000160_0001
The title compound was prepared in analogous manner to Example 26, using 3- methoxy-5-trifluoromethylphenylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.75 min. Mass Spectrum (ES+, m/z): 552 (M+H)+.
Example 121 N-(3-benzyloxyphenyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide
Figure imgf000161_0001
The title compound was prepared in analogous manner to Example 26, using 3- benzyloxyphenylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.76 min. Mass Spectrum (ES+, m/z): 560 (M+H)+.
Example 122 N-(naphthalen-l-yl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxamide
Figure imgf000161_0002
The title compound was prepared in analogous manner to Example 26, using naphthalen-1-ylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.71 min.
Mass Spectrum (ES+, m/z): 504 (M+H) Example 123 N-(2-methoxyphenyl)-5-(4-acetylaminophenyl)-2-(4-t6rt-butylphenyl)oxazole-4-carboxamide
Figure imgf000162_0001
The title compound was prepared in analogous manner to Example 26, using 2- methoxyphenylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.68 min. Mass Spectrum (ES+, m/z): 484 (M+H)+.
Example 124 N-(3,3-diphenylpropyl)-5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxamide
Figure imgf000162_0002
The title compound was prepared in analogous manner to Example 26, using 3,3- diphenylpropylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.72 min. Mass Spectrum (ES+, m/z): 572 (M+H)+.
Example 125 N-(2,3-dihydrobenzo l,4]dioxin-6-yl)-5-(4-acetylaminophenyl)-2-(4-tgrt- butylphenyl)oxazole-4-carboxamide
Figure imgf000163_0001
The title compound was prepared in analogous manner to Example 26, using 2,3- dihydrobenzo[l,4]dioxin-6-ylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.56 min. Mass Spectrum (ES+, m/z): 512 (M+H)+.
Example 126 N-(pyridin-4-ylmethyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide
Figure imgf000164_0001
The title compound was prepared in analogous manner to Example 26, using pyridin- 4-ylmethy lamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 0.96 min. Mass Spectrum (ES+, m/z): 469 (M+H)+.
Example 127 N-[3-(4-methylpiperazin-l-yl)propyl]-5-(4-acetylaminophenyl)-2-(4-tgrt- butylphenyl)oxazole-4-carboxamide
Figure imgf000164_0002
The title compound was prepared in analogous manner to Example 26, using 3-(4- methylpiperazin- 1 -yl)propylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 0.76 min. Mass Spectrum (ES+, m/z): 518 (M+H)+.
Example 128 5-(4-Acetylaminophenyl)-2-(4-tert-butylphenyl)-4-rr4-(2-dimethylaminoethyl)piperazin-l- yl] carbonyl] oxazole
Figure imgf000165_0001
The title compound was prepared in analogous manner to Example 26, using 4-(2- dimethylaminoethyl)piperazine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 0.80 min. Mass Spectrum (ES+, m/z): 518 (M+H)+.
Example 129 N-(3-methylsulfanylphenyl)-5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxamide
Figure imgf000166_0001
The title compound was prepared in analogous manner to Example 26, using 3- methyl-sulfanylphenylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.68 min. Mass Spectrum (ES+, m/z): 500 (M+H)+.
Example 130 N-(2-benzylphenyl)-5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxamide
Figure imgf000166_0002
The title compound was prepared in analogous manner to Example 26, using 2- benzylphenylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.78 min. Mass Spectrum (ES+, m/z): 544 (M+H)+. Example 131 N-[4-(piperidin-l-yl)phenyl1-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide
Figure imgf000167_0001
The title compound was prepared in analogous manner to Example 26, using 4- (piperidin- 1 -yl)phenylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.12 min. Mass Spectrum (ES+, m/z): 537 (M+H)+.
Example 132 N-(4-methoxyphenyl)-5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxamide
Figure imgf000167_0002
The title compound was prepared in analogous manner to Example 26, using 4- methoxyphenylamine instead of 2-trifluoromethylbenzylamine. HPLC: Retention time = 1.58 min. Mass Spectrum (ES+, m/z): 484 (M+H)+.
Example 133 N-propyl-5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxamide
Figure imgf000168_0001
The title compound was prepared in analogous manner to Example 26, using n- propylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.47 min. Mass Spectrum (ES+, m/z): 420 (M+H)+.
Example 134 N-r2-(2-methoxyphenyl)ethyl]-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide
Figure imgf000168_0002
The title compound was prepared in analogous manner to Example 26, using 2-(2- methoxyphenyl)ethylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.60 min. Mass Spectrum (ES+, m/z): 512 (M+H)+.
Example 135 N-(4-methoxybiphenyl-3-yl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide
Figure imgf000169_0001
The title compound was prepared in analogous manner to Example 26, using 4- methoxybiphenyl-3-y lamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.84 min. Mass Spectrum (ES+, m/z): 560 (M+H)+. Example 136 5-(4-Acetylaminophenyl)-2-(4-tgrt-butylphenyl)-4-[r4-(2-morpholin-4-ylethyl)piperazin-l- yllcarbonylloxazole
Figure imgf000170_0001
The title compound was prepared in analogous manner to Example 26, using 4-(2- morpholin-4-ylethyl)piperazine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 0.80 min. Mass Spectrum (ES+, m/z): 560 (M+H)+.
Example 137 N-(5-methylisoxazol-3-yl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide
Figure imgf000170_0002
The title compound was prepared in analogous manner to Example 26, using 5- methyl-isoxazol-3-y lamine instead of 2-trifluoromethylbenzylamine. HPLC: Retention time = 1.50 min.
Mass Spectrum (ES+, m/z): 459 (M+H)+.
Example 138 N-(3-ethoxycarbonyl-4-methylthiophene-2-yl)-5-(4-acetylaminophenyl)-2-(4-tert- butylphenyl)-oxazole-4-carboxamide
Figure imgf000171_0001
The title compound was prepared in analogous manner to Example 26, using 3- ethoxycarbonyl-4-methylthiophene-2-ylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.83 min. Mass Spectrum (ES+, m/z): 546 (M+H)+.
Example 139 N-(2-methylsulfanylphenyl)-5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxamide
Figure imgf000171_0002
The title compound was prepared in analogous manner to Example 26, using 2- methylsulfanylphenylamine instead of 2-trifluoromethylbenzylamine.
HPLC: Retention time = 1.75 min. Mass Spectrum (ES+, m/z): 500 (M+H)+.
Example 140 5-(4-Dimethylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4-carboxylic acid
Figure imgf000172_0001
The title compound was prepared from ethyl 5-(4-dimethylaminophenyl)-2-(4- trifluoromethylphenyl)oxazole-4-carboxylate in analogous manner to that described in Example 5 above in 82 % yield.
1H -Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ (ppm): 8.26 (doublet, J = 7.8 Hz, 2H); 8.09 (doublet, J = 7.5 Hz, 2H); 7.82 (doublet, J = 6.9 Hz, 2H); 6.82 (doublet, J = 7.2 Hz, 2H);
3.02 (singlet, 6H).
HPLC: Rt = 1.16 min.
Mass Spectrum (ES+, m/z): 377.09 (M+H)+.
Example 141 Ethyl 5-(4-acetylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4-carboxylate
Figure imgf000173_0001
The title compound was prepared from ethyl 5-(4-aminophenyl)-2-(4-trifluoromethyl- phenyl)oxazole-4-carboxylate in analogous manner to that described in Example 23 above in 37 % yield.
1H -Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ (ppm):
8.26 (doublet, J = 7.8 Hz, 2H);
8.13 (doublet, J = 8.7 Hz, 2H);
7.75 (doublet, J = 8.7 Hz, 2H);
7.67 (doublet, J = 9 Hz, 2H);
4.45 (quartet, J = 9 Hz, 2H);
2.20 (singlet, 3H);
1.42 (triplet, J = 9 Hz, 3H); 1.38 (singlet, 9H).
HPLC: Rt = 1.22 min.
Mass Spectrum (ES+, m/z): 419.16 (M+H)+.
Example 142
5-(4-Acetylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4-carboxylic acid
Figure imgf000174_0001
A 10%) aqueous sodium hydroxide solution (2 ml) was added to ethyl 5-(4- acetylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4-carboxylate (0.19 mmol, 80 mg), prepared as described in Example 141 above, in methanol (3 ml) and tetrahydrofuran (2 ml) and stirred for 4 hours at room temperature. At the end of this time, the solvent was removed in vacuo, 2M hydrochloric acid (3 ml) was added. The resulting precipitate was filtered, washed with diethyl ether and dried providing the title compound (54 mg, 73%) as an off white solid.
1H -Nuclear Magnetic Resonance Spectrum (300 MHz, DMSO-d6) δ (ppm):
10.23 (singlet, IH);
8.30 (doublet, J = 7.2 Hz, 2H);
8.15 (doublet, J = 7.2 Hz, 2H);
7.95 (doublet, J = 7.2 Hz, 2H); 7.75 (doublet, J = 7.2 Hz, 2H);
2.02 (singlet, 3H).
HPLC: Rt = 1.03 min.
Mass Spectrum (ES+, m/z): 391.13 (M+H)+.
Example 143
N-(2-trifluoromethylbenzyl)-5-(4-acetylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4- carboxamide
Figure imgf000175_0001
2-Chloro-l,3-dimethyI-2-imidazolinium chloride (DMC) (0.16 mmol, 27 mg) was added to a solution of 5-(4-acetylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4- carboxylic acid (0.08 mmol, 31.6 mg), prepared as described in Example 142 above, in acetonitrile (0.8 ml) and pyridine (0.2 ml). 2-Trifluoromethylbenzylamine (0.08 mmol, 11.3 μl) was then added and the resulting reaction mixture was stirred for 2 hours at room temperature. At the end of this time, the solvent was removed in vacuo and the crude residue partitioned between chloroform (50 ml) and 2M hydrochloric acid (20 ml). The organic layer was washed with brine (20 ml), dried over sodium sulfate and the solvent was then removed in vacuo. Flash chromatography (20 % ethyl acetate/hexanes) was performed on the resulting residue to give the title compound (25 mg, 57 %>) as a yellow solid.
!H -Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ (ppm):
8.38 (doublet, J = 7.8 Hz, 2H);
8.18 (doublet, J = 8.7 Hz, 2H);
7.30-7.80 (multiplet, 8H);
7.40 (triplet, J = 7.2 Hz, IH);
4.85 (doublet, J = 6.9 Hz, 2H);
2.23 (singlet, 3H).
HPLC: Rt = 1.53 min.
Mass Spectrum (ES+, m/z): 548.01 (M+H)+.
Example 144 Ethyl 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylate
Figure imgf000176_0001
The title compound was prepared from ethyl 5-(4-aminophenyl)-2-phenyloxazole-4- carboxylate, prepared as described in Example 12 above, in a manner analogous to that described in Example 24 above, in 97% yield. 1H -Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ (ppm):
8.10 (multiplet, 4H);
7.68 (doublet, J = 8 Hz, 2H);
7.50 (multiplet, 3H);
4.45 (quartet, J = 9Hz, 2H);
2.21 (singlet, 3H);
1.42 (triplet, J = 9 Hz, 3H).
HPLC: Rt = 1.09 min.
Mass Spectrum (ES+, m/z): 351 (M+H)+.
Example 145 5-(4-Acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid
Figure imgf000177_0001
Ethyl 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylate (2.57 g, 7.34 mmol), prepared as described in Example 144 above, was suspended in ethanol (25 ml). A solution of IN potassium hydroxide in ethanol was then added (9 ml, 9 mmol) and the resulting reaction mixture was heated for 1 hour at reflux. At the end of this time, the reaction mixture was cooled to 0°C. A solution of 0. IN hydrochloric acid was then added (150 ml) and the resulting precipitate was recovered via filtration to give the title compound (2.15 g, 91% yield).
1H -Nuclear Magnetic Resonance Spectrum (300 MHz, DMSO-d6) δ (ppm):
10.35 (singlet, IH);
8.12 (doublet, J = 6Hz, 2H);
8.04 (doublet, J = 6Hz, 2H);
7.80 (doublet, J = 6Hz, 2H);
7.52 (multiplet, 3H);
2.10 (singlet, 3H).
HPLC: Rt = 0.83 min.
Mass Spectrum (ES+, m/z): 323 (M+H)+.
Example 146 Ethyl 2-(4-tert-butylphenyl)-5-(2-nitrophenyl)oxazole-4-carboxylate
Figure imgf000178_0001
The title compound was prepared in 75 % yield in an analogous manner to that described in Example 1 above, using 2-nitrobenzoyl chloride instead of 4-nitrobenzoyl chloride.
1H -Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ (ppm):
8.12 (doublet, J = 8.6 Hz, 2H);
7.97 (doublet, J = 8.6 Hz, 2H);
7.91 (multiplet, 2H);
7.69 (multiplet, 2H);
7.51 (doublet, J = 8.6 Hz, 2H);
4.46 (quartet, J = 7.1 Hz, 2H);
1.43 (triplet, J = 1.1 Hz, 3H);
1.35 (singlet, 9H).
HPLC: Rt = 1.52 min.
Mass Spectrum (ES+, m/z): 395.17 (M+H)+.
Example 147 Ethyl 5-(2-aminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylate
Figure imgf000179_0001
The title compound was prepared in 80% yield from ethyl 2-(4-tert-butylphenyl)-5-(2- nitrophenyl)oxazole-4-carboxylate, prepared as described in Example 146 above, in analogous manner to that described in Example 9 above.
1H -Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ (ppm):
8.04 (doublet, J = 8.6 Hz, 2H);
7.90 (doublet, J = 9.4 Hz, 2H);
7.51 (doublet, J = 10.7 Hz, 2H);
7.23 (doublet, J = 8.5 Hz, 2H);
6.76 (multiplet, 2H);
5.98 (multiplet, 2H);
4.42 (quartet, J = 7.1 Hz, 2H);
1.41 (triplet, J = 1.1 Hz, 3H);
1.37 (singlet, 9H).
HPLC: Rt = 1.57 min.
Mass Spectrum (ES+, m/z): 365.59 (M+H)+.
Example 148 Ethyl 5-(2-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylate
Figure imgf000180_0001
The title compound was prepared in 96 % yield from ethyl 5-(2-aminophenyl)-2-(4- tert-butylphenyl)oxazole-4-carboxylate, prepared as described in Example 147 above, in analogous manner to that described in Example 24 above.
1H -Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ (ppm):
8.77 (doublet, J = 8.4 Hz, IH);
8.10 (doublet, J = 8.6 Hz, 2H);
8.05 (doublet, J = 9.4 Hz, 2H);
7.53 (doublet, J = 11.0 Hz, 2H);
7.48 (doublet, J = 8.6 Hz, 2H);
7.18 (triplet, J = 8 Hz, IH);
4.42 (quartet, J = 7.1 Hz, 2H); 2.34 (singlet, 3H);
1.43 (triplet, J = 7.1 Hz, 3H); 1.37 (singlet, 9H).
HPLC: Rt = 1.68 min.
Mass Spectrum (ES+, m/z): 407.25 (M+H)+.
Example 149 5-(2-Acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid
Figure imgf000181_0001
The title compound was prepared in 98 % yield from ethyl 5-(2-acetylaminophenyl)- 2-(4-tert-butylphenyl)oxazole-4-carboxylate, prepared as described in Example 148 above, in a manner analogous to that described in Example 25 above.
Η -Nuclear Magnetic Resonance Spectrum (300 MHz, DMSO-d6) δ (ppm):
8.50 (doublet, J = 8.6 Hz, IH);
8.12 (multiplet, 3H);
7.54 (multiplet, 3H);
7.26 (triplet, J = 8 Hz, IH);
2.20 (singlet, 3H);
1.33 (singlet, 9H).
HPLC: Rt = 1.33 min.
Mass Spectrum (ES+, m/z): 379.14 (M+H)+.
Example 150 N-(2-trifluoromethylbenzyl)-5-(2-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide
Figure imgf000182_0001
The title compound was prepared in 56 % yield from 5-(2-acetylaminophenyl)-2-(4- tert-butylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 149 above, in a manner analogous to that described in Example 26 above.
1H -Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ (ppm):
8.71 (doublet, J = 8.6 Hz, IH);
8.24 (doublet, J = 8.5 Hz, 2H);
8.06 (doublet, J = 8.0 Hz, IH);
7.71 (triplet, J = 8.1 Hz, 2H);
7.54 (doublet, J = 8.5 Hz, 2H);
7.54 (multiplet, 2H);
7.19 (multiplet, 2H);
4.86 (doublet, J = 6.5 Hz, 2H);
2.12 (singlet, 3H);
1.37 (singlet, 9H).
HPLC: Rt = 1.70 min.
Mass Spectrum (ES+, m/z): 536.10 (M+H)+.
Example 151 Ethyl 5 -(3 -acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylate
Figure imgf000183_0001
The title compound was prepared in 76 % yield from ethyl 5-(3-aminophenyl)-2-(4- tert-butylphenyl)oxazole-4-carboxylate, prepared as described in Example 10 above, in a manner analogous to that described in Example 24 above.
1H -Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ (ppm):
8.10 (singlet, IH);
8.05 (doublet, J = 7.8 Hz, 2H);
7.85 (triplet, J = 7.2 Hz, 2H);
7.50 (doublet, J = 7.8 Hz, 2H);
7.43 (triplet, J = 7.2 Hz, IH);
7.39 (singlet, IH);
4.42 (quartet, J = 6.9 Hz, 2H); 2.20 (singlet, 3H);
1.40 (triplet, J = 6.9 Hz, 3H); 1.37 (singlet, 9H).
HPLC: Rt = 1.49 min.
Mass Spectrum (ES+, m/z): 407.16 (M+H)+.
Example 152 5-(3-Acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid
Figure imgf000184_0001
The title compound was prepared in 82 % yield from ethyl 5-(3-acetylaminophenyl)- 2-(4-tert-butylphenyl)oxazole-4-carboxylate, prepared as described in Example 151 above, in a manner analogous to that described in Example 25 above.
1H -Nuclear Magnetic Resonance Spectrum (300 MHz, DMSO-d6) δ (ppm):
10.23 (singlet, IH);
8.40 (singlet, J = 7.2 Hz, IH);
8.00 (doublet, J = 7.2 Hz, 2H);
7.75 (multiplet, 2H);
7.58 (doublet, J = 7.2 Hz, 2H);
7.48 (triplet, J = 6.9 Hz, IH);
2.09 (singlet, 3H);
1.35 (singlet, 9H).
HPLC: Rt = 1.17 min.
Mass Spectrum (ES+, m/z): 379.13 (M+H)+.
Example 153
N-(2-trifluoromethylbenzyl)-5-(3-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide
Figure imgf000186_0001
The title compound was prepared in 45 % yield from 5-(3-acetylaminophenyl)-2-(4- tert-butylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 152 above, in a manner analogous to that described in Example 26 above.
1H -Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ (ppm):
8.26 (doublet, J = 7.8 Hz, 2H);
8.17 (2,1H);
7.79 (multiplet, IH);
7.68 (multiplet, 4H);
7.30-7.50 (multiplet, J = 8.5 Hz, 6H);
4.84 (doublet, J = 6.5 Hz, 2H);
2.20 (singlet, 3H);
1.37 (singlet, 9H).
HPLC: Rt = 1.64 min.
Mass Spectrum (ES+, m/z): 536.07 (M+H)+.
Example 154 N-r2-(4-methoxyphenyl)ethyl]-2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000187_0001
A solution of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 20 above, in a 4:1 by volume mixture of acetonitrile and pyridine (800 μl, 0.125M, 100 μmol) was added to a 2-dram reaction vial. A solution of 2-chloro-l,3-dimethylimidazolinium chloride (DMC) in a 4:1 by volume mixture of acetonitrile and pyridine (800 μl, 0.25M, 200 μmol) was then added followed by the addition of a solution of 2-(4-methoxyphenyl)ethylamine in acetonitrile (400 μl, 0.25M, 100 μmol). The reaction mixture was then allowed to stand for 4 hours at room temperature. At the end of this time, the solvent was removed in vacuo and the resulting crude material submitted for HPLC purification.
HPLC: Rt = 1.78 min.
Mass Spectrum (ES+, m/z): 498.06 (M+H)+.
Example 155 N-(4-acetylphenyl)-2-(4-te7<t-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000188_0001
The title compound was prepared in analogous manner to Example 154, using 4- acetyl-phenylamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.85 min.
Mass Spectrum (ES+, m/z): 482.08 (M+H)+.
Example 156 N-[2-(3-methoxyphenyl)ethyl]-2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000188_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-(3-methoxyρhenyl)ethylamine instead of 2-(4- methoxyphenyl)ethylamine.
HPLC: Rt = 1.82 min. Mass Spectrum (ES+, m/z): 498.09 (M+H)+.
Example 157 N-(3-morpholin-4-ylpropyl)-2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000189_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 3 -morpholin-4-ylpropy lamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.06 min.
Mass Spectrum (ES+, m/z): 491.17 (M+H)+.
Example 158 2-(4-tert-Butylphenyl)-5-(3-dimethylaminophenyl)-4-(thiazolidin-3-ylcarbonyl)oxazole
Figure imgf000189_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using thiazolidine instead of 2-(4-methoxyphenyl)ethylamine. HPLC: Rt = 1.65 min.
Mass Spectrum (ES+, m/z): 436.05 (M+H)+.
Example 159 2-(4-tert-Butylphenyl)-5-(3-dimethylaminophenyl)-4-[[4-(2-ethoxycarbonyl)piperidin-l-yl]- carbonyl]oxazole
The title compound was prepared in analogous manner to that described in Example
154 above, using 4-(2-ethoxycarbonyl)piperidine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.62 min.
Mass Spectrum (ES+, m/z): 504.22 (M+H)+
Example 160 N-cyclobutyl-2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000191_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using cyclobutylamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.77 min.
Mass Spectrum (ES+, m/z): 418.11 (M+H)+
Example 161 N-(tetrahydrofuran-2-ylmethyl)-2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000191_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using tetrahydrofuran-2-ylmethylamine instead of 2-(4- methoxyphenyl)ethylamine.
HPLC: Rt = 1.67 min.
Mass Spectrum (ES+, m/z): 448.10 (M+H)+ Example 162 N-(2-methoxybenzyl)-2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000192_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-methoxybenzy lamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.79 min.
Mass Spectrum (ES+, m/z): 484.10 (M+H)+
Example 163 N-[3-(pyrrolidin-l-yl)propyl]-2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000192_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 3-(pyrrolidin-l-yl)propylamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.10 min.
Mass Spectrum (ES+, m/z): 475.18 (M+H)+
Example 164 N-methyl-N-phenyl-2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000193_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using N-methylphenylamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.67 min.
Mass Spectrum (ES+, m/z): 454.10 (M+H)+
Example 165 N-(2-methoxyethyl)-2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000194_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-methoxyethylamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.64 min.
Mass Spectrum (ES+, m/z): 422.32 (M+H)+
Example 166 2-(4-tert-Butylphenyl)-5-(3-dimethylaminophenyl)-4-(pyrrolidin-l-ylcarbonyl)oxazole
Figure imgf000194_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using pyrrolidine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.60 min.
Mass Spectrum (ES+, m/z): 418.34 (M+H)+ Example 167 N-( 1 -ethylpropyl)-2-(4-tert-butylphenyl)-5 -(3 -dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000195_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 1-ethylpropylamine instead of 2-(4-methoxyphenyl)ethy lamine.
HPLC: Rt = 1.84 min.
Mass Spectrum (ES+, m/z): 434.13 (M+H)+
Example 168 N-(2,3-dihydrobenzo[l,4]dioxin-6-yl)-2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)- oxazole-4-carboxamide
Figure imgf000195_0002
The title compound was prepared in analogous manner to that described in Example
154 above, using 2,3-dihydrobenzo[l,4]dioxin-6-ylamine instead of 2-(4- methoxypheny l)ethylamine . HPLC: Rt = 1.82 min.
Mass Spectrum (ES+, m/z): 498.10 (M+H)+
Example 169 N-(benzo [1,3] dioxol-5 -ylmethyl)-2-(4-tert-butylphenyl)-5 -(3 -dimethylaminophenyl)oxazole- 4-carboxamide
Figure imgf000196_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using benzo[l,3]dioxol-5-ylmethylamine instead of 2-(4- methoxyphenyl)ethylamine.
HPLC: Rt = 1.76 min.
Mass Spectrum (ES+, m/z): 498.07 (M+H)+
Example 170 N-[3-(imidazol-l-yl)propyl]-2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000197_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 3-(imidazol-l-yl)propylamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.07 min.
Mass Spectrum (ES+, m/z): 472.15 (M+H)+
Example 171 N-[4-(piperidin-l-yl)phenyn-2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000197_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-(piperidin-l-yl)pheny lamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.39 min.
Mass Spectrum (ES+, m/z): 523.07 (M+H)+ Example 172 N-(4-methoxyphenyl)-2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000198_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-methoxyphenylamine instead of 2-(4-methoxyphenyl)ethy lamine.
HPLC: Rt = 1.80 min.
Mass Spectrum (ES+, m/z): 470.10 (M+H)+
Example 173 N-propyl-2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000198_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using propylamine instead of 2-(4-methoxyphenyl)ethylamine. HPLC: Rt = 1.75 min.
Mass Spectrum (ES+, m/z): 406.32 (M+H)+
Example 174 N-phenyl-2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carbonylhydrazide
Figure imgf000199_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using Ν-phenylhydrazine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.72 min.
Mass Spectrum (ES+, m/z): 455.08 (M+H)+
Example 175 2-(4-tert-Butylphenyl)-4-[(2,5-dihydro-pyrrol-l-yl)carbonyl]-5-(3- dimethylaminophenyl)oxazole
Figure imgf000199_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 2,5-dihydropyrrole instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.63 min.
Mass Spectrum (ES+, m/z): 416.20 (M+H)+
Example 176 2-(4-tgrt-Butylphenyl)-5-(3-dimethylaminophenyl)-4-(thiomorpholin-4-ylcarbonyl)oxazole
Figure imgf000200_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using thiomorpholine instead of 2-(4-methoxyphenyl)ethy lamine.
HPLC: Rt = 1.63 min.
Mass Spectrum (ES+, m/z): 450.07 (M+H)+
Example 177 2-(4-tert-Butylphenyl)-5 -(3 -dimethylaminophenyl)-4- [(4-methylpiperidin- 1 - yl)carbonyl]oxazole
Figure imgf000201_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-methylpiperidine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.73 min.
Mass Spectrum (ES+, m/z): 446.12 (M+H)+
Example 178 N-(benzo[l,3]dioxol-5-yl)-N-ethyl-2-(4-tgrt-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000201_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using N-ethyl-(benzo[l,3]dioxol-5-yl)amine instead of 2-(4- methoxyphenyl)ethylamine.
HPLC: Rt = 1.68 min.
Mass Spectrum (ES+, m/z): 512.06 (M+H)+ Example 179 4-[(4-Benzylpiperazin-l-yl)carbonyl]-2-(4-tert-butylphenyl)-5-(3- dimethylaminophenyl)oxazole
Figure imgf000202_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 1-benzylpiperazine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.15 min.
Mass Spectrum (ES+, m/z): 523.15 (M+H)+
Example 180 2-(4-tert-Butylphenyl)-5-(3-dimethylaminophenyl)-4-[[4-(3-trifluoromethylphenyl)piperazin- 1 -yl]carbonyl]oxazole
Figure imgf000202_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using l-(3-trifluoromethylphenyl)piperazine instead of 2-(4- methoxyphenyl)ethylamine.
HPLC: Rt = 1.79 min.
Mass Spectrum (ES+, m/z): 577.03 (M+H)+
Example 181 N-[2-(pyrrolidin-l-yl)ethyl]-2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000203_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-(pyrrolidin-l-yl)ethy lamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.09 min.
Mass Spectrum (ES+, m/z): 461.17 (M+H)+
Example 182 < N-(2-trifluoromethylbenzyl)-2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000204_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-trifluoromethylbenzylamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.84 min.
Mass Spectrum (ES+, m/z): 522.12 (M+H)+
Example 183 2-(4-tert-Butylphenyl)-5-(3-dimethylaminophenyl)-4-[(4-phenylpiperazin-l- yl)carbonyl]oxazole
Figure imgf000204_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 1-phenylpiperazine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.72 min.
Mass Spectrum (ES+, m/z): 509.11 (M+H)+ Example 184 N-allyl-2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000205_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using allylamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.71 min.
Mass Spectrum (ES+, m/z): 404.35 (M+H)+
Example 185 N-(4-methoxyphenyl)-N-methyl-2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole- 4-carboxamide
Figure imgf000205_0002
The title compound was prepared in analogous manner to that described in Example
154 above, using N-methyl-4-methoxyphenylamine instead of 2-(4- methoxypheny l)ethylamine . HPLC: Rt = 1.64 min.
Mass Spectrum (ES+, m/z): 484.29 (M+H)+
Example 186 2-(4-tgrt-Butylphenyl)-5-(3-dimethylaminophenyl)-4-r(2,6-dimethylmorpholin-4- yl)carbonyl]-oxazole
Figure imgf000206_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2,6-dimethylmorpholine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.57 min.
Mass Spectrum (ES+, m/z): 462.10 (M+H)+
Example 187 N-(4-chlorophenyl)-N-methyl-2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000206_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using N-methyl-4-chlorophenylamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC: Rt = 1.75 min.
Mass Spectrum (ES+, m/z): 488.02 (M+H)+
Example 188 N-(l,2,3,4-tetrahydronaphthalen-l-yl)-2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)- oxazole-4-carboxamide
Figure imgf000207_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 1,2,3,4-tetrahydronaphthalen-l-ylamine instead of 2-(4- methoxypheny l)ethylamine .
HPLC: Rt = 1.90 min.
Mass Spectrum (ES+, m/z): 494.13 (M+H)+
Example 189 N-(2-ethyl-2H-pyrazol-3-yl)-2-(4-te7jt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000208_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-ethyl-2H-pyrazol-3-y lamine instead of 2-(4-methoxyphenyl)ethylamine.
ΗPLC: Rt = 1.70 min.
Mass Spectrum (ES+, m/z): 458.11 (M+H)+
Example 190 N-methyl-N-phenyl-5-(4-dimethylaminophenyl)-2-(4-trifluoromethylρhenyl)oxazole-4- carboxamide
Figure imgf000208_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using N-methylphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- dimethylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 140 above, instead of 2-(4-tert-butylphenyl)-5-(3- dimethylaminophenyl)-oxazole-4-carboxylic acid. HPLC: Rt = 1.51 min.
Mass Spectrum (ES+, m/z): 466.15 (M+H)+
Example 191 N-(2,3-dihydrobenzo[l,4]dioxin-6-yl)-5-(4-dimethylaminophenyl)-2-(4- trifluoromethylphenyl)-oxazole-4-carboxamide
Figure imgf000209_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2,3-dihydrobenzo[l,4]dioxin-6-ylamine instead of 2-(4- methoxyphenyl)ethylamine and 5-(4-dimethylaminophenyl)-2-(4- trifluoromethylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 140 above, instead of2-(4-tgrt-butylphenyl)-5-(3-dimethylamino-phenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.61 min.
Mass Spectrum (ES+, m/z):510.13 (M+H)+
Example 192 N-allyl-5-(4-dimethylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4-carboxamide
Figure imgf000210_0001
The title compound was prepared in analogous manner to that described in Example
154 above, using allylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- dimethylamino-phenyl)-2-(4-trifluoromethylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 140 above, instead of 2-(4-tert-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.52 min.
Mass Spectrum (ES+, m/z): 416.15 (M+H)+
Example 193 N-(4-chlorophenyl)-N-methyl-5-(4-dimethylaminophenyl)-2-(4- trifluoromethylphenyl)oxazole-4-carboxamide
Figure imgf000210_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using N-methyl-4-chlorophenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4-dimethylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 140 above, instead of 2-(4-tert-butylphenyl)-5-(3- dimethylaminophenyl)-oxazole-4-carboxylic acid.
HPLC: Rt = 1.60 min.
Mass Spectrum (ES+, m/z): 500.11 (M+H)+
Example 194 N-(2-trifluoromethylbenzyl)-5-(4-dimethylaminophenyl)-2-(4- trifluoromethylphenyl)oxazole-4-carboxamide
Figure imgf000211_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-trifluoromethylbenzylamine instead of 2-(4-methoxyphenyl)ethy lamine and 5-(4-dimethylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 140 above, instead of 2-(4-tert-butylphenyl)-5-(3- dimethylaminophenyl)-oxazole-4-carboxylic acid.
HPLC: Rt = 1.68 min.
Mass Spectrum (ES+, m/z): 534.13 (M+H)+ Example 195 N-(3-methylsulfanylphenyl)-5-(4-dimethylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole- 4-carboxamide
Figure imgf000212_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 3 -methylsulfanylpheny lamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4-dimethylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 140 above, instead of 2-(4-tgrt-butylphenyl)-5-(3- dimethylaminophenyl)-oxazole-4-carboxylic acid.
HPLC: Rt = 1.72 min.
Mass Spectrum (ES+, m/z): 498.12 (M+H)+
Example 196 4-[(2,5-Dihydropyrrol-l-yl)carbonyl]-5-(4-dimethylaminophenyl)-2-(4- trifluoromethylphenyl)-oxazole
Figure imgf000212_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 2,5-dihydropyrrole instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- dimethylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 140 above, instead of 2-(4-tgrt-butylphenyl)-5-(3- dimethylaminophenyl)-oxazole-4-carboxylic acid.
HPLC: Rt = 1.45 min.
Mass Spectrum (ES+, m/z): 428.13 (M+H)+
Example 197 N-(3 -methoxy-5 -trifluoromethylphenyl)-5 -(4-dimethylaminophenyl)-2-(4-trifluoromethyl- phenyl)oxazole-4-carboxamide
Figure imgf000213_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 3 -methoxy-5 -trifluoromethylpheny lamine instead of 2-(4-methoxyphenyl)- ethylamine and 5-(4-dimethylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 140 above, instead of 2-(4-tert-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.80 min.
Mass Spectrum (ES+, m/z): 550.12 (M+H)+ Example 198 N-benzyl-5-(4-dimethylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4-carboxamide
Figure imgf000214_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using benzylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- dimethylamino-phenyl)-2-(4-trifluoromethylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 140 above, instead of 2-(4-tert-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.59 min.
Mass Spectrum (ES+, m/z): 466.15 (M+H)+
Example 199 5-(4-Dimethylaminophenyl)-4-(thiomorpholin-4-ylcarbonyl)-2-(4-trifluoromethylphenyl)- oxazole
Figure imgf000214_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using thiomorpholine instead of2-(4-methoxyphenyl)ethylamine and 5-(4- dimethylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 140 above, instead of 2-(4-tert-butylphenyl)-5-(3- dimethylaminophenyl)-oxazole-4-carboxylic acid.
HPLC: Rt = 1.46 min.
Mass Spectrum (ES+, m/z): 462.13 (M+H)+
Example 200 N-(benzo[l,3]dioxol-5-ylmethyl)-5-(4-dimethylaminophenyl)-2-(4-trifluoromethylphenyl)- oxazole-4-carboxamide
Figure imgf000215_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using benzo[l,3]dioxol-5-ylmethylamine instead of 2-(4- methoxyphenyl)ethylamine and 5-(4-dimethylaminophenyl)-2-(4- trifluoromethylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 140 above, instead of 2-(4-tgrt-butylphenyI)-5-(3-dimethylaminophenyl)-oxazoIe-4-carboxyIic acid.
HPLC: Rt = 1.57 min.
Mass Spectrum (ES+, m/z): 510.14 (M+H)+ Example 201 N-(4-methylphenyl)-5-(4-dimethylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4- carboxamide
Figure imgf000216_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-methylphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- dimethylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 140 above, instead of 2-(4-tert-butylphenyl)-5-(3- dimethylaminophenyl)-oxazole-4-carboxylic acid.
HPLC: Rt = 1.69 min.
Mass Spectrum (ES+, m/z): 466.15 (M+H)+
Example 202 N-[4-(piperidin-l-yl)phenyl]-5-(4-dimethylaminophenyl)-2-(4- trifluoromethylphenyl)oxazole-4-carboxamide
Figure imgf000217_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-(piperidin-l-yl)phenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4-dimethylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 140 above, instead of 2-(4-tert-butylphenyl)-5-(3- dimethylaminophenyl)-oxazole-4-carboxylic acid.
HPLC: Rt = 1.20 min.
Mass Spectrum (ES+, m/z): 535.21 (M+H)+
Example 203 N-phenyl-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000217_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using phenylamine instead of 2-(4-methoxyphenyl)ethylamine and 2-(biphenyl-2- yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt= 1.62 min.
Mass Spectrum (ES+, m/z): 460.18 (M+H)+
Example 204 N-methyl-N-phenyl-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000218_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using N-methylphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 2- (biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole- 4-carboxylic acid.
HPLC: Rt = 1.47 min.
Mass Spectrum (ES+, m/z): 474.20 (M+H)+
Example 205 2-(Biphenyl-2-yl)-5-(4-dimethylaminophenyl)-4-[(4-methylpiperidin-l-yl)carbonyl1oxazole
Figure imgf000219_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-methylpiperidine instead of 2-(4-methoxyphenyl)ethylamine and 2- (biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert-butyIphenyI)-5-(3-dimethylaminophenyl)oxazole- 4-carboxylic acid.
HPLC: Rt = 1.56 min.
Mass Spectrum (ES+, m/z): 466.22 (M+H)+
Example 206 N-(4-methoxyphenyl)-N-methyl-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000219_0002
The title compound was prepared in analogous manner to that described in Example
154 above, using N-methyl-4-methoxyphenylamine instead of 2-(4- methoxyphenyl)ethylamine and 2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tg?-t- butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.43 min.
Mass Spectrum (ES+, m/z): 504.19 (M+H)+
Example 207 N-(3-ethoxyphenyl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000220_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 3-ethoxyphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 2- (biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole- 4-carboxylic acid.
HPLC: Rt = 1.68 min.
Mass Spectrum (ES+, m/z): 504.22 (M+H)+ Example 208 N-(naphthalen-l-yl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000221_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using naphthalen-1-y lamine instead of 2-(4-methoxyphenyl)ethy lamine and 2- (biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole- 4-carboxylic acid.
HPLC: Rt = 1.71 min.
Mass Spectrum (ES+, m/z): 510.21 (M+H)+
Example 209 N-(2-methoxyphenyl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000221_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-methoxyphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 2- (biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole- 4-carboxylic acid.
HPLC: Rt = 1.69 min.
Mass Spectrum (ES+, m/z): 490.20 (M+H)+
Example 210 N-(2,3-dihydrobenzori,4]dioxin-6-yl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole- 4-carboxamide
Figure imgf000222_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2,3-dihydrobenzo[l,4]dioxin-6-ylamine instead of 2-(4- methoxyphenyl)ethy lamine and 2-(biphenyl-2-y l)-5 -(4-dimethylaminophenyl)oxazole-4- carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tgrt- butylphenyl)-5-(3-dimethylamino-phenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.57 min.
Mass Spectrum (ES+, m/z): 518.19 (M+H)+ Example 211 N-(5-methylisoxazol-3-yl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000223_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 5-methylisoxazol-3-ylamine instead of 2-(4-methoxyphenyl)ethy lamine and 2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.54 min.
Mass Spectrum (ES+, m/z): 565.18 (M+H)+
Example 212 N-(biphenyl-2-yl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000223_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using biphenyl-2-ylamine instead of 2-(4-methoxyphenyl)ethylamine and 2- (biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole- 4-carboxylic acid.
HPLC: Rt = 1.81 min.
Mass Spectrum (ES+, m/z): 536.20 (M+H)+
Example 213 N-allyl-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000224_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using allylamine instead of 2-(4-methoxyphenyl)ethylamine and 2-(biphenyl-2- yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.46 min.
Mass Spectrum (ES+, m/z): 424.19 (M+H)+ Example 214 N-(4-chlorophenyl)-N-methyl-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000225_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using N-methyl-4-chlorophenylamine instead of 2-(4-methoxyphenyl)ethylamine and 2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.54 min.
Mass Spectrum (ES+, m/z): 508.15 (M+H)+
Example 215 N-(2-methoxybenzyl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000225_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-methoxybenzylamine instead of 2-(4-methoxyphenyl)ethylamine and 2- (biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxyIic acid, prepared as described in Example 21 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole- 4-carboxylic acid.
HPLC: Rt = 1.59 min.
Mass Spectrum (ES+, m/z): 504.21 (M+H)+
Example 216 2-(Biphenyl-2-yl)-4-[(3,4-dihydro-2H-quinolin-l-yl)carbonyl]-5-(4-dimethylaminophenyl)- oxazole
Figure imgf000226_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 3,4-dihydro-2H-quinoline instead of 2-(4-methoxyphenyl)ethyIamine and 2- (biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylammophenyl)oxazole- 4-carboxylic acid. ΗPLC: Rt = 1.57 min. Mass Spectrum (ES+, m/z): 500.21 (M+H)+ Example 217 N-(2-methoxy-5-methylphenyl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000227_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-methoxy-5-methylpheny lamine instead of 2-(4- methoxyphenyl)ethylamine and 2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tgrt- butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.74 min.
Mass Spectrum (ES+, m/z): 504.21 (M+H)+
Example 218 N-(4-methoxyphenyl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000227_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-methoxyphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 2- (biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole- 4-carboxylic acid. HPLC: Rt = 1.59 min. Mass Spectrum (ES+, m/z): 490.20 (M+H)+
Example 219 N-(2-trifluoromethylbenzyl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000228_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-trifluoromethylbenzylamine instead of 2-(4-methoxyphenyl)ethylamine and 2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert-butylρhenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.67 min.
Mass Spectrum (ES+, m/z): 542.18 (M+H)+ Example 220 N-(3-methylsulfanylphenyl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000229_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 3 -methylsulfanylpheny lamine instead of 2-(4-methoxyphenyl)ethy lamine and 2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tgrt-butylphenyI)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.68 min.
Mass Spectrum (ES+, m/z): 506.18 (M+H)+
Example 221 2-(Biphenyl-2-yl)-5-(4-dimethylaminophenyl)-4-r(4-phenylpiperazin-l-yl)carbonyl]oxazole
Figure imgf000229_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 1-phenylpiperazine instead of 2-(4-methoxyphenyl)ethylamine and 2- (biphenyI-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazoIe- 4-carboxylic acid.
HPLC: Rt = 1.56 min.
Mass Spectrum (ES+, m/z): 529.24 (M+H)+
Example 222 2-(Biphenyl-2-yl)-4-(2,5-dihydropyrrol-l-ylcarbonyl)-5-(4-dimethylaminophenyl)oxazole
Figure imgf000230_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2,5-dihydropyrrole instead of 2-(4-methoxyphenyl)ethylamine and 2- (biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole- 4-carboxylic acid.
HPLC: Rt = 1.42 min.
Mass Spectrum (ES+, m/z): 436.17 (M+H)+ Example 223 2-(Biphenyl-2-yl)-5-(4-dimethylaminophenyl)-4-[[4-(3-trifluoromethylphenyl)piperazin-l- yl]carbonyl]oxazole
Figure imgf000231_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using l-(3-trifluoromethylphenyl)piperazine instead of 2-(4- methoxyphenyl)ethylamine and 2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tgrt- butylphenyl)-5-(3-dimethylamino-phenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.68 min.
Mass Spectrum (ES+, m/z): 597.18 (M+H)+
Example 224 N-(3-methoxy-5-trifluoromethylphenyl)-2-(biphenyl-2-yl)-5-(4- dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000231_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 3-methoxy-5-trifluoromethylphenylamine instead of 2-(4-methoxyphenyl)- ethylamine and 2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tgrt-butylphenyl)-5-(3- dimethylaminophenyl)-oxazole-4-carboxylic acid.
HPLC: Rt = 1.74 min.
Mass Spectrum (ES+, m/z): 558.16 (M+H)+
Example 225
N-(3-benzyloxyphenyl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000232_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 3 -benzyloxypheny lamine instead of 2-(4-methoxyphenyl)ethylamine and 2- (biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole- 4-carboxylic acid.
HPLC: Rt = 1.75 min.
Mass Spectrum (ES+, m/z): 566.20 (M+H)+ Example 226 N-(3,5-bis-trifluoromethylbenzyl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000233_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 3,5-bis-trifluoromethylbenzylamine instead of 2-(4- methoxyphenyl)ethy lamine and 2-(biphenyl-2-yl)-5 -(4-dimethylaminophenyl)oxazole-4- carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert- butylphenyl)-5 -(3 -dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.72 min.
Mass Spectrum (ES+, m/z): 610.13 (M+H)+
Example 227 N-(2-acetylphenyl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000233_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-acetylphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 2- (biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxyIic acid, prepared as described in Example 21 above, instead of 2-(4-tg7-t-butylphenyl)-5-(3-dimethylaminophenyl)oxazole- 4-carboxylic acid.
HPLC: Rt = 1.65 min.
Mass Spectrum (ES+, m/z): 502.19 (M+H)+
Example 228 N-(2-methylsulfanylphenyl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000234_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-methylsulfanylphenylamine instead of 2-(4-methoxyphenyl)ethyIamine and 2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tgrt-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxy lie acid.
HPLC: Rt = 1.75 min. Mass Spectrum (ES+, m/z): 506.18 (M+H)+
Example 229 N-benzyl-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000235_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using benzylamine instead of 2-(4-methoxyphenyl)ethylamine and 2-(biphenyl-2- yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.56 min.
Mass Spectrum (ES+, m/z): 474.20 (M+H)+
Example 230 2-(Biphenyl-2-yl)-5-(4-dimethylaminophenyl)-4-(thiomorpholin-4-ylcarbonyl)oxazole
Figure imgf000235_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using thiomorpholine instead of 2-(4-methoxyphenyl)ethylamine and 2-(biphenyl- 2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.47 min.
Mass Spectrum (ES+, m/z): 470.17 (M+H)+
Example 231 N-(benzo[l,3]dioxol-5-ylmethyl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000236_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using benzo[l,3]dioxol-5-ylmethylamine instead of 2-(4- methoxyphenyl)ethylamine and 2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert- butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid. HPLC: Rt = 1.53 min. Mass Spectrum (ES+, m/z): 518.21 (M+H)+ Example 232 N-(benzo[l,3]dioxol-5-yl)-N-ethyl-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000237_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using N-ethylbenzo[l,3]dioxol-5-ylamine instead of 2-(4- methoxyphenyl)ethylamine and 2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tgrt- butylphenyl)-5-(3-dimethylamino-phenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.46 min.
Mass Spectrum (ES+, m/z): 532.20 (M+H)+
Example 233 N-(2-benzylphenyl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000237_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-benzylphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 2- (biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole- 4-carboxylic acid. HPLC: Rt = 1.78 min. Mass Spectrum (ES+, m/z): 550.22 (M+H)+
Example 234 N-(4-methylphenyl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000238_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-methylphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 2- (biphenyl-2-yl)-5-(4-dimethylaminophenyI)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole- 4-carboxylic acid.
HPLC: Rt = 1.67 min.
Mass Spectrum (ES+, m/z): 474.21 (M+H)+ Example 235 N-(2,5-dimethoxyphenyl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000239_0001
The title compound was prepared in analogous manner to that described in Example
154 above, using 2,5-dimethoxyphenylamine instead of 2-(4-methoxyphenyl)ethylamine and
2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tert-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.69 min.
Mass Spectrum (ES+, m/z): 520.22 (M+H)+
Example 236 N-(biphenyl-4-yl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000239_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using biphenyl-4-ylamine instead of 2-(4-methoxyphenyl)ethylamine and 2- (biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole- 4-carboxylic acid.
HPLC: Rt = 1.76 min.
Mass Spectrum ,(ES+, m/z): 536.22 (M+H)+
Example 237 N-(2,6-dimethoxybenzyl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000240_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2, 6-dimethoxybenzy lamine instead of 2-(4-methoxyphenyl)ethylamine and 2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tgrt-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.61 min. Mass Spectrum (ES+, m/z): 534.22 (M+H)+
Example 238 N-(4-piperidin-l-ylphenyl)-2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000241_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-(piperidin-l-yl)pheny lamine instead of 2-(4-methoxyphenyl)ethylamine and 2-(biphenyl-2-yl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 21 above, instead of 2-(4-tgrt-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.15 min.
Mass Spectrum (ES+, m/z): 543.26 (M+H)+
Example 239 N-phenyl-5-(4-dimethylammophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000241_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using phenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- dimethylamino-phenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.59 min.
Mass Spectrum (ES+, m/z): 384.11 (M+H)+
Example 240 N-methyl-N-phenyl-5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000242_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using N-methylphenylamine instead of 2-(4-methoxyphenyl)ethy lamine and 5-(4- dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.34 min.
Mass Spectrum (ES+, m/z): 398.10 (M+H)+ Example 241 5 -(4-Dimethylaminophenyl)-4- [(4-methylpiperidin- 1 -yl)carbonyl] -2-phenyloxazole
Figure imgf000243_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-methylpiperidine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.41 min.
Mass Spectrum (ES+, m/z): 390.15 (M+H)+
Example 242 5-(4-Dimethylaminophenyl)-4-[[4-(2-methoxyphenyl)piperazin-l-yl]carbonyl]-2- phenyloxazole
Figure imgf000243_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-(2-methoxyphenyl)piperazine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.38 min.
Mass Spectrum (ES+, m/z): 483.16 (M+H)+
Example 243 N-(3-ethoxyphenyl)-5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000244_0001
The title compound was prepared in analogous manner to that described in Example 154'above, using 3-ethoxyphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- dimethylammophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.64 min.
Mass Spectrum (ES+, m/z): 428.11 (M+H)+ Example 244 N-(2,3-dihydrobenzo[l,4]dioxin-6-yl)-5-(4-dimethylammophenyl)-2-phenyloxazole-4- carboxamide
Figure imgf000245_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2,3-dihydrobenzo[l,4]dioxin-6-ylamine instead of 2-(4- methoxyphenyl)ethylamine and 5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tgrt-butylphenyl)-5-(3- dimethyIaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.52 min.
Mass Spectrum (ES+, m/z): 442.08 (M+H)+
Example 245 N-allyl-5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000245_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using ally lamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- dimethylamino-phenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.41 min.
Mass Spectrum (ES+, m/z): 348.15 (M+H)+
Example 246 N-(4-chlorophenyl)-N-methyl-5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000246_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using N-methyl-4-chlorophenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.45 min.
Mass Spectrum (ES+, m/z): 432.08 (M+H)+ Example 247 N-(2-methoxybenzyl)-5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000247_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-methoxybenzylamine instead of 2-(4-methoxyphenyl)ethylamine and 5- (4-dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.55 min.
Mass Spectrum (ES+, m/z): 428.12 (M+H)+
Example 248 N-(4-methoxyphenyl)-5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000247_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-methoxyphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5- (4-dimethylaminophenyl)-2-ρhenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.53 min.
Mass Spectrum (ES+, m/z): 414.11 (M+H)+
Example 249 N-(3-methylsulfanylphenyl)-5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000248_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 3-methylsulfanylphenylamine instead of 2-(4-methoxyphenyl)ethy lamine and 5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.64 min.
Mass Spectrum (ES+, m/z): 430.09 (M+H)+
Example 250 5-(4-Dimethylaminophenyl)-2-phenyl-4-[(4-phenylpiperazin-l-yl)carbonyl]oxazole
Figure imgf000249_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 1-phenylpiperazine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.42 min.
Mass Spectrum (ES+, m/z): 453.15 (M+H)+
Example 251 4-(2,5-Dihydropyrrol-l-ylcarbonyl)-5-(4-dimethylaminophenyl)-2-phenyloxazole
Figure imgf000249_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 2,5-dihydropyrrole instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.28 min.
Mass Spectrum (ES+, m/z): 360.15 (M+H)+
Example 252 5-(4-Dimethylaminophenyl)-2-phenyl-4-[[4-(3-trifluoromethylphenyl)piperazin-l- yl]carbonyl]-oxazole
Figure imgf000250_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using l-(3-trifluoromethylphenyl)piperazine instead of 2-(4- methoxyphenyl)ethylamine and 5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tert-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.55 min.
Mass Spectrum (ES+, m/z): 521.15 (M+H)+ Example 253 N-(3-methoxy-5-trifluoromethylphenyl)-5-(4-dimethylaminophenyl)-2-phenyloxazole-4- carboxamide
Figure imgf000251_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 3 -methoxy-5 -trifluoromethylphenylamine instead of 2-(4-methoxyphenyl)- ethylamine and 5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tert-butylphenyl)-5-(3- dimethylaminophenyl)-oxazole-4-carboxylic acid.
HPLC: Rt = 1.72 min.
Mass Spectrum (ES+, m/z): 482.10 (M+H)+
Example 254 N-(3-benzyloxyphenyl)-5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000251_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 3 -benzyloxypheny lamine instead of 2-(4-methoxyphenyl)ethylamine and 5- (4-dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.72 min.
Mass Spectrum (ES+, m/z): 490.14 (M+H)+
Example 255 N-(3,5-bis-trifluoromethylbenzyl)-5-(4-dimethylaminophenyl)-2-phenyloxazole-4- carboxamide
Figure imgf000252_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 3,5-bis-trifluoromethylbenzylamine instead of 2-(4- methoxyphenyl)ethylamine and 5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tgrt-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.68 min. Mass Spectrum (ES+, m/z): 534.08 (M+H)+
Example 256 N-benzyl-5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000253_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using benzylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- dimethylamino-phenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.52 min.
Mass Spectrum (ES+, m/z): 398.14 (M+H)+
Example 257 5-(4-Dimethylaminophenyl)-2-phenyl-4-(thiomorpholin-4-ylcarbonyl)oxazole
Figure imgf000253_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using thiomorpholine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.30 min.
Mass Spectrum (ES+, m/z): 394.12 (M+H)+
Example 258 N-(benzo [1,3 ]dioxol-5 -ylmethy l)-5-(4-dimethylaminophenyl)-2-phenyloxazole-4- carboxamide
Figure imgf000254_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using benzo[l,3]dioxol-5-ylmethylamine instead of 2-(4- methoxyphenyl)ethylamine and 5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tert-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid. HPLC: Rt = 1.47 min.
Mass Spectrum (ES+, m/z): 442.11 (M+H)+
Example 259 N-(benzo[l,3]dioxol-5-yl)-N-ethyl-5-(4-dimethylaminophenyl)-2-phenyloxazole-4- carboxamide
Figure imgf000255_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using N-ethylbenzo[l,3]dioxol-5-ylamine instead of 2-(4- methoxyphenyl)ethylamine and 5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tert-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxyIic acid.
HPLC: Rt = 1.36 min.
Mass Spectrum (ES+, m/z): 456.13 (M+H)+
Example 260 N-(2,6-dimethoxybenzyl)-5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000256_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2, 6-dimethoxybenzy lamine instead of 2-(4-methoxyphenyI)ethy lamine and 5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.56 min.
Mass Spectrum (ES+, m/z): 458.16 (M+H)+
Example 261 N-(4-piperidin-l-ylphenyl)-5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000256_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-(piperidin-l-yl)phenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4-dimethylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 22 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.09 min.
Mass Spectrum (ES+, m/z): 467.18 (M+H)+
Example 262
N-phenyl-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000257_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using phenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- acetylamino-phenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.32 min.
Mass Spectrum (ES+, m/z): 398.11 (M+H)+
Example 263 N-methyl-N-phenyl-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000258_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using N-methylphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.07 min.
Mass Spectrum (ES+, m/z): 412.13 (M+H)+
Example 264 5-(4-Acetylaminophenyl)-4-[(4-methylpiperidin-l-yl)carbonyl]-2-phenyloxazole
Figure imgf000258_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-methylpiperidine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- acety!aminophenyl)-2-phenyloxazoIe-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.13 min.
Mass Spectrum (ES+, m/z): 404.17 (M+H)+
Example 265 N-(4-methoxyphenyl)-N-methyl-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000259_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using N-methyl-4-methoxyphenylamine instead of 2-(4- methoxyphenyl)ethylamine and 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tert-butylphenyl)~5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.05 min.
Mass Spectrum (ES+, m/z): 442.14 (M+H)+
Example 266 5-(4-Acetylaminophenyl)-4-[[4-(2-methoxyphenyl)piperazin-l-yl]carbonyl]-2-phenyloxazole
Figure imgf000260_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using l-(2-methoxyphenyl)piperazine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.11 min.
Mass Spectrum (ES+, m/z): 497.18 (M+H)+
Example 267 N-(3-ethoxyphenyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000260_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 3-ethoxyphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.38 min.
Mass Spectrum (ES+, m/z): 442.14 (M+H)+
Example 268
N-(naphthalen-l-yl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000261_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using naphthalen-1-y lamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.43 min.
Mass Spectrum (ES+, m/z): 448.12 (M+H)+
Example 269 N-(2-methoxyphenyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000262_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-methoxyphenylamine instead of 2-(4-methoxyphenyl)ethy lamine and 5- (4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tert-butylphenyI)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.40 min.
Mass Spectrum (ES+, m/z): 428.12 (M+H)+
Example 270 N-(2,3 -dihydrobenzo[ 1 ,4] dioxin-6-yl)-5 -(4-acetylaminophenyl)-2-phenyloxazole-4- carboxamide
Figure imgf000262_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 2,3-dihydrobenzo[l,4]dioxin-6-ylamine instead of 2-(4- methoxyphenyl)ethylamine and 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.27 min.
Mass Spectrum (ES+, m/z): 456.12 (M+H)+
Example 271 N-(5-methylisoxazol-3-yl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000263_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 5-methylisoxazol-3-ylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.21 min.
Mass Spectrum (ES+, m/z): 403.11 (M+H)+
Example 272 N-(biphenyl-2-yl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide.
Figure imgf000264_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using biphenyl-2-ylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.55 min.
Mass Spectrum (ES+, m/z): 474.15 (M+H)+
Example 273 N-allyl-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000264_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using allylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.10 min.
Mass Spectrum (ES+, m/z): 362.16 (M+H)+
Example 274 N-(4-chlorophenyl)-N-methyl-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000265_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using N-methyl-4-chlorophenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.19 min.
Mass Spectrum (ES+, m/z): 446.10 (M+H)+
Example 275 N-(2-methoxybenzyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000266_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-methoxybenzylamine instead of 2-(4-methoxyphenyl)ethylamine and 5- (4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.29 min.
Mass Spectrum (ES+, m/z): 442.15 (M+H)+
Example 276 5-(4-Acetylaminophenyl)-4-(3 ,4-dihydro-2H-quinolin- 1 -ylcarbonyl)-2-phenyloxazole
Figure imgf000266_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 3,4-dihydro-2H-quinoline instead of 2-(4-methoxyphenyl)ethylamine and 5- (4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.19 min.
Mass Spectrum (ES+, m/z): 438.16 (M+H)+
Example 277 N-(2-methoxy-5-methylphenyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000267_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-methoxy-5-methylpheny lamine instead of 2-(4- methoxyphenyl)ethylamine and 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.47 min.
Mass Spectrum (ES+, m/z): 442.15 (M+H)+
Example 278 N-(4-methoxyphenyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000268_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-methoxyphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5- (4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.28 min.
Mass Spectrum (ES+, m/z): 428.13 (M+H)+
Example 279 N-(2-trifluoromethylbenzyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000268_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-trifluoromethylbenzylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid. HPLC: Rt = 1.39 min.
Mass Spectrum (ES+, m/z): 480.12 (M+H)+
Example 280 N-(4-methoxybiphenyl-3-yl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000269_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-methoxybiphenyl-3-ylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.60 min.
Mass Spectrum (ES+, m/z): 504.16 (M+H)+
Example 281 N-(3-methylsulfanylphenyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000270_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 3-methylsulfanylphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.40 min.
Mass Spectrum (ES+, m/z): 444.11 (M+H)+
Example 282 5 -(4-Acetylaminophenyl)-2-phenyl-4-[(4-phenylpiperazin- 1 -yl)carbonyl] oxazole
Figure imgf000270_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 1-phenylpiperazine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.18 min.
Mass Spectrum (ES+, m/z): 467.17 (M+H)+
Example 283 5-(4-Acetylaminophenyl)-4-(2,5-dihydropyrrol-l-ylcarbonyl)-2-phenyloxazole
Figure imgf000271_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2,5-dihydropyrrole instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 0.97 min.
Mass Spectrum (ES+, m/z): 374.15 (M+H)+
Example 284
5-(4-Acetylaminophenyl)-2-phenyl-4-[[4-(3-trifluoromethylphenyl)piperazin-l- yl]carbonyl]-oxazole
Figure imgf000272_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using l-(3-trifluoromethylphenyl)piperazine instead of 2-(4- methoxyphenyl)ethy lamine and 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.33 min.
Mass Spectrum (ES+, m/z): 535.15 (M+H)+
Example 285 N-(3-methoxy-5-trifluoromethylphenyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4- carboxamide
Figure imgf000272_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 3 -methoxy-5 -trifluoromethylphenylamine instead of 2-(4-methoxyphenyl)- ethylamine and 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylamino- phenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.49 min.
Mass Spectrum (ES+, m/z): 496.12 (M+H)+
Example 286 N-(3-benzyloxyphenyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000273_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 3 -benzyloxypheny lamine instead of 2-(4-methoxyphenyl)ethylamine and 5- (4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.51 min.
Mass Spectrum (ES+, m/z): 504.16 (M+H)+
Example 287 N-(3,5-bis-trifluoromethylphenyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000274_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 3,5-bis-trifluoromethylphenylamine instead of 2-(4- methoxyphenyl)ethylamine and 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.60 min.
Mass Spectrum (ES+, m/z): 534.10 (M+H)+
Example 288 N-(2-methylsulfanylphenyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000274_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-methylsulfanylphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.47 min.
Mass Spectrum (ES+, m/z): 444.12 (M+H)+
Example 289 N-benzyl-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000275_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using benzylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- acetylamino-phenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.26 min.
Mass Spectrum (ES+, m/z): 412.15 (M+H)+
Example 290 N-(benzo[l,3]dioxol-5-ylmethyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000276_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using benzo[l,3]dioxol-5-ylmethylamine instead of 2-(4- methoxyphenyl)ethy lamine and 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.23 min.
Mass Spectrum (ES+, m/z): 456.13 (M+H)+
Example 291 N-benzo[l,3]dioxol-5-yl-N-ethyl-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000276_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using N-ethylbenzo[l,3]dioxol-5-ylamine instead of 2-(4- methoxyphenyl)ethylamine and 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3- dimethylaminophenyl)oxazole-4-carboxylic acid. HPLC: Rt = 1.12 min.
Mass Spectrum (ES+, m/z): 470.15 (M+H)+
Example 292 N-(2-benzylphenyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000277_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 2-benzylphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.53 min.
Mass Spectrum (ES+, m/z): 488.18 (M+H)+
Example 293 N-(4-methylphenyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000278_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-methylphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.37 min.
Mass Spectrum (ES+, m/z): 412.15 (M+H)+
Example 294 N-(2,5-dimethoxyphenyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000278_0002
The title compound was prepared in analogous manner to that described in Example 154 above, using 2,5-dimethoxyphenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tert-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 1.40 min.
Mass Spectrum (ES+, m/z): 458.15 (M+H)+
Example 295 N-(biphenyl-4-yl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000279_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using biphenyl-4-ylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4- acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butylphenyl)-5-(3-dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC: Rt = 1.51 min.
Mass Spectrum (ES+, m/z): 474.16 (M+H)+
Example 296 N-(4-piperidin-l-ylphenyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxamide
Figure imgf000280_0001
The title compound was prepared in analogous manner to that described in Example 154 above, using 4-(piperidin-l-yl)phenylamine instead of 2-(4-methoxyphenyl)ethylamine and 5-(4-acetylaminophenyl)-2-phenyloxazole-4-carboxylic acid, prepared as described in Example 145 above, instead of 2-(4-tgrt-butyIphenyl)-5-(3-dimethylaminophenyl)oxazole-4- carboxylic acid.
HPLC: Rt = 0.84 min.
Mass Spectrum (ES+, m/z): 481.20 (M+H)+
Example 297 N-[2-(4-methoxyphenyl)ethyl]-2-(4-tgrt-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000280_0002
A solution of 2-(4-tgrt-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxylic acid, prepared as described in Example 19 above, in a 4:1 by volume mixture of acetonitrile and pyridine (800 μl, 0.125M, 100 μmol) was added to a 2-dram reaction vial. A solution of 2-chloro-l,3-dimethylimidazolinium chloride (DMC) in a 4:1 by volume mixture of acetonitrile and pyridine (800 μl, 0.25M, 200 μmol) was added followed by the addition of a solution of 2-(4-methoxyphenyl)ethylamine in acetonitrile (400 μl, 0.25M, 100 μmol). The reaction mixture was then allowed to stand for 4 hours at room temperature. At the end of this time, the solvent was removed in vacuo and the crude material submitted for HPLC purification.
HPLC Rt = 1.69 min;
Mass Spectrum (ES+, m/z): 498.64 (M+H)+
Example 298
N-(4-acetylphenyl)-2-(4-tert-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000281_0001
The title compound was prepared in analogous manner to Example 297 above, using 4-acetylphenylamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC Rt = 1.73 min;
Mass Spectrum (ES+, m/z): 482.56 (M+H)+ Example 299 N-benzhydryl-2-(4-tgrt-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4-carboxamide
Figure imgf000282_0001
The title compound was prepared in analogous manner to Example 297 above, using benzhy dry lamine instead of 2-(4-methoxyphenyl)ethy lamine.
HPLC Rt = 1.84 min;
Mass Spectrum (ES+, m/z): 530.49 (M+H)+
Example 300 N-(4-trifluoromethylphenyl)-2-(4-tgrt-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000282_0002
The title compound was prepared in analogous manner to Example 297 above, using 4-trifluoromethylpheny lamine instead of 2-(4-methoxyphenyl)ethylamine .
HPLC Rt = 1.84 min;
Mass Spectrum (ES+, m/z): 508.62 (M+H)+
Example 301 N-( 1 , 1 -dimethylpropyl)-2-(4-te7't-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000283_0001
The title compound was prepared in analogous manner to Example 297 above, using 1,1-dimethylpropylamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC Rt = 1.79 min;
Mass Spectrum (ES+, m/z): 434.67 (M+H)+
Example 302 N-[l-(ethoxycarbonyl)piperidin-4-yl]-2-(4-tgrt-butylphenyl)-5-(4-dimethylaminophenyl)- oxazole-4-carboxamide
Figure imgf000284_0001
The title compound was prepared in analogous manner to Example 297 above, using l-ethoxycarbonylpiperidin-4-ylamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC Rt = 1.61 min;
Mass Spectrum (ES+, m/z): 519.69 (M+H)+
Example 303 N-(4-methylphenyl)-2-(4-tgrt-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000284_0002
The title compound was prepared in analogous manner to Example 297 above, using 4-methylphenylamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC Rt = 1.79 min;
Mass Spectrum (ES+, m/z): 454.64 (M+H)+ Example 304 N-(3-benzyloxyphenyl)-2-(4-tgrt-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000285_0001
The title compound was prepared in analogous manner to Example 297 above, using 3 -benzyloxypheny lamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC Rt = 1.91 min;
Mass Spectrum (ES+, m/z): 545.72 (M+H)+
Example 305 N-(naphthalen-l-yl)-2-(4-tert-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000285_0002
The title compound was prepared in analogous manner to Example 297 above, using naphthalen-1-y lamine instead of 2-(4-methoxyphenyl)ethylamine. HPLC Rt = 1.85 min;
Mass Spectrum (ES+, m/z): 490.60 (M+H)+
Example 306 N-(3,3-diphenylpropyl)-2-(4-tert-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000286_0001
The title compound was prepared in analogous manner to Example 297 above, using 3,3-diphenylpropylamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC Rt = 1.83 min;
Mass Spectrum (ES+, m/z): 558.71 (M+H)+
Example 307 2-(4-tgrt-Butylphenyl)-4-[[4-(2-dimethylaminoethyl)piperazin-l-yl]carbonyl1-5-(4- dimethylaminophenyl)oxazole
Figure imgf000287_0001
The title compound was prepared in analogous manner to Example 297 above, using 1 -(2-dimethylaminoethyl)piperazine instead of 2-(4-methoxyphenyl)ethy lamine.
HPLC Rt = 0.97 min;
Mass Spectrum (ES+, m/z): 504.69 (M+H)+
Example 308 N-(5-methylisoxazol-3-yl)-2-(4-tgrt-butylphenyl)-5-(4-dimethylaminophenyl)oxazole-4- carboxamide
Figure imgf000287_0002
The title compound was prepared in analogous manner to Example 297 above, using 5 -methylisoxazol-3-y lamine instead of 2-(4-methoxyphenyl)ethylamine.
HPLC Rt = 1.70 min;
Mass Spectrum (ES+, m/z): 445.57 (M+H)+ Example 309 N-r2-(4-methoxyphenyl)ethyl]-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide
Figure imgf000288_0001
The title compound was prepared in analogous manner to Example 297 above, using 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 25 above, instead of 2-(4-tert-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid.
HPLC Rt = 1.55 min;
Mass Spectrum (ES+, m/z): 512.72 (M+H)+
Example 310 N-cyclopropylmethyl-N-propyl-5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4- carboxamide
Figure imgf000289_0001
The title compound was prepared in analogous manner to Example 297 above, using 5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 25 above, instead of 2-(4-tgrt-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid and N-cyclopropylmethyl-N-propylamine instead of 2-(4-methoxyphenyI)-ethylamine.
HPLC Rt = 1.51 min;
Mass Spectrum (ES+, m/z): 474.78 (M+H)+
Example 311 5-(4-Acetylaminophenyl)-2-(4-tert-butylphenyl)-4-(octahydroquinolin-l-ylcarbonyl)oxazole
Figure imgf000289_0002
The title compound was prepared in analogous manner to Example 297 above, using 5-(4-acetylaminophenyl)-2-(4-tgrt-butylphenyl)oxazole-4-carboxylic acid, prepared as described in Example 25 above, instead of 2-(4-tgrt-butylphenyl)-5-(4- dimethylaminophenyl)oxazole-4-carboxylic acid and octahydroquinoline instead of 2-(4- methoxyphenyl)ethylamine.
HPLC Rt = 1.60 min;
Mass Spectrum (ES+, m/z): 500.67 (M+H)+
Example 312
2-(4-tert-Butyl-phenyl)-5-(4-methylamino-phenyl)-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000290_0001
A solution of 2-(4-tert-butyl-phenyl)-5-(4-methylamino-phenyl)-oxazole-4-carboxylic acid in CH3CN:pyridine 4:1 (800 μL, 0.125M, 100 μmol) was added to a 2-dram reaction vial. A solution of 2-chloro-l,3-dimethylimidazolinium chloride (DMC) in CH3CN:pyridine 4:1 (800 μL, 0.25M, 200 μmol) was added followed by the addition of a solution of 2- trifluoromethylbenzylamine in CH3CN (400 μL, 0.25M, 100 μmol). The reaction was allowed to stand for 4 hours at room temperature. The solvent was removed in vacuo and the crude material submitted for HPLC purification.
Example 313 2-(4-tert-Butyl-phenyl)-5-(3-dimethylamino-phenyl)-oxazole-4-carboxylic acidthiazol-2- ylamide
Figure imgf000291_0001
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = min; MS (ES+, m/z) (M+H)+
Example 314 2-(4-tert-Butyl-phenyl)-5-(3-dimethylamino-phenyl)-oxazole-4-carboxylic acid phenylamide
Figure imgf000291_0002
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.66 min; MS (ES+, m/z) 426.14 (M+H)
Example 315 2-(4-Tert-butyl-phenyl)-5-(3-dimethylamino-phenyl)-oxazole-4-carboxylic acid biphenyl-2- ylamide
Figure imgf000292_0001
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.80 min; MS (ES+, m/z) 502.14 (M+H)+
Example 316 2-(4-tert-Butyl-phenyl)-5-(3-dimethylamino-phenyl)-oxazole-4-carboxylic acid benzylamide
Figure imgf000292_0002
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.60 min; MS (ES+, m/z) 440.15 (M+H)+
Example 317 r2-(4-tert-Butyl-phenyl)-5-(4-methylamino-phenyl)-oxazol-4-yl]-(2,5-dihydro-pyrrol-l-yl)- methanone
Figure imgf000293_0001
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt =1.42 min; MS (ES+, m/z) 402.16 (M+H)+
Example 318 [2-(4-tert-Butyl-phenyl)-5-(4-methylamino-phenyl)-oxazol-4-yl]-thiomorpholin-4-yl- methanone
Figure imgf000293_0002
The titled compound was prepared in analogous manner to Example 312. HPLC Rt = 1.41 min; MS (ES+, m/z) 436.14 (M+H)+
Example 319 2-(4-tert-Butyl-phenyl)-5-(4-methylamino-ρhenyl)-oxazole-4-carboxylic acid (4-chloro- phenyD-methyl-amide
Figure imgf000294_0001
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.52 min; MS (ES+, m/z) 474.11 (M+H)
Example 320 2-(4-tert-Butyl-phenyl)-5-(4-methylamino-phenyl)-oxazole-4-carboxylic acid (4-methoxy- phenyl)-methyl-amide
Figure imgf000294_0002
The titled compound was prepared in analogous manner to Example 312. HPLC Rt = 1.42 min; MS (ES+, m/z) 470.15 (M+H)+
Example 321 2-(4-tert-Butyl-phenyl)-5-(4-methylamiho-phenyl)-oxazole-4-carboxylic acid 2-methoxy- benzylamide
Figure imgf000295_0001
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.61 min; MS (ES+, m/z) 470.76 (M+H) +
Example 322 [2-(4-tert-Butyl-phenyl)-5-(4-methylamino-phenyl)-oxazol-4-yl]-[4-(3-trifluoromethyl- phenyl)-piperazin- 1 -yl]-methanone
Figure imgf000296_0001
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.60 min; MS (ES+, m/z)563.16 (M+H)
Example 323
2-(4-tert-Butyl-phenyl)-5-(4-methylamino-phenyl)-oxazole-4-carboxylic acid benzo [ 1 ,3] dioxol-5 -yl-ethyl-amide
Figure imgf000296_0002
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.45 min; MS (ES+, m/z) 498.15 (M+H)+ Example 324 [2-(4-tert-Butyl-phenyl)-5-(4-methylamino-phenyl)-oxazol-4-yl]-[4-(2-methoxy-phenyl)- piperazin-1 -yl]-methanone
Figure imgf000297_0001
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.46 min; MS (ES+, m/z) 525.21 (M+H) +'
Example 325 [2-(4-tert-Butyl-phenyl)-5-(4-methylamino-phenyl)-oxazol-4-yl]-(3,4-dihydro-2H-quinolin- l-yl)-methanone
Figure imgf000297_0002
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.53 min; MS (ES+, m/z) 466.20 (M+H)+ Example 326 2-(4-tert-Butyl-phenyl)-5-(4-methylamino-phenyl)-oxazole-4-carboxylic acid (3-methoxy-5- trifluoromethyl-phenyl)-amide
Figure imgf000298_0001
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.79 min; MS (ES+, m/z) 523.13 (M+H)
Example 327 2-(4-tert-Butyl-phenyl)-5 -(4-methylamino-phenyl)-oxazole-4-carboxylic acid (3 -ethoxy- phenyl)-amide
Figure imgf000298_0002
The titled compound was prepared in analogous manner to Example 312. HPLC Rt = 1.71 min; MS (ES+, m/z) 470.15 (M+H)+
Example 328 2-(4-tert-Butyl-phenyl)-5-(4-methylamino-phenyl)-oxazole-4-carboxylic acid naphthalen-1- ylamide
Figure imgf000299_0001
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.74 min; MS (ES+, m/z) 476.17 (M+H)
Example 329 2-(4-tert-Butyl-phenyl)-5-(4-methylamino-phenyl)-oxazole-4-carboxylic acid (4-methoxy- phenyl)-amide
Figure imgf000299_0002
The titled compound was prepared in analogous manner to Example 312. HPLC Rt = 1.62 min; MS (ES+, m/z) 456.14 (M+H)+
Example 330 2-(4-tert-Butyl-phenyl)-5-(4-methylamino-phenyl)-oxazole-4-carboxylic acid (2,5- dimethoxy-phenyl)-amide
Figure imgf000300_0001
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.71 min; MS (ES+, m/z) 486.14 (M+H)+
Example 331 2-(4-tert-Butyl-pheny l)-5 -(4-methylamino-phenyl)-oxazole-4-carboxylic acid (2-methoxy- phenyl)-amide
Figure imgf000300_0002
The titled compound was prepared in analogous manner to Example 312. HPLC Rt = 1.72 min; MS (ES+, m/z) 456.15 (M+H)+
Example 332 2-(4-tert-Butyl-phenyl)-5 -(4-methylamino-phenyl)-oxazole-4-carboxylic acid 3 , 5 -bis- trifluoromethyl-benzylamide
Figure imgf000301_0001
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.73 min; MS (ES+, m/z) 576.11 (M+H)+
Example 333 2-(4-tert-Butyl-phenyl)-5-(3-dimethylamino-phenyl)-oxazole-4-carboxylic acid biphenyl-4- ylamide
Figure imgf000302_0001
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.79 min; MS (ES+, m/z) 502.18 (M+H)
Example 334 2-(4-tert-Butyl-phenyl)-5-(4-methylamino-phenyl)-oxazole-4-carboxylic acid (2,3-dihydro- benzo[l ,4]dioxin-6-yl)-amide
Figure imgf000302_0002
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.60 min; MS (ES+, m/z) 484.14 (M+H)÷ Example 335 2-(4-tert-Butyl-phenyl)-5 -(4-methylamino-phenyl)-oxazole-4-carboxylic acid (4-methoxy- biphenyl-3 -yl)-amide
Figure imgf000303_0001
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.85 min; MS (ES+, m/z) 532.19 (M+H)+
Example 336 2-(4-tert-Butyl-phenyl)-5-(4-methylamino-phenyl)-oxazole-4-carboxylic acid (2-acetyl- phenyl)-amide
Figure imgf000303_0002
The titled compound was prepared in analogous manner to Example 312. HPLC Rt = 1.72 min; MS (ES+, m/z) 468.16 (M+H)+
Example 337 2-(4-tert-Butyl-phenyl)-5-(4-methylamino-phenyl)-oxazole-4-carboxylic acid 2,6-dimethoxy- benzylamide
Figure imgf000304_0001
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.62 min; MS (ES+, m/z) 500.18 (M+H)+
Example 338 2-(4-tert-Butyl-phenyl)-5-(4-methylamino-phenyl)-oxazole-4-carboxylic acid (5-methyl- isoxazol-3-yl)-amide
Figure imgf000304_0002
The titled compound was prepared in analogous manner to Example 312. HPLC Rt = 1.60 min; MS (ES+, m z) 431.13 (M+H)+
Example 339 2-(4-tert-Butyl-phenyl)-5 -(4-methylamino-phenyl)-oxazole-4-carboxylic acid (3 - methylsulfanyl-phenyl)-amide
Figure imgf000305_0001
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.73 min; MS (ES+, m/z) 472.12 (M+H)+
Example 340 2-(4-tert-Butyl-phenyl)-5-(4-methylamino-phenyl)-oxazole-4-carboxylic acid (2- methylsulfanyl-phenyl)-amide
Figure imgf000305_0002
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = 1.77 min; MS (ES+, m/z) 472.12 (M+H)+
Example 341 5-(4-Methylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid2-trifluoromethyl- benzylamide
Figure imgf000306_0001
The titled compound was prepared in analogous manner to Example 312.
HPLC Rt = min; MS (ES+, m/z) (M+H)
Example 342 5-(4-Benzoylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid 2-trifluoromethyl- benzylamide
Figure imgf000306_0002
A solution of 5-(4-amino-phenyl)-2-phenyl-oxazole-4-carboxylic acid 2-trifluoromethyl- benzylamide in CHCl3:pyridine 1:1 (1 mL, 0.2M, 200 μmol) was added to a 2-dram reaction vial. A solution of benzoyl chloride in CHC13 (1 mL, 0.5M, 500 μmol). Solvent was removed and diluted with DMSO (800 μl) and submitted for purification.
HPLC Rt = 1.47 min; MS (ES+, m/z) 542.08 (M+H)+
Example 343 5-[4-(2-Methyl-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000307_0001
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.50 min; MS (ES+, m/z) 556.10 (M+H)+
Example 344 N-{4-[2-phenyl-4-(2-trifluoromethyl-benzylcarbamoyl)-oxazol-5-yl1-phenyl}-nicotinamide
Figure imgf000308_0001
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.38 min; MS (ES+, m/z) 543.09 (M+H)+
Example 345 5-[4-(2-Methoxy-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000308_0002
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.56 min; MS (ES+, m/z) 572.09 (M+H)+ Example 346 5 - [4-(3 -Cyclopentyl-propionylamino)-phenyl] -2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000309_0001
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.62 min; MS (ES+, m/z) 562.15 (M+H)+
Example 347 5-(4-Pentanoylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid 2-trifluoromethyl- benzylamide
Figure imgf000309_0002
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.47 min; MS (ES+, m/z) 522.14 (M+H)+
Example 348 5-[4-(Cyclopropanecarbonyl-amino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000310_0001
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.38 min; MS (ES+, m/z) 506.11 (M+H)
Example 349 5-[4-(2-Phenoxy-acetylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000310_0002
The titled compound was prepared in analogous manner to Example 342. HPLC Rt = 1.34 min; MS (ES+, m/z) 510.11 (M+H)+
Example 350 5-r4-(2-Phenoxy-acetylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000311_0001
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.50 min; MS (ES+, m/z) 572.10 (M+H)4
Example 351 5-[4-(4-Methoxy-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000312_0001
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.48 min; MS (ES+, m/z) 572.09 (M+H)4
Example 352 5-[4-(3-Methoxy-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000313_0001
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.49 min; MS (ES+, m/z) 572.08 (M+H)+
Example 353 N- (4- [2-Phenyl-4-(2-trifluoromethyl-benzylcarbamoyl)-oxazol-5-yl] -phenyl } - isonicotinamide
Figure imgf000313_0002
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.38 min; MS (ES+, m/z) 543.09 (M+H)+ Example 354 5-[4-(4-Fluoro-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000314_0001
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.50 min; MS (ES+, m/z) 560.07 (M+H)+
Example 355 5-(4-Isobutyrylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid 2-trifluoromethyl- benzylamide
Figure imgf000314_0002
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.40 min; MS (ES+, m z) 508.13 (M+H)+
Example 356 5-r4-(3-Methyl-butyrylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000315_0001
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.47 min; MS (ES+, m/z) 522.13 (M+H)4
Example 357 2-Phenyl-5-[4-(3-phenyl-propionylamino)-phenyl]-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000316_0001
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.51 min; MS (ES+, m/z) 570.08 (M+H)+
Example 358 2-Phenyl-5-[4-(2-thiophen-2-yl-acetylamino)-phenyl]-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000316_0002
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.49 min; MS (ES+, m/z) 572.08 (M+H)+ Example 359 5-F4-(3-Chloro-propionylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000317_0001
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.38 min; MS (ES+, m/z) 528.06 (M+H)+
Example 360 5-{4-[(Furan-2-carbonyl)-amino]-phenyl}-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000318_0001
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.39 min; MS (ES+, m/z) 532.06 (M+H)+
Example 361 5-r4-(3-Methyl-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000318_0002
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.55 min; MS (ES+, m/z) 556.09 (M+H)+ Example 362 5-[4-(3-Fluoro-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000319_0001
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.51 min; MS (ES+, m/z) 560.07 (M+H)+
Example 363 5-[4-(4-Ethyl-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2-trifluoromethyl- benzylamide
Figure imgf000319_0002
The titled compound was prepared in analogous manner to Example 342. HPLC Rt = 1.58 min; MS (ES+, m/z) 570.10 (M+H)+
Example 364 2-Phenyl-5-r4-(3-phenyl-acryloylamino)-phenyl]-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000320_0001
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.54 min; MS (ES+, m/z) 568.07 (M+H)4
Example 365 5-(4-Butyrylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid 2-trifluoromethyl- benzylamide
Figure imgf000320_0002
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.41 min; MS (ES+, m/z) 508.13 (M+H)4
Example 366 5-[4-(Cyclohexanecarbonyl-amino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000321_0001
The titled compound was prepared in analogous manner to Example 342.
HPLC Rt = 1.54 min; MS (ES+, m/z) 548.14 (M+H)4
Example 367 5-[4-(3,3-Dimethyl-butyrylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000322_0001
The titled compound was prepared in analogous manner to Example 342. HPLC Rt = 1.53 min; MS (ES+, m z) 536.15 (M+H)+
Example 368 5-r4-(2.2-Dichloro-acetylamino)-phenyfl-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000322_0002
The titled compound was prepared in analogous manner to Example 342. HPLC Rt = 1.44 min; MS (ES+, m/z) 549.98 (M+H)+ Example 369 5-[4-(4-Methylτbenzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000323_0001
The titled compound was prepared in analogous manner to Example 342. HPLC Rt= 1.53 min; MS (ES+, m/z) 556.11 (M+H)+
Example 370 2-Phenyl-5-{4-[(thiophene-2-carbonyl)-amino]-phenyl)-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000323_0002
The titled compound was prepared in analogous manner to Example 342. HPLC Rt = 1.47 min; MS (ES+, m/z) 548.04 (M+H)4
Example 371 5-[4-(2-Fluoro-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000324_0001
The titled compound was prepared in analogous manner to Example 342. HPLC Rt = 1.48 min; MS (ES+, m/z) 560.06 (M+H)+
Example 372 2-Phenyl-5- (4-propionylamino-phenyl)-oxazole-4-carboxylic acid 2-trifluoromethyl- benzylamide
Figure imgf000325_0001
The titled compound was prepared in analogous manner to Example 342. HPLC Rt = 1.36 min; MS (ES+, m/z) 494.11 (M+H)+
Example 373 2-Phenyl-5-(4-phenylacetylamino-phenyl)-oxazole-4-carboxylic acid 2-trifluoromethyl- benzylamide
Figure imgf000325_0002
The titled compound was prepared in analogous manner to Example 342. HPLC Rt = 1.47 min; MS (ES+, m/z) 556.10 (M+H)+ Example 374 5-(4-Hexanoylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid 2-trifluoromethyl- benzylamide
Figure imgf000326_0001
The titled compound was prepared in analogous manner to Example 342. HPLC Rt = 1.53 min; MS (ES+, m/z) 536.15 (M+H)
Example 375 5-[4-(2,2-Dimethyl-propionylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000326_0002
The titled compound was prepared in analogous manner to Example 342. HPLC Rt = 1.50 min; MS (ES+, m/z) 522.14 (M+H)+ Example 376 5-[4-(2-Chloro-ρropionylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid 2- trifluoromethyl-benzylamide
Figure imgf000327_0001
The titled compound was prepared in analogous manner to Example 342. HPLC Rt = 1.43 min; MS (ES+, m/z) 528.05 (M+H)+
Example 377 N-{4-[2-Phenyl-4-(2-trifluoromethyl-benzylcarbamoyl)-oxazol-5-yl]-phenyl}-succinamic acid methyl ester
Figure imgf000327_0002
The titled compound was prepared in analogous manner to Example 342. HPLC Rt = 1.32 min; MS (ES+, m/z) 552.07 (M+H)+ Example 378
Acetic acid {4-[2-phenyl-4-(2-trifluoromethyl-benzylcarbamoyl)-oxazol-5-yl]- phenylcarbamoyl) -methyl ester
Figure imgf000328_0001
The titled compound was prepared in analogous manner to Example 342. HPLC Rt = 1.30 min; MS (ES+, m/z) 538.08 (M+H)+
Example 379 5-[4-(2-Methyl-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid (2,5-dimethoxy- phenyl)-amide
Figure imgf000328_0002
A solution of 5-(4-amino-phenyl)-2-phenyl-oxazole-4-carboxylic acid (2,5-dimethoxy- phenyl)-amide in CHC13 -.pyridine 1:1 (1 mL, 0.2M, 200 μmol) was added to a 2-dram reaction vial. A solution of benzoyl chloride in CHC13 (1 mL, 0.5M, 500 μmol). Solvent was removed and diluted with DMSO (800 μl) and submitted for purification. PLC Rt = 1.53 min; MS (ES+, m/z) 534.14 (M+H)+
Example 380 N-{4-[4-(2,5-dimethoxy-phenylcarbamoyl)-2-phenyl-oxazol-5-yl]-phenyl}-nicotinamide
Figure imgf000329_0001
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.43 min; MS (ES+, m/z) 521.12 (M+H)
Example 381 5-[4-(2-Methoxy-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid (2,5- dimethoxy-phenyl)-amide
Figure imgf000329_0002
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.57 min; MS (ES+, m/z) 550.11 (M+H)+
Example 382 5-[4-(3-Cyclopentyl-propionylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid (2,5- dimethoxy-phenyl)-amide
Figure imgf000330_0001
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.63 min; MS (ES+, m/z) 540.16 (M+H)4
Example 383 5 -(4-Pentanoylamino-ρhenyl)-2-phenyl-oxazole-4-carboxylic acid (2, 5 -dimethoxy-phenyl)- amide
Figure imgf000330_0002
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.50 min; MS (ES+, m/z) 500.16 (M+H)4
Example 384 5-[4-(Cyclopropanecarbonyl-amino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid (2,5- dimethoxy-phenyl)-amide
Figure imgf000331_0001
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.40 min; MS (ES+, m/z) 484.13 (M+H)+
Example 385 5-[4-(2-Methoxy-acetylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid (2,5-dimethoxy- phenyl)-amide
Figure imgf000331_0002
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.37 min; MS (ES+, m/z) 488.11 (M+H)4
Example 386 5-r4-(2-Phenoxy-acetylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid (2,5-dimethoxy- phenyl)-amide
Figure imgf000332_0001
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.52 min; MS (ES+, m/z) 550.10 (M+H)+
Example 387 5 - [4-(3 -Methoxy-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid (2, 5 - dimethoxy-phenyl)-amide
Figure imgf000332_0002
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.51 min; MS (ES+, m/z) 550.11 (M+H)4
Example 388 N-{4-[4-(2,5-Dimethoxy-phenylcarbamoyl)-2-phenyl-oxazol-5-yl]-phenyl}-isonicotinamide
Figure imgf000333_0001
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.40 min; MS (ES+, m/z) 521.12 (M+H)4
Example 389 5-[4-(4-Fluoro-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid (2,5-dimethoxy- phenyl)-amide
Figure imgf000333_0002
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.52 min; MS (ES+, m/z) 538.11 (M+H)4
Example 390 5-(4-Isobutyrylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid (2,5-dimethoxy-phenyl)- amide
Figure imgf000334_0001
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.43 min; MS (ES+, m/z) 486.15 (M+H)4
Example 391 5-[4-(3-Methyl-butyrylamino)-phenyl1-2-phenyl-oxazole-4-carboxylic acid (2,5-dimethoxy- phenyl)-amide
Figure imgf000335_0001
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.48 min; MS (ES+, m/z) 500.16 (M+H)4
Example 392 2-phenyl-5-[4-(3-phenyl-propionylamino)-phenyl]-oxazole-4-carboxylic acid (2,5- dimethoxy-phenyl)-amide
Figure imgf000335_0002
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.52 min; MS (ES+, m/z) 548.14 (M+H)4 Example 393 2-Phenyl-5-r4-(2-thiophen-2-yl-acetylamino)-phenyl]-oxazole-4-carboxylic acid (2,5- dimethoxy-phenyl)-amide
Figure imgf000336_0001
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.47 min; MS (ES+, m/z) 540.09 (M+H)4
Example 394 5-[4-(3-Chloro-propionylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid (2,5- dimethoxy-phenyl)-amide
Figure imgf000336_0002
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.39 min; MS (ES+, m/z) 506.10 (M+H)4 Example 395 5-{4-r(Furan-2-carbonyl)-amino]-phenyl)-2-phenyl-oxazole-4-carboxylic acid (2,5- dimethoxy-phenyl)-amide
Figure imgf000337_0001
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.42 min; MS (ES+, m/z) 510.11 (M+H)4
Example 396 5-[4-(3-Methyl-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid (2,5 -dimethoxy- phenyl)-amide
Figure imgf000337_0002
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.58 min; MS (ES+, m/z) 534.14 (M+H)4 Example 397 5-r4-(3-Fluoro-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid (2,5 -dimethoxy- phenyl)-amide
Figure imgf000338_0001
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.53 min; MS (ES+, m/z) 538.11 (M+H)4
Example 398 5-[4-(4-Ethyl-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid (2,5-dimethoxy- phenyl)-amide
Figure imgf000338_0002
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.61 min; MS (ES+, m/z) 548.13 (M+H)4 Example 399 5-(4-Butyrylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid (2,5-dimethoxy-phenyl)- amide
Figure imgf000339_0001
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.42 min; MS (ES+, m/z) 486.14 (M+H)4
Example 400 5-[4-(Cyclohexanecarbonyl-amino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid (2,5- dimethoxy-phenyl)-amide
Figure imgf000339_0002
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.58 min; MS (ES+, m/z) 526.17 (M+H)4 Example 401 5-[4-(3,3-Dimethyl-butyrylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid (2,5- dimethoxy-phenyl)-amide
Figure imgf000340_0001
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.55 min; MS (ES+, m/z) 514.17 (M+H)4
Example 402 5-[4-(4-Methyl-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid (2,5-dimethoxy- phenyl)-amide
Figure imgf000340_0002
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.56 min; MS (ES+, m/z) 534.15 (M+H)4 Example 403 2-Phenyl-5 - { 4-[(thiophene-2-carbonyl)-amino] -phenyl} -oxazole-4-carboxy lie acid (2, 5 - dimethoxy-phenyl)-amide
Figure imgf000341_0001
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.48 min; MS (ES+, m/z) 526.07 (M+H)4
Example 404 2-Phenyl-5-(4-propionylamino-phenyl)-oxazole-4-carboxylic acid (2,5-dimethoxy-phenyl)- amide
Figure imgf000341_0002
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.39 min; MS (ES+, m/z) 472.14 (M+H)4
Example 405 5-[4-(2-Chloro-propionylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid (2.5- dimethoxy-phenyl)-amide
Figure imgf000342_0001
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.44 min; MS (ES+, m/z) 506.09 (M+H)4
Example 406 N-{4-r4-(2,5-dimethoxy-phenylcarbamoyl)-2-phenyl-oxazol-5-yl]-phenyl}-succinamic acid methyl ester
Figure imgf000342_0002
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.34 min; MS (ES+, m/z) 530.12 (M+H)4
Example 407
Acetic acid {4-r4-(2,5-dimethoxy-phenylcarbamoyl)-2-phenyl-oxazol-5-yl]- phenylcarbamoyl) -methyl ester
Figure imgf000343_0001
The titled compound was prepared in analogous manner to Example 379. HPLC Rt = 1.35 min; MS (ES+, m/z) 516.12 (M+H)4
Example 408 N-{4-r2-phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazoϊ-5-yl]-pheι yl}-benzamide
Figure imgf000343_0002
A solution of [5-(4-amino-phenyl)-2-phenyl-oxazol-4-yl]-(4-phenyl-piperazin-l-yl)- methanone in CHC13.'pyridine 1:1 (1 mL, 0.2M, 200 μmol) was added to a 2-dram reaction vial. A solution of benzoyl chloride in CHC13 (1 mL, 0.5M, 500 μmol). Solvent was removed and diluted with DMSO (800 μl) and submitted for purification. HPLC Rt = 1.31 min; MS (ES+, m/z) 529.16 (M+H)4
Example 409 2-Methy 1-N- { 4-[2-phenyl-4-(4-phenyl-piperazine- 1 -carbonyl)-oxazol-5 -yl] -phenyl} - benzamide
Figure imgf000344_0001
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.35 min; MS (ES+, m/z) 543.17 (M+H)+
Example 410 N-{4-[2-Phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yl]-phenyl}-nicotinamide
Figure imgf000344_0002
The titled compound was prepared in analogous maimer to Example 408. HPLC Rt = 1.19 min; MS (ES+, m/z) 530.13 (M+H)4
Example 411 2-Methoxy-N-{4-[2-phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yl]-phenyl}- benzamide
Figure imgf000345_0001
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.39 min; MS (ES+, m/z) 559.15 (M+H)4
Example 412 3-Cyclopentyl-N-{4-[2-phenyl-4-(4-phenyl-ρiperazine-l-carbonyl)-oxazol-5-yl]-phenyl}- propionamide
Figure imgf000345_0002
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.44 min; MS (ES+, m/z) 549.20 (M+H)
Example 413 Pentanoic acid {4-[2-phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yn-phenyl}-amide
Figure imgf000346_0001
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.28 min; MS (ES+, m/z) 509.19 (M+H)4
Example 414 Cyclopropanecarboxylic acid {4-[2-phenyl-4-(4-phenyl-piperazine- l-carbonyl)-oxazol-5-yl]- phenyl} -amide
Figure imgf000347_0001
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.18 min; MS (ES+, m/z) 493.17 (M+H)+
Example 415 2-Methoxy-N-{4-[2-phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yl]-phenyl}- acetamide
Figure imgf000347_0002
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.13 min; MS (ES+, m/z) 497.18 (M+H)4 Example 416 2-Phenoxy-N-{4-[2-phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yl]-phenyl}- acetamide
Figure imgf000348_0001
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.34 min; MS (ES+, m/z) 559.15 (M+H)4
Example 417 4-Methoxy-N-{4-[2-phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yI]-phenyl}- benzamide
Figure imgf000349_0001
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.31 min; MS (ES+, m/z) 559.15 (M+H)4
Example 418 3-Methoxy-N-{4-[2-phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yl]-phenyl}- benzamide
Figure imgf000349_0002
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.30 min; MS (ES+, m/z) 559.14 (M+H)4 Example 419 N-{4-[2-Phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yl]-phenyl}-isonicotinamide
Figure imgf000350_0001
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.12 min; MS (ES+, m/z) 530.14 (M+H)+
Example 420 4-Fluoro-N-{4-r2-phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yl]-phenyl}- benzamide
Figure imgf000350_0002
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.31 min; MS (ES+, m/z) 547.13 (M+H)4 Example 421 N- {4-[2-Phenyl-4-(4-phenyl-piperazine- 1 -carbonyl)-oxazol-5-yl] -phenyl} -isobutyramide
Figure imgf000351_0001
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.21 min; MS (ES+, m/z) 495.19 (M+H)4
Example 422 3 -Methyl-N- {4- [2-pheny l-4-(4-phenyl-piperazine- 1 -carbonyl)-oxazol-5 -yl] -phenyl } - butyramide
Figure imgf000351_0002
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.28 min; MS (ES+, m/z) 509.20 (M+H)4 Example 423 3 -Phenyl-N- {4- [2-phenyl-4-(4-phenyl-piperazine- 1 -carbonyl)-oxazol-5 -yl] -phenyl } - propionamide
Figure imgf000352_0001
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.35 min; MS (ES+, m/z) 557.18 (M+H)+
Example 424 3-Methyl-N-{4-[2-phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yl]-phenyl}- benzamide
Figure imgf000352_0002
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.35 min; MS (ES+, m/z) 543.16 (M+H) Example 425 3-Fluoro-N-{4-[2-phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yl]-phenyl}- benzamide
Figure imgf000353_0001
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.34 min; MS (ES+, m/z) 547.14 (M+H)4
Example 426 4-Ethyl-N-{4-[2-phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yl]-phenyl}- benzamide
Figure imgf000353_0002
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.42 min; MS (ES+, m/z) 557.17 (M+H)+ Example 427 3-Phenyl-N-{4-[2-phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yl]-phenyl}- acrylamide
Figure imgf000354_0001
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.35 min; MS (ES+, m/z) 555.16 (M+H)4
Example 428 N-{4-[2-Phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yl]-phenyl}-butyramide
Figure imgf000354_0002
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.20 min; MS (ES+, m/z) 495.19 (M+H)4 Example 429 Cyclohexanecarboxylic acid {4- r2-phenyl-4-(4-phenyl-piperazine- 1 -carbonyl)-oxazol-5 -yl] - phenyl} -amide
Figure imgf000355_0001
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.37 min; MS (ES+, m/z) 535.22 (M+H)4
Example 430 3,3-Dimethyl-N-{4-[2-phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yl]-phenyl}- butyramide
Figure imgf000355_0002
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.34 min; MS (ES+, m/z) 523.20 (M+H)4 Example 431 4-Methyl-N-{4-r2-phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yl]-phenyl}- benzamide
Figure imgf000356_0001
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.35 min; MS (ES+, m/z) 543.17 (M+H)4
Example 432 2-Fluoro-N-{4-[2-phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yl1-phenyl}- benzamide
Figure imgf000356_0002
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.29 min; MS (ES+, m/z) 547.14 (M+H)+ Example 433 N- |4-[2-Phenyl-4-(4-phenyl-piperazine-l -carbonyl)-oxazol-5-yl] -phenyl} -propionamide
Figure imgf000357_0001
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.15 min; MS (ES+, m/z) 481.18 (M+H)+
Example 434 2-Phenyl-N- { 4-[2-phenyl-4-(4-phenyl-piperazine- 1 -carbonyl)-oxazol-5 -yl] -phenyl } - acetamide
Figure imgf000357_0002
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.28 min; MS (ES+, m/z) 543.17 (M+H)4 Example 435 Hexanoic acid {4-[2-phenyl-4-(4-phenyl-piperazine-l-carbonyl)-oxazol-5-yl]-phenyl}-amide
Figure imgf000358_0001
The titled compound was prepared in analogous manner to Example 408. HPLC Rt = 1.36 min; MS (ES+, m/z) 523.20 (M+H)4
Example 436 5 -(4-B enzoy lamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid pyridin-2-ylamide
Figure imgf000358_0002
A solution of 5-(4-amino-phenyl)-2-phenyl-oxazole-4-carboxylic acid pyridin-2-ylamide in CHCl3:pyridine 1:1 (1 mL, 0.2M, 200 μmol) was added to a 2-dram reaction vial. A solution of benzoyl chloride in CHC13 (1 mL, 0.5M, 500 μmol). Solvent was removed and diluted with DMSO (800 μl) and submitted for purification. HPLC Rt = 1.31 min; MS (ES+, m/z) 529.16 (M+H)+
Example 437 5-[4-(2-methyl-benzoylamino)-phenyl1-2-phenyl-oxazole-4-carboxylic acid pyridin-2- ylamide
Figure imgf000359_0001
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.37 min; MS (ES+, m/z) 475.12 (M+H)4
Example 438 N-{4-r2-Phenyl-4-(pyridin-2-ylcarbamoyl)-oxazol-5-yl]-phenyl}-nicotinamide
Figure imgf000359_0002
The titled compound was prepared in analogous manner to Example 436. HPLC Rt= 1.21 min; MS (ES+, m/z) 462.11 (M+H)4
Example 439 5-[4-(3-Cyclopentyl-propionylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid pyridin-2- ylamide
Figure imgf000360_0001
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.45 min; MS (ES+, m/z) 491.12 (M+H)4
Example 440 5-r4-(Cyclopropanecarbonyl-amino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid pyridin-2- ylamide
Figure imgf000360_0002
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.21 min; MS (ES+, m/z) 425.15 (M+H)+
Example 441 5-[4-(2-Methoxy-acetylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid pyridin-2 - ylamide
Figure imgf000361_0001
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.17 min; MS (ES+, m/z) 429.13 (M+H)4
Example 442 5 - [4-(4-Methoxy-benzoylamino)-phenyl] -2-pheny l-oxazole-4-carboxy lie acid pyridin-2- ylamide
Figure imgf000361_0002
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.37 min; MS (ES+, m/z) 491.12 (M+H)4
Example 443 5-[4-(3-Methoxy-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid pyridin-2- ylamide
Figure imgf000362_0001
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.34 min; MS (ES+, m/z) 491.11 (M+H)4
Example 444 5-[4-(4-Fluoro-benzoylamino)-phenyl1-2-phenyl-oxazole-4-carboxylic acid pyridin-2- ylamide
Figure imgf000362_0002
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.37 min; MS (ES+, m/z) 479.11 (M+H)4 Example 445 5-(4-Isobutyrylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid pyridin-2-ylamide
Figure imgf000363_0001
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.25 min; MS (ES+, m/z) 427.13 (M+H)4
Example 446 5-[4-(3-Methyl-butyrylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid pyridin-2- ylamide
Figure imgf000363_0002
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.33 min; MS (ES+, m/z) 441.16 (M+H)4 Example 447 2-Phenyl-5-[4-(3-phenyl-propionylamino)-phenyl1-oxazole-4-carboxylic acid pyridin-2- ylamide
Figure imgf000364_0001
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.39 min; MS (ES+, m/z) 489.14 (M+H)4
Example 448 2-Phenyl-5-[4-(2-thiophen-2-yl-acetylamino)-phenyn-oxazole-4-carboxylic acid pyridin-2- ylamide
Figure imgf000364_0002
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.32 min; MS (ES+, m/z) 481.07 (M+H)4 Example 449 5 - { 4- [(Furan-2-carbonyD-aminol -phenyl} -2-phenyl-oxazole-4-carboxylic acid pyridin-2- ylamide
Figure imgf000365_0001
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.25 min; MS (ES+, m/z) 451.09 (M+H)4
Example 450 5-[4-(3-Methyl-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid pyridin-2- ylamide
Figure imgf000365_0002
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.42 min; MS (ES+, m/z) 475.12 (M+H)4 Example 451 5-[4-(3-Fluoro-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxy lie acid pyridin-2- ylamide
Figure imgf000366_0001
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.38 min; MS (ES+, m/z) 479.10 (M+H)4
Example 452 5-r4-(4-Ethyl-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxy lie acid pyridin-2-ylamide
Figure imgf000366_0002
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.49 min; MS (ES+, m/z) 489.14 (M+H)4 Example 453 2-Phenyl-5-[4-(3-phenyl-acryloylamino)-phenyl]-oxazole-4-carboxylic acid pyridin-2- ylamide
Figure imgf000367_0001
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.43 min; MS (ES+, m/z) 487.12 (M+H)4
Example 454 5-(4-Butyrylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid pyridin-2-ylamide
Figure imgf000367_0002
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.25 min; MS (ES+, m/z) 427.13 (M+H) Example 455 5-[4-(Cyclohexanecarbonyl-amino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid pyridin-2- ylamide
Figure imgf000368_0001
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.43 min; MS (ES+, m/z) 467.16 (M+H)4
Example 456 5-r4-(3,3-Dimethyl-butyrylamino)-phenyl]-2-phenyl-oxazole-4-carboxy lie acid pyridin-2- ylamide
Figure imgf000368_0002
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.39 min; MS (ES+, m/z) 455.15 (M+H)4 Example 457 5-[4-(4-Methyl-benzoylamino)-phenyl]-2-phenyl-oxazole-4-carboxylic acid pyridin-2 - ylamide
Figure imgf000369_0001
The titled compound was prepared in analogous manner to Example 436. HPLC Rt = 1.41 min; MS (ES+, m/z) 475.12 (M+H)4
Example 458 2-Phenyl-5-pyridin-4-yl-oxazole-4-carboxylic acid ethyl ester
Figure imgf000369_0002
Isonicotinyl chloride (80.7 mmol, 14 g) and triethylamine (161.4 mmol, 22.4 mL) were added to a solution of {[methylsulfanyl-(phenyl)-methylene] -amino} -acetic acid ethyl ester 6 (26.9 mmol, 6 g) in CH2C12 (120 mL) and the reaction was stirred for 24 hours at room temperature. The organic layer was washed IM HCl (100 mL) and brine (100 mL), dried over Na2SO4 and the solvent removed in vacuo. The titled compound was recrystallized from EtOH (2.28 g) as a yellow solid in 26 % yield. Example 459 (1) 2-Phenyl-5-pyridin-4-yl-oxazole-4- arboxylic acϊd
Aqueous IM KOH (12 ml) was added to a suspension of 2-phenyl-5-pyridin-4-yl-oxazoIe-4- carboxylic acid ethyl ester in EtOH and heated to 50 °C. Suspension was filtered after 12 and solid washed with EtOH providing the titled compound in quantitative yield.
Η NMR (300 MHz, CDC13) δ 8.33 (s, 4H), 4.42 (q, J = 7.2 Hz, 2H), 2.6 (s, 3H), 1.42 (t, J =
7.2 Hz, 3H); -
HPLC Retention time = 1.08 mm;
Mass Spectrum (ES+, m/z) 277.31 (M+H)+
Example 459 (2) 2-Phenyl-5-pyridin-4-yl-oxazol&-4-carboxylic acid phcnylamide
Figure imgf000370_0001
A solution of 2-phenyl-5-pyridin-4-y_-oxazole-4-carboxy_ic acid in CH3CN:pγridine 4:1 (800 μL, 0.125M, 100 μmol) was added to a 2-dram reaction vial. A solution of 2-chloro-l,3- dimethylimidazolinium chloride (DMC) in CH3CN:pyridine 4:1 (800 μL, 0.25M, 200 μmol) was added followed by the addition of a solution of aniline in CH3CN (400 uL, 0.25M, 100 μmol). Solvent was removed and diluted with DMSO (800 μl) and submitted for purification. HPLC Retention rime = 1.33 min;
Mass Spectrum (ES+, m/z) 342.23 (M+H)+
Example 460 (4-Methyl-pipcridiπ- 1 -ylK2-phenyl-5-pyridiπ-4-yl.oχazol-4-vπ-methanone
Figure imgf000371_0001
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.10 min;
Mass Spectrum (ES+, m/z) 348.27 (M+H)+
Example 461 T4-(2-Memoxy-phenvIVpiperazin-l-yπ^2-phenγI-5-pyridin-4-y -oxazol-4-vπ-methanone
Figure imgf000371_0002
The titJe compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.12 min;
Mass Spectrum (ES+, m/z) 441.24 (M+Hf Example 462 2-Phenyl-5-pyridin-4-yl-oxazole-4-carboxylic acid (3-ethoxy-phenylVamide
Figure imgf000372_0001
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.44 min;
Mass Spectrum (ES+, m/z) 386.24 (M+H)'
Example 463 2-Phenyl-5-ρyridin-4-yl-oxazoIe-4-carboxylic acid (2-methoxy-phenylVamide
Figure imgf000372_0002
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.51 min;
Mass Spectrum (ES+, m/z) 372.22 (M+H)+ Example 464 2-Phenyl-5-ρyridin-4-yl-oxazole-4-carboxylic acid (5-methyl-isoxazol-3~yl)-amide
Figure imgf000373_0001
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.16 min;
Mass Spectrum (ES+, m/z) 347.21 (M+H)+
Example 465 2-PhenyI-5-pyπdin-4-yl-oxazole-4-carboχylic acid biphenyl-2-ylamide
Figure imgf000373_0002
The titled compound was prepared in analogous maimer to Example 459.
HPLC Retention time = 1.71 min;
Mass Spectrum (ES+, m/z) 418.20 (M+H)+ Example 466 2-Phenyl-5-pyridin-4-yl-oxazoIe-4-carboxylic acid allylamide
Figure imgf000374_0001
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.03 min:
Mass Spectrum (ES+, m z) 306.25 (M+H)+
Example 467 2-Phenyl-5-pyridin-4-yl-oxazole-4-carboxylic acid f4-chloro-phenyl)-methyl-amide
Figure imgf000374_0002
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.22 mm;
Mass Spectrum (ES+, m/z) 390.16 (M+H)* Example 468 2-Phcnyl-5-pyridin-4-yl-oxazolc-4-carboxylic acid 2-methoxy-ben2γlamide
Figure imgf000375_0001
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1J4 min;
Mass Spectrum (ES+, m/z) 386.21 (M+Hf
Example 469 (3.4-Dihvdro-2H-quinolin-l-vπ-(2-phenyl-5-pyridirι -yl--oxazol-4-yπ-methanone
Figure imgf000375_0002
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1 ,19 min;
Mass Spectrum (ES+, m/z) 382.23 (M+H)+ Example 470 2-PhcnyI-5-pyridin-4-yl-oxazole- -carboxylic acid (2-mcthoχy-5-mcthyl-phcnylVamidc
Figure imgf000376_0001
The titled compound was prepared in analogous manner to Example 459. HPLC Retention time = 1.59 min; Mass Spectmm (ES+, m/z) 386.22 (M+H)+
Example 471 2-Phenyl-5-pyridin-4-yl-oxazole-4-carboxylic acid (4-methoχy-phenyl)-amide
Figure imgf000376_0002
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.30 min;
Mass Spectrum (ES+, m/z) 372.21 (M+H)+ Example 472 2-Phenyl-5-pyridin-4-yl-oxazole-4-carboxylic acid 2-trifluoromethyl-benrylamide
Figure imgf000377_0001
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.47 min;
Mass Spectrum (ES+, m/z) 424.19 (M+H)+
Example 473 2-Phenyl-5-pyridm-4-yl-oxazole-4-carboχylic acid (3-methylsulfanyl-phenyl)-amide
Figure imgf000377_0002
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.46 min;
Mass Spectrum (ES+, m/z) 388.17 (M+H)+ Example 474 (4-Phenyl-piperazin-l-yl -(2-phenyl-5-pyridin-4-yl-oxazol-4-ylVmethanone
Figure imgf000378_0001
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.18 min;
Mass Spectrum (ES+, m/z) 411.23 (M+H)+
Example 475 (2,5-Dihydro-pyrrol-l-yn-(2-phenyl-5-pyridin-4-yl-oxazol-4-yl')-methanone
Figure imgf000378_0002
The titled compound was prepared in analogous manner to Example 459,
HPLC Retention time = 0.89 min;
Mass Spectrum (ES+, m/z) 318.24 (M+H)+ Example 476 fOctahydro-quinoliπ- 1 -yl)-(2-phenyl-5-pyridin-4-yl-oxazol-4-yl)-methanone.
Figure imgf000379_0001
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.32 min;
Mass Spectrum (ES+, mlz) 388.27 (M+H)"
Example 477 (2-Phenyl-5-pyri--in -yl 3xazol -ylVr4-(3-trifluoromethyl-phenyl)-piperazin-l-yl1- methanone
Figure imgf000379_0002
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.38 min;
Mass Spectrum (ES+, m/z) 479.21 (M+H)÷ Example 478 2-Phenyl-5-pyridin-4-yl-oxazole-4-carboxylic acid (3-bcnzyloχy-phcnvD-amidc
Figure imgf000380_0001
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.61 min;
Mass Spectrum (ES+, m/z) 448.22 (M+H)+
Example 479 2-P-ιenyl-5 ?yridm-4-yt-oxazole-4-carboxylic acid 3.5-bis-trifluoromethyl-benzyl-amidc
Figure imgf000380_0002
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.57 min;
Mass Spectrum ES+, m/z) 492.14 (M+H Example 480 2-Phenyl-5-pyridiπ-4-y.-oxazo_e-4-carboxylic acid (2-acctyl-phenvD-amidc
Figure imgf000381_0001
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.50 min;
Mass Spectrum (ES+, m/z) 384.20 (M+H)+
Example 481 2-Phenyl-5-pyridin-4-yl-oxazole-4-carboχylic acid (2-mc-hylsulfanyl-phenyl)-amide
Figure imgf000381_0002
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.60 min;
Mass Spectrum (ES+, m/z) 388.16 (M+H)+ Example 482 (2-Phenyl-5-pyridin-4-yl-oxazol-4-yl)-thiomorpholin-4-yl-methaπone
Figure imgf000382_0001
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 0.93 min;
Mass Spectrum (ES+, m/z) 352.20 (M+Hf
Example 483 2-Phenyl-5-pyridin-4-γl-oxazole-4-carboxylic cidbenzofl.31dioxol-5-yl-ethyl-amide
Figure imgf000382_0002
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.10 min;
Mass Spectrum (ES+, m/z) 414.21 (M+H)+ Example 484 2-Phenyl-5-pyridin-4-yl-oxazole-4-carbQxylic acid (2-benzyI-phenyD-amide.
Figure imgf000383_0001
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.65 min;
Mass Spectrum (ES+, m/z) 43223 Qvl+H
Example 485 2-Phenyl-5"Pyridin-4-yI-<,xazole-4-carboχylic acid (4-methylphenyl)-amide
Figure imgf000383_0002
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time =• 1.43 min;
Mass Spectrum (ES+, m/z) 356.24 (M+Hf Example 486 2-Phenyl-5-pyridin-4-yl-oxazole-4-carboxylic acid 2,6-d_mcthoxybcnzytamidc
Figure imgf000384_0001
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 1.39 min;
Mass Spectrum (ES+, m z) 416.21 (M+H)+
Example 487 2-Phenyl-5-pyridin -γl-oxazole-4-carboxyrιc actd (4-piperidin-l-yl-phenyl)-amide
Figure imgf000384_0002
The titled compound was prepared in analogous manner to Example 459.
HPLC Retention time = 0.76 min;
Mass Spectrum (ES+, m/z) 425,24 (M+H)+ Example 488 (1) 4-ri-Ethoxycarbonyl-2-(4-nitro-phenyl)-2-oxo-ethylcarbamoyll-piperidine-l-carboxylic acid tert-butyl ester
2-Diazo-3-oxo-3-(4-nitro-phenyl)-propionic acid ethyl ester (10 mmol, 2.63 g) in CHC13 (20 ml) was added over lh to 4-carbamoyl-piperidine-l -carboxylic acid tert-butyl ester (10 mmol, 2.28 g) and rhodium acetate (0.5 mmol, 221 mg) in CHC13 (100 mL) at reflux. Heating was continued for 1 h after complete addition. The solvent was removed and crude oil was purified by flash chromatography (40% EtOAc/hexanes) providing the titled compound (1.2g) as a light purple solid (contaminated with small amount of catalyst) in 26% yield.
1H NMR (300 MHz, CDC13) δ 8.35 (d, J = 7.8 Hz, 2H), 8.25 (d, J = 7.5 Hz, 2H), 6.83 (d, J = 7.5 Hz, IH), 6.15 (d, J = 7.2 Hz, IH), 4.18 (q, J = 7.2 Hz, 2H), 2.78 (bt, J = 7.2 Hz, 2H), 2.40 (m, IH), 1.82 (bt, J = 6.9 Hz, 2H), 1.62 (m, 2H), 1.42 (s, 9), 1.15 (t, J = 7.2 Hz, 3H); HPLC Retention time = 1.06 min; Mass Spectrum (ES+, m/z) 408 (M-tBu)+.
Example 488 (2) 4-F4-ethoxycarbonyl-5-(4-nitro-phenyl)-oxazol-2-yll-piperidine- 1 -carboxylic acid tert-butyl ester
Figure imgf000385_0001
Triethyl amine (8.6 mmol, 1.2 mL) followed by 4-[l-Ethoxycarbonyl-2-(4-nitro-phenyl)-2- oxo-ethylcarbamoyl]-piperidine-l-carboxylic acid tert-butyl ester (2.16 mmol, 1 g) in CH2C12 (5 mL) were added to a solution of iodine (4.3 mmol, 1.1 g) and triphenylphosphine (4.3 mmol, 1.13 g) in CH2C12 (15 mL). The solvent was removed after 10 min and crude material purified by flash chromatography (40 % EtOAc/hexanes) providing the titled compound (440 mg) as a light brown foam in 46 % yield.
!H NMR (300 MHz, CDC13) δ 8.28 (dd, J = 12, 7.5 Hz, 4H), 4.21 (q, J = 7.2 Hz, 2H), 4.18 (b,
2H), 3.10 (m, IH), 2.90 (bt, J = 7.2 Hz, 2H), 2.08 (b, J = 6.9 Hz, 2H), 1.82 (m, 2H), 1.42 (s,
9), 1.38 (t, J = 7.2 Hz, 3H);
HPLC Retention time = 1.36 min;
Mass Spectrum (ES+, m/z) 408 (M-tBu)+.
Example 489 4-r5-(4-Amino-phenyl)-4-ethoxycarbonyl-oxazol-2-yll-piperidine-l-carboxylic acid tert- butyl ester
Figure imgf000386_0001
4- [4-ethoxycarbonyl-5-(4-nitro-phenyl)-oxazol-2-yl] -piperidine- 1 -carboxylic acid tert-butyl ester (7.3 mmol, 3.28 g) and 10% palladium on carbon (0.4 mmol, 390 mg) were placed in a Parr flask with EtOAc (25 mL) and shaken for 8h and reaction filtered through a pad of Celite. The filtrate was concentrated to provide the titled compound (2.95 g) as a light yellow solid in 97 % yield.
Example 490 4-r5-(4-N-acetylamino-phenyl)-4-ethoxycarbonyl-oxazol-2-yl1-piperidine-l-carboxylic acid tert-butyl ester
Figure imgf000387_0001
Acetyl chloride (7.81 mmol, 550 μL) in CH2C1 (5 mL) was added to a solution 4-[4- ethoxycarbonyl-5-(4-amino-phenyl)-oxazol-2-yl]-piperidine-l -carboxylic acid tert-butyl ester (7.1 mmol, 2.95 g) and pyridine (14.2 mmol, 1.15 mL) in CH C1 (60 mL) and stirred for lh. The solvent was removed and partitioned between EtOAc (100 mL) and IM HCl (50 mL). The organic layer was washed with brine (50 mL) and dried over Na2SO and solvent removed to provide the titled compound (3.17 g) as bright yellow solid in 97 % yield.
Example 491 4-r5-(4-acetylamino-phenyl)-4-carboxy-oxazol-2-yll-piperidine-l -carboxylic acid tert-butyl ester
Figure imgf000387_0002
10%) NaOH (10 mL) was added to 5-4-[5-(4-N-acetylamino-phenyl)-4-ethoxycarbonyl- oxazol-2-yl]-piperidine-l -carboxylic acid tert-butyl ester (40 mg, 0.08 mmol) in a mixture of MeOH (20 mL) and THF (10 mL). After 3h the hydrolysis of the ester was complete and the solvent was removed to afford the titled compound (25 mg, 66%).
Example 492
4-r5-(4-Acetylamino-phenyl)-4-(2-trifluoromethyl-benzylcarbamoyl)-oxazol-2-yll- piperidine-1 -carboxylic acid tert-butyl ester
Figure imgf000388_0001
Trifluoromethyl benzyl amine was added to 4-[5-(4-acetylamino-phenyl)-4-carboxy-oxazol- 2-yl]-piperidine-l -carboxylic acid tert-butyl ester (0.77mmol, 20 mg) and DMC (0.15 mmol, 26 mg) and stirred for 4h.
Example 493 5 -(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid 2-trifluoromethyl- benzylamide
Figure imgf000388_0002
Trifluoroacetic acid (400 μL) was added to 4-[5-(4-acetylamino-phenyl)-4-(2- trifluoromethyl-benzylcarbamoyl)-oxazol-2-yl]-piperidine-l -carboxylic acid tert-butyl ester and stirred at room temperature for 2h. The solvent was removed and crude product purified by flash chromatography (50 % EtOAc/hexanes) to provide titled compound (15 mg) as an off white solid in 47 % yield..
Example 494 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid phenylamide
Figure imgf000389_0001
A solution of 4- [5 -(4-acetylamino-phenyl)-4-carboxy-oxazol-2-yl] -piperidine- 1 -carboxylic acid tert-butyl ester in CH3CN:pyridine 4:1 (800 μL, 0.125M, 100 μmol) was added to a 2- dram reaction vial. A solution of 2-chIoro-l,3-dimethylimidazolinium chloride (DMC) in CH3CN:pyridine 4:1 (800 μL, 0.25M, 200 μmol) was added followed by the addition of a solution of aniline in CH3CN (400 μL, 0.25M, 100 μmol). The reaction was allowed to stand for 4 hours at room temperature. Solvent was removed. Methylene chloride (0.8 mL) was added and TFA (200 μL) and allowed to stand for 4h. Solvent was removed and diluted with DMSO (800 μl) and submitted for purification.
HPLC Retention time = 0.55 min;
Mass Spectrum (ES+, m/z) 405.35 (M+H)+
Example 495 5-(4 Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid methyl-phenylamide
Figure imgf000389_0002
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.43 min;
Mass Spectrum (ES+, m/z) 419.36 (M+H)+
Example 496
Figure imgf000390_0001
HPLC Retention time = 0.45 min;
Mass Spectrum (ES+, m/z) 411.41 (M+H)+
Example 497 5-(4«Acetylamino-phenylV2-piperidin-4-yl-oxazole-4-carboxylic acid methyl-f4- methoxyphcnylVamide
Figure imgf000390_0002
The titled compound was prepared in analogous manner to Example 494. HPLC Retention time = 0.46 min; Mass Spectrum (ES+, m/z) 449.39 (M+H)÷ Example 498 N-(4-{4-r4-(2-Methoxy-phenyl)-piperazine-l-carbonyl1-2-piperidin-4-yl-oxazol-5-yl>- phenyl)-acetamide
Figure imgf000391_0001
The titled compound was prepared in analogous manner to Example 494. . HPLC Retention time = 0.49 min; Mass Spectrum (ES+, m/z) 504.42 (M+H)+
Example 499 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid (3 -ethoxy-phenyl)- amide
Figure imgf000391_0002
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.53 min;
Mass Spectrum (ES+, m/z) 449.39 (M+H)+ Example 500 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid 1 -naphthyl amide
Figure imgf000392_0001
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.64 min;
Mass Spectrum (ES+, m/z) 455.37 (M+H)+
Example 501 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid (2-methoxy-phenyl)- amide
Figure imgf000392_0002
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.63 min;
Mass Spectrum (ES+, m/z) 435.37 (M+H)+ Example 502 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid (2,3 -dihydro- benzori,4]dioxin-6-yl)-amide
Figure imgf000393_0001
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.55 min;
Mass Spectrum (ES+, m/z) 463.37 (M+H)
Example 503 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid (5-methyl-isoxazol-3- yl)-amide
Figure imgf000393_0002
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.49 min;
Mass Spectrum (ES+, m/z) 410.35 (M+H)+ Example 504 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid biphenyl-2-ylamide
Figure imgf000394_0001
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.73 min;
Mass Spectrum (ES+, m/z) 481.39 (M+H)+
Example 505 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid allylamide
Figure imgf000394_0002
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.38 min;
Mass Spectrum (ES+, m/z) 369.34 (M+H)+
Example 506 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid methyl-(4-chloro- phenyl)-amide
Figure imgf000395_0001
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.52 min;
Mass Spectrum (ES+, m/z) 453.34 (M+H)+
Example 507 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid 2-methoxy- benzylamide
Figure imgf000395_0002
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.56 min;
Mass Spectrum (ES+, m/z) 449.40 (M+H)+ Example 508 N- {4-f4-(3 ,4-Dihydro-2H-quinoline- 1 -carbonyl)-2-piperidin-4-yl-oxazol-5-yl1-phenyl} - acetamide
Figure imgf000396_0001
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.50 min;
Mass Spectrum (ES+, m/z) 445.38 (M+H)+
Example 509 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid (2-methoxy-5-methyl- phenyl)-amide
Figure imgf000396_0002
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.68 min;
Mass Spectrum (ES+, m/z) 449.38 (M+H)+ Example 510 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid (4-methoxy-phenyl)- amide
Figure imgf000397_0001
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.55 min;
Mass Spectrum (ES+, m/z) 435.37 (M+H)+
Example 511 5-(4-acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid (4-methoxy-biphenyl-
3-yl)-amide
Figure imgf000397_0002
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.79 min:
Mass Spectrum (ES+, m/z) 511.51 (M+H) Example 512 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid (3-ethylsulfanyl- phenyl)-amide
Figure imgf000398_0001
The titled compound was prepared in analogous marmer to Example 494.
HPLC Retention time = 0.65 min;
Mass Spectrum (ES+, m/z) 451.35 (M+H)+
Example 513 N-(4-{4-r4-Phenylpiperazine-l-carbonyll-2-piperidin-4-yl-oxazol-5-yl}-phenyl)-acetamide
Figure imgf000398_0002
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.52 min;
Mass Spectrum (ES+, m/z) 474.42 (M+H)+
Example 514 N- {4-f4-(2,5 -dihydro-pyrrole- 1 -carbonyl)-2-piperidin-4-yl-oxazol-5 -yll -phenyl} -acetamide
Figure imgf000398_0003
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.33 min;
Mass Spectrum (ES+, m/z) 381.34 (M+H)+
Example 515 N-(4-{2-Piperidm-4-yl-4-r4-(3-trifluoromethyl-phenyl)-piperazine-l-carbonyl]-oxazol-5-yl}- phenyl)-acetamide
Figure imgf000399_0001
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.68 min;
Mass Spectrum (ES+, m/z) 542.42 (M+H)+
Example 516 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid (3-methoxy-5- trifluoromethyl-phenyl)-amide
Figure imgf000399_0002
The titled compound was prepared in analogous manner to Example 494. HPLC Retention time = 0.73 min;
Mass Spectrum (ES+, m/z) 503.50 (M+H)+
Example 517 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic cid (3-benzyloxy-phenyl)- amide
Figure imgf000400_0001
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.76 min;
Mass Spectrum (ES+, m/z) 511.56 (M+H)+
Example 518 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid (3,5-bis- trifluoromethyl-phenylVamide
Figure imgf000400_0002
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.83 min; Mass Spectrum (ES+, m/z) 541.46 (M+H)4
Example 519 5-(4-acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid 3,5-bis-trifluoromethyl- benzylamide
Figure imgf000401_0001
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.75 min;
Mass Spectrum (ES+, m/z) 555.53 (M+H)4
Example 520 5 -(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid (2-acetyl-phenyl)- amide
Figure imgf000401_0002
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.61 min;
Mass Spectrum (ES+, m/z) 447.37 (M+H)4 Example 521 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid (2-ethylsulfanyl- phenyl)-amide
Figure imgf000402_0001
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.65 min;
Mass Spectrum (ES+, m/z) 450.35 (M+H)+
Example 522 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid benzyl amide
Figure imgf000402_0002
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.54 min;
Mass Spectrum (ES+, m/z) 419.36 (M+H)+ Example 523 N-{4-r2-Piperidin-4-yl-4-(thiomorpholine-4-carbonyl)-oxazol-5-yl1-phenyl}-acetamide
Figure imgf000403_0001
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.37 min;
Mass Spectrum (ES+, m/z) 415.34 (M+H)+
Example 524 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid (1,3-dihydro- isobenzofuran-5-ylmethyl)-amide
Figure imgf000403_0002
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.54 min;
Mass Spectrum (ES+, m/z) 463.37 (M+H)+ Example 525 5 -(4-Acetylammo-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid benzo \ 1 ,31 dioxol-5 -yl- ethyl-amide
Figure imgf000404_0001
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.50 min;
Mass Spectrum (ES+, m/z) 477.38 (M+H)+
Example 526 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid (2-benzyl-phenyl)- amide
Figure imgf000404_0002
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.73 min:
Mass Spectrum (ES+, m/z) 495.57 (M+H)' Example 527 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid (4-methyl-phenyl)- amide
Figure imgf000405_0001
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.62 min;
Mass Spectrum (ES+, m/z) 419.38 (M+H)+
Example 528 5 -(4-Acety lamino-phenyl)-2-piperidin-4-y l-oxazole-4-carboxylic acid (2,5 -dimethoxy- phenyl)-amide
Figure imgf000405_0002
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.63 min;
Mass Spectrum (ES+, m/z) 465.39 (M+H)+ Example 529 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid biphenyl-4-ylamide
Figure imgf000406_0001
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.75 min;
Mass Spectrum (ES+, m/z) 481.41 (M+H)+
Example 530 5-(4-Acetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid 2,6-dimethoxy- benzylamide
Figure imgf000406_0002
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.59 min;
Mass Spectrum (ES+, m/z) 479.39 (M+H)+ Example 531 5 -(4-Aetylamino-phenyl)-2-piperidin-4-yl-oxazole-4-carboxylic acid (4-piperidin- 1 -yl- phenyl)-amide
Figure imgf000407_0001
The titled compound was prepared in analogous manner to Example 494.
HPLC Retention time = 0.33 min;
Mass Spectrum (ES+, m/z) 488.41 (M+H)+
Example 532 5-(4-Acetylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid (2-methoxy-ethyl)-amide
Figure imgf000407_0002
A solution of 5-(4-acetylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid in CH3CN:pyridine 4:1 (800 μL, 0.125M, 100 μmol) was added to a 2-dram reaction vial. A solution of 2-chloro-l,3-dimethylimidazolinium chloride (DMC) in CH3CN:pyridine 4:1 (800 μL, 0.25M, 200 μmol) was added followed by the addition of a solution of 2-(4-methoxy- phenyl)-ethyl amine in CH3CN (400 μL, 0.25M, 100 μmol). The reaction was allowed to stand for 4 hours at room temperature. The solvent was removed in vacuo and the crude material submitted for HPLC purification.
HPLC Rt = 0.99 min.
Mass Spectrum (ES+, m/z) : 380.22 (M+H)+
Example 533 jV-{4-f4-(Morpholine-4-carbonyl)-2-phenyl-oxazol-5-yll-phenyl}-acetamide
Figure imgf000408_0001
The titled compound was prepared in analogous manner to Example 532.
HPLC Rt = 0.85 min.
Mass Spectrum (ES+, m/z) : 392.21 (M+H)+
Example 534 5-(4-Acetylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid (3-morpholin-4-yl-propyl)- amide.
Figure imgf000408_0002
The titled compound was prepared in analogous manner to Example 532.
HPLC Rt = 0.62 min.
Mass Spectrum (ES+, m/z) : 449.27 (M+H)+
Example 535 N-{4-r2-Phenyl-4-(pyrrolidine-l-carbonyl)-oxazol-5-yll-phenyl}-acetamide.
Figure imgf000409_0001
The titled compound was prepared in analogous manner to Example 532.
HPLC Rt = 0.94 min.
Mass Spectrum (ES+, m/z) : 376.23 (M+H)+
Example 536 N-{4-[4-(2,6-Dimethyl-morpholine-4-carbonyl)-2-phenyl-oxazol-5-yll-phenyl}-acetamide
Figure imgf000409_0002
The titled compound was prepared in analogous manner to Example 532. HPLC Rt = 0.98 min
Mass Spectrum (ES+, m/z) : 420.23 (M+H)+
Example 537 N-{4-r2-Phenyl-4-(thiazolidine-3-carbonyl)-oxazol-5-yll-phenyl}-acetamide.
Figure imgf000410_0001
The titled compound was prepared in analogous manner to Example 532.
HPLC Rt = 1.02 min.
Mass Spectrum (ES+, m/z) : 394.47 (M+H)+
Example 538 5 -(4-Acetylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid (4-methyl-thiazol-2-yl) - amide.
Figure imgf000410_0002
The titled compound was prepared in analogous manner to Example 532.
HPLC Rt = 1.25 min.
Mass Spectrum (ES+, m/z) : 419.18 (M+H)+
Example 539 5 -(4-Acety lamino-phenyl)-2-phenyl-oxazole-4-carboxy lie acid cyclobutylamide
Figure imgf000411_0001
The titled compound was prepared in analogous manner to Example 532.
HPLC Rt = 1.17 min.
Mass Spectrum (ES+, m/z) : 376.24 (M+H)+
Example 540 5 -(4-Acety lammo-phenyl)-2-phenyl-oxazole-4-carboxy lie acid (tetrahydiO-furan-2- ylmethyl)-amide
Figure imgf000411_0002
The titled compound was prepared in analogous manner to Example 532.
HPLC Rt = 1.06 min.
Mass Spectrum (ES+, m/z) : 406.23 (M+H)4"
Example 541 5-(4-Acetylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid (3-imidazol-l-yl-propyl)- amide
Figure imgf000412_0001
The titled compound was prepared in analogous manner to Example 532.
HPLC Rt = 0.63 min.
Mass Spectrum (ES+, m/z) : 430.20 (M+H)+
Example 542 5-(4-Acetylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid propylamide
Figure imgf000412_0002
The titled compound was prepared in analogous manner to Example 532.
HPLC Rt = 1.13 min
Mass Spectrum (ES+, m/z) : 364.24 (M+H)+
Example 543 5-(4-Acetylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid (pyridin-4-ylmethyl)-amide
Figure imgf000413_0001
The titled compound was prepared in analogous manner to Example 532.
HPLC Rt = 0.66 min.
Mass Spectrum (ES+, m/z) : 413.20 (M+H)+
Example 544 5-(4-Acetylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid (3-methyl-isoxazol-5-yl)- amide
Figure imgf000413_0002
The titled compound was prepared in analogous manner to Example 532.
HPLC Rt = 1.18 min.
Mass Spectrum (ES+, m/z) : 403.22 (M+H)+
Example 545 5-(4-Acetylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid (1-methyl-lH-benzoimidazol-
2-yD-amide
Figure imgf000414_0001
The titled compound was prepared in analogous manner to Example 532.
HPLC Rt = 0.97 min.
Mass Spectrum (ES+, m/z) : 452.22 (M+H)+
Example 546 5-(4-Acetylammo-plιenyl)-2-plιenyl-oxazole-4-carboxylic acid pyridin-2-ylamide
Figure imgf000414_0002
The titled compound was prepared in analogous manner to Example 532.
HPLC Rt = 1.19 min. Mass Spectrum (ES+, m/z) : 399.21 (M+H)+
Example 547 5 -(4- Acetylamino-phenyl)-2-phenyl-oxazole-4-carboxylic acid (3 -pyrrolidin- 1 -yl-propyl)- amide
Figure imgf000415_0001
The titled compound was prepared in analogous manner to Example 532.
HPLC Rt = 0.65 min.
Mass Spectrum (ES+, m/z) : 433.27 (M+H)+
Reference Examples
Reference Example 1
Ethyl r(4-tert-butylbenzoyl)aminolacetate
Triethylamine (7.4 ml, 5.4 g, 53 mmol) was added to a suspension of glycine ethyl ester hydrochloride (3.3 g, 23.6 mmol) in dichloromethane (50 ml). The reaction mixture was then cooled to 0°C. A solution of 4-tert-butylbenzoyl chloride (4.64 g, 23.9 mmol) in dichloromethane (5 ml) was added dropwise to the cooled mixture and the solution was stirred for 2 hours at 0°C. At the end of this time, the reaction mixture was poured into dichloromethane (100 ml), extracted with water and brine and dried over magnesium sulfate. Removal of the solvent in vacuo yielded a crude residue that was purified via flash chromatography (2:1 hexanes: ethyl acetate) to afford the title compound as a yellow oil (5.91 g, 95%).
1H-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
7.75 (doublet, J = 10 Hz, 2H);
7.45 (doublet, J = 10 Hz, 2H);
6.68 (singlet, IH);
4.26 (quartet, 2H);
4.24 (doublet, 2H);
1.32 (singlet, 9H);
1.30 (triplet, 3H).
HPLC: Retention time = 1.07 min.
Mass Spectrum (ES+, m/z): 264 (M+H)+.
Reference Example 2
Ethyl r(biphenyl-2-carbonyl)aminolacetate
The title compound was prepared from biphenyl-2-carbonyl chloride in a manner analogous to Reference Example 1 above. 'H-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
7.72 (doublet of doublets, Jλ = 8 Hz, J2= 2 Hz, IH);
7.50 (multiplet, IH);
7.41 (multiplet, 7H);
5.85 (singlet, IH);
4.12 (quartet, 2H);
3.95 (doublet, 2H);
1.23 (triplet, 3H).
HPLC: Retention time = 0.93 min.
Mass Spectrum (ES+, m/z): 284 (M+H)+.
Reference Example 3
Ethyl r(4-tert-butylthiobenzoyl)amino1 acetate
Ethyl [(4-tert-butylbenzoyl)amino)]acetate (5.85 g, 22.2 mmol), prepared as described in Reference Example 1 above, was dissolved in tefrahydrofuran (80 ml). Lawesson's reagent (5.39 g, 13.3 mmol) was added to the reaction mixture and the resulting mixture was heated to reflux for 1 hour. At the end of this time, the reaction mixture was cooled to room temperature, concentrated in vacuo and applied to a flash column. Elution with a mixture of 3:1 hexanes:ethyl acetate afforded the title compound as a yellow oil (5.70 g, 92%>).
'H-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm: 8.11 (singlet, IH);
7.77 (doublet, J = 10 Hz, 2H);
7.42 (doublet, J = 10 Hz, 2H);
4.57 (doublet, 2H);
4.30 (quartet, 2H);
1.32 (singlet, 9H);
1.32 (triplet, 3H).
HPLC: Retention time = 1.31 min.
Mass Spectrum (ES+, m/z): 280 (M+H)+.
Reference Example 4
Ethyl r(biphenyl-2-carbothioyl)amino]acetate
The title compound was prepared from ethyl [(biphenyl-2-carbonyl)amino]acetate, prepared as described in Reference Example 2 above, in a manner analogous to Reference Example 3 above.
'H-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
7.80 (doublet of doublets, Ji = 8 Hz, J2= 2 Hz, IH);
7.46 (multiplet, 3H);
7.35 (multiplet, 7H);
4.17 (doublet, J = 6 Hz, IH);
4.12 (quartet, 2H); 1.22 (triplet, 3H).
HPLC: Retention time = 1.18 min.
Mass Spectrum (ES+, m/z): 300 (M+H)+-
Reference Example 5
Ethyl (th i ohenzny 1 am in o)a etate
The title compound was prepared from ethyl (benzoylamino)acetate (purchased from Research Plus, Inc) in a manner analogous to Reference Example 3 above.
H-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC ) δ ppm: 8.15 (singlet, IH);
7.83 (doublet of doublets, Ji = 6 Hz, h = 2 Hz, 2H); 7.49 (multiplet, IH); 7.41 (multiplet, 2H); 4.56 (doublet, J = 4 Hz, 2H);
4.33 (quartet, 2H);
1.34 (triplet, 3H).
HPLC: Retention time = 0.98 min. Mass Spectrum (ES+, m/z): 224 (M+H)+.
Reference Example 6
Ethyl [[[l -(4-tβrt-bιιtylphenyl)-l-methy]sιιlfany1]metby1ide.ne.]amino]λcetate Ethyl [(4-tert-butylthiobenzoyl)amino]acetate (5.69 g, 20.4 mmol), prepared as described in Reference Example 3 above, was dissolved in dichloromethane (75 ml) and the reaction was cooled to -78°C. Trimethyloxonium tetrafluoroborate (3.20 g, 21.6 mmol) was added in one portion and the reaction mixture was allowed to warm to 0°C. Stirring was continued for an additional 3 hours. At the end of this time, the reaction mixture was poured into dichloromethane (75 ml) and extracted with sodium hydrogencarbonate (x2) and brine and then dried over magnesium sulfate. Removal of the solvent in vacuo afforded the title compound as a yellow oil (5.75 g, 96%) as a 2:1 mixture of isomers.
Major isomer:
'H-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
7.42 (doublet, J = 10Hz, 2H);
7.22 (doublet, J = 10 Hz, 2H);
4.20 (quartet, 2H);
4.18 (singlet, 2H);
2.48 (singlet, 3H);
1.33 (singlet, 9H);
1.27 (triplet, 3H).
HPLC: Retention time = 0.89 min.
Minor isomer:
Η-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm: 7.48 (doublet, J = 10Hz, 2H);
7.25 (doublet, J = 10 Hz, 2H); 4.45 (singlet, 2H);
4.26 (quartet, 2H); 2.18 (singlet, 3H); 1.32 (triplet, 3H); 1.32 (singlet, 9H).
HPLC: Retention time = 0.83 min. Mass Spectrum (ES+, m/z): 294 (M+H)+.
Reference Example 7 Ethyl rrri-(biphenyl-2-yl)-l-methylsulfanyl1methylidenelamino1acetate
The title compound was prepared as a 3:1 mixture of isomers from ethyl [(biphenyl-2- carbothioyl)amino]acetate, prepared as described in Reference Example 4 above, in a manner analogous to Reference Example 6 above.
Major isomer:
Η-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
7.40 (multiplet, 9H);
4.05 (quartet of doublets, 2H);
3.78 (doublet, J = 17 Hz, IH)
3.55 (doublet, J = 17 Hz, IH) 2.42 (singlet, 3H);
1.19 (triplet, 3H).
HPLC: Retention time = 0.93 min.
Minor isomer:
Η-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
7.40 (multiplet, 9H);
4.26 (quartet, 2H);
4.25 (singlet, 2H);
1.58 (singlet, 3H);
1.34 (triplet, 3H).
HPLC: Retention time = 0.81 min.
Mass Spectrum (ES+, m/z): 314 (M+H)4".
Reference Example 8 Ethyl 1T( 1 -methylsulfanyl- 1 -phenyl)methylidenelamino1acetate
The title compound was prepared as a 3:2 mixture of isomers from ethyl (thiobenzoylamino)acetate, prepared as described in Reference Example 5 above, in a manner analogous to Reference Example 6 above.
Major isomer:
Η-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm: 7.54 (multiplet, IH);
7.40 (multiplet, 3H);
7.28 (multiplet, IH);
4.18 (quartet, 4H);
4.14 (singlet, 2H);
2.48 (singlet, 3H);
1.25 (triplet, 3H).
HPLC: Retention time = 0.55 min.
Minor isomer:
Η-Nuclear Magnetic Resonance Spectrum (300 MHz, CDC13) δ ppm:
7.54 (multiplet, IH);
7.40 (multiplet, 3H);
7.28 (multiplet, IH);
4.45 (singlet, 2H);
4.25 (quartet, 2H);
2.13 (singlet, 3H);
1.30 (triplet, 3H).
HPLC: Retention time = 0.43 min.
Mass Spectrum (ES+, m/z): 238 (M+H)4". Formulation Examples
A pharmaceutical preparation containing a compound of the present invention having the above formula (I), or a pharmacologically acceptable salt thereof as its active ingredient can be produced according to, for example, the following methods.
Formulation Example 1 Powder
5 g of the compound of Example 26, 895 g of lactose and 100 g of corn starch were mixed in a blender to provide the desired powder.
Formulation Example 2 Granules 5 g of the compound of Example 95, 865 g of lactose and 100 g of low- substituted hydroxypropylcellulose were mixed, 300 g of a 10%> aqueous hydroxypropyl cellulose solution were added to the resulting mixture, and this was then kneaded. The product thus obtained was then granulated using an extrusion granulating machine and dried to provide the desired granules.
Preparation Example 3 Capsules
5 g of the compound of Example 114, 115 g of lactose, 58 g of corn starch and
2 g of magnesium stearate were mixed using a V-shaped mixer, no. 3 capsules were chosen and then each of said no. 3 capsules was filled with 180 mg of the resulting mixture to provide the desired capsules. Preparation Example 4 Tablets
5 g of the compound of Example 192, 90 g of lactose, 34 g of corn starch, 20 g of crystalline cellulose and 1 g of magnesium stearate were mixed in a blender, and the resulting mixture was then formed into tablets with a tablet machine to provide the desired tablets.
Test Examples
The biological activity of the compounds of the present invention is illustrated by the following Test Examples.
Ee.yt Example 1
Measurement of Inhibition of IL-4 Production in vitro and of Cellular Viability
1. Reagents
Anti-mouse CD3 antibodies were purchased from Pharmingen. Mouse IL-4 (Interleukin-4) ΕLISA (enzyme linked immunosorbent assay) kit was purchased from Genzyme Techne Inc. RPMI-1640 medium, penicillin, and streptomycin were purchased from Life Technologies, Inc.
2. Cell Lines
Mouse Th2 clone D10.G4.1 cells [obtainable from the American Type Culture Collection (ATCC No. TIB-224)] were kindly provided by Dr. Nariuchi (Institute of Medical Science, University of Tokyo). The cells were maintained in RPMI-1640 medium supplemented with 10%» fetal bovine serum (Cansera International Inc., Canada), 100 units/ml of penicillin, and 100 g/ml of streptomycin, in a humidified atmosphere of 5%> CO2 at 37°C.
3. Cytokine Production
2.5 x IO4 D10.G4.1 cells were cultured in each well of a 96-well flat-bottomed plate (Corning Costar Inc.), each well being coated with immobilized anti-mouse CD3 antibody at 0.4 g/well in the absence or presence of compounds. 24 h after incubation, the amounts of IL-4 produced by the cells and secreted into the supernatant were measured by mouse IL-4 ELISA kit. The absorbance at 450 nm was measured by microplate reader (MODEL 3550, Bio-Rad laboratories). The amounts of IL-4 were calculated as a percentage of IL-4 production relative to the untreated control cells (percentage of control). By measuring the percentage inhibition at different test compound concentrations, the IC50 values for the test compounds were determined.
4. Cellular Viability
1.5 x 104 Jurkat cells were cultured with graded concentrations of the test compounds in 96-well flat-bottomed plates containing 200 μl of growth medium. After incubating at room temperature for 24 hours, 50 μl of phosphate buffer solution containing XTT [2,3-bis(2- methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] at 1 mg/ml and PMS (phenazine methosulfate) at 7.5 μg/ml were added to each well of the 96-well flat-bottomed plate. After incubation for 6 hours at room temperature, the absorbance at 450 nm was measured by microplate reader. The cell viability was measured at each concentration of test compound as a percentage of the control containing no test compound. IC50 values were determined by plotting the logarithm of the compound concentrations against the percentage cell viability.
The activity in inhibiting IL-4 production and the cellular viability for the compounds of the present invention were compared with those for the closest prior art compound disclosed in WO-A-99/33827, the structure of which is as follows:
Figure imgf000427_0001
Compound A
The results obtained are shown in Tables 1 to 3 below.
Table 1
Figure imgf000427_0002
Table 2
Figure imgf000428_0001
Table 3
Figure imgf000428_0002
It will be immediately apparent from the results above that the compounds of the present invention show excellent activity in inhibiting IL-4 production as well as low toxicity.

Claims

WHAT IS CLAIMED IS:
1. A compound of formula (I):
Figure imgf000429_0001
(I) wherein:
X represents a substituent selected from the group consisting of phenyl groups, heteroaryl groups defined below and heterocyclyl groups defined below, said substituent X being substituted with at least one of substituents R1 defined below and optionally further being substituted with at least one of Substituents β defined below, said heteroaryl groups and heterocyclyl groups optionally further being fused with an aryl group defined below or
X represents a pyridine group or a pyrimidine group;
Y represents a substituent selected from the group consisting of phenyl groups, heteroaryl groups defined below and heterocyclyl groups defined below, said substituent Y optionally being substituted with from 1 to 5 substituents R3 defined below, said heteroaryl groups and heterocyclyl groups optionally further being fused with an aryl group defined below;
R1 represents a nitro group or a group of formula -NR4R5 wherein R4 and R5 are the same or different and each is selected from the group consisting of hydrogen atoms, lower alkyl groups defined below, alkoxy groups defined below, alkylcarbonyl groups defined below which are unsubstituted or are substituted with at least one substituent selected from Substituents ε defined below, aryl groups defined below, arylcarbonyl groups defined below which are unsubstituted or are substituted with at least one substituent selected from Substituents δ defined below, heteroarylcarbonyl groups defined below, cycloalkylcarbonyl groups defined below and alkenylcarbonyl groups defined below which are unsubstituted or are substituted with aryl group(s); R2 represents a substituent selected from the group consisting of hydroxy groups, alkoxy groups defined below and groups of formula -NR6R7 wherein R6 and R7 are the same or different and each is selected from the group consisting of: hydrogen atoms; lower alkyl groups defined below which are unsubstituted or are substituted with at least one substituent selected from Substituents defined below; lower alkenyl groups defined below; cycloalkyl groups defined below which are unsubstituted or are substituted with at least one lower alkyl group defined below, said cycloalkyl groups optionally being fused with an aryl group as defined below; groups of formula -NR4R5 wherein R4 and Rs are as defined above; aryl groups defined below which are unsubstituted or are substituted with at least one substituent selected from Substituents β defined below; aralkyl groups defined below which are unsubstituted or are substituted with at least one substituent selected from the group consisting of alkoxy groups defined below and haloalkyl groups defined below; diarylalkyl groups defined below; heterocyclyl groups defined below which are attached to the nitrogen atom of the group -NR6R7 via a ring carbon atom thereof and which are unsubstituted or are substituted with at least one substituent selected from Substituents γ defined below, said heterocyclyl groups further optionally being fused with an aryl group or cycloalkyl group defined below; and heteroaryl groups defined below which are attached to the nitrogen atom of the group -NR6R7 via a ring carbon atom thereof and which are unsubstituted or are substituted with at least one substituent selected from Substituents γ defined below, or
R6 and R7 together with the nitrogen atom to which they are attached represent a heterocyclyl group defined below or a heteroaryl group defined below, said groups being unsubstituted or substituted with at least one substituent selected from the group consisting of lower alkyl groups which are unsubstituted or are substituted with at least one substituent selected from the group consisting of groups of formula -NR4R5 wherein R4 and R5 are as defined above and heterocyclyl groups defined below, aryl groups defined below which are unsubstituted or are substituted with at least one substituent selected from Substituents δ defined below, aralkyl groups defined below, carboxy groups, and alkoxycarbonyl groups defined below, said heterocyclyl and heteroaryl groups further optionally being fused with an aryl group defined below;
R3 represents a substituent selected from the group consisting of lower alkyl groups defined below, alkoxy groups defined below, alkylthio groups defined below, haloalkyl groups defined below, halogen atoms, alkylcarbonyl groups defined below, aryl groups defined below which are unsubstituted or are substituted with at least one alkoxy group defined below, aralkyl groups defined below, aralkyloxy groups defined below, heterocyclyl groups defined below and heteroaryl groups defined below; and
Substituents α are selected from the group consisting of alkoxy groups defined below, cycloalkyl groups defined below, arylamino groups defined below, heterocyclyl groups defined below which are unsubstituted or are substituted with at least one lower alkyl group defined below, and heteroaryl groups defined below which are unsubstituted or are substituted with at least one substituent selected from the group consisting of lower alkyl groups defined below and alkoxycarbonyl groups defined below;
Substituents β are selected from the group consisting of lower alkyl groups defined below, alkoxy groups defined below, alkylthio groups defined below, haloalkyl groups defined below, halogen atoms, alkylcarbonyl groups defined below, aryl groups defined below which are unsubstituted or are substituted with at least one alkoxy group defined below, aralkyl groups defined below, aralkyloxy groups defined below, heterocyclyl groups defined below and heteroaryl groups defined below;
Substituents γ are selected from the group consisting of lower alkyl groups defined below, carboxy groups and alkoxycarbonyl groups defined below;
Substituents δ are selected from the group consisting of lower alkyl groups defined below, haloalkyl groups defined below and alkoxy groups defined below;
or a pharmacologically acceptable salt thereof.
2. A compound of formula (I) or a pharmacologically acceptable salt thereof according to Claim 1, wherein X represents a phenyl group which is substituted with one of substituents R1 or X represents a pyridine group or a pyrimidine group.
3. A compound of formula (I) or a pharmacologically acceptable salt thereof according to Claim 1, wherein X represents a phenyl group which is substituted with one of substituents R1, wherein R1 is selected from the group consisting of nitro groups and groups of formula - NR4R5 wherein R4 andR5 are the same or different and each is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 4 carbon atoms, alkylcarbonyl groups the alkyl moiety thereof having from 1 to 4 carbon atoms and aryl groups having from 6 to 10 carbon atoms or X represents a pyridine group.
4. A compound of formula (I) or a pharmacologically acceptable salt thereof according to Claim 1, wherein X represents a phenyl group which is substituted with a group of formula - NR4R5 wherein R4 andR5 are the same or different and each is selected from the group consisting of hydrogen atoms, methyl groups, ethyl groups, acetyl groups and phenyl groups or X represents a pyridine group.
5. A compound of formula (I) or a pharmacologically acceptable salt thereof according to Claim 1, wherein X represents a phenyl group which is substituted with a substituent selected from the group consisting of amino, methylamino, dimethylamino and acetylamino groups or X represents a pyridine group.
6. A compound of formula (I) or a pharmacologically acceptable salt thereof according to Claim 1, wherein X is selected from the group consisting of 4-aminophenyl, 4-acetylamino and 4-dimethylamino groups.
7. A compound of formula (I) or a pharmacologically acceptable salt thereof according to Claim 1, wherein Y represents a phenyl group which is optionally substituted with one or 2 of substituents R3.
8. A compound of formula (I) or a pharmacologically acceptable salt thereof according to Claim 1, wherein Y represents a phenyl group which is optionally substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, haloalkyl groups having from 1 to 4 carbon atoms and phenyl groups.
9. A compound of formula (I) or a pharmacologically acceptable salt thereof according to Claim 1, wherein Y represents a phenyl group which is substituted with a substituent selected from the group consisting of methyl, ethyl, tert-butyl and trifluoromethyl groups.
10. A compound of formula (I) or a pharmacologically acceptable salt thereof according to Claim 1, wherein Y represents a 4-tert-butylphenyl group or a 4-trifluoromethylphenyl group.
11. A compound of formula (I) or a pharmacologically acceptable salt thereof according to Claim 1, wherein R2 is selected from the group consisting of hydroxy groups, alkoxy groups having from 1 to 6 carbon atoms and groups of formula -NR6R7 wherein R6 and R7 are the same or different and each is selected from the group consisting of: hydrogen atoms; alkyl groups having from 1 to 6 carbon atoms which are optionally substituted with 1 or 2 of Substituents ' defined below; alkenyl groups having from 2 to 4 carbon atoms; cycloalkyl groups having from 3 to 6 carbon atoms which are optionally substituted with an alkyl group having from 1 to 4 carbon atoms, said cycloalkyl groups optionally being fused with an aryl group having from 6 to 10 carbon atoms; groups of formula -NR4R5 wherein R4 andR5 are the same or different and each is selected from the group consisting of hydrogen atoms and aryl groups having from 6 to 10 carbon atoms; aryl groups having from 6 to 10 carbon atoms which are optionally substituted with 1 or 2 of Substituents β' defined below and which are further optionally fused with a 4- to 7- membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms; alkyl groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 aryl groups having from 6 to 10 carbon atoms, said aryl groups optionally being substituted with 1 or 2 substituents selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms and haloalkyl groups having from 1 to 4 carbon atoms, said aryl groups optionally being fused with a 4- to 7- membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms;
4- to 7- membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heterocyclyl groups optionally being substituted with 1 or 2 of Substituents γ1 defined below; 5- or 6- membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heteroaryl groups optionally being substituted with 1 or 2 of Substituents γ' defined below and further optionally being fused with ah aryl group having from 6 to 10 carbon atoms; or R6 and R7 together with the nitrogen atom to which they are attached represent a 4- to 7-membered heterocyclyl group or a 5- or 6-membered heteroaryl group, said heterocyclyl and heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, said heterocyclyl and heteroaryl groups optionally being substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms which are optionally substituted with 1 or 2 substituents selected from the group consisting of groups of formula -NR4R5 wherein R4 andR5 are the same or different and each is selected from the group consisting of hydrogen atoms and alkyl groups having from 1 to 4 carbon atoms, and 4- to 7-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, aryl groups having from 6 to 10 carbon atoms which are optionally substituted with 1 or 2 of Substituents δ' defined below, alkyl groups having from 1 to 4 carbon atoms which are substituted with an aryl group having from 6 to 10 carbon atoms, and alkoxycarbonyl groups wherein the alkoxy moiety has from 1 to 4 carbon atoms, said heterocyclyl and heteroaryl groups optionally being fused with an aryl group having from 6 to 10 carbon atoms;
Substituents ce' are selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms, cycloalkyl groups having from 3 to 6 carbon atoms, 4- to 7-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with 1 or 2 alkyl groups having from 1 to 4 carbon atoms, and 5- or 6-membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms and alkoxycarbonyl groups the alkoxy moiety thereof having from 1 to 4 carbon atoms; Substituents β' are selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, alkylthio groups having from 1 to 4 carbon atoms, haloalkyl groups having from 1 to 4 carbon atoms, halogen atoms, alkylcarbonyl groups the alkyl moiety thereof having from 1 to 4 carbon atoms, aryl groups having from 6 to 10 carbon atoms which are unsubstituted or are substituted with 1 or 2 alkoxy groups having from 1 to 4 carbon atoms, alkyl groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 aryl groups having from 6 to 10 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 aryl groups having from 6 to 10 carbon atoms, 4- to 7-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms and 5- or 6- membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms;
Substituents γ' are selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, carboxy groups and alkoxycarbonyl groups the alkoxy moiety thereof having from 1 to 4 carbon atoms;
Substituents δ' are selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms and haloalkyl groups having from 1 to 4 carbon atoms.
12. A compound of formula (I) or a pharmacologically acceptable salt thereof according to Claim 1, wherein R2 is selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms and groups of formula -NR6R7 wherein R6 and R7 are the same or different and each is selected from the group consisting of: hydrogen atoms; alkyl groups having from 1 to 6 carbon atoms which are optionally substituted with 1 or 2 of Substituents α2 defined below; alkenyl groups having from 2 to 4 carbon atoms; cycloalkyl groups having from 4 to 6 carbon atoms which are optionally substituted with an alkyl group having from 1 to 4 carbon atoms, said cycloalkyl groups optionally being fused with a phenyl group; groups of formula -NR4R5 wherein R4 andR5 are the same or different and each is selected from the group consisting of hydrogen atoms and phenyl groups; aryl groups having from 6 to 10 carbon atoms which are optionally substituted with 1 or 2 of Substituents β2 defined below and which are further optionally fused with a 5- or 6- membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms; alkyl groups having from 1 to 4 carbon atoms which are substituted with 1 or 2 phenyl groups, said phenyl groups optionally being substituted with 1 or 2 substituents selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms and haloalkyl groups having from 1 to 4 carbon atoms, said phenyl groups optionally further being fused with a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms;
5- or 6- membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heterocyclyl groups optionally being substituted with an alkoxycarbonyl group the alkoxy moiety thereof having from 1 to 4 carbon atoms;
5- or 6- membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heteroaryl groups optionally being substituted with 1 or 2 of Substituents γ2 defined below and further optionally being fused with a phenyl group;
or R6 and R7 together with the nitrogen atom to which they are attached represent a 5- or 6-membered heterocyclyl or heteroaryl group, said heterocyclyl and heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, said heterocyclyl and heteroaryl groups optionally being substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms which are optionally substituted with a group of formula -NR4R5 wherein R4 and R5 are the same or different and each is an alkyl group having from 1 to 4 carbon atoms, or a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, aryl groups having from 6 to 10 carbon atoms which are optionally substituted with a Substituent δ2 defined below, alkyl groups having from 1 to 4 carbon atoms which are substituted with a phenyl group, and alkoxycarbonyl groups wherein the alkoxy moiety has from 1 to 4 carbon atoms, said heterocyclyl and heteroaryl groups optionally being fused with a phenyl group; Substituents α2 are selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms, cyclopropyl groups, cyclobutyl groups, 5- or 6-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with an alkyl group having from 1 to 4 carbon atoms, and 5- or 6-membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms and alkoxycarbonyl groups the alkoxy moiety thereof having from 1 to 4 carbon atoms;
Substituents β2 are selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, alkylthio groups having from 1 to 4 carbon atoms, haloalkyl groups having from 1 to 4 carbon atoms, fluorine atoms, chlorine atoms, alkylcarbonyl groups the alkyl moiety thereof having from 1 to 4 carbon atoms, aryl groups having from 6 to 10 carbon atoms which are unsubstituted or are substituted with an alkoxy group having from 1 to 4 carbon atoms, alkyl groups having from 1 to 4 carbon atoms which are substituted with a phenyl group, alkoxy groups having from 1 to 4 carbon atoms which are substituted with a phenyl group and 5- or 6-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms;
Substituents γ2 are selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms and alkoxycarbonyl groups the alkoxy moiety thereof having from 1 to 4 carbon atoms;
Substituents δ' are selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms and haloalkyl groups having from 1 to 4 carbon atoms;
13. A compound of formula (I) or a pharmacologically acceptable salt thereof according to Claim 1, wherein R2 is selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms and groups of formula -NR6R7 wherein R6 and R7 are the same or different and each is selected from the group consisting of: hydrogen atoms; alkyl groups having from 1 to 6 carbon atoms which are optionally substituted with a Substituent α3 defined below; allyl groups; cycloalkyl groups having from 4 to 6 carbon atoms which are optionally substituted with a methyl or ethyl group, said cycloalkyl groups optionally being fused with a phenyl group; phenylhydrazido groups; phenyl and naphthyl groups and phenyl groups which are optionally substituted with 1 or 2 of Substituents β3 defined below and which are further optionally fused with a 5- or 6- membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms; alkyl groups having from 1 to 3 carbon atoms which are substituted with 1 or 2 phenyl groups, and benzyl and phenethyl groups which are substituted with 1 or 2 substituents selected from the group consisting of alkoxy groups having from 1 to 4 carbon atoms and haloalkyl groups having from 1 to 4 carbon atoms, the phenyl groups of these aralkyl groups optionally further being fused with a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms;
5- or 6- membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heterocyclyl groups optionally being substituted with a methoxycarbonyl or ethoxycarbonyl group;
5- or 6- membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heteroaryl groups optionally being substituted with 1 or 2 of Substituents γ2 defined above and further optionally being fused with a phenyl group; or R6 and R7 together with the nitrogen atom to which they are attached represent a 5- or 6-membered heteroaryl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, or a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, said heterocyclyl group optionally being substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms which are optionally substituted with a group of formula -NR4R5 wherein R4 and R5 are the same or different and each is a methyl or ethyl group, or a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, phenyl groups which are optionally substituted with a Substituent δ2 defined above, benzyl groups, and methoxycarbonyl and ethoxycarbonyl groups, said heterocyclyl group optionally being fused with a phenyl group;
Substituents α3 are selected from the group consisting of methoxy groups, ethoxy groups, cyclopropyl groups, cyclobutyl groups, 5- or 6-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with a methyl or ethyl group, and 5- or 6-membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms which are unsubstituted or are substituted with 1 or 2 substituents selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, methoxycarbonyl groups and ethoxycarbonyl groups; and
Substituents β3 are selected from the group consisting of methyl groups, ethyl groups, methoxy groups, ethoxy groups, methylthio groups, ethylthio groups, methyl or ethyl groups which are substituted with from 1 to 3 fluorine or chlorine atoms, fluorine atoms, chlorine atoms, acetyl groups, propionyl groups, phenyl groups which are unsubstituted or are substituted with a methoxy or ethoxy group, benzyl groups, benzyloxy and 5- or 6-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms;
14. A compound of formula (I) or a pharmacologically acceptable salt thereof according to Claim 1, wherein R2 is selected from the group consisting of methoxy groups, ethoxy groups and groups of formula -NR6R7 wherein R6 and R7 are the same or different and each is selected from the group consisting of: hydrogen atoms; methyl, ethyl, 1-methylbutyl and 1-ethylpropyl groups, methyl, ethyl and propyl groups substituted with a Substituent 4 defined below; allyl groups; cyclobutyl and cyclohexyl groups which are optionally substituted with a methyl group, said cyclobutyl and cyclohexyl groups optionally being fused with a phenyl group; phenylhydrazido groups; phenyl and naphthyl groups and phenyl groups which are optionally substituted with 1 or 2 of Substituents β4 defined below and which are further optionally fused with a 5- or 6- membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen and oxygen atoms; benzyl, diphenylmethyl and 3,3-diphenylpropyl groups, and benzyl and phenethyl groups which are substituted with 1 or 2 substituents selected from the group consisting of methoxy, ethoxy and trifluoromethyl groups, the phenyl groups of these aralkyl groups optionally further being fused with a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms;
6- membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen and oxygen atoms, said heterocyclyl groups optionally being substituted with a methoxycarbonyl or ethoxycarbonyl group;
5- or 6- membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, said heteroaryl groups optionally being substituted with 1 or 2 substituents selected from the group consisting of methyl, ethyl, methoxycarbonyl and ethoxycarbonyl groups and said heteroaryl groups further optionally being fused with a phenyl group;
or R6 and R7 together with the nitrogen atom to which they are attached represent a 5- or 6-membered heteroaryl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, or a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, at least one of said heteroatoms being a nitrogen atom, said heterocyclyl group optionally being substituted with 1 or 2 substituents selected from the group consisting of methyl and ethyl groups which are optionally substituted with a dimethylamino group or a 5- or 6-membered heterocyclyl group having 1 or 2 heteroatoms selected from the group consisting of nitrogen and oxygen atoms, phenyl groups which are optionally substituted with a substituent selected from the group consisting of methoxy, ethoxy and trifluoromethyl groups, benzyl groups, and methoxycarbonyl and ethoxycarbonyl groups, said heterocyclyl group optionally being fused with a phenyl group;
Substituents 4 are selected from the group consisting of methoxy groups, cyclopropyl groups, 5- or 6-membered heterocyclyl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen and oxygen atoms which are unsubstituted or are substituted with a methyl group, and 5- or 6-membered heteroaryl groups having 1 or 2 heteroatoms selected from the group consisting of nitrogen and sulfur atoms which are unsubstituted or are substituted with 1 or 2 substituents selected from the group consisting of methyl groups and methoxycarbonyl groups; and
Substituents β4 are selected from the group consisting of methyl groups, methoxy groups, ethoxy groups, trifluoromethyl groups, methylthio groups, chlorine atoms, acetyl groups, phenyl groups which are unsubstituted or are substituted with a methoxy group, benzyl groups, benzyloxy groups and 5- or 6-membered heterocyclyl groups having 1 or 2 nitrogen heteroatoms.
15. A compound of formula (I) or a pharmacologically acceptable salt thereof according to Claim 1, wherein R2 is selected from the group consisting of ethoxy groups and groups of formula -NR6R7 wherein R6 and R7 are the same or different and each is selected from the group consisting of: hydrogen atoms; methyl, ethyl, 1-methylbutyl and 1-ethylpropyl groups, 2-methoxyethyl, cyclopropylmethyl, 3-(morpholin-4-yl)propyl, tetrahydrofuran-2-ylmethyl, 2-(pyrrolidin-l-yl)ethyl, 3 -(pyrrolidin- l-yl)propyl, 3-(4-methylpiperazin-l-yl)propyl, 2- methoxycarbonyl-4-methylthiophen-3 -ylmethyl, 3 -(imidazol- 1 -yl)propy 1, thiophen-2- ylmethyl and pyridin-2-ylmethyl groups; allyl groups; cyclobutyl groups, 2-methylcyclohexyl groups and 1,2,3,4-tetrahydro-naphthalen-l-yl groups; phenylhydrazido groups; phenyl and naphthyl groups; 2-, 3-, 4-, 5- and 6-methylphenyl, 2-, 3-, 4-, 5- and 6-ethylphenyl, 2-, 3-, 4-, 5- and 6- methoxyphenyl, 2-, 3-, 4-, 5- and 6-ethoxyphenyl, 2-, 3-, 4-, 5- and 6-methyl-sulfanylphenyl, 2-, 3-, 4-, 5- and 6-trifluoromethylphenyl, 2-, 3-, 4-, 5- and 6-chloro-phenyl, 2-, 3-, 4-, 5- and 6-acetylphenyl, biphenyl-2-yl, biphenyl-3-yl, 2-, 3-, 4-, 5- and 6-benzylphenyl, 2-, 3-, 4-, 5- and 6-benzyloxyphenyl, 2-, 3-, 4-, 5- and 6-(piperidin-l-yl)phenyl, 2,5-dimethoxyphenyl, 3- methoxy-5-trifluoromethylphenyl, 2-methoxy-5-methylphenyl, 3, 5 -bis-trifluoromethylphenyl and 4-methoxybiphenyl-3-yl groups;
2,3-dihydrobenzo[l,4]dioxin-6-yl groups; benzyl, diphenylmethyl and 3, 3 -diphenylpropyl groups; 2-trifluoromethylbenzyl, 3,5-bis-trifluoromethylbenzyl, 2-methoxybenzy 1, 2-(2- methoxyphenyl)ethyl, 2-(3-methoxyphenyl)ethyl, 2-(4-methoxyphenyl)ethyl and 2,6- dimethoxybenzyl groups; benzo[l ,3]dioxol-5-ylmethyl groups, 1 -ethoxycarbonylpiperidin-4-yl groups; thiazol-2-yl groups;
2-ethyl-2H-pyrazol-3-yl, 5-methylisoxazol-3-yl, 2-ethoxycarbonyl-4-methyl- thiophen-2-yl and 2-methoxy carbonylthiophen-2-yl groups; and benzothiazol-2-yl groups; or R6 and R7 together with the nitrogen atom to which they are attached represent a substituent selected from the group consisting of thiazolidin-3-yl, pyrrolidin- 1-yl, pyrrolin-1- yl, piperidin-1-yl, piperazin-1-yl, morpholin-4-yl, thiomorpholin-1-yl, 2,5-dihydropyrrol-l-yl, decahydroquinolin-1-yl, 4-methylpiperidin-l-yl, 2,6-dimethyl-morpholin-4-yl, 4- methylpiperazin- 1 -yl, 4-(2-dimethylaminoethyl)piperazin- 1 -yl, 4- [2-(morpholin-4- yl)ethyl]piperazin-l-yl, 4-phenylpiperazin-l-yl, 4-(2-morpholin-4-yl-ethyl)piperazin-l-yl, 4- (3-trifluoromethylphenyl)piperazin- 1 -yl, 4-(2-methoxyphenyl)-piperazin- 1 -yl, 4- benzylpiperazin-1-yl, 3,4-dihydro-2H-quinolin-l-yl and 4-ethoxycarbonylpiperidin-l-yl groups.
16. A compound of formula (I) or a pharmacologically acceptable salt thereof according to Claim 1, wherein R2 is selected from the group consisting of ethoxy groups and groups of formula -NR6R7 wherein R6 and R7 are the same or different and each is selected from the group consisting of: hydrogen atoms, methyl groups, thiophen-2-ylmethyl groups, cyclobutyl groups, phenyl groups, naphthyl groups, 2-methoxyphenyl groups, 4-methoxyphenyl groups, 3- ethoxyphenyl groups, 3-methylsulfanylphenyl groups, 4-chlorophenyl groups, biphenyl-2-yl groups, 3-benzyloxyphenyl groups, 4-(piperidin-l-yl)phenyl groups, 2,5-dimethoxyphenyl groups, 3-methoxy-5-trifluoromethylphenyl groups, 2-methoxy-5 -methylphenyl groups, 2- trifluoromethylbenzyl groups, l-ethoxycarbonylpiperidin-4-yl groups, thiazoI-2-yl groups and 5-methylisoxazol-3-yl groups; or R6 and R7 together with the nitrogen atom to which they are attached represent a substituent selected from the group consisting of thiazolidin-3-yl, 3,4-dihydro-2H-quinolin-l- yl, 2,5-dihydropyrrol-l-yl, 4-phenylpiperazin-l-yl, 4-(2-methoxyphenyl)piperazin-l-yl and 4- benzylpiperazin-1-yl groups.
17. A compound of formula (I) or a pharmacologically acceptable salt thereof according to claim 1 wherein the compound is selected from the group consisting of
N-(2-trifluoromethylbenzyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole- 4-carboxamide;
5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)-4-[(4-phenylpiperazin-l- yl)carbonyl]oxazole;
5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)-4-[[4-(2-methoxyphenyl)piperazin-l- yl]carbonyl]oxazole;
N-(2,5-dimethoxyphenyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide;
N-(naphthalen-l-yl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide;
N-(2-methoxyphenyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide;
N-(3-methylsulfanylphenyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole- 4-carboxamide;
N-[4-(piperidin-l-yl)phenyl]-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole- 4-carboxamide;
N-(4-methoxyphenyl)-5-(4-acetylaminophenyl)-2-(4-tert-butylphenyl)oxazole-4- carboxamide;
N-allyl-5-(4-dimethylaminophenyl)-2-(4-trifluoromethylphenyl)oxazole-4- carboxamide;
N-(2-methoxy-5-methylphenyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4- carboxamide;
N-(2-trifluoromethylbenzyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4- carboxamide;
N-(3-methoxy-5-trifluoromethylphenyl)-5-(4-acetylaminophenyl)-2-phenyloxazole-4- carboxamide; and N-cyclopropylmethyl-N-propyl-5-(4-acetylaminophenyl)-2-(4-tert- butylphenyl)oxazole-4-carboxamide.
18. A method of preventing or treating a disease mediated by cytokines comprising administering an effective amount of a compound according to claim 17.
19. A method as claimed in claim 18 wherein the disease is an allergic disease.
20. A method of preventing or treating a disease mediated by cytokines comprising administering an effective amount of a compound according to claim 1.
21. A method as claimed in claim 20 wherein the disease is an allergic disease.
PCT/US2002/004326 2001-02-14 2002-02-13 Oxazole derivatives, their preparation and their use as cytokine inhibitors WO2002064558A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002248432A AU2002248432A1 (en) 2001-02-14 2002-02-13 Oxazole derivatives, their preparation and their use as cytokine inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26877101P 2001-02-14 2001-02-14
US60/268,771 2001-02-14

Publications (2)

Publication Number Publication Date
WO2002064558A2 true WO2002064558A2 (en) 2002-08-22
WO2002064558A3 WO2002064558A3 (en) 2003-11-20

Family

ID=23024411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/004326 WO2002064558A2 (en) 2001-02-14 2002-02-13 Oxazole derivatives, their preparation and their use as cytokine inhibitors

Country Status (2)

Country Link
AU (1) AU2002248432A1 (en)
WO (1) WO2002064558A2 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009502816A (en) * 2005-07-29 2009-01-29 ４エスツェー アクチェンゲゼルシャフト Novel heterocyclic NF-κB inhibitor
JP2009502948A (en) * 2005-07-26 2009-01-29 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Bactericidal carboxamide
JP2009524678A (en) * 2006-01-25 2009-07-02 シンタ ファーマシューティカルズ コーポレーション Phenyl and pyridyl compounds for inflammation and immune related applications
JP2009529555A (en) * 2006-03-15 2009-08-20 ４エスツェー アクチェンゲゼルシャフト Novel heterocyclic NF-κB inhibitor
US7691843B2 (en) 2002-07-11 2010-04-06 Pfizer Inc. N-hydroxyamide derivatives possessing antibacterial activity
US7812041B2 (en) * 2004-09-20 2010-10-12 4Sc Ag Heterocyclic NF-κB inhibitors
US8163746B2 (en) 2006-04-19 2012-04-24 Astellas Pharma Inc. Azolecarboxamide derivative
US8299267B2 (en) 2007-09-24 2012-10-30 Comentis, Inc. (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
US8304547B2 (en) 2007-10-24 2012-11-06 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
US8648079B2 (en) 2011-10-07 2014-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds
US8741960B2 (en) 2006-01-25 2014-06-03 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
US9126944B2 (en) 2013-02-28 2015-09-08 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
WO2022255764A1 (en) * 2021-06-01 2022-12-08 주식회사 에즈큐리스 Novel oxazole derivative and pharmaceutical composition containing same for prevention or treatment of allergic disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OIKAWA ET AL.: 'Synthesis of pimprinine and related oxazolylindole alkaloids from N-acyl derivatives of tryptamine and tryptophan methyl ester by DDQ oxidation' HETEROCYCLES vol. 12, no. 11, 1979, pages 1457 - 1462, XP002923129 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691843B2 (en) 2002-07-11 2010-04-06 Pfizer Inc. N-hydroxyamide derivatives possessing antibacterial activity
US7812041B2 (en) * 2004-09-20 2010-10-12 4Sc Ag Heterocyclic NF-κB inhibitors
JP2009502948A (en) * 2005-07-26 2009-01-29 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Bactericidal carboxamide
US8586611B2 (en) 2005-07-26 2013-11-19 E. I. Du Pont De Nemours And Company Fungicidal carboxamides
JP2009502816A (en) * 2005-07-29 2009-01-29 ４エスツェー アクチェンゲゼルシャフト Novel heterocyclic NF-κB inhibitor
US8741960B2 (en) 2006-01-25 2014-06-03 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
JP2009524678A (en) * 2006-01-25 2009-07-02 シンタ ファーマシューティカルズ コーポレーション Phenyl and pyridyl compounds for inflammation and immune related applications
JP2009529555A (en) * 2006-03-15 2009-08-20 ４エスツェー アクチェンゲゼルシャフト Novel heterocyclic NF-κB inhibitor
US8163746B2 (en) 2006-04-19 2012-04-24 Astellas Pharma Inc. Azolecarboxamide derivative
US8299267B2 (en) 2007-09-24 2012-10-30 Comentis, Inc. (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
US8304547B2 (en) 2007-10-24 2012-11-06 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
US8865717B2 (en) 2011-10-07 2014-10-21 Takeda Pharmaceutical Company Limited Heterocyclic compounds
US9586930B2 (en) 2011-10-07 2017-03-07 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
US8871766B2 (en) 2011-10-07 2014-10-28 Takeda Pharmaceutical Co., Ltd. Heterocyclic compounds
US11174272B2 (en) 2011-10-07 2021-11-16 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
US9193709B2 (en) 2011-10-07 2015-11-24 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
US9440990B2 (en) 2011-10-07 2016-09-13 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
US10717748B2 (en) 2011-10-07 2020-07-21 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
US8648079B2 (en) 2011-10-07 2014-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds
US10550129B2 (en) 2011-10-07 2020-02-04 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
US10144743B2 (en) 2011-10-07 2018-12-04 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
US10273245B2 (en) 2011-10-07 2019-04-30 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9458110B2 (en) 2013-02-28 2016-10-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9126944B2 (en) 2013-02-28 2015-09-08 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
WO2022255764A1 (en) * 2021-06-01 2022-12-08 주식회사 에즈큐리스 Novel oxazole derivative and pharmaceutical composition containing same for prevention or treatment of allergic disease

Also Published As

Publication number Publication date
AU2002248432A1 (en) 2002-08-28
WO2002064558A3 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
EP1194421B1 (en) Selective npy (y5) antagonists
WO2002064558A2 (en) Oxazole derivatives, their preparation and their use as cytokine inhibitors
CA2649043C (en) Azolecarboxamide derivative
JP5321467B2 (en) Azole carboxamide compound or salt thereof
TWI406862B (en) Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
JP5734628B2 (en) Indole compounds and their pharmaceutical uses
US7514429B2 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
EP1740583B1 (en) Oxadiazolone derivatives as ppar delta agonists
EP1654238A1 (en) 2-aminopyrimidine and 2-aminopyridine-4-carbamates for use in the treatment of autoimmune diseases
JPWO2006054652A1 (en) Amide compounds
JP2005536533A (en) Substituted benzimidazole compounds
JP2007507428A (en) Substituted benzazoles and their use as inhibitors of Raf kinase
JP2011513231A (en) Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors
JP2005529089A (en) Substituted benzazoles and their use as Raf kinase inhibitors
WO2005076990A2 (en) Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
BR122019017002B1 (en) PHARMACEUTICAL COMPOSITION COMPRISING SUBSTITUTED PYRIDINES
US20050113370A1 (en) Therapeutic substituted indazole derivatives
WO2004072050A1 (en) Heterocyclic compounds useful as nurr-1 activators
WO2011085128A1 (en) Hedgehog inhibitors
US6214853B1 (en) Selective NPY (Y5) antagonists (bicyclics)
US7273880B2 (en) Selective NPY (Y5) antagonists
US6225330B1 (en) Selective NPY (Y5) antagonists (tricyclics)
MX2007015998A (en) Alkyl sulfonamide derivatives.
US20030105073A1 (en) Quinolone derivatives
AU2004262482A1 (en) 2-`4(phenylamino)-piperidin-1-yl-n-phenyl-acetamine derivatives and related compounds as neuropeptide Y5 (NPY5) ligands for the treatement of obesity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN CO CZ HU ID IL IN JP KR MX NO NZ PH PL RU SG SK US VN ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP